%PDF-1.2 % 2 0 obj << /Length 16561 >> stream 0 g /GS2 gs 1 i 391.011 642.16 0.51 -198.765 re f BT /F1 1 Tf 14.944 0 0 14.944 95.131 722.324 Tm 0.0211 Tc [(Methotrexate)-329.8(pneumonitis:)-332.6(review)-332.2(of)-332.6(the)-333.6(l)2.4(iterature)-329.8(a)0.3(nd)]TJ 2.9781 -1.0319 TD 0.0208 Tc [(histopathological)-331.7(findings)-333.9(in)-332.6(nine)-333.9(patients)]TJ /F2 1 Tf 10.959 0 0 10.959 172.857 669.543 Tm 0 Tc [(S.)-330.8(Imokawa,)-330(T.V.)-330.8(Colby,)-329.5(K.O.)-334.5(Leslie,)-329.2(R.A.)-335.4(Helmers)]TJ /F3 1 Tf 8.966 0 0 8.966 58.28 632.693 Tm [(Methotr)29(exate)-321.6(pneumonitis:)-322.4(r)30.9(eview)-320(of)-317.5(the)-323.1(literatur)30.8(e)-321.7(and)-314.6(histopathological)-322.7(findings)-320.4(in)-323.9(nine)]TJ 0 -1.0559 TD [(patients.)-335.7(S.)-331.2(Imokawa,)-336.9(T)71.5(.)0(V)126.9(.)-331.7(Colby)46.3(,)-331.7(K.O.)-335.3(Leslie,)-332.7(R.A.)-334.2(Helmers.)]TJ /F4 1 Tf 24.8554 0 TD 0 Tw (#)Tj /F3 1 Tf 0.999 0 TD [(ERS)-334.2(Journals)-335.6(Ltd)-334.6(2000.)]TJ /F5 1 Tf -25.8544 -1.0559 TD [(ABSTRACT)66.7(:)-234.4(Pneumonitis)-241(is)-242.8(a)-239.8(serious)-239.6(and)-235.9(unpredictab)10(le)-241.4(side-effect)-246.1(of)-240.2(tr)12.9(eatment)-243.5(with)]TJ T* [(methotr)9.4(exate)-333.1(\(MTX\))-329.1(that)-327.3(may)-327.7(become)-330.4(life-threate)6.1(ning.)-329.2(The)-324(clinical)-332.4(and)-330.8(histological)]TJ T* [(feature)10.1(s)-297.9(o)0(f)-290.8(nine)-294.5(cases)-296.6(of)-290.8(MTX)-296.6(pneumonitis)-293(are)-288.9(r)13.4(eported)-297.4(and)-292.8(the)-295(literature)-283.8(reviewed.)]TJ 0.999 -1.0559 TD [(The)-336.7(typical)-335.6(clinical)-332.4(symptoms)-340.2(include)-331.6(progr)17.1(essive)-330.1(shortness)-338.1(of)-335.1(breath)-323.4(and)-330.8(cough,)]TJ -0.999 -1.0559 TD [(often)-465.6(associated)-466.7(with)-464.8(fever)78.1(.)-464.5(Hypoxaemia)-465.9(and)-463.5(tachypnoea)-465.4(ar)13.9(e)-467.2(always)-465.4(present)-456.6(and)]TJ T* [(crackles)-414.5(ar)13.9(e)-410.3(frequently)-405.3(audible.)-410.6(Chest)-412.2(radiography)-409.4(reveals)-404(a)-410.5(diffuse)-409.9(interstitial)-416.6(or)]TJ T* [(mixed)-283.2(interstitial)-290.2(and)-280.2(alveolar)-284.8(infiltrate,)-284.2(with)-287.7(a)-277.7(predilection)-281.4(for)-277.4(the)-288.7(lower)-280.9(lung)-282(fields.)]TJ T* [(Pulmonary)-333.8(function)-330.9(tests)-330.3(show)-329.8(a)-334.6(r)13.4(estrictive)-337(pattern)-330.2(with)-332(diminished)-332.9(diffusion)-334.2(capa-)]TJ T* [(city)49.5(.)-508.8(Lung)-512(biopsy)-509.8(reveals)-498.8(cellular)-513.1(interstitial)-517.8(infiltrates,)-518.8(granulomas)-508(or)-510.9(a)-511.7(diffuse)]TJ T* [(alveolar)-354.3(damage)-349.8(pattern)-355.5(accompanied)-352.7(by)-351.7(perivascular)-350.2(inflammation.)-358(These)-355.6(clinical)]TJ T* [(and)-292.8(pathological)-302.4(findings)-295.8(are)-288.9(not)-295.2(specific)-297.9(to)-297.1(MTX)-296.6(pneumonitis)-299.4(and)-292.8(can)-294(be)-300.8(seen)-294.5(with)]TJ T* [(other)-331.7(drug-induced)-335.8(lung)-339(toxicities.)]TJ 0.999 -1.0559 TD [(It)-260.4(is)-261.8(important)-269(that)-264(all)-256.2(patients)-270.2(r)13.4(eceiving)-264.2(methotr)9.4(exate)-263.5(be)-262.9(educated)-263.8(concerning)-264(this)]TJ -0.999 -1.0559 TD [(potential)-220.3(adverse)-223.2(r)13.4(eaction)-219.2(and)-223.3(instructed)-216.8(to)-221.3(contact)-224.1(their)-220.2(physicians)-218.9(should)-217.6(significant)]TJ 0 -1.0496 TD [(new)-310(pulmonary)-303.6(symptoms)-308.6(develop)-311.7(while)-307.4(undergoing)-307.3(therapy)50.1(.)-306.4(I)0(f)-304.6(methotrexate)-304.7(pneu-)]TJ 0 -1.0559 TD [(monitis)-558.8(is)-552.7(suspected,)-559.5(methotr)9.4(exate)-554.4(should)-559(be)-553.8(discontinued,)-558.9(supportive)-551.1(measures)]TJ T* [(instituted)-656.9(and)-653.2(carefu)10.5(l)-653.1(examination)-655.1(for)-656.8(differen)9.6(t)-651.7(causes)-655(of)-651.2(respiratory)-647.9(distress)]TJ T* (conducted.)Tj /F3 1 Tf T* [(Eur)-331.9(Respir)-333.8(J)-334.4(2000;)-333.5(15:)-334.6(373\261381.)]TJ /F6 1 Tf 7.97 0 0 7.97 401.499 633.656 Tm [(Dept)-386.7(of)-387.2(Laboratory)-380.7(Medicine)-382.3(and)-383.9(Patho-)]TJ 0 -1.0599 TD [(logy)70(,)-383.1(Mayo)-380.9(Clinic)-382.4(Scottsd)12(ale,)-384.2(Scottsdale)10.8(,)]TJ T* [(Arizona,)-328.7(USA)]TJ 0 -2.1268 TD [(Corresponde)11.8(nce:)-781.5(T)77.6(.)0(V)121.5(.)-781.4(Colby)67.4(,)-781.4(Dept)-777.9(of)]TJ 0 -1.067 TD [(Laboratory)-1006.7(Medicine)-1015.4(and)-1017(Pathology)74.3(,)]TJ 0 -1.0599 TD [(Mayo)-331.1(Clinic)-332.6(Scottsdale)10.8(,)-333.3(13400)-330.9(East)-331.2(Shea)]TJ T* [(Boulevard,)-454.7(Scottsd)12(ale,)-462.5(AZ)-456.3(85259,)-457.9(USA.)]TJ 0 -1.067 TD [(Fax:)-325.1(60)-330.1(23018372)]TJ 0 -2.1197 TD [(Keywords)11.5(:)-313.3(Cellular)-306.2(interstitial)-303.8(pneumonia)]TJ 0 -1.067 TD [(diff)12.8(use)-328.2(alveolar)-326.5(damage)]TJ 0 -1.0599 TD (granuloma)Tj 0 -1.067 TD [(methotrexa)11.7(te)-338.6(pneumo)13.3(nitis)]TJ 0 -1.0599 TD [(surg)14.1(ical)-328.7(lung)-328.3(biopsy)]TJ 0 -2.1268 TD [(Received:)-327.9(April)-324.1(28)-330.1(1999)]TJ 0 -1.0599 TD [(Accepted)-176.1(after)-175.2(revision)-180.4(Septembe)12.3(r)-183(3)0(0)-180.7(1999)]TJ 9.963 0 0 9.963 68.258 417.203 Tm [(Me)13.2(t)13.9(h)0(o)15.5(t)0(r)17.3(e)0(x)15.1(a)0(t)18.4(e)-354(\(M)17.7(TX)18.9(\))-355.2(i)0(s)-346.5(a)-354(fo)19.6(li)16.5(c)-354(a)0(c)20.4(i)0(d)-345.3(a)0(n)15.1(t)0(a)18.4(g)0(o)15.5(n)0(i)18.9(s)0(t)-346.5(t)13.9(ha)15.1(t)-356(i)0(n)18.9(-)]TJ -1.0015 -1.0527 TD [(hi)18.9(bi)18.9(ts)-170.1(ce)20.4(ll)16.5(ul)18.9(ar)-168.6(re)19.2(pr)13.9(od)21.2(uc)15.1(ti)16.5(on)-166.6(by)-160.9(ca)14.7(us)20(in)13.2(g)-171.5(a)0(n)-167(a)0(c)14.7(u)0(t)18.9(e)-171.9(in)13.2(tr)17.3(ac)20.4(el)18.5(lu)13.2(la)18.4(r)]TJ 0 -1.0471 TD [(de)15.1(fi)17.3(ci)18.5(en)20.8(cy)-161.3(of)-145.4(fo)13.9(l)13.9(a)0(t)12.8(e)-166.2(co)20.8(en)15.1(zy)20.8(me)12(s)-167([)0(1)19.6(])0(.)-179.1(Initially)-185.8(used)-181.1(as)-179.5(an)-178.3(anti-)]TJ 0 -1.0528 TD [(neopla)-7.8(stic)-293.9(drug,)-289.6(MT)-7.6(X)-289.2(has)-288.4(b)-6.5(een)-287.6(show)-8.2(n)-285.3(t)0(o)-294.1(b)0(e)-292.2(a)0(n)-286.5(effective)]TJ 0 -1.0471 TD [(anti-inf)-11.1(lammat)-10.7(ory)-237.2(agent,)-240.7(and)-241.7(is)-238.4(now)-239.5(widely)-241.3(used)-243.7(for)-238.8(non-)]TJ 0 -1.0527 TD [(neopla)-7.8(stic)-128.9(infl)-9.4(ammator)-10.7(y)-126(condition)-8.7(s)-127.1(incl)-8.2(uding)-131.4(psoriasis)-136.7([2],)]TJ 0 -1.0471 TD [(primary)-213.6(biliary)-213.6(cirr)-9(hosis)-207.7([3],)-210.7(inflammato)-12.1(ry)-208(bowe)-7.4(l)-202.3(disea)-8.2(ses)]TJ 0 -1.0527 TD [([4])-335.5(and,)-338.8(most)-339.8(commonl)-8.7(y)61.8(,)-336.1(rheumatoi)-11.5(d)-330.8(arthr)-9.8(itis)-335.7(\(RA\))-339.2([5].)]TJ 1.0015 -1.0527 TD [(Pn)16.3(eu)20.8(mo)12.4(ni)18.9(ti)16.5(s)-218.2(i)0(s)-215.6(a)-223.1(se)19.6(ri)17.3(ou)21.2(s)-223.9(a)0(n)15.1(d)-217(un)15.5(pr)19.6(ed)15.1(ic)18.4(ta)18.4(bl)13.2(e)-217.4(s)0(i)17.7(d)0(e)15.1(-)0(e)19.2(f)20.4(fe)13.5(ct)-214.9(of)]TJ -1.0015 -1.0471 TD [(tr)17.3(ea)14.7(tm)21.4(en)15.1(t)-549.4(w)0(i)14.9(t)0(h)-538.8(M)0(T)15.2(X)-551([6)19.6(],)-560.4(the)-562.8(preval)-9.4(ence)-561.9(of)-560.8(which)-562.5(is)]TJ 0 -1.0527 TD [(report)-10.6(ed)-297.8(to)-299.8(be)-297.8(0.3\2617.5%)-309.3([7].)-301.8(Since)-302.1(its)-298.5(firs)-9.8(t)-299.1(descripti)-11.9(on)-297.4(in)]TJ 0 -1.0471 TD [(1969)-355.9([8],)]TJ /F7 1 Tf 4.1086 0 TD (>)Tj /F6 1 Tf 0.552 0 TD [(120)-355.1(cases)-360.2(have)-356.7(b)-6.5(een)-355.9(reported)-359.6(in)-356.7(the)-357.9(Englis)-9(h)]TJ -4.6606 -1.0527 TD [(langua)-7.8(ge)-280.8(literat)-11.6(ure.)-283.5(The)-285.7(clin)-8.2(ical)-287.5(features)-287.2([6])-290(and)-281.5(risk)-287.1(fac-)]TJ 0 -1.0471 TD [(tors)-281.4(for)-278.6(MTX)-279.7(pneum)-7.4(onitis,)-280.7(especi)-9.4(ally)-275.7(in)-277.1(RA)-283.3(patients)-282.7([9],)]TJ 0 -1.0528 TD [(have)-356.7(been)-356.7(report)-10.6(ed)-354.7(recent)-9.8(ly)64.4(.)-353.2(Lun)-6.4(g)-353.6(biops)-7.4(y)-353.6(has)-356.7(been)-356.7(per-)]TJ 0 -1.0471 TD [(forme)-10.6(d)-313.7(i)0(n)-316.9(a)-314.2(min)-7.8(ority)-323.2(of)-316.1(patients)-322.5(wi)-7.8(th)-316.9(MTX)-319.6(pneum)-7.4(onitis)]TJ 0 -1.0528 TD [(and)-287.2(has)-282.7(demon)-7.4(strated)-286.8(inte)-8.2(rstitial)-288.7(infl)-9.4(ammation)-291.1(and)-281.5(fibr)-8.6(o-)]TJ 0 -1.0471 TD [(sis,)-274.9(non-nec)-7.7(rotizing)-282.7(granulomas)-11.1(,)-273.5(giant)-276.4(cells,)-272.7(tis)-8.2(sue)-271.3(eosin)-7.8(-)]TJ 0 -1.0527 TD [(ophils,)-534.4(type)-529.4(II)-522.6(pne)-8.4(umocyte)-529.5(hyperpl)-9.7(asia)-531(and)-526.2(incre)-8.6(ased)]TJ 0 -1.0471 TD [(intra-al)-11.5(veolar)-225.6(macrophages)-226.5([10\26113])-8.5(.)-216.6(Many)-221.7(o)-6.5(f)-212.9(the)-221.3(descri)-10.6(p-)]TJ 0 -1.0527 TD [(tions)-339.8(have)-333.9(b)-6.5(een)-333.2(brief)-9.8(,)-330.4(with)-341.8(few)-338.3(details.)]TJ 1.0015 -1.0471 TD [(He)16.9(re)-305.1(th)18.9(e)-314.2(c)0(l)18.5(i)0(n)18.9(i)0(c)12.8(a)0(l)-300.2(a)0(n)15.1(d)-313.7(hi)18.9(st)17.7(op)21.2(at)12.8(ho)21.2(lo)18.9(gi)13.2(ca)20.4(l)-310.4(f)0(e)13.5(a)0(t)18.4(u)0(r)19.6(e)0(s)-304.7(o)0(f)-304.7(l)0(u)18.9(n)0(g)]TJ -1.0015 -1.0528 TD [(bi)18.9(op)15.5(sy)-173.4(sp)14.4(ec)20.4(im)15.7(en)15.1(s)-184.1(f)0(r)18(o)0(m)-181.1(p)0(a)20.8(t)0(i)16.5(e)0(n)15.1(t)0(s)-175.8(w)0(i)14.9(t)0(h)-174.6(p)0(r)13.9(e)0(s)19.6(u)0(m)18.1(e)0(d)-178.3(M)0(T)15.2(X)-186.8(pn)21.2(eu)15.1(-)]TJ 0 -1.0471 TD [(mo)18.1(ni)18.9(ti)16.5(s)-411.7(a)0(r)13.5(e)-410.9(pr)19.6(es)19.6(en)15.1(te)18.4(d)-410.5(a)0(n)15.1(d)-410.5(th)18.9(e)-410.9(l)0(i)16.5(t)0(e)18.4(r)0(a)19.2(t)0(u)18.9(r)0(e)-407.6(o)0(n)-399.9(t)0(h)18.9(i)0(s)-403.4(p)0(r)19.6(o)0(b)15.5(l)0(e)18.4(m)]TJ 0 -1.0528 TD [(re)19.2(vi)13.2(ew)16.9(ed)20.8(.)]TJ /F5 1 Tf 6.436 -2.3786 TD [(Ma)-8.4(terials)-338.1(and)-336.5(methods)]TJ /F6 1 Tf -5.4345 -1.9519 TD [(Th)17.1(e)-228.8(c)0(o)15.1(n)0(s)20(u)0(l)13.2(t)13.9(at)12.8(io)18.9(n)-228.4(a)0(n)15.1(d)-228.4(te)18.4(ac)14.7(hi)18.9(ng)-223.5(fi)17.3(le)18.4(s)-229.6(o)0(f)-225.1(o)0(n)21.2(e)-234.5(of)-219.4(th)18.9(e)-234.5(a)0(u)20.8(t)0(h)18.9(o)0(r)13.9(s)]TJ -1.0015 -1.0471 TD [(\(T)89.5(.V)142.9(.)-273.5(C)11.6(ol)18.9(by)15.5(\))-275.5(w)12.4(er)13.5(e)-268.6(s)0(e)13.9(a)0(r)19.2(c)0(h)15.1(e)0(d)-263.7(f)0(o)19.6(r)-275.5(ca)20.4(se)13.9(s)-269.4(i)0(n)-265.7(w)0(h)17.3(i)0(c)18.4(h)-273.9(a)-268.6(d)0(i)13.2(a)0(g)20.8(n)0(o)15.5(s)0(i)17.7(s)]TJ 25.1977 30.581 TD [(of)-287.7(MT)20.8(X-)15.7(in)18.9(du)15.5(ce)14.7(d)-291(l)0(u)18.9(n)0(g)-280.4(t)0(o)18.9(x)0(i)13.2(c)0(i)18.5(t)0(y)-282.7(h)0(a)20.8(d)-296.7(be)20.8(en)-286.5(su)20(gg)21.2(es)13.9(te)18.4(d)-291(d)0(u)15.5(r)0(i)17.3(n)0(g)]TJ 0 -1.0755 TD [(th)13.2(e)-319.8(p)0(e)15.1(r)0(i)17.3(o)0(d)-314.5(J)0(a)19.6(n)0(u)15.5(a)0(r)19.2(y)-325.1(1,)-314.1(19)15.5(87)21.2(\261J)14.3(un)21.2(e)-325.5(3)0(0)15.5(,)-319.1(19)15.5(98)15.5(.)]TJ 1.0015 -1.0528 TD [(Ca)16.1(se)14(s)-314.9(w)0(e)11.2(r)0(e)-305.1(s)0(e)13.9(l)0(e)18.4(c)0(t)18.4(e)0(d)-309.2(o)0(n)-314.5(t)0(h)18.9(e)-319.8(ba)20.8(si)17.7(s)-320.6(o)0(f)-310.4(t)0(h)18.9(e)-319.8(cl)18.5(in)18.9(ic)12.8(al)-305.9(hi)13.2(st)17.7(or)19.6(y)]TJ -1.0015 -1.0755 TD [(me)12(et)18.5(in)18.8(g)-222.7(t)0(h)18.8(e)-223.1(cr)19.2(it)16.5(er)19.2(ia)-214.9(ou)21.2(tl)16.5(in)18.8(ed)-212.5(in)-214.5(ta)18.4(bl)18.8(e)-223.1(1)-222.7([9,)-231.1(14\26116].)-234.2(Su)-6.4(rgi)10.8(cal)]TJ T* [(lung)-529(biops)-7.4(y)-524.3(was)-525.7(required)-530.3(for)-529(inclusio)-9.1(n)-524.3(i)0(n)-521.8(this)-526.8(study)55.2(.)]TJ T* [(Clini)-10(cal)-557.5(findings,)-566(chest)-560.2(radiographi)-11.5(c)-558.8(features,)-560.7(thera)-8.6(py)]TJ 0 -1.0698 TD [(param)-9.4(eters)-624.4(and)-623(follo)-10.2(w-up)-623.2(informat)-11.9(ion)-619.3(wer)-8.2(e)-615.7(o)-6.5(btained)]TJ 0 -1.0755 TD [(from)-339.4(the)-340.8(referring)-340.8(phy)-8(sicians)-337.7(and)-338.4(the)-335.1(medi)-9(cal)-335.5(record)-8.6(s.)]TJ 1.0015 -1.0528 TD [(Ha)11.2(em)17.7(at)18.5(ox)15.5(yl)18.9(in)-453.5(an)15.1(d)-461.7(e)0(o)15.1(s)0(i)17.7(n)0(-)19.6(s)0(t)17.7(a)0(i)18.5(n)0(e)15.1(d)-461.7(se)14(ct)18.4(io)18.9(ns)-458(w)12.4(e)0(r)13.5(e)-462.1(ev)15.1(al)18.5(u-)]TJ -1.0015 -1.0755 TD [(at)12.8(ed)-320.6(fo)19.6(r)-332.4(t)0(h)18.9(e)-331.2(pr)19.6(es)19.6(en)15.1(ce)-321(an)15.1(d)-325.1(e)0(x)15.1(t)0(e)18.4(n)0(t)-322.6(o)0(f)-321.8(e)0(a)20.4(c)0(h)-326.3(o)0(f)-316.1(t)0(h)13.2(e)-325.5(fo)14(ll)16.5(ow)17.3(in)18.8(g)]TJ T* [(fe)13.5(at)18.4(ur)19.6(es)-350.3(on)-354.3(a)-359.7(s)0(c)19.6(a)0(l)18.5(e)-359.7(of)-350.2(0)-359.3(\()0(n)13.9(o)0(n)21.2(e)0(\))-350.6(t)0(o)-351(3)-359.3(\(w)15.7(id)18.8(es)13.9(pr)19.6(ea)14.7(d/)18.9(se)19.6(ve)15.1(re)19.2(\):)]TJ T* [(in)13.2(te)18.4(r)20.4(-)0(s)18.4(t)0(i)16.5(t)0(i)16.5(a)0(l)-305.9(i)0(n)18.8(f)0(l)17.3(a)0(m)12(m)0(a)17.7(t)0(i)16.5(o)0(n)21.2(,)-313.4(in)13.2(te)18.4(rs)18.4(ti)16.5(ti)16.5(al)-305.9(fi)17.3(br)19.6(os)14.4(is)17.7(,)-313.4(h)0(o)15.5(n)0(e)20.8(y)0(c)15.1(o)0(m)18.1(b)0(-)]TJ T* [(in)13.2(g,)-211.7(br)19.6(on)15.5(ch)20.8(io)18.9(li)16.5(ti)16.5(s)-223.9(o)0(b)21.2(l)0(i)16.5(t)0(e)18.4(r)0(a)13.5(n)0(s)20(-)0(o)19.6(r)14.7(ga)20.8(ni)18.9(zi)12.8(ng)-212.1(pn)21.2(eu)15.1(mo)18.1(ni)18.9(a)-223.1(p)0(a)15.1(t)13.9(te)12.8(rn)19.6(,)]TJ 0 -1.0698 TD [(in)13.2(tr)17.3(a-)19.2(al)18.4(ve)15.1(ol)18.8(ar)-282.4(ma)17.7(cr)19.2(op)15.5(ha)15.1(ge)-280.8(ac)20.4(cu)15.1(mu)18.1(la)18.4(ti)16.5(on)15.5(,)-284.9(f)0(o)13.9(a)0(m)17.7(y)-291(ma)17.7(cr)19.2(op)15.5(h-)]TJ 0 -1.0755 TD [(ag)15.1(e)-217.4(a)0(c)20.4(c)0(u)15.1(m)0(u)18.1(l)0(a)18.4(t)0(i)16.5(o)0(n)21.2(,)-216.6(hy)15.5(al)18.4(in)18.9(e)-217.4(m)0(e)17.7(m)0(b)18.1(r)0(a)19.2(n)0(e)15.1(s)0(,)-207.2(t)0(y)18.8(p)0(e)-206.8(I)0(I)-203.9(p)0(n)15.5(e)0(u)20.8(m)0(o)12.4(c)0(y)20.8(t)0(e)]TJ T* [(hy)15.5(pe)15.1(rp)19.6(la)18.4(si)17.7(a,)-251.9(t)13.9(i)0(s)12(s)0(u)20(e)-257.2(eo)15.1(si)17.7(no)21.2(ph)15.5(il)16.5(s,)-247(pe)20.8(ri)17.3(va)15.1(sc)19.6(ul)13.2(ar)-248.2(in)18.9(fl)17.3(am)17.7(ma)12(ti)22.2(on)15.5(,)]TJ T* [(pe)15.1(ri)17.3(br)19.6(on)15.5(ch)20.8(ia)12.8(l)-151.1(i)0(n)18.8(f)0(l)17.3(a)0(m)12(m)0(a)17.7(t)0(i)16.5(o)0(n)21.2(,)-154(co)15.1(ns)20(tr)17.3(ic)18.4(ti)16.5(ve)-144.2(br)13.9(on)21.2(ch)15.1(io)18.8(li)16.5(ti)16.5(s,)-138.9(al)12.8(ve)20.8(-)]TJ T* [(ol)13.2(ar)-373.4(ep)20.8(it)16.5(he)15.1(li)16.5(al)-368.5(ce)14.7(ll)-376.2(at)18.5(yp)21.2(ia)12.8(,)-381.7(b)0(r)19.6(o)0(n)15.5(c)0(h)20.8(i)0(a)18.5(l)-384.4(ep)15.1(i)13.9(t)0(h)13.2(e)0(l)18.4(i)0(a)18.5(l)-384.4(at)18.4(yp)15.5(i)13.9(a)-382.4(an)15.1(d)]TJ T* [(gr)13.9(an)20.8(ul)13.2(om)18.1(as)19.6(.)-404.4(T)0(h)17.1(e)-410.9(re)19.2(su)20(lt)16.5(s)-406(o)0(f)-401.5(s)0(p)20(e)0(c)14.7(i)13.9(fi)17.3(c)-410.9(s)0(t)17.7(a)0(i)18.5(n)0(s)-395.4(f)0(o)13.9(r)-406.4(or)31(ga)15.1(ni)18.8(sm)16.9(s)]TJ ET 309.316 180.397 237.09 -0.51 re f 309.316 135.553 237.09 -0.51 re f BT /F2 1 Tf 8.966 0 0 8.966 309.316 198.709 Tm [(Table)-338.2(1.)-330.4(\261)-333.2(Diagnostic)-769.2(criteria)-762.4(for)-768.8(methotrexate)-760.9(\(MTX\))]TJ 0 -1.0559 TD (pneumonitis)Tj /F6 1 Tf 0 -2.3774 TD [(Exposure)-336.5(to)-336.5(MTX)-328.4(preceding)-339.5(the)-335.8(onset)-329.6(of)-335.1(pulmonary)-335.5(symptoms)]TJ 0 -1.0559 TD [(Exclusion)-339.7(of)-328.7(infection)-338.2(or)-335.1(alternative)-339.1(pulmonary)-335.5(disease)]TJ T* [(Lung)-336.6(pathology)-335.1(consistent)-332.8(with)-334.8(drug-induced)-339.2(lung)-329.2(toxicity)]TJ T* [(New)-340(or)-328.7(evolving)-335.6(infiltrates)-337.8(on)-334.1(chest)-335.7(radiographs)]TJ 0 -1.9411 TD [(All)-790.6(of)-784(the)-784.7(above)]TJ /F7 1 Tf 8.0174 0 TD (=)Tj /F6 1 Tf 0.5501 0 TD [(probable)-789.2(MTX)-783.7(pneumonitis;)-784(the)-784.7(first)]TJ -8.5675 -1.0559 TD (three)Tj /F7 1 Tf 1.9727 0 TD (=)Tj /F6 1 Tf 0.5501 0 TD [(possible)-338(MTX)-328.4(pneumonitis.)-336.1([9,)-338(14\26116].)]TJ ET 1 g 536.485 185.839 13.436 -10.091 re f* 536.485 144 13.436 -13.606 re f* BT /F2 1 Tf 6.974 0 0 6.974 58.28 797.499 Tm 0 g 0.0001 Tc [(Eur)-334.8(Respir)-337.8(J)-337.2(2000;)-339.7(15:)-330.1(373\261381)]TJ 0 -1.1462 TD 0 Tc [(Printed)-341.4(i)0(n)-335.6(U)-0.1(K)-331.2(\261)-334.1(all)-337(rights)-335.9(r)0(e)-9.2(s)0(erved)]TJ 52.703 2.2844 TD 0.0001 Tc (Copyright)Tj /F4 1 Tf 5.928 0 0 5.928 457.909 806.456 Tm 0 Tc (#)Tj /F2 1 Tf 6.974 0 0 6.974 463.805 805.436 Tm 0.0001 Tc [(ERS)-339.8(Journals)-337.8(L)0(td)-338.3(2000)]TJ -4.4305 -1.1381 TD [(European)-338.6(Res)-10.1(piratory)-336.9(Journal)]TJ 3.2843 -1.1462 TD [(ISSN)-335.2(0903-1936)]TJ ET endstream endobj 3 0 obj << /ProcSet [/PDF /Text ] /Font << /F1 4 0 R /F2 5 0 R /F3 6 0 R /F4 7 0 R /F5 8 0 R /F6 9 0 R /F7 10 0 R >> /ExtGState << /GS2 11 0 R >> >> endobj 14 0 obj << /Length 20006 >> stream BT /F6 1 Tf 9.963 0 0 9.963 58.28 771.647 Tm 0 g /GS2 gs 0 Tc [(\(G)15.7(om)18.1(or)13.9(i)]TJ /F8 1 Tf 3.3404 0 TD 0 Tw (')Tj /F6 1 Tf 0.2105 0 TD [(s)-212.5(m)0(e)12(t)13.9(he)15.1(na)15.1(mi)21.4(ne)-206.8(si)17.7(lv)18.9(er)-208.4(an)20.8(d/)18.9(or)-208(ac)20.4(id)18.9(-f)12.4(as)19.6(t)-213.7(s)0(t)17.7(a)0(i)18.4(n)0(s)20(\))-212.9(we)11.2(re)]TJ -3.5509 -1.0471 TD [(al)18.4(so)-315.7(re)19.2(co)15.1(rd)19.6(ed)15.1(.)]TJ 1.0015 -1.0528 TD [(En)17.1(gl)18.9(is)17.7(h)-518.6(l)0(a)18.4(n)0(g)15.5(u)0(a)15.1(g)0(e)-508.4(a)0(r)19.2(t)0(i)16.5(c)0(l)18.5(e)0(s)-509.6(d)0(a)15.1(t)0(i)16.5(n)0(g)-508(b)0(a)20.8(c)0(k)-514.1(t)0(o)-510.4(1)0(9)21.2(6)0(6)-508(w)0(e)11.2(r)0(e)]TJ -1.0015 -1.0471 TD [(se)19.6(ar)13.5(ch)20.8(ed)-275.1(in)13.2(it)16.5(i)13.9(a)0(l)12.8(l)0(y)-271.4(t)0(h)13.2(r)0(o)19.6(u)0(g)15.5(h)-279.6(ME)15.2(DL)13.2(IN)21.4(E)]TJ /F4 1 Tf 14.6702 0 TD (1)Tj /F6 1 Tf 1.2861 0 TD [(\(N)15.7(at)18.4(io)18.9(na)15.1(l)-282(L)0(i)14.7(b)0(r)19.6(a)0(r)13.5(y)]TJ -15.9563 -1.0528 TD [(of)-509.6(Me)13.2(di)18.9(ci)18.5(ne)15.1(,)-518.2(B)0(e)16.1(t)0(h)18.9(e)0(s)19.6(d)0(a)15.1(,)-518.2(MD)15.3(,)-518.2(U)0(S)12.4(A)12.4(\))-520.2(us)14.4(in)18.9(g)-518.6(t)0(h)13.2(e)-519(Me)18.9(di)18.9(ca)14.7(l)]TJ 0 -1.0471 TD [(S)11.4(u)0(b)15.5(j)0(e)18.4(c)0(t)-414(H)0(e)16.9(a)0(d)15.1(i)13.9(ng)15.5(s)-423.1(k)0(e)20.8(y)0(w)17.3(o)0(r)14(d)0(s)-406.7(")0(m)15.1(e)0(t)18.4(h)0(o)15.5(t)0(r)17.3(e)0(x)20.8(a)0(t)12.8(e)0(")17.9(,)-415.8("p)18.3(ne)15.1(um)18.1(on)15.5(i-)]TJ 0 -1.0528 TD [(ti)16.5(s")-278.8(an)20.8(d)-285.3(")0(l)15.9(u)0(n)15.5(g)-285.3(to)18.9(xi)18.9(ci)12.8(t)13.9(y)0(")12.6(.)-284.9(Ma)18.9(nu)15.5(al)-277.5(se)19.6(ar)13.5(ch)20.8(es)-276.3(of)-282(ot)18.9(he)20.8(r)-286.9(E)0(n)17.1(g)0(l)13.2(i)0(s)17.7(h)]TJ 0 -1.0471 TD [(la)18.4(ng)15.5(ua)20.8(ge)-394.6(li)16.5(te)18.4(ra)19.2(tu)13.2(re)-390.5(da)20.8(ta)12.8(ba)20.8(se)13.9(s)-400.3(w)12.4(er)13.5(e)-399.5(a)0(l)18.4(s)0(o)-395.4(p)0(e)20.8(r)0(f)18(o)0(r)14(m)0(e)17.7(d)0(.)-393.8(O)12.4(nl)13.2(y)]TJ 0 -1.0527 TD [(li)16.5(te)18.4(ra)19.2(tu)13.2(re)-345(ca)14.7(se)19.6(s)-360.5(w)12.4(it)16.5(h)-359.3(d)0(e)20.8(t)0(a)12.8(i)0(l)16.5(e)0(d)-343.4(c)0(l)12.8(i)0(n)18.9(i)0(c)18.4(a)0(l)-351.4(s)0(u)20(m)0(m)14.9(a)0(r)19.2(i)0(e)18.4(s)-360.5(we)16.9(re)-350.7(in)18.9(-)]TJ T* [(cl)18.4(ud)15.5(ed)-576.7(in)-578.7(th)18.9(is)-579.8(re)19.2(vi)18.9(ew)79.5(.)-586.5(P)0(e)15.9(r)0(t)17.3(i)0(n)18.9(e)0(n)15.1(t)-589.3(cl)18.4(in)18.9(ic)18.4(al)18.5(,)-586.5(r)0(a)13.5(d)0(i)18.9(o)0(g)21.2(r)0(a)13.5(p)0(h)21.2(i)0(c)12.8(,)]TJ 0 -1.0471 TD [(la)18.4(bo)15.5(ra)19.2(to)18.9(ry)-316.1(an)15.1(d)-325.1(h)0(i)18.9(s)0(t)17.7(o)0(l)18.9(o)0(g)15.5(i)0(c)18.4(a)0(l)-317.3(d)0(a)20.8(t)0(a)-317.3(w)0(e)16.9(r)0(e)-316.5(a)0(b)20.8(s)0(t)17.7(r)0(a)13.5(c)0(t)18.4(e)0(d)15.1(.)]TJ /F3 1 Tf 0 -2.5608 TD [(Litera)-10.1(tur)28.3(e)-331.2(r)26.5(eview)]TJ /F6 1 Tf 1.0015 -1.5478 TD [(Th)17.1(er)19.2(e)-484.9(h)0(a)15.1(v)0(e)-474.3(b)0(e)20.8(e)0(n)-474.2(a)0(p)15.1(p)0(r)19.6(o)0(x)15.5(i)0(m)15.7(a)0(t)18.4(e)0(l)18.4(y)-484.5(12)21.2(3)-484.5(c)0(a)14.7(s)0(e)19.6(s)-480(of)-475.4(MT)15.2(X-)]TJ -1.0015 -1.0471 TD [(in)18.9(du)15.5(ce)20.4(d)-302.4(p)0(n)15.5(e)0(u)20.8(m)0(o)12.4(n)0(i)18.9(t)0(i)16.5(s)-297.9(re)13.5(po)21.2(rt)17.3(ed)-297.8(i)13.9(n)-302.4(th)13.2(e)-297.1(E)0(n)17.1(g)0(l)13.2(i)0(s)17.7(h)-302.4(l)13.9(a)0(n)15.1(g)0(u)15.5(a)0(g)20.8(e)-302.8(li)16.5(t-)]TJ 0 -1.0528 TD [(er)19.2(at)12.8(ur)19.6(e)-416.6(\()0(t)17.3(a)0(b)20.8(l)0(e)-408.3(2\2616\))-420.1([8,)-424.6(10)-7.2(,)-421.5(14,)-428.7(15,)-423(17)-7.2(\26171].)-426.1(The)-6.8(se)-424.2(com-)]TJ 0 -1.0471 TD [(prised)-243.5(47)-240.5(\(38.2%)-8.2(\))-235.7(mal)-8.2(es)-236.4(and)-241.7(76)-240.5(\(61.8%)-8.2(\))-235.7(fema)-8.6(les)-239.6(of)-242.1(mean)]TJ 0 -1.0528 TD [(age)-384.4(49.3)-383.9(yrs)-380.7(\(range)-389.8(3\26179)-384.3(yrs\).)-383.4(The)-382.4(lung)-386.7(was)-383.4(exami)-10.1(ned)]TJ 0 -1.0471 TD [(histolog)-8.7(ical)-8.6(ly)-220.2(in)-220.2(49)-217.8(cases)-229.3([8,)-219.7(10,)-218.1(14,)-223.8(17\26149]:)-225.6(surgical)-219.3(lung)]TJ 0 -1.0527 TD [(biops)-7.4(y)-353.6(i)0(n)-351(2)0(2)-354.3([8,)-356.3(10,)-354.7(14,)-354.7(17\26128],)-359.4(transbronch)-10.3(ial)-354.6(lung)-358.2(bi-)]TJ T* [(opsy)-300.2(in)-294.1(14)-297.4([29\26140])-304.4(and)-298.6(percut)-9.4(aneous)-302.5(lung)-295.7(biops)-7.4(y)-296.7(i)0(n)-299.8(one)]TJ 0 -1.0471 TD ([41].)Tj /F3 1 Tf 2.2819 0 TD [(Post)-386.3(mortem)]TJ /F6 1 Tf 5.5654 0 TD [(histolog)-8.7(ical)-384.2(ex)-7.6(amination)-393.5(was)-383.4(carri)-10.2(ed)]TJ -7.8473 -1.0527 TD [(out)-454.2(in)-447.8(15)-451.1([25,)-453.8(26,)-451.5(29,)-445.8(30,)-451.5(42\26148],)-456.1(four)-455.8(of)-447(whom)-459.7(had)]TJ 0 -1.0471 TD [(undergone)-441.7(previ)-8.2(ous)-447.3(lung)-443.6(biops)-7.4(y)-444.6([25,)-448.1(26,)-440.1(29)-7.2(,)-438.6(30].)-448.1(The)]TJ 0 -1.0527 TD [(metho)-9.7(d)-330.8(o)0(f)-333.2(b)-6.5(iopsy)-337.4(was)-337.9(not)-334.7(described)-343.3(in)-334(one)-338.4(case)-335.5([49].)]TJ 1.0015 -1.0471 TD [(Th)17.1(e)-154.8(b)0(a)15.1(c)0(k)20.8(g)0(r)13.9(o)0(u)21.2(n)0(d)-149.5(i)13.9(ll)16.5(ne)15.1(ss)18.9(es)-145.4(fo)13.9(r)-156(w)12.4(hi)13.2(ch)-144.2(MT)15.2(X)-152.7(h)0(a)15.1(d)-154.4(be)20.8(en)-149.9(gi)18.9(ve)15.1(n)]TJ -1.0015 -1.0527 TD [(in)18.9(cl)18.4(ud)15.5(ed)-337.7(RA)18.3(,)-347.5(l)0(e)18.4(u)0(k)15.5(a)0(e)14.7(m)13.2(ia)-340.1(\(i)17.3(n)-347.9(r)0(e)19.2(m)0(i)15.7(s)0(s)18.9(i)0(o)13.2(n)0(\))19.6(,)-347.5(ca)20.4(nc)15.1(er)47.7(,)-347.5(p)0(s)20(o)0(r)19.6(i)0(a)18.4(s)0(i)12(s)0(,)]TJ 0 -1.0471 TD [(pr)19.6(im)15.7(ar)13.5(y)-228.4(b)0(i)18.9(l)0(i)16.5(a)0(r)13.5(y)-228.4(ci)18.5(rr)12.4(ho)21.2(si)17.7(s,)-224.3(ly)18.9(mp)18.1(ho)15.5(ma)17.7(,)-233.7(p)0(o)21.2(l)0(y)13.2(m)0(y)18.1(o)0(s)20(i)0(t)16.5(i)0(s)17.7(,)-233.7(ec)20.4(to)18.9(pi)13.2(c)]TJ 0 -1.0527 TD [(pr)19.6(eg)15.1(na)15.1(nc)20.8(y)73.2(,)-125.6(as)13.9(th)18.9(ma)17.7(,)-125.6(m)0(y)18.1(c)0(o)15.1(s)0(i)17.7(s)-121.5(fu)13.9(ng)21.2(oi)13.2(de)20.8(s,)-116.1(pe)15.1(mp)18.1(hi)18.9(gu)15.5(s)-121.5(v)0(u)15.5(l)0(g)18.9(a)0(r)13.5(i)0(s)17.7(,)]TJ 0 -1.0471 TD [(me)17.7(du)15.5(ll)16.5(ob)21.2(la)18.4(st)17.7(om)12.4(a,)-200.7(po)21.2(ly)13.2(ar)19.2(ti)16.5(cu)20.8(la)12.8(r)-207.2(j)0(u)13.2(v)0(e)20.8(n)0(i)18.9(l)0(e)-203.5(R)0(A)12.6(,)-205.2(ps)14.4(or)19.6(ia)18.4(ti)16.5(c)-211.7(a)0(r)13.5(t)0(h)18.9(-)]TJ 0 -1.0528 TD [(ri)17.3(ti)16.5(s)-343.4(a)0(n)20.8(d)-342.2(ch)15.1(ro)19.6(ni)18.9(c)-342.6(o)0(b)15.5(s)0(t)17.7(r)0(u)19.6(c)0(t)12.8(i)13.9(ve)-337.7(pu)21.2(lm)15.7(on)15.5(ar)19.2(y)-342.2(d)0(i)18.9(s)0(e)13.9(a)0(s)19.6(e)-342.6(\(t)17.3(ab)15.1(le)-334.4(2\).)]TJ 0 -1.0471 TD [(The)-416.5(doses)-416.3(of)-412.8(MTX)-410.6(among)-417.1(the)-414.8(cases)-417.1(ranged)-416.7(2.5\2611)-9.1(,400)]TJ 0 -1.0528 TD (mg)Tj /F9 1 Tf 1.2747 0.1992 TD (.)Tj /F6 1 Tf 0.2675 -0.1992 TD (week)Tj 7.472 0 0 6.641 94.564 431.773 Tm (-1)Tj 9.963 0 0 9.963 104.485 427.351 Tm [(\(table)-381.6(2\).)-379.1(Fo)-6.4(rty-seven)-384.3(\(38.2%)-8.2(\))-377.9(patients)-385.1(wer)-8.2(e)]TJ -4.6378 -1.0471 TD [(treated)-297.4(with)-290.6(MTX)-291.1(only)57.2(.)-284.9(Con)-7(comitant)-296(drugs)-291.1(adminis)-9.1(tered)]TJ 0 -1.0528 TD [(with)-262.1(MTX)-257(includ)-9.7(ed)-252.3(anti)-8.2(neoplasti)-10.3(c)-251.6(agents)-265([19,)-254.7(24,)-258(25,)-258(30,)]TJ 0 -1.0471 TD [(35,)-411.6(44,)-411.6(45,)-411.6(48,)-411.6(53,)-411.6(54],)-414(nonst)-7.4(eroidal)-416.5(anti-inf)-11.1(lammat)-10.7(ory)]TJ 0 -1.0527 TD [(drugs)-336.7(\(NSA)-11.7(IDs\))-335.7([14,)-340(17,)-337.6(20,)-332(21,)-337.7(23,)-337.7(27,)-332(28)-7.2(,)-330.4(31,)-337.6(33,)-337.7(36,)]TJ 0 -1.0471 TD [(41,)-275.1(57,)-269.4(59,)-275.1(60,)-269.4(63,)-275.1(66,)-269.4(6)-6.5(8)0(,)-268.6(69])-271.3(an)-7.6(d)-268.2(other)-8.2(s)-269.4([10,)-271.7(15)-7.2(,)-267.8(17,)-275.1(22,)]TJ 0 -1.0527 TD [(27,)-263.7(32,)-263.7(34,)-269.4(37,)-263.7(38,)-263.7(42,)-263.7(46,)-263.7(49,)-263.7(59)-7.2(\26161,)-264.4(65,)-263.7(67,)-263.7(69].)-266(Thirt)-8.6(y-)]TJ 25.1977 40.8581 TD [(nine)-142.4(pati)-8.2(ents)-137.9(recei)-9(ved)-139.3(syst)-7.8(emic)-140.3(corticost)-11.9(eroid)-8.2(s)-138.5(\(prednisone)]TJ 0 -1.0755 TD [(5\2615)-8(0)-234.1(m)0(g)]TJ /F9 1 Tf 3.5111 0.1992 TD (.)Tj /F6 1 Tf 0.2731 -0.1992 TD (day)Tj 7.472 0 0 6.641 361.361 765.354 Tm (-1)Tj 9.963 0 0 9.963 367.54 760.932 Tm [(,)-233.7(o)0(r)-236.4(met)-8.2(hylprednis)-9.9(olone)-239.9(4)-234.1(m)0(g)]TJ /F9 1 Tf 11.677 0.1992 TD (.)Tj /F6 1 Tf 0.5065 -0.1992 TD (day)Tj 7.472 0 0 6.641 503.263 765.354 Tm (-1)Tj 9.963 0 0 9.963 509.386 760.932 Tm [(;)-236.5(doses)]TJ -20.0819 -1.0755 TD [(wer)-8.2(e)-285.7(not)-289.2(described)-292.1(in)-288.4(five\))-294.3(during)-287.4(MT)-7.6(X)-283.5(thera)-8.6(py)-286.1([10,)-288.8(14,)]TJ T* [(15,)-184(17,)-184(19,)-178.3(20,)-184(22\26124,)-186.3(27,)-178.3(32,)-184(34,)-178.3(35,)-184(37,)-184(42,)-178.3(45,)-184(49,)-178.3(59,)-184(61,)]TJ T* [(65,)-337.7(66,)-337.7(69].)]TJ 1.0015 -1.0471 TD [(MT)15.2(X)-238(p)0(n)15.5(e)0(u)20.8(m)0(o)12.4(n)0(i)18.9(t)0(i)16.5(s)-235.3(us)14.4(ua)20.8(ll)16.5(y)-239.8(d)0(e)20.8(v)0(e)15.1(l)0(o)18.9(p)0(e)20.8(d)-239.8(du)15.5(ri)17.3(ng)-229.2(MT)20.9(X)-238(t)0(h)13.2(e)0(r)30.6(-)]TJ -1.0015 -1.0755 TD [(ap)15.1(y)73.2(,)-284.9(bu)21.2(t)-287.7(a)-280(de)15.1(la)18.4(ye)20.8(d)-285.3(t)0(y)18.8(p)0(e)-275.1(o)0(c)15.1(c)0(u)20.8(r)0(r)18(i)0(n)18.9(g)-285.3(1\261)15.5(4)-279.6(w)0(e)16.9(e)0(k)15.1(s)-280.8(af)19.2(te)12.8(r)-281.2(d)0(i)18.9(s)0(c)13.9(o)0(n)21.2(-)]TJ T* [(ti)16.5(nu)15.5(at)18.4(io)18.9(n)-279.6(o)0(f)-270.6(t)0(h)18.8(e)-280(dr)13.9(ug)-269(wa)16.9(s)-280.8(a)0(l)18.4(s)0(o)-270.2(r)0(e)19.2(p)0(o)15.5(r)0(t)17.3(e)0(d)-269.4([)0(2)19.6(5)0(,)-280(36,)-292.1(57].)-294.5(Most)]TJ T* [(pati)-8.2(ents)-433.8(wi)-7.8(th)-430.7(MT)-7.6(X)-431.5(pneum)-7.4(onitis)-439.7(showe)-9.3(d)-433.3(subacute)-437.7(type)]TJ T* [(wi)-7.8(th)-271.4(progre)-8.2(ssion)-276(over)-272.5(severa)-8.6(l)-276.3(weeks)-277.2([7,)-271(1)27.7(1],)-271(but)-277.8(an)-269.4(acute)]TJ T* [(type)-250.5(with)-250.7(rapid)-247.2(progre)-8.2(ssion)-247.6(over)-249.7(several)-250.7(days)-249.3([15,)-243.3(20,)-246.6(32,)]TJ T* [(51,)-292.1(59,)-292.1(70])-294.1(and)-292.9(a)-291.4(chroni)-9(c)-291.4(type)-296.1(presentation)-299.1(wi)-7.8(th)-288.4(a)-291.4(progr-)]TJ 0 -1.0698 TD [(essi)-8.2(on)-308.8(of)-304.7(severa)-8.6(l)-310.4(months)-312.9([45])-307.8(wer)-8.2(e)-308.5(also)-308.6(recogni)-10.1(zed.)-310.8(The)]TJ 0 -1.0755 TD [(most)-169.1(freque)-8.6(nt)-163.2(presen)-8.2(ting)-161.5(symp)-7.4(tom)-7.8(s)-161.3(were)-163(d)-6.5(yspnoea)-7.3(,)-159.7(cough)]TJ T* [(and)-327.1(fever)-332.2(\(table)-330.4(3\).)-327.9(T)63.4(achypnoe)-7.3(a)-325.5(and)-327.1(crackl)-9.8(es)-321.8(wer)-8.2(e)-319.8(often)]TJ T* [(presen)-8.2(t)-264.9(o)-6.5(n)-262.5(physi)-7.4(cal)-267.2(examin)-10.9(ation)-270.7(\(table)-267.8(3\).)-271(The)-268.6(peripheral)]TJ T* [(blood)-273.7(e)-6.9(osinophil)-277(count)-274.1(was)-275.3(elevated)-274.2(\()]TJ /F7 1 Tf 15.1426 0 TD (>)Tj /F6 1 Tf 0.5577 0 TD [(600)-269.7(cells)]TJ /F9 1 Tf 3.5737 0.1992 TD (.)Tj /F6 1 Tf 0.2731 -0.1992 TD (mm)Tj 7.472 0 0 6.641 519.42 604.97 Tm (-3)Tj 9.963 0 0 9.963 528.264 600.548 Tm (or)Tj -21.9769 -1.0755 TD [(6%)-237.2(of)-236.4(leukoc)-7.8(ytes\))-237(in)-231.5(25)-234.8(\(20.3%)-8.2(\).)-236.1(Bronchoal)-10.7(veolar)-237(lavage)]TJ T* [(\(B)-7.8(AL\))-250.9(flui)-9.4(d)-245.5(c)-6.9(ell)-252.1(analysis)-258.8(usual)-7.8(ly)-248.6(show)-8.2(ed)-252.3(hyperce)-8.1(llularity)]TJ T* [(and)-298.6(lympho)-10.1(cytosis)-297.4([37,)-300.2(40,)-292.1(49,)-297.8(58,)-292.1(65,)-297.8(72\26175],)-296.8(and)-298.6(mild)]TJ T* [(eosin)-7.8(ophil)-8.6(ia)-305.9([72])-313.5(or)-310.4(neutr)-8.2(ophilia)-314.5([27,)-311.6(38,)-309.2(4)-6.5(0)0(,)-308.4(49,)-309.2(65,)-309.2(75])]TJ T* [(wer)-8.2(e)-189(a)-6.9(lso)-193.6(reported.)-200.6(An)-193.2(incre)-8.6(ased)-192.8(percent)-10.5(age)-196.6(of)-190.9(eith)-8.2(er)-191.3(CD4)]TJ T* [(or)-338.9(CD8)-335.3(lym)-7.8(phocyt)-7.4(es)-333.2(were)-339.4(reported)-342.5([37,)-340(72\26175].)]TJ 1.0015 -1.0471 TD [(Co)16.5(nc)15.1(om)18.1(it)16.5(an)15.1(t)-190.9(s)0(i)17.7(d)0(e)20.8(-)0(e)13.5(f)20.4(fe)19.2(ct)12.8(s)-189.7(d)0(u)21.2(e)-194.6(to)-180.3(MT)15.2(X)-192.5(w)0(e)16.9(r)0(e)-185.6(p)0(r)19.6(e)0(s)13.9(e)0(n)20.8(t)-190.9(in)-186(32)]TJ -1.0015 -1.0755 TD [(ca)14.7(se)19.6(s)-201.1([)0(1)13.9(0)0(,)-200.3(14,)-212.5(15,)-212.5(22,)-212.5(29,)-212.5(30,)-206.8(37)-7.2(,)-205.2(39,)-212.5(40,)-212.5(42,)-212.5(43,)-212.5(45,)-212.5(48,)-212.5(50,)]TJ T* [(55\261)-8(57,)-229.5(60,)-229.5(61,)-229.5(63,)-229.5(67,)-229.5(68]:)-234.6(live)-8.2(r)-224.3(e)-6.9(nzyme)-229.7(elevat)-10.6(ion)-232.3(or)-230.8(liver)]TJ T* [(dysfun)-7.4(ctio)-8.2(n)-393.4(\(12)-396.5(cases\))-9.8(,)-393(oral)-400.1(ulcer)-401.2(\(six)-400.9(cases\))-9.8(,)-393(skin)-399.3(rash)]TJ T* [(\(six)-304.1(cases\),)-300.4(stom)-9.8(atitis)-300.2(\(three)-301.2(cases\))-9.8(,)-296.3(haema)-8.2(tological)-301.7(com-)]TJ T* [(plic)-8.2(ations)-420.7(such)-420.1(as)-412.8(pancyt)-7.8(openia)-423.2(or)-412.8(leukop)-7.4(enia)-421.6(or)-412.8(acute)]TJ 0 -1.0698 TD [(megal)-10.1(oblas)-7.8(tic)-303.4(anaem)-8.2(ia)-305.9(\(five)-305.7(cases\))-9.8(,)-302(hyperca)-8.1(lcaemia)-310.8(\(one)]TJ 0 -1.0755 TD [(case\);)-267(and)-258.8(convul)-7.4(sion)-262.7(\(one)-261.1(case\).)-264.3(The)-257.2(cumul)-9.7(ative)-259.8(dose)-260.7(of)]TJ T* [(these)-423.6(pati)-8.2(ents)-422.4(ranged)-422.4(42\2619,800)-421.1(mg.)-420.5(So)-6.4(me)-420.5(patients)-425(had)]TJ T* [(more)-343.9(than)-335.9(one)-332.7(e)-6.9(xtrapulm)-10.3(onary)-335.9(compl)-9.7(ication.)]TJ 1.0015 -1.0527 TD [(Pu)16.3(lm)15.7(on)15.5(ar)19.2(y)-279.6(f)0(u)19.6(n)0(c)20.8(t)0(i)16.5(o)0(n)-269(s)0(t)17.7(u)0(d)15.5(i)0(e)18.4(s)-275.1(we)16.9(re)-271(de)20.8(sc)13.9(ri)17.3(be)20.8(d)-279.6(i)0(n)-265.7(2)0(7)-269(c)0(a)14.7(s)0(e)19.6(s)0(.)]TJ -1.0015 -1.0755 TD [(Fo)16.3(ur)13.9(t)13.9(e)0(e)14.7(n)-319.4(of)-316.1(19)-314.5(pa)20.8(ti)16.5(en)15.1(ts)-312.4(in)-311.2(wh)11.6(om)-312(vi)18.9(ta)18.4(l)-327.5(c)0(a)20.4(p)0(a)15.1(c)0(i)18.5(t)0(y)-311.2(w)0(a)16.9(s)-326.3(me)17.7(a-)]TJ T* [(su)14.4(re)19.2(d)-251.2(s)0(h)20(o)0(w)17.3(e)0(d)-240.9(a)-245.9(re)13.5(st)17.7(ri)17.3(ct)18.4(iv)18.9(e)-251.6(v)0(e)20.8(n)0(t)18.9(i)0(l)16.5(a)0(t)18.4(o)0(r)13.9(y)-245.5(ab)15.1(no)21.2(rm)10.8(al)18.4(it)16.5(y)-245.5([)0(1)19.6(0)0(,)-251.5(27,)]TJ 0 -1.0698 TD [(29,)-292.1(36\26139,)-288.7(41,)-292.1(69,)-286.4(71])-288.4(and)-292.9(two)-287.4(of)-287.7(seven)-296(in)-288.4(whom)-289(forced)]TJ 0 -1.0755 TD [(exp)-8.4(iratory)-343.7(volum)-9.3(e)-336.9(i)0(n)-345.3(one)-344.1(second)-342.3(was)-343.6(meas)-8.2(ured)-340.8(show)-8.2(ed)]TJ T* [(an)-474.3(obstructi)-11.5(ve)-468.6(venti)-9(latory)-478(pattern)-473.4([10,)-476.6(36,)-468.5(39].)-476.6(All)-471.9(18)]TJ T* [(pati)-8.2(ents)-246(exami)-10.1(ned)-241.7(for)-250.2(dif)10.8(fusi)-8.2(ng)-240.5(ca)-8(pacity)-249.1(exhibited)-248.1(a)-245.9(decr-)]TJ T* [(eased)-279.4(single-br)-10.7(eath)-273.7(dif)10.8(fusi)-8.2(ng)-269(capaci)-8.6(ty)-271.4(for)-272.9(carbon)-274.4(monox)-7(-)]TJ T* [(ide)-261.2([10,)-266(15,)-258(27,)-258(37\261)-8(39,)-258(41,)-258(42,)-263.7(58,)-258(67,)-258(69].)-266(Arterial)-265.9(blood)]TJ T* [(gas)-407.9(analys)-9(is)-403.4(was)-406.2(report)-10.5(ed)-400.3(in)-407.9(77)-405.6(cases,)-406.1(and)-406.7(76)-405.6(of)-401.5(these)]TJ T* [(show)-8.2(ed)-292.1(hypoxaem)-10.1(ia)-294.5(\(3.5\26110.)-6.9(1)-291(k)0(P)-6.4(a)-291.4(\(26\26176)-296.4(mm)-7.8(Hg\)\))-294.7([10,)]TJ T* [(14,)-303.5(15,)-303.5(17)-7.2(,)-296.3(2)0(0)-7.2(,)-296.3(2)-6.5(1)0(,)-297.1(2)-6.5(3\26125,)-305(27\26129,)-305.8(31\26140,)-305.8(42,)-303.5(43,)-303.5(45\26147,)]TJ T* [(49,)-337.7(52,)-337.7(55,)-332(57\26159,)-339.9(61\26163,)-339.9(67\26169,)-334.2(70].)]TJ ET 1 i 58.28 329.386 227.168 -0.51 re f 58.28 294.009 227.168 -0.51 re f 58.28 145.077 227.168 -0.51 re f BT /F2 1 Tf 8.966 0 0 8.966 58.28 343.162 Tm [(Table)-331.9(2.)-336.7(\261)-333.2(Background)-449(diseases)-443(of)-444.2(methotrexate)-451.1(\(MTX\))]TJ 0 -1.0559 TD [(pneumonitis:)-331.9(literature)-338.9(review)]TJ /F6 1 Tf 12.14 -1.7072 TD [(T)60.2(otal)-723.3(Histological)]TJ 4.0783 -1.0559 TD (study)Tj -0.2719 -1.0559 TD (\(n)Tj /F7 1 Tf 0.822 0 TD (=)Tj /F6 1 Tf 0.5564 0 TD (49\))Tj 3.8001 2.1119 TD [(Dose)-337.3(of)]TJ 0.4995 -1.0559 TD (MTX)Tj -1.0243 -1.0559 TD (mg)Tj /F9 1 Tf 1.2709 0.2276 TD (.)Tj /F6 1 Tf 0.2719 -0.2276 TD (week)Tj 6.725 0 0 5.977 275.584 303.477 Tm (-1)Tj 8.966 0 0 8.966 58.28 281.537 Tm [(RA)-11432.5(62)-3147.8(24)-3305.9(2.5\26115)]TJ 0 -1.0559 TD [(Leukaemia)-337.4(\(in)-330.6(remission\))-2503.2(23)-3647.3(8)-3553(20\26180)]TJ T* [(Cancer)-337(\(breast,)-333.2(lung,)-332(other\))-1720.9(10)-3647.3(9)-3553(15\2611400)]TJ T* [(Psoriasis)-9809.9(8)-3647.8(2)-3306.4(2.5\26137.5)]TJ T* [(Primary)-336.1(biliary)-339.4(cirrhosis)-3507.2(6)-3647.8(1)-4261.2(15)]TJ T* [(L)53.9(ymphoma)-8788.8(3)-3647.8(2)-2806.9(6.25\26180)]TJ T* [(Polymyositis)-8143.8(2)-3647.8(1)-3553(20\26150)]TJ T* [(Ectopic)-333(pregnancy)-5831.7(2)-3647.8(0)-2806.9(12.5\26188*)]TJ T* [(Asthma)-10235.9(1)-3647.8(1)-4052.5(5\26115)]TJ 0 -1.0496 TD [(Mycosis)-336.8(fungoides)-5703(1)-3647.8(1)-4261.2(50)]TJ 0 -1.0559 TD [(Pemphigus)-334.3(vulgaris)-5383.4(1)-3647.8(0)-3553(50\26175)]TJ T* [(Medulloblastoma)-6384.8(1)-3647.8(0)-4134.7(7.5)]TJ T* [(Polyarticular)-337.8(juvenile)-337.7(RA)-2985.1(1)-3647.8(0)-3635.2(0.5**)]TJ T* [(Psoriatic)-338(arthritis)-6488.8(1)-3647.8(0)-4261.2(15)]TJ T* [(COPD)-10662(1)-3647.8(0)-3306.4(7.5\26115)]TJ 0 -1.9475 TD [(*:)-456.6(single)-464.3(intrathecal)-459.2(administration;)-465.5(**:)-456.1(mg)]TJ /F9 1 Tf 18.0962 0.2213 TD (.)Tj /F6 1 Tf 0.2719 -0.2213 TD (kg)Tj 6.725 0 0 5.977 231.931 135.609 Tm (-1)Tj /F9 1 Tf 8.966 0 0 8.966 237.487 133.568 Tm (.)Tj /F6 1 Tf 0.2719 -0.2213 TD (week)Tj 6.725 0 0 5.977 258.69 135.609 Tm (-1)Tj 8.966 0 0 8.966 264.246 131.584 Tm [(.)-458.2(RA:)]TJ -22.9711 -1.0559 TD [(rheumatoid)-583.8(arthritis;)-591.4(COPD:)-585.1(chronic)-581(obstructive)-584.9(pulmonary)]TJ T* [(disease.)-338.5(\(Data)-332.4(from)-336.9([8,)-331.6(10,)-330.7(14,)-337(15,)-330.7(17\26171].\))]TJ ET 309.316 253.644 227.168 -0.51 re f 309.316 227.735 227.168 -0.51 re f 309.316 135.553 227.168 -0.51 re f BT /F2 1 Tf 8.966 0 0 8.966 309.316 267.42 Tm [(Table)-338.2(3.)-330.4(\261)-333.2(Clinical)-346.7(features)-336(of)-343(methotrexate)-337.3(pneumonitis:)]TJ 0 -1.0496 TD [(literature)-338.9(review)]TJ /F6 1 Tf 15.2698 -1.7135 TD [(T)60.2(otal)-2898.4(Histological)]TJ 6.2534 -1.0559 TD (study)Tj -21.5232 -1.998 TD [(Subjects)-335.1(n)-11349.1(123)-5069.5(49)]TJ 0 -1.0559 TD [(Age)-336.7(yrs)-12374.6(49.3)-4572.9(52.1)]TJ T* [(Sex)-338.3(M/F)-11615.3(47/76)-4046.5(24/25)]TJ T* [(Shortness)-340.9(of)-328.8(breath/Dyspnoea)-2113.5(101)-333.6(\(82.1\))-2506.2(38)-334.1(\(77.6\))]TJ T* [(Cough)-11503.5(100)-333.6(\(81.3\))-2506.2(38)-334.1(\(77.6\))]TJ T* [(Fever)-12168.1(94)-334.1(\(76.4\))-2759.1(38)-334.1(\(77.6\))]TJ T* [(Chest)-340.6(pain)-10363.4(12)-334.1(\(9.8\))-3259.1(5)-334.6(\(10.2\))]TJ T* [(T)60.2(achypnoea)-9624.3(52)-334.1(\(42.3\))-2759.1(28)-334.1(\(57.1\))]TJ 0 -1.0496 TD [(Crackles)-10962.1(64)-334.1(\(52.0\))-2759.1(32)-334.1(\(65.3\))]TJ 0 -1.9475 TD [(Data)-268.8(are)-264.6(presented)-271.2(as)-265.5(n)-258.7(\(%\).)-269.3(M:)-267.6(male;)-262.9(F:)-265.5(female.)-270(\(Data)-269.2(from)-261([8,)]TJ 0 -1.0559 TD [(10,)-337(14,)-330.7(15,)-330.7(17\26171].\))]TJ -27.9978 76.3808 TD (374)Tj 7.472 0 0 7.472 262.431 797.499 Tm 0.0001 Tc [(S.)-328.4(IMO)-9.6(K)0(A)70.4(W)102.5(A)-329(E)0(T)-263.8(AL.)]TJ ET endstream endobj 15 0 obj << /ProcSet [/PDF /Text ] /Font << /F2 5 0 R /F3 6 0 R /F4 7 0 R /F6 9 0 R /F7 10 0 R /F8 16 0 R /F9 17 0 R >> /ExtGState << /GS2 11 0 R >> >> endobj 19 0 obj << /Length 17271 >> stream BT /F6 1 Tf 9.963 0 0 9.963 68.258 771.647 Tm 0 g /GS2 gs -0.0195 Tc [(C)-19.5(h)-3(e)-19.5(s)0.1(t)-591.7(r)-19.5(a)-6(d)-19.5(io)-19.5(gr)-19.5(a)-6(p)-19.5(hi)-19.5(c)-587.2(f)-19.5(in)-19.5(di)-19.5(ng)-19.5(s)-585.6(r)-19.5(an)-19.5(g)-4(e)-19.5(d)-579.1(f)-19.5(r)-7.1(o)-19.5(m)-581.9(n)-19.5(or)-19.5(ma)-19.5(l)-587.2(t)-19.5(o)]TJ -1.0015 -1.0471 TD 0 Tc [(wi)14.9(de)20.8(sp)14.4(re)19.2(ad)-218.2(di)18.9(f)20.4(f)0(u)13.9(s)0(e)-213.7(i)0(n)18.9(f)0(i)17.3(l)0(t)16.5(r)0(a)13.5(t)0(e)18.4(s)-223.9(\(t)17.3(ab)15.1(le)-214.9(4\).)-225.4(Most)-241.9(cases)-240.7(demon)-7.4(-)]TJ 0 -1.0528 TD [(strated)-486(an)-474.2(inte)-8.2(rstitial)-482.1(or)-481.1(mixed)-482.1(interstiti)-13.7(al)-476.6(and)-475(alveol)-10.1(ar)]TJ 0 -1.0471 TD [(pattern.)-280.3(Six)-277(cases)-280.6(presen)-8.2(ted)-278.2(with)-279.2(an)-275.1(alveol)-10.1(ar)-271(p)-6.5(attern)-279.2(only)]TJ 0 -1.0528 TD [([15,)-214.8(2)-6.5(5)0(,)-211.7(27,)-218.2(32,)-212.5(53,)-218.1(67].)-214.8(Most)-219.1(of)-219.4(the)-215.6(patie)-9.4(nts)-216.4(demonstra)-10.3(ted)]TJ 0 -1.0471 TD [(diffuse)-211.7(and/or)-219.5(lower)-217(lobe-)-8.2(dominant)-219.3(infilt)-10(rates.)-215(Uppe)-7.4(r)-212.9(lobe)]TJ 0 -1.0528 TD [(predom)-9.7(inance)-486.2(was)-485.8(presen)-8.2(t)-481.2(i)0(n)-481.9(only)-489.1(three)-486.6([10,)-482.3(59,)-485.6(64].)]TJ 0 -1.0471 TD [(Pleura)-8.6(l)-225.1(eff)11.2(usion)-229.3(was)-229.7(present)-227.6(in)-225.8(three)-224.8([10,)-226.2(18,)-223.8(47])-225.8(and)-224.6(hila)-8.2(r)]TJ 0 -1.0527 TD [(or)-287.7(mediastinal)-296.6(adenopat)-9.7(hy)-280.4(in)-288.4(five)-286.3([10,)-283.1(2)-6.5(4)0(,)-280(50,)-286.4(52].)-288.8(High-)]TJ T* [(resolu)-10.1(tion)-320.8(compu)-7.4(ted)-323.7(tom)-7.8(ography)-326(may)-324.5(show)-326.8(heter)-8.6(ogene-)]TJ 0 -1.0471 TD [(ous)-424.6(or)-418.5(patchy)-428.9(areas)-428.9(of)-418.5(ground-)-8.5(glass)-424.4(appe)-9.6(arance,)-423.6(septa)-8.2(l)]TJ 0 -1.0528 TD [(lines)-340.2(and/or)-339(fibrosis)-340.8([27,)-340(38,)-332(6)-6.5(3)0(,)-331.2(73].)]TJ 1.0015 -1.0471 TD [(Th)17.1(e)-302.8(h)0(i)18.9(s)0(t)17.7(o)0(l)13.2(o)0(g)21.2(i)0(c)18.4(a)0(l)-300.2(f)0(i)17.3(n)0(d)21.2(i)0(n)18.9(g)0(s)-298.6(a)0(r)19.2(e)-302.8(su)14.4(mm)14.9(ar)19.2(iz)18.4(ed)-297.8(in)-294.1(ta)18.4(bl)18.9(e)-308.5(5)-302.4([8,)]TJ -1.0015 -1.0527 TD [(10,)-218.1(14,)-218.1(1)-6.5(7\26149].)-222(Interstiti)-12.9(al)-220.6(inflammati)-14.5(on)-217.8(and)-218.9(fibr)-8.6(osis)-218.4(wer)-8.2(e)]TJ 0 -1.0471 TD [(the)-238.4(most)-237.4(common)-238.9(findings.)-241.7(Giant)-240.5(cells,)-238.6(tissue)-239.7(eosinophil)-10.7(s)]TJ 0 -1.0527 TD [(and)-446.6(type)-449.7(II)-442.9(pneum)-7.4(ocyte)-450.9(hyperplasi)-10.3(a)-445(were)-447.6(found)-449.3(in)-447.8(13)]TJ 0 -1.0471 TD [(\(26.5%)-8.2(\),)-201.9(nine)-210.7(\(18.4%\))-209.7(and)-201.9(1)-6.5(9)-199.9(\(38.8%)-8.2(\))-201.5(cases,)-212.6(respec)-8.6(tively)56.2(.)]TJ 0 -1.0528 TD [(Granu)-9.7(loma)-361.8(forma)-10.6(tion)-360.6(was)-360.6(report)-10.5(ed)-360.4(in)-362.4(17)-360(\(34.7%)-8.2(\),)-361.2(non-)]TJ 0 -1.0471 TD [(necrot)-9.4(izing)-225.2(or)-225.1(noncase)-7.7(ating)-225.2(granul)-9(omas)-229.7(in)-220.2(seven)-227.7(of)-225.1(these)-8.2(,)]TJ 0 -1.0527 TD [(and,)-264.8(in)-265.7(the)-266.8(rema)-8.6(ining)-264.7(10,)-269.4(the)-266.8(character)-270.5(of)-264.9(the)-266.8(granul)-9(omas)]TJ 0 -1.0471 TD [(was)-320.8(not)-323.3(descri)-10.6(bed.)-321.7(Hyaline)-327.8(membranes)-330.1(were)-322.4(report)-10.6(ed)-320.6(in)]TJ 0 -1.0528 TD [(four)-336.3(\(8.2%\))-9.7(.)]TJ 1.0015 -1.0471 TD [(T)69.1(a)0(b)20.8(l)0(e)-305.9(6)-313.7(summariz)-12.7(es)-321.8(the)-323.7(treatmen)-11.1(t)-321.8(and)-327.1(follow)-9.2(-up)-322.6(data.)]TJ -1.0015 -1.0527 TD [(Thirt)-8.6(y-two)-523.9(cases)-525.2(were)-521.5(treated)-525.1(wi)-7.8(th)-516.1(disco)-7.8(ntinuati)-10.3(on)-519.4(of)]TJ 0 -1.0471 TD [(MTX)-262.7(thera)-8.6(py)-263.3(alone)-263.1([8,)-265.3(10,)-263.7(14,)-258(17,)-263.7(19,)-263.7(29,)-258(40)-7.2(,)-256.5(43,)-263.7(46,)-263.7(48,)]TJ 0 -1.0528 TD [(52,)-240.9(55,)-240.9(57,)-240.9(60,)-240.9(66,)-240.9(70],)-243.3(and)-241.7(sixty-fiv)-12.7(e)-234.5(w)0(i)-7.8(t)0(h)-237.2(corti)-10.6(costeroids)]TJ 0 -1.0471 TD [(and)-475(disco)-7.8(ntinuati)-10.3(on)-473.8(of)-469.7(MT)-7.6(X.)-471.7(Most)-480.9(patients)-481.9(were)-476(also)]TJ 0 -1.0527 TD [(treated)-257.6(with)-256.4(a)-245.9(combi)-9.7(nation)-254.4(of)-253.5(empirica)-11.1(l)-247.8(antibiot)-10.3(ics)-251(and/or)]TJ 0 -1.0471 TD [(oxygen)-403.3(support.)-403.5(Follow)-399.4(up)-399.9(data)-398.9(were)-396.3(d)-6.5(escribed)-399.4(in)-402.2(121)]TJ 0 -1.0528 TD [(cases:)-295.1(99)-291.7(improved,)-292.8(some)-298(of)-287.6(whom)-294.7(resolved)-296.6(completel)-12.7(y)61.8(.)]TJ 0 -1.0471 TD [(There)-255(were)-254.1(21)-246.2(\(15.8%)-8.2(\))-247.1(deaths)-259.3([10,)-249(23,)-246.6(26,)-252.3(27,)-246.6(3)-6.5(0)0(,)-245.8(31,)-252.3(33,)]TJ 0 -1.0528 TD [(40,)-286.4(42\26149,)-288.7(61],)-283.1(16)-286.1(caused)-291.5(by)-280.4(respi)-9.4(ratory)-289.4(disease)-290.2([23,)-288.8(26,)]TJ 0 -1.0471 TD [(27,)-400.2(31,)-400.2(33,)-400.2(42)-7.2(\26149,)-401(61].)-402.6(Methotrex)-10.3(ate)-403.8(was)-400.5(conti)-9(nued)-401.8(in)]TJ 0 -1.0527 TD [(eight)-322(ca)-8(ses)-318.1([8,)-322.2(22,)-320.6(53],)-322.9(and)-321.4(all)-320.4(imp)-7.8(roved)-324.5(without)-323.7(ster)-8.6(oid)]TJ 0 -1.0471 TD [(thera)-8.6(py)61.1(.)-541(Sixte)-8.2(en)-542.5(additional)-552.9(pati)-8.2(ents)-541.9(wer)-8.2(e)-541.8(treated)-553.5(with)]TJ 0 -1.0527 TD [(reintroduc)-10.7(tion)-286.7(of)-276.3(MTX)-285.4([8,)-276.6(1)-6.5(0)0(,)-274.3(14,)-280.7(15,)-280.7(17,)-280.7(18,)-280.7(22,)-280.7(29,)-280.8(42,)]TJ 0 -1.0471 TD [(45,)-286.4(54,)-286.4(60,)-286.4(69],)-288.8(resulting)-290.3(in)-288.4(recurr)-10.2(ence)-288.8(of)-282(pneum)-7.4(onit)-7.8(is)-283.9(in)]TJ 0 -1.0528 TD [(25%)-334.7([14,)-340(17,)-337.7(29,)-332(45].)]TJ /F5 1 Tf 6.2027 -2.3559 TD [(Res)-7.8(ults)-337.5(of)-333.2(current)-331.3(study)]TJ /F6 1 Tf -5.2012 -1.4454 TD [(Fi)19.6(ft)17.3(ee)14.7(n)-353.6(c)0(a)14.7(s)0(e)19.6(s)-354.8(of)-344.6(pr)19.6(es)13.9(um)18.1(ed)-343.4(MT)15.2(X-)15.7(in)18.9(du)15.5(ce)20.4(d)-359.3(l)13.9(un)15.5(g)-353.6(t)0(o)18.9(x)0(i)18.9(c)0(i)12.8(t)0(y)]TJ -1.0015 -1.0528 TD [(we)16.9(re)-350.7(fo)19.6(un)15.5(d;)-351(ad)20.8(eq)15.1(ua)20.8(te)-351.4(cl)18.4(in)13.2(ic)18.4(al)-351.4(hi)18.9(st)17.7(or)19.6(y)-359.3(a)0(n)15.1(d)-359.3(fo)19.6(ll)16.5(ow)17.3(-u)19.6(p)-359.3(d)0(a)15.1(t)0(a)]TJ 25.1977 26.757 TD [(we)16.9(re)-345(av)20.8(ai)12.8(la)18.4(bl)18.9(e)-348.3(f)0(o)13.9(r)-349.5(ni)18.9(ne)-343.4(an)20.8(d)-353.6(t)0(h)18.8(e)0(s)19.6(e)-354(co)20.8(mp)12.4(ri)17.3(se)19.6(d)-347.9(t)0(h)13.2(e)-348.3(ca)20.4(se)13.9(s)-349.1(i)0(n)]TJ 0 -1.0584 TD [(th)13.2(e)-274.3(s)0(t)17.7(u)0(d)21.2(y)73.2(.)-273.5(T)0(h)17.1(e)-274.3(cl)18.4(in)18.8(ic)12.8(al)-260.4(fi)11.6(nd)21.2(in)18.9(gs)-264.5(ar)13.5(e)-274.3(s)0(u)20(m)0(m)14.9(a)0(r)19.2(i)0(z)18.4(e)0(d)-269.4(i)0(n)-260(t)0(a)12.8(b)0(l)18.8(e)-274.3(7.)]TJ T* [(Eig)-8.8(ht)-220.1(pati)-8.2(ents)-223.3(fulf)-8.6(illed)-227.6(the)-227("criteria")-235.6(outlined)-229.9(in)-225.8(table)-225.6(1)-222.7(for)]TJ T* [(probabl)-9.7(e)-359.7(MTX)-365.1(pneumonit)-9.5(is)-357.9(and)-361.2(the)-363.6(remainin)-10.7(g)-353.6(one)-361.2(\(pa-)]TJ T* [(tien)-8.2(t)-310.4(2)0(\))-316.1(for)-318.5(possible)-320.9(MTX)-319.6(pneum)-7.4(onitis.)-320.6(The)-314.1(backgro)-7.7(und)]TJ 0 -1.0527 TD [(disea)-8.2(ses)-517.2(includ)-9.7(ed)-514.1(RA)-516.6(in)-516.1(five,)-520(psoriasis)-523.7(in)-516.1(two,)-515.4(poly-)]TJ 0 -1.0584 TD [(myal)-9(gia)-323.7(rheum)-9(atica)-328.5(in)-322.6(one,)-327.4(and)-321.4(combi)-9.7(ned)-321.4(RA)-328.9(and)-327.1(giant)]TJ T* [(cell)-378.5(arter)-10.2(itis)-375.6(in)-379.5(one.)-373(The)-6.8(re)-373.4(wer)-8.2(e)-371.1(three)-384.2(males)-375.5(an)-7.6(d)-370.7(six)-375.8(fe-)]TJ T* [(mal)-8.2(es)-344.6(of)-350.2(age)-344.5(range)-347.6(5)-6.5(7\26176)-344.5(yrs)-346.5(\(mea)-8.6(n)-342.2(69.)-7.6(1)-342.2(yrs\).)-349.2(One)-348.1(pa-)]TJ T* [(tien)-8.2(t)-521(was)-525.7(known)-525.6(to)-521.8(have)-521.7(pre-ex)-8.6(isting)-525.1(inte)-8.2(rstitial)-527.6(lung)]TJ 0 -1.0528 TD [(disea)-8.2(se,)-333.6(presum)-10.9(ed)-332(to)-334(be)-332(due)-332.7(to)-334(RA.)-334.9(Reg)-7.4(arding)-333.3(concom)-8.5(-)]TJ 0 -1.0584 TD [(it.an)-8.6(t)-213.7(drugs,)-217.5(tw)-7.8(o)-211.3(pati)-8.2(ents)-217.6(were)-219.9(treated)-223.5(with)-216.6(predni)-9(sone)-215.2(\(30)]TJ T* (mg)Tj /F9 1 Tf 1.2747 0.1992 TD 0 Tw (.)Tj /F6 1 Tf 0.2731 -0.1992 TD (day)Tj 7.472 0 0 6.641 339.08 480.812 Tm (-1)Tj 9.963 0 0 9.963 349.001 476.39 Tm [(in)-385.2(one)-384(and)-384(unknow)-8.5(n)-382(dose)-385.9(in)-379.5(the)-386.3(other)-8.2(\),)-378.3(three)]TJ -3.9834 -1.0584 TD [(wi)-7.8(th)-242.9(NSAID)-10.7(s,)-241.3(and)-247.4(one)-241.7(other)-247.2(wi)-7.8(th)-242.9(both)-244.4(predni)-9(sone)-243.6(\(5)-247.8(mg)]TJ /F9 1 Tf 22.5289 0.1992 TD (.)Tj /F6 1 Tf -22.5289 -1.2519 TD (day)Tj 7.472 0 0 6.641 323.716 459.779 Tm (-1)Tj 9.963 0 0 9.963 329.839 455.357 Tm [(\))-355.2(and)-355.5(NSA)-9.4(IDs.)-356.5(One)-359.4(patien)-10.2(t)-350.3(exhibi)-9.7(ted)-357.9(dizziness)-362.3(as-)]TJ -2.06 -1.0584 TD [(cribe)-8.6(d)-234.1(t)0(o)-237.2(the)-238.4(extra)-8.6(pulmonary)-242(advers)-8.2(e)-234.5(effects)-235.2(of)-236.4(MTX.)-240.3(All)]TJ T* [(pati)-8.2(ents)-211.9(show)-8.2(ed)-212.5(acute-to-s)-12.3(ubacut)-7.8(e)-211.7(shortness)-219.7(of)-208(breat)-8.6(h)-211.3(and)]TJ T* [(seven)-216.4(cough.)-209.5(Bec)-7.8(ause)-209.9(of)-208(progre)-8.2(ssive)-213.8(or)-208(severe)-213.4(symp)-7.4(toms,)]TJ T* [(surgical)-179.5(lung)-187.5(biopsy)-184.6(was)-184.2(perfor)-9.8(med.)-182.6(The)-183.2(durat)-8.2(ion)-181.1(of)-179.5(MT)-7.6(X)]TJ 0 -1.0528 TD [(treat)-11(ment)-276.4(prior)-282.5(to)-277.1(biops)-7.4(y)-273.9(ranged)-280.1(3)-273.9(mont)-8.6(hs\2614)-277.4(yrs,)-278.6(and)-275.8(the)]TJ 0 -1.0584 TD [(dose)-203.8(ranged)-206.2(2.5\26120)-203.4(mg)]TJ /F9 1 Tf 9.1561 0.1992 TD (.)Tj /F6 1 Tf 0.2731 -0.1992 TD (week)Tj 7.472 0 0 6.641 424.12 396.567 Tm (-1)Tj 9.963 0 0 9.963 430.299 392.145 Tm [(.)-199.6(The)-200.3(dose)-203.8(was)-207(unknown)-202.7(in)]TJ -12.1436 -1.0584 TD [(one)-332.7(patient.)-338(The)-331.2(descriptions)-339.7(of)-327.5(the)-329.4(chest)-332.6(radio)-8.2(graphs)-332.1(at)]TJ T* [(presen)-8.2(tation)-182.8(incl)-8.2(uded)-179.9(dif)10.8(fuse)-182.7(or)-179.5(bilateral)-184.2(infilt)-10(rates)-180.5(in)-180.3(eight)]TJ T* [(pati)-8.2(ents,)-274.9(and)-270.2(the)-272.5(dist)-9(ribution)-276.6(was)-275.3(lower)-273.9(lobe-)-8.2(dominant)-276.2(in)]TJ 0 -1.0527 TD [(five.)-343.6(One)-336.7(patient)-337.7(exhibi)-9.7(ted)-335.1(only)-335.5(hy)-7.2(perinflation.)]TJ 1.0015 -1.0527 TD [(Lu)17.1(ng)-365.7(ti)16.5(ss)18.9(ue)-366.1(cu)15.1(lt)16.5(ur)19.6(e)-376.8(r)0(e)19.2(s)0(u)20(l)0(t)16.5(s)-377.5(w)12.4(e)0(r)13.5(e)-371.1(av)15.1(ai)18.5(la)18.5(bl)13.2(e)-371.1(i)0(n)-368.1(s)0(i)17.7(x)-370.7(ca)14.7(se)19.6(s)]TJ -1.0015 -1.0584 TD [(an)15.1(d)-251.2(a)0(l)12.8(l)-253.5(w)12.4(e)0(r)13.5(e)-251.6(ne)15.1(ga)20.8(ti)16.5(ve)15.1(.)-250.8(S)0(p)16.3(e)0(c)20.4(i)0(f)11.6(i)13.9(c)-257.2(c)0(u)20.8(l)0(t)16.5(u)0(r)13.9(e)-251.6(re)19.2(su)14.4(lt)16.5(s)-252.3(c)0(o)20.8(u)0(l)13.2(d)-251.2(no)15.5(t)-253.5(b)0(e)]TJ 0 -1.0528 TD [(ob)15.5(ta)18.4(in)18.8(ed)-349.1(fo)19.6(r)-360.9(t)0(h)18.9(e)-354(re)13.5(m)13.2(a)0(i)12.8(n)0(i)18.9(n)0(g)-348.7(c)0(a)20.4(s)0(e)19.6(s)0(,)-349.5(a)0(l)18.4(t)0(h)18.8(o)0(u)15.5(g)0(h)21.2(,)-358.9(ba)20.8(se)13.9(d)-353.6(o)0(n)-348.7(t)0(h)18.9(e)]TJ 0 -1.0584 TD [(fo)13.9(ll)16.5(ow)17.3(-u)19.6(p,)-314.1(th)18.8(e)-325.5(c)0(u)15.1(l)0(t)16.5(u)0(r)19.6(e)0(s)-316.1(w)0(e)16.9(r)0(e)-316.5(p)0(r)19.6(e)0(s)14(u)0(m)18.1(e)0(d)-314.9(t)0(o)-316.9(b)0(e)-314.9(n)0(e)20.8(g)0(a)15.1(t)0(i)16.5(v)0(e)20.8(.)]TJ ET 1 i 58.28 301.039 227.168 -0.51 re f 58.28 275.131 227.168 -0.51 re f 58.28 154.545 227.168 -0.51 re f BT /F2 1 Tf 8.966 0 0 8.966 58.28 314.816 Tm [(Table)-331.9(4.)-336.7(\261)-333.2(Radiographic)-497(findings)-495.1(of)-501.1(methotrexate)-495.3(pneu-)]TJ 0 -1.0559 TD [(monitis:)-333.3(literature)-338.9(review)]TJ /F6 1 Tf 15.6998 -1.7072 TD [(T)60.2(otal)]TJ -0.588 -1.0559 TD (\(n)Tj /F7 1 Tf 0.822 0 TD (=)Tj /F6 1 Tf 0.5564 0 TD (123\))Tj 3.5155 1.0559 TD (Histological)Tj -0.177 -1.0559 TD [(study)-336.2(\(n)]TJ /F7 1 Tf 3.3132 0 TD (=)Tj /F6 1 Tf 0.5501 0 TD (49\))Tj -23.6919 -1.998 TD [(Interstitial)-339.6(infiltrate)-7286(46)-327.8(\(37.4\))-1987.7(16)-334.1(\(32.7\))]TJ 0 -1.0559 TD [(Alveolar)-339.6(infiltrate)-8354.5(6)-328.3(\(4.9\))-2987.2(3)-334.6(\(6.1\))]TJ T* [(Interstitial)-339.6(and)-333.4(alveolar)-336.1(infiltrate)-2006.3(40)-327.8(\(32.5\))-1987.7(20)-334.1(\(40.8\))]TJ T* [(Normal)-12499.3(5)-328.3(\(4.1\))-3360.3(0)-334.6(\(0\))]TJ T* (Other)Tj 0.3351 -1.0559 TD [(Interstitial)-339.6(and)-333.4(nodular)]TJ 0.3288 -1.0559 TD [(\(small)-340.6(nodules,)-331.5(3\2615)-333.6(mm\))-4688.5(3)-328.3(\(2.4\))-2987.2(3)-334.6(\(6.1\))]TJ -0.3288 -1.0559 TD [(Interstitial)-339.6(,)-331.7(alveolar)-336.1(and)]TJ 0.6639 -1.0559 TD [(nodular*)-10988.3(1)-328.3(\(0.8\))-3360.3(0)-334.6(\(0\))]TJ -0.6639 -1.0559 TD [(Nodular)-331.6(\(small)-340.6(nodules,)-331.5(~1)-334.7(cm\))-2239.4(3)-328.3(\(2.4\))-2987.2(1)-334.6(\(2.0\))]TJ 0 -1.0496 TD [(Alveolar)-333.3(and)-333.4(nodular*)-6094.3(1)-328.3(\(0.8\))-3360.3(0)-334.6(\(0\))]TJ 0 -1.0559 TD [(Not)-332.9(fully)-332(described)-6878.6(18)-327.8(\(14.6\))-2240.6(6)-328.3(\(12.2\))]TJ -0.3351 -1.9475 TD [(Data)-553.3(are)-555.4(presented)-555.7(as)-556.4(n)-555.9(\(%\).)-553.9(*:)-551.5(size)-557.5(of)-556.4(nodules)-549.9(not)-557.3(fully)]TJ 0 -1.0559 TD [(described.)-274.1("Interstitial)-281.4(infiltrate")-278.8(includes)-279.6(reticular)-275.7(shadows)-273.8(and)]TJ T* [(ground-glass)-348.1(shadows;)-345.2("alveolar)-347.4(infiltrate")-354.7(includes)-342.9(consolida-)]TJ T* [(tion.)-334.4(\(Data)-338.8(from)-330.6([8,)-338(10,)-330.7(14,)-330.7(15,)-337(17\26171].\))]TJ ET 309.316 758.834 227.168 -0.51 re f 309.316 649.247 227.168 -0.51 re f BT /F2 1 Tf 8.966 0 0 8.966 309.316 772.667 Tm [(Table)-338.2(5.)-330.4(\261)-333.2(Histological)-693.6(findings)-691.1(of)-684.5(methotrexate)-691.4(pneu-)]TJ T* [(monitis:)-339.6(literature)-332.6(review)]TJ /F6 1 Tf 0 -1.7072 TD [(Interstitial)-346(inflammation)-11603.9(35)-334.1(\(71.4\))]TJ 0 -1.0559 TD [(Interstitial)-346(fibrosis)-13966(29)-334.1(\(59.2\))]TJ T* [(Intra-alveolar)-344.4(or)12.7(ganization)-11167.6(5)-334.6(\(10.2\))]TJ T* [(Hyaline)-339.2(membranes)-13759.3(4)-334.6(\(8.2\))]TJ T* [(Increased)-339.1(tissue)-332.7(eosinophils)-10575.6(9)-334.6(\(18.4\))]TJ T* [(Granuloma)-338.6(formation)-12605.3(17)-334.1(\(34.7\))]TJ T* [(Giant)-340.4(cells)-16954.7(13)-334.1(\(26.5\))]TJ T* [(T)60.2(ype)-333.4(II)-336(pneumocyte)-333.6(hyperplasia)-8252(19)-334.1(\(38.8\))]TJ T* [(Increased)-339.1(intra-alveolar)-339.5(macrophages)-6314.1(13)-334.1(\(26.5\))]TJ T* [(Bronchiolitis)-340.7(obliterans)-12396.7(4)-334.6(\(8.2\))]TJ T* [(Bronchial)-340.5(epithelial)-334.9(cell)-337.4(atypia)-9384.5(1)-334.6(\(2.0\))]TJ 0 -1.9411 TD [(Data)-154.9(are)-157.1(presented)-151(as)-151.7(n\(%\))-158.4(\(n)]TJ /F7 1 Tf 11.2295 0 TD (=)Tj /F6 1 Tf 0.5501 0 TD [(49\).)-154.1(\(Data)-155.4(from)-153.5([8,)-154.6(10,)-147.3(14,)-153.6(17\26149].\))]TJ ET 309.316 272.693 227.168 -0.51 re f 309.316 246.784 227.168 -0.51 re f 309.316 126.255 227.168 -0.51 re f BT /F2 1 Tf 8.966 0 0 8.966 309.316 286.526 Tm [(Table)-338.2(6.)-330.4(\261)-333.2(Summary)-340.2(of)-336.7(therapeutic)-341.8(and)-335.7(follow-up)-342.4(data)-332.9(of)]TJ 0 -1.0559 TD [(methotrexate)-337.3(\(MTX\))-331.8(pneumonitis)-334.7(literature)-338.9(review)]TJ /F6 1 Tf 16.4902 -2.7631 TD [(T)60.2(otal)]TJ 3.5219 1.0559 TD (Histological)Tj -0.177 -1.0559 TD [(study)-329.8(\(n)]TJ /F7 1 Tf 3.3132 0 TD (=)Tj /F6 1 Tf 0.5501 0 TD (49\))Tj -23.6983 -1.998 TD (Therapy)Tj 0.3351 -1.0559 TD [(Discontinuation)-337.1(of)-335.1(MTX)-6638.7(32)-3938.2(1)32.1(1)]TJ T* [(Discontinuation)-337.1(of)-335.1(MTX+steroid)-3392.5(65)-3925.5(30)]TJ T* [(Other)-339(therapies/not)-333.2(fully)-338.3(described)-2661.2(26)-4342.8(8)]TJ T* [(Continuation)-336.7(of)-335.1(MTX)-8200.4(8)-4425.5(2)]TJ -0.3351 -1.0559 TD [(Reintroduction)-342.7(of)-328.8(MTX)-7359.5(16)-4342.8(6)]TJ 0.3351 -1.0559 TD [(Recurrence)-12589.3(4)-4425.5(4)]TJ T* [(No)-331.1(recurrence)-10966.9(12)-4342.8(2)]TJ -0.3351 -1.0559 TD [(Follow-up)-338.1(\(n)]TJ /F7 1 Tf 5.2923 0 TD (=)Tj /F6 1 Tf 0.5501 0 TD (121\))Tj -5.5073 -1.0559 TD [(Improving)-12483(99)-3925.5(31)]TJ T* [(Progressive)-334.3(disease)-9288.9(1)-4425.5(0)]TJ T* [(Death)-337.8(caused)-332.6(by)-334.1(respiratory)-337.9(disease)-2150.3(16)-3925.5(14)]TJ -0.3351 -1.9411 TD [(\(Data)-338.8(from)-336.9([8,)-331.6(10,)-330.7(14,)-337(15,)-330.7(17\26171].\))]TJ 23.8374 76.3618 TD (375)Tj 7.472 0 0 7.472 241.285 797.499 Tm 0.0001 Tc [(METHOTR)-11(EXA)105.4(TE)-339.7(PNEUMONITIS)]TJ ET endstream endobj 20 0 obj << /ProcSet [/PDF /Text ] /Font << /F2 5 0 R /F5 8 0 R /F6 9 0 R /F7 10 0 R /F9 17 0 R >> /ExtGState << /GS2 11 0 R >> >> endobj 22 0 obj << /Length 17607 >> stream BT /F6 1 Tf 9.963 0 0 9.963 68.258 304.724 Tm 0 g /GS2 gs 0 Tc [(Af)15.7(te)18.4(r)-252.7(t)0(h)18.9(e)-251.6(pr)13.9(es)19.6(um)18.1(pt)13.2(i)13.9(v)0(e)-246.6(d)0(i)18.9(a)0(g)15.1(n)0(o)21.2(s)0(i)17.7(s)-252.3(of)-242.1(MT)15.2(X)-249.4(t)0(o)13.2(x)0(i)18.9(c)0(i)18.4(t)0(y)81.4(,)-250.8(MT)15.2(X)]TJ -1.0015 -1.0528 TD [(wa)16.9(s)-172.7(d)0(i)18.9(s)0(c)13.9(o)0(n)21.2(t)0(i)16.5(n)0(u)21.2(e)0(d)-167(i)0(n)-163.2(a)0(l)18.4(l)-173.9(ca)20.4(se)13.9(s)-167(a)0(n)15.1(d)-171.5(co)20.8(rt)17.3(ic)12.8(os)20(te)18.4(ro)13.9(id)-163.2(th)18.9(er)19.2(ap)15.1(y)-171.5(w)0(a)16.9(s)]TJ 0 -1.0471 TD [(st)17.7(ar)19.2(te)12.8(d)-336.5(i)0(n)-328.3(e)0(i)18.4(g)0(h)15.5(t)0(.)-327.9(O)0(n)17.3(e)-336.9(pa)15.1(t)13.9(i)0(e)12.8(n)0(t)]TJ /F8 1 Tf 11.125 0 TD 0 Tw (')Tj /F6 1 Tf 0.2106 0 TD [(s)-337.7(i)0(l)22.2(l)0(n)13.2(e)0(s)19.6(s)-337.7(re)19.2(so)14.4(lv)18.9(ed)-326.3(co)15.1(mp)18.1(le)18.4(te)12.8(ly)]TJ -11.3356 -1.0527 TD [(wi)14.9(th)18.9(in)-277.1(1)-285.3(w)0(e)16.9(e)0(k)20.8(.)-284.9(Fi)14(ve)-275.1(pa)15.1(ti)22.2(en)15.1(ts)-278.2(im)15.7(pr)19.6(ov)15.5(ed)-275.1(st)17.7(ea)20.4(di)13.2(ly)-277.1(du)21.2(ri)17.3(ng)-274.7(th)13.2(e)]TJ 0 -1.0471 TD [(fo)19.6(ll)16.5(ow)17.3(-u)13.9(p)-171.5(p)0(e)20.8(r)0(i)17.3(o)0(d)-160.9(\()0(3)-162.5(w)0(e)16.9(e)0(k)15.1(s)0(\261)20(5)-171.5(mo)18.1(nt)18.9(hs)14.4(\),)-162.1(an)20.8(d)-171.5(o)0(n)15.5(e)-166.2(co)15.1(nt)18.9(in)18.9(ue)15.1(d)-171.5(t)0(o)]TJ 0 -1.0527 TD [(ha)15.1(ve)-275.1(re)19.2(sp)14.4(ir)17.3(at)18.5(or)19.6(y)-285.3(i)0(n)13.2(s)0(u)20(f)20.4(fi)17.3(ci)12.8(en)20.8(cy)-280.8(re)19.2(qu)21.2(ir)11.6(i)13.9(n)0(g)-280.4(p)0(e)20.8(r)0(i)17.3(o)0(d)15.5(i)0(c)18.4(a)0(l)-277.5(o)0(x)15.5(y)0(g)21.2(e)0(n)]TJ 0 -1.0471 TD [(su)20(pp)15.5(or)19.6(t)-219.4(a)0(t)-203.5(1)0(9)-206.4(m)0(o)18.1(n)0(t)18.9(h)0(s)-207.6(f)0(o)13.9(l)13.9(l)0(o)13.2(w)12.4(-u)13.9(p.)-206(T)74.8(w)0(o)-210.3(p)0(a)20.8(t)0(i)16.5(e)0(n)15.1(t)0(s)-204.3(d)0(i)18.9(e)0(d)-206.8(b)0(e)15.1(c)0(a)20.4(u)0(s)14.4(e)]TJ 0 -1.0527 TD [(of)-401.5(re)13.5(sp)20(ir)17.3(at)18.4(or)13.9(y)-410.5(f)0(a)19.2(i)0(l)16.5(u)0(r)19.6(e)-416.6(6)-410.5(a)0(n)20.8(d)-410.5(9)-416.2(d)0(a)20.8(y)0(s)-401.1(a)0(f)13.5(t)0(e)18.4(r)-412.1(ad)15.1(mi)21.4(ss)13.2(io)18.9(n,)-399.5(re)13.5(s-)]TJ T* [(pe)15.1(ct)18.5(iv)18.8(el)18.4(y)73.2(.)-250.8(No)-238.8(ca)14.7(us)20(e)-251.6(o)0(f)-242.1(p)0(u)21.2(l)0(m)15.7(o)0(n)15.5(a)0(r)19.2(y)-251.2(di)18.9(se)19.6(as)13.9(e)-245.9(o)0(t)18.9(h)0(e)15.1(r)-247.1(th)13.2(an)-235.3(MT)15.2(X)]TJ 0 -1.0471 TD [(wa)16.9(s)-326.3(i)0(d)18.9(e)0(n)20.8(t)0(i)16.5(f)0(i)17.3(e)0(d)-314.9(i)0(n)-316.9(a)0(n)15.1(y)-325.1(of)-310.4(th)13.2(e)-319.8(n)0(i)13.2(n)0(e)-314.9(c)0(a)20.4(s)0(e)13.9(s)0(.)]TJ /F3 1 Tf 0 -1.8893 TD [(Pathol)-7.8(ogical)-339.8(findings)]TJ /F6 1 Tf 1.0015 -1.6503 TD [(Th)17.1(e)-302.8(h)0(i)13.2(s)0(t)17.7(o)0(l)18.9(o)0(g)21.2(i)0(c)12.8(a)0(l)-294.5(f)0(i)17.3(n)0(d)15.5(i)0(n)18.9(g)0(s)-298.6(a)0(r)19.2(e)-302.8(sh)14.4(ow)17.3(n)-302.4(i)0(n)-299.8(f)0(i)17.3(g)0(u)21.2(r)0(e)13.5(s)-303.6(1\2615)-309.6(and)]TJ -1.0015 -1.0528 TD [(are)-277.8(summ)-10.5(arized)-282.9(in)-277.1(table)-282.5(8.)-274.3(T)57.7(w)0(o)-278.6(main)-282.1(patterns)-281.9(wer)-8.2(e)-274.3(iden-)]TJ 0 -1.0471 TD [(tified:)-415.2(1\))-412.8(acute)-411.4(and)-412.4(organizing)-413.1(dif)10.8(fuse)-416(alveolar)-417.7(damag)-7.8(e)]TJ 0 -1.0528 TD [(\(DAD)-10.7(\))-377.9(i)0(n)-385.2(four)-387.5(pati)-8.2(ents;)-385.7(and)-384(2\))-384.4(cellu)-9.4(lar)-382.2(inte)-8.2(rstitial)-391.1(infil-)]TJ 0 -1.0471 TD [(trates)-343(with)-336.1(or)-338.9(without)-340.8(granuloma)-344.8(formati)-11.1(on)-331.6(in)-334(five.)]TJ 1.0015 -1.0528 TD [(Hy)17.3(al)18.4(in)13.2(e)-183.3(m)0(e)17.7(m)0(b)18.1(r)0(a)13.5(n)0(e)20.8(s)-184.1(we)11.2(re)-174.2(id)18.9(en)15.1(ti)16.5(fi)17.3(ed)-172.7(in)-180.3(t)13.9(h)0(r)14(e)0(e)-173.1(o)0(f)-168.1(f)0(o)19.6(u)0(r)-179.5(c)0(a)20.4(s)0(e)13.9(s)]TJ -1.0015 -1.0471 TD [(wi)14.9(th)-373.8(th)18.9(e)-382.4(D)0(A)13.4(D)-386(pa)20.8(tt)16.5(er)19.2(n.)-376.7(In)19.6(te)18.4(rs)12.8(ti)22.2(ti)16.5(al)-374.2(wi)14.9(de)15.1(ni)18.9(ng)-371.4(by)-377.1(a)-382.4(c)0(o)15.1(m)0(b)18.1(i)0(-)]TJ 25.1977 19.291 TD [(na)15.1(ti)16.5(on)-166.6(of)-168.2(oe)15.1(de)15.1(m)13.2(a)0(,)-172.3(f)0(i)17.3(b)0(r)19.6(o)0(b)15.5(l)0(a)18.4(s)0(t)-170.1(p)0(r)19.6(o)0(l)18.9(i)0(f)17.3(e)0(r)13.5(a)0(t)18.5(i)0(o)18.9(n)-177.2(an)15.1(d)-177.2(i)0(n)18.8(f)0(l)17.3(a)0(m)17.7(m)0(a)12(t)0(o)18.9(r)0(y)]TJ 0 -1.0755 TD [(ce)14.7(ll)16.5(s,)-269.8(ch)20.8(ar)19.2(ac)14.7(te)18.5(ri)17.3(st)17.7(ic)-271.8(of)-264.9(th)13.2(e)-274.3(o)0(r)25.3(g)0(a)20.8(n)0(i)13.2(z)0(i)18.5(n)0(g)-269(p)0(h)21.2(a)0(s)14(e)-274.3(of)-270.6(DA)19.1(D,)-272.5(we)16.9(re)]TJ T* [(ob)15.5(se)19.6(rv)13.9(ed)-314.9(in)-316.9(t)13.9(w)0(o)11.6(.)]TJ 1.0015 -1.0471 TD [(Gr)15.7(an)15.1(ul)18.8(om)18.1(a)-382.4(f)0(o)19.6(r)0(m)16.5(a)0(t)18.4(i)0(o)13.2(n)-376.3(wa)16.9(s)-377.5(i)0(d)18.9(e)0(n)15.1(t)0(i)16.5(f)0(i)17.3(e)0(d)-366.1(i)0(n)-373.8(t)0(h)18.9(r)0(e)19.2(e)-382.4(su)20(ba)15.1(cu)20.8(te)]TJ -1.0015 -1.0755 TD [(gr)13.9(ou)21.2(p)-262.5(c)0(a)20.4(s)0(e)14(s)0(,)-247(t)0(w)14.9(o)-256.8(ha)15.1(d)-256.8(n)0(o)15.5(n)0(-)19.6(n)0(e)20.8(c)0(r)13.5(o)0(t)18.9(i)0(z)18.4(i)0(n)18.9(g)-262.5(gr)19.6(an)15.1(ul)18.9(om)18.1(as)-253.5(an)20.8(d)-256.8(o)0(n)15.5(e)]TJ T* [(ha)15.1(d)-586.9(b)0(o)15.5(t)13.9(h)-592.6(n)0(e)20.8(c)0(r)19.2(o)0(t)13.2(i)0(z)18.4(i)0(n)18.8(g)-586.9(an)15.1(d)-586.9(n)0(o)21.2(n)0(-)13.9(n)0(e)20.8(c)0(r)13.5(o)0(t)18.9(i)0(z)18.4(i)0(n)18.9(g)-586.9(gr)13.9(an)20.8(ul)18.9(om)12.4(as)19.6(.)]TJ T* [(Lu)17.1(ng)-217.8(cu)20.8(lt)16.5(ur)14(es)-213.7(we)16.9(re)-214.1(ne)15.1(ga)20.8(ti)16.5(ve)-212.5(fo)13.9(r)-224.3(o)0(r)31(g)0(a)15.1(n)0(i)18.9(s)0(m)16.9(s)-223.9(in)-214.5(th)18.9(e)-228.8(c)0(a)20.4(s)0(e)-213.7(w)0(i)14.9(t)0(h)]TJ T* [(ne)15.1(cr)19.2(ot)13.2(i)13.9(z)0(i)12.8(n)0(g)-314.5(g)0(r)19.6(a)0(n)15.1(u)0(l)18.9(o)0(m)18.1(a)0(s)13.9(.)]TJ 1.0015 -1.0471 TD [(Al)14.9(l)-185.2(c)0(a)20.4(s)0(e)13.9(s)-184.1(ex)20.8(hi)18.9(bi)18.9(te)12.8(d)-182.9(h)0(y)21.2(p)0(e)15.1(r)0(p)19.6(l)0(a)18.4(s)0(t)17.7(i)0(c)-175(t)0(y)18.9(p)0(e)-178.3(I)0(I)-175.4(p)0(n)21.2(e)0(u)15.1(m)0(o)18.1(c)0(y)20.8(t)0(e)12.8(s)-178.4(an)15.1(d)]TJ -1.0015 -1.0755 TD [(in)13.2(te)18.4(rs)18.4(ti)16.5(ti)16.5(al)-254.7(ly)18.9(mp)12.4(ho)21.2(cy)15.1(ti)16.5(c)-262.9(i)0(n)18.9(f)0(i)17.3(l)0(t)16.5(r)0(a)13.5(t)0(i)22.2(o)0(n)15.5(.)-262.1(Pe)15.9(ri)17.3(va)15.1(sc)19.6(ul)18.9(ar)-259.6(\(p)19.6(re)13.5(do)21.2(mi)15.7(-)]TJ T* [(na)15.1(nt)18.9(ly)-322.6(pe)20.8(ri)17.3(ve)15.1(nu)21.2(la)12.8(r\))-317.7(in)18.9(fl)17.3(am)12(ma)17.7(ti)16.5(on)-320.2(w)12.4(a)0(s)-321.8(p)0(r)14(e)0(s)19.6(e)0(n)20.8(t)-333.2(in)-316.9(se)13.9(ve)20.8(n)-330.8(o)0(f)]TJ T* [(ni)13.2(ne)-223.9(\(7)19.6(7.)15.9(8%)18.9(\))-235.7(c)0(a)20.4(s)0(e)14(s)0(.)-224.3(H)12.4(on)15.5(ey)15.1(co)20.8(mb)-226.6(ch)15.1(an)20.8(ge)-223.9(wa)16.9(s)-235.3(n)0(o)15.5(t)-230.8(id)18.9(en)15.1(ti)16.5(fi)17.3(ed)]TJ 0 -1.0698 TD [(hi)13.2(st)17.7(ol)18.9(og)21.2(ic)12.8(al)18.5(ly)-157.6(in)-163.2(an)20.8(y)-171.5(c)0(a)20.4(s)0(e)14(s)0(.)-156(A)0(l)14.9(v)0(e)15.1(o)0(l)18.9(a)0(r)-162.9(e)0(p)20.8(i)0(t)16.5(h)0(e)20.8(l)0(i)16.5(a)0(l)-163.7(a)0(t)18.5(y)0(p)15.5(i)13.9(a)-171.9(\()0(s)18.4(e)0(v)15.1(e)0(n)]TJ 0 -1.0755 TD [(ca)14.7(se)19.6(s\))12.8(,)-336.1(i)0(n)13.2(c)0(r)19.2(e)0(a)14.7(s)0(e)19.6(d)-342.2(in)18.9(tr)17.3(a-)19.2(al)12.8(ve)20.8(ol)18.9(ar)-333.6(ma)12(cr)19.2(op)15.5(ha)20.8(ge)-332(ac)14.7(cu)20.8(mu)12.4(la)18.4(ti)16.5(on)]TJ T* [(\(e)13.5(ig)18.8(ht)-129.1(ca)14.7(se)19.6(s\))18.4(,)-142.6(a)0(i)18.5(r)0(s)18.4(p)0(a)15.1(c)0(e)-127.5(f)0(o)14(a)0(m)17.7(y)-137.3(ma)12(cr)19.2(op)15.5(ha)20.8(ge)-132.8(ac)20.4(cu)15.1(mu)18.1(la)18.4(ti)16.5(on)-132.4(\(s)18.4(ix)]TJ T* [(ca)14.7(se)19.6(s\))-231.9(an)15.1(d)-239.8(t)0(i)16.5(s)0(s)18.9(u)0(e)-229.6(e)0(o)15.1(s)0(i)17.7(n)0(o)21.2(p)0(h)15.5(i)0(l)16.5(s)-235.3(\(t)17.3(hr)13.9(ee)-230(ca)20.4(se)13.9(s\))-231.9(w)12.4(e)0(r)13.5(e)-240.2(al)18.5(so)-230.4(ob)15.5(se)19.6(r)20.4(-)]TJ T* [(ve)15.1(d.)-160.5(Ot)14.9(he)15.1(r)-173.1(p)0(a)20.8(t)0(h)13.2(o)0(l)18.9(o)0(g)21.2(y)-177.2(no)21.2(te)18.4(d)-177.2(i)0(n)18.8(c)0(l)18.5(u)0(d)15.5(e)0(d)-161.3(m)0(u)18.1(c)0(o)15.1(s)0(t)17.7(a)0(s)19.6(i)0(s)-164.4(i)0(n)-168.9(o)0(n)21.2(e)-171.9(ca)14.7(se)]TJ 0 -1.0698 TD [(an)15.1(d)-251.2(o)0(r)25.3(g)0(a)20.8(n)0(i)13.2(z)0(i)18.4(n)0(g)-240.5(t)0(h)18.9(r)0(o)13.9(m)0(b)18.1(i)-253.5(in)-242.9(on)15.5(e)-251.6(c)0(a)20.4(s)0(e)14(.)-250.8(S)11.4(p)0(e)15.1(c)0(i)18.5(a)0(l)-243.3(s)0(t)17.7(a)0(i)12.8(n)0(s)-241.7(f)0(o)19.6(r)-252.8(or)25.3(g-)]TJ 0 -1.0755 TD [(an)15.1(is)17.7(ms)-318.8(w)12.4(e)0(r)13.5(e)-325.5(pe)20.8(rf)18(or)14(me)17.7(d)-325.1(i)0(n)-311.2(a)0(l)12.8(l)-321.8(ca)14.7(se)19.6(s)-326.3(a)0(n)20.8(d)-325.1(we)16.9(re)-316.5(ne)15.1(ga)20.8(ti)16.5(ve)20.8(.)]TJ ET 1 i 58.28 768.302 478.205 -0.51 re f 58.28 732.926 478.205 -0.51 re f 58.28 432.567 478.205 -0.51 re f BT /F2 1 Tf 8.966 0 0 8.966 58.28 772.667 Tm [(Table)-331.9(7.)-336.7(\261)-333.2(Clinical)-334(features)-336(of)-330.4(methotrexate)-337.3(\(MTX\))-331.8(pneumonitis:)-338.2(current)-330.2(study)]TJ /F6 1 Tf 0 -1.7135 TD (Pt)Tj 0 -1.0496 TD (No.)Tj 2.4912 1.0496 TD (Age)Tj 0.2213 -1.0496 TD (yrs)Tj 2.1371 1.0496 TD [(Sex)-705(Background)]TJ 3.1994 -1.0496 TD (disease)Tj 4.5651 1.0496 TD (MTX)Tj 0.196 -1.0496 TD (dose)Tj 3.1994 1.0496 TD (Therapy)Tj 0 -1.0496 TD (duration)Tj 4.5272 1.0496 TD [(Duration)-333.5(of)]TJ 0.2023 -1.0496 TD (respiratory)Tj 0.0948 -1.0559 TD (symptoms)Tj 5.1721 2.1055 TD [(Symptoms)-861.7(Phys)]TJ 5.0014 -1.0496 TD (exam)Tj 4.1415 1.0496 TD [(Chest)-334.3(XR)]TJ 0.3667 -1.0496 TD (findings)Tj 6.3545 1.0496 TD (Path)Tj -0.7461 -1.0496 TD (findings)Tj 5.463 1.0496 TD (Outcome/)Tj -0.1138 -1.0496 TD (Follow-up)Tj 0.4173 -1.0559 TD (duration)Tj -46.8907 -2.0044 TD [(1)-2320(7)0(1)-1497.5(F)-2919.3(RA)-3086.3(7.5)-1272.8(3)-328.3(months)-1184.8(2\2613)-333.6(weeks)-987.9(Dyspnoea,)]TJ 26.0947 -1.0559 TD [(chest)-335.7(pain)]TJ 5.3555 1.0559 TD (Cr;)Tj -0.3098 -1.0559 TD (TPN)Tj 3.7052 1.0559 TD (Interstitial+)Tj -0.9864 -1.0559 TD [(nodular)32.1(,)-338(diff)10.4(use,)]TJ 0.9737 -1.0559 TD [(lower)-332.7(lobe-)]TJ 0.43 -1.0559 TD (dominant)Tj 6.0321 3.1678 TD [(CII+Gr)-1039.7(Alive,)-337(improved)]TJ 5.0457 -1.0559 TD (completely)Tj 0.7335 -1.0559 TD [(1)-334.6(week)]TJ -47.0741 -2.1055 TD [(2)-2320(7)0(4)-1497.5(F)-2919.3(RA)-3048.3(20)-1535.5(16)-327.8(weeks)-931(1\2612)-333.6(months)-767.5(Dyspnoea,)]TJ 26.7902 -1.0559 TD (cough,)Tj -0.2466 -1.0559 TD (sputum,)Tj 0.5754 -1.0559 TD (fever)Tj 4.3312 3.1678 TD (Cr;)Tj -0.3098 -1.0559 TD (TPN)Tj 3.0856 1.0559 TD [(Hyperinflation)-1252.8(CII+Gr)-875.3(Alive,)-330.7(improving)]TJ 12.6585 -1.0559 TD [(6)-328.3(weeks)]TJ -46.8844 -3.1678 TD [(3)-2320(7)0(1)-1333.1(M)-2750.7(RA)-2827(NA)-1346(5)-328.3(months)-1684.3(2)-334.6(weeks)-1487.4(Dyspnoea,)]TJ 26.082 -1.0559 TD [(dry)-334.6(cough)]TJ 5.3682 1.0559 TD (Cr;)Tj -0.3098 -1.0559 TD (TPN)Tj 3.9834 1.0559 TD (Interstitial)Tj 0.6513 -1.0559 TD [(diff)10.4(use)]TJ 5.8993 1.0559 TD [(DAD)-3663(Dead)]TJ 5.5389 -1.0559 TD [(9)-328.3(days)]TJ -47.2132 -2.1118 TD [(4)-2320(6)0(5)-1333.1(M)-2750.7(RA)-3086.3(7.5)-2132.7(4)-328.3(yrs)-2510.8(1)-334.6(month)-1443.3(Dyspnoea;)]TJ 27.119 -1.0559 TD (fever)Tj 7.8783 1.0559 TD (Interstitial,)Tj 0.5311 -1.0559 TD (bilateral)Tj 6.1459 1.0559 TD [(DAD)-3663(Dead)]TJ 5.5389 -1.0559 TD [(6)-328.3(days)]TJ -47.2132 -2.1118 TD [(5)-2320(7)0(6)-1333.1(M)-2750.7(RA)-3086.3(7.5)-1038.9(1)32.1(1)-328.3(months)-1418.7(1)-334.6(month)-1456(Dyspnoea,)]TJ 26.082 -1.0559 TD [(dry)-334.6(cough)]TJ 5.5009 1.0559 TD [(Cr)-2552.8(Interstitial)]TJ 3.9455 -1.0559 TD (bilateral)Tj 6.5632 1.0559 TD [(CII)-1680.7(Alive,)-330.7(improving)]TJ 4.7928 -1.0559 TD [(6)-328.3(weeks)]TJ -46.8844 -2.1119 TD [(6)-2320(5)0(7)-1497.5(F)-1857(Psoriasis)-2026.4(2.5)-1272.8(6)-328.3(months)-1184.8(1\2612)-333.6(weeks)-987.9(Dyspnoea,)]TJ 25.9619 -1.0559 TD [(dry)-334.6(cough,)]TJ 1.1571 -1.0559 TD (fever)Tj 4.464 2.1119 TD [(Cr)-2552.8(Interstitial)]TJ 3.25 -1.0559 TD [(lower)-332.7(lobe-)]TJ 0.43 -1.0559 TD (dominant)Tj 5.8613 2.1119 TD [(CII+)-334.6(Gr)-711.4(Alive,)-330.7(improving)]TJ 5.7602 -1.0559 TD [(3)-328.3(weeks)]TJ -46.8844 -2.1119 TD [(7)-2320(6)0(4)-1497.5(F)-1857(Psoriasis)-1988.5(15)-1560.8(3)-328.3(months)-1760.2(10)-334.1(days)-1567(Dyspnoea,)]TJ 26.082 -1.0559 TD [(dry)-334.6(cough)]TJ 9.2188 1.0559 TD (Infiltrate,)Tj 0.1075 -1.0559 TD (bilateral,)Tj -0.5754 -1.0559 TD [(lower)-332.7(lobe-)]TJ 0.43 -1.0496 TD (dominant)Tj 6.4114 3.1615 TD [(DAD)-1418.4(Alive,)-337(improved)]TJ 3.6799 -1.0559 TD [(but)-329.7(chronic)-334.4(res-)]TJ 0.177 -1.0559 TD [(piratory)-331.2(failure)]TJ 0.8789 -1.0496 TD [(19)-334.1(months)]TJ -46.4102 -1.0559 TD [(8)-2320(7)0(0)-1497.5(F)-1547.2(Polymyal-)]TJ 8.8774 -1.0559 TD (gia)Tj -1.5934 -1.0559 TD (rheumatica)Tj 5.9372 2.1119 TD [(15)-2812.7(3.5)]TJ 2.9718 -1.0559 TD (months)Tj 5.2038 1.0559 TD (Several)Tj 0.5691 -1.0559 TD (days)Tj 4.053 1.0559 TD (Dyspnoea,)Tj -0.0569 -1.0559 TD [(dry)-334.6(cough,)]TJ 1.1571 -1.0559 TD (fever)Tj 4.464 2.1119 TD [(Cr)-2274.6(Interstitial+)]TJ 3.857 -1.0559 TD [(alveolar)24.3(,)]TJ -1.3278 -1.0559 TD [(bilateral,)-343.2(lower)]TJ 0.1391 -1.0559 TD (lobe-dominant)Tj 7.4231 3.1678 TD [(DAD)-1254(Alive,)-330.7(improving)]TJ 5.2101 -1.0559 TD [(3)-328.3(weeks)]TJ -46.8844 -3.1678 TD [(9)-2320(7)0(4)-1497.5(F)-1793.8(RA/giant)]TJ 7.107 -1.0559 TD [(cell)-337.4(arteritis)]TJ 6.1143 1.0559 TD [(15)-1307.8(36)-334.1(months)-1608.4(Several)]TJ 8.4158 -1.0559 TD (weeks)Tj 4.3818 1.0559 TD (Dyspnoea,)Tj -0.0569 -1.0559 TD [(dry)-334.6(cough,)]TJ 0.1328 -1.0559 TD [(chest)-335.7(pain)]TJ 5.4883 2.1119 TD [(Cr)-2274.6(Interstitial+)]TJ 2.6746 -1.0559 TD [(alveolar)-336.1(lower)]TJ -0.0063 -1.0559 TD (lobe-dominant)Tj 7.8404 2.1119 TD [(CII)-1680.7(Alive,)-330.7(improving)]TJ 4.5651 -1.0559 TD [(5)-334.6(months)]TJ -46.6568 -3.0034 TD [(Patient)-242(\(Pt\))-234.8(1:)-241.6(negative)-240.3(immunofluoresence)-242.3(stains)-237.8(for)]TJ /F3 1 Tf 21.2513 0 TD (Legionella)Tj /F6 1 Tf 4.4766 0 TD (and)Tj /F3 1 Tf 1.6693 0 TD [(Pneumocystic)-239.6(carinii)]TJ /F6 1 Tf 8.3715 0 TD [(;)-235.8(negative)-240.3(bacterial,)-245.8(acid-fast)-236.6(and)-238.5(fungal)-240.3(cul-)]TJ -35.7687 -1.0559 TD [(ture)-216.1(of)-208.6(lung)-215.3(tissue;)-214.4(pat)-209.3(3:)-210(negative)-215(immunoperoxidase)-216.8(stains)-212.5(for)-215.4(herpes)-213.6(I)-209.1(and)-213.2(II)-215.9(cytomegalovirus;)-213.4(negative)-215(bacterial)-217.6(and)-213.2(fungal)-208.7(culture)-216.7(of)]TJ 0 -1.0496 TD [(lung)-386.1(tissue;)-391.4(pt)-387.1(4:)-387.1(negative)-385.7(fungal,)-388.7(bacterial,)-391.2(acid-fast)-394.6(and)]TJ /F3 1 Tf 23.9006 0 TD (Legionella)Tj /F6 1 Tf 4.6284 0 TD [(culture)-387.4(of)-385.7(lung)-386.1(tissue;)-391.4(negative)-392(viral,)]TJ /F3 1 Tf 15.5733 0 TD (Legionella)Tj /F6 1 Tf 4.2427 0 TD [(,)-382.3(fungal)-392.1(and)]TJ -48.345 -1.0559 TD [(bacterial)-299.8(culture)-298.9(of)-290.8(bronchoalveolar)-301.6(lavage)-295.8(\(BAL\))-295.4(fluid;)-295.9(negative)-297.2(BAL)-294.5(fluid)-294.1(smear)-298.2(for)]TJ /F3 1 Tf 34.972 0 TD [(Pneumocystic)-296.6(carinii)]TJ /F6 1 Tf 8.4284 0 TD [(;)-292.7(negative)-297.2(serum)-298.5(titre)-296.2(for)]TJ /F3 1 Tf -43.4005 -1.0559 TD (Histoplasma)Tj /F6 1 Tf 5.0204 0 TD (,)Tj /F3 1 Tf 0.5058 0 TD (Coccidioides)Tj /F6 1 Tf 5.4377 0 TD (and)Tj /F3 1 Tf 1.6945 0 TD (Blastomyces)Tj /F6 1 Tf 4.9445 0 TD [(;)-261.1(negative)-259.2(serum)-260.5(antigen)-260(for)]TJ /F3 1 Tf 11.3876 0 TD (Cryptococcus)Tj /F6 1 Tf 5.463 0 TD [(;)-254.8(negative)-259.2(bacterial)-261.9(and)-257.5(fungal)-259.3(culture)-261(of)-259.2(blood;)]TJ -34.4535 -1.0559 TD [(Pt)-214.9(5:)-210(negative)-215(fungal,)-211.6(bacterial)]TJ /F3 1 Tf 12.1716 0 TD (Legionella)Tj /F6 1 Tf 4.2427 0 TD [(,)-211.6(acid-fast)-217.6(and)-206.9(viral)-217.9(culture)-216.7(of)-208.6(lung)-215.3(tissue;)-214.4(negative)-215(lung)-215.3(tissue)-212.5(smear)-216(for)]TJ /F3 1 Tf 28.3583 0 TD [(Pneumocystis)-215.8(carinii)]TJ /F6 1 Tf 8.2893 0 TD (;)Tj -53.0619 -1.0559 TD [(negative)-290.9(direct)-286.7(immunofluorescence)-292.2(for)]TJ /F3 1 Tf 16.1867 0 TD (Legionella)Tj /F6 1 Tf 4.2364 0 TD [(;)-286.4(p)0(t)-285.9(7)0(:)-292.2(negative)-284.5(acid-fast,)-290.1(fungal)-290.9(and)-289.1(bacterial)-287.1(culture)-292.6(of)-284.5(lung)-284.9(tissue;)-290.3(pt)-285.9(9:)-292.2(negative)]TJ -20.423 -1.0559 TD [(acid-fast,)-347(fungal)-347.8(and)-346(bacterial)-350.4(culture)-349.5(of)-341.4(lung)-348.1(tissue.)-348.2(M:)-343.5(male;)-345.1(F:)-347.7(female;)-351.1(Phys)-345.5(exam:)-342.7(physical)-349.2(examination;)-352.4(XR:)-344(radiography;)-347.9(RA:)]TJ T* [(rheumatoid)-280.3(arthritis;)-281.6(Cr:)-278.4(crackles;)-279.6(TPN:)-277.6(tachypnoea;)-282.8(CII:)-278.9(cellular)-281.6(interstitial)-284.1(infiltrate;)-282.1(Gr:)-277(granuloma;)-280.3(DAD:)-275.8(diffuse)-273.6(alveolar)-279.2(damage;)]TJ T* [(NA:)-336.2(not)-329.6(available.)]TJ 0 51.7024 TD (376)Tj 7.472 0 0 7.472 262.431 797.499 Tm 0.0001 Tc [(S.)-328.4(IMO)-9.6(K)0(A)70.4(W)102.5(A)-329(E)0(T)-263.8(AL.)]TJ ET endstream endobj 23 0 obj << /ProcSet [/PDF /Text ] /Font << /F2 5 0 R /F3 6 0 R /F6 9 0 R /F8 16 0 R >> /ExtGState << /GS2 11 0 R >> >> endobj 24 0 obj << /Type /XObject /Subtype /Image /Name /Im1 /Width 228 /Height 226 /BitsPerComponent 8 /ColorSpace /DeviceGray /Length 37739 /Filter /DCTDecode >> stream AdobedC    o!1AQ"aq2 #BR3$bC4% rS&cD5Ts6'E7F򃓣dU()8GHVe*9:IJWXYZftugvwhijxyz?.f7lk0Pu3NLJ†^j*:eZJz l> 򷖨oL:\S\u55]WU; KMQ#%4wŚXhL[oHY̙_T7]l8Qq&|+,aV(8qIf05A?L=*_M:Aa?n㹇^l[J|Մa䤃 x<;DIHaZEbՙKcFVb#Je0I_RDc!OxTd,'~;0κz\;#QRؖ[ U5uj3[KFޯ`'g/Q93g8sD̲UQQ$"(i(ibvFćڄ)Efb9/bWth,NhLS!$^U<3;vx՟Q}r=*^Q8d୬RG| ubʉ*9GHD<gM)2OD[j9YI.f|? ZT88]]F#V @rDެ>c4b:s\^,p*'6TRW̍QLPJ婉%Y$C+7Uhb.rԑ×V TPԚjhi3N~hur0d,L|s=:l˅`pVUKY%bCGF&T++tuQfz #(è$$-L،C N'@)%b5}ī-l[7uʙ3U.Uu5)(ZPB(2SGZS\K}ٛDuU-LيX*M[aX̃%iM4{BL>LUjz=Lfxs!1ڪL^/LG|8F4JMeed8֡Ov輏/owk};)}]R6eZ:Weؼ&h\2qã4U(#GN YrcGN`nTa1U:lB,RpO0ıEZX MP@ ~k9l?Mos]>cnؖw^ f !>^j*zJd2p__,YөմMCrji12(s&AE'$')]#9·qٕ<*p,j#x[W(ğ If`]l/)z-TzyW2 eLrVQR>ec3:QXJXmb qҊ\|# S5,T55JK aTB60D:-OBYԾ#SO8Vj\lQyte 2K*y T#̗^b/Ϗ_3dUFWècƤ̕O8&:&+ӬC͕OX&)tپy[ A5m_P`Yq:]eJcqSQ*/f81ĩz$$>tʁcS /M˖q}xL_au!r<*%GWS^xhcg1ggdy8/*ux\l)0]Zo14Ayr3T~C*yο|ϙkg۽ѭ~QcNO3x̹lsJ(1q!d^QVo{3xJhimLq&ˢ͒i)%j{JIJ,^p.p=/RԓKFJj5/&K TSURR=2<|ةB JZ9D5g}()ߢroAV c;BaX$"IjJ谣KNk(W7qT$q_$@ƞ,ĺז@8T3`Ο9[GC %! Q#OD2gGjETḕ\tT8~;^t,/Ү=Nr9O[O&%AZ*) EC4|ULUEfoH}5t/ N`91RY[c51ڊkH#g(2ƥɰL=W^rK~ẹG]Wq̽1?T,8e5R觠3r~|[x\`/| Ca8/-E%ᧄM7oVY2/̘\Gs%E$m5TOSAVS>j * >Jjy`}/]#bu2ɲVA@s>\æ["%sE@şxKy-rΫx=br}z1:k1"eS5~{S'ٵc^)\G/QŅaؤuxqtY&gvg  )pjhTq$0Ċ,4*[>8Cz|Qd)rT9 J\$DB]GpqGzplG2z ._Y+Ď^|j,O2%. -]'X\-IBΘ`?L<;'7eܩ5 v/8t < ´E6J"* ;eOGE~^+6ȷos-+5fsw&ɸVe&tcDSCTtsb8uPnr(*gJ+2~g5ƣ1wkjjġayI!5!lo)cə2z//R:lt$u]=/ -JAL`AkJf=挩pND'ԘfXkë)Ejh3%^ji<1Ȟ[eT\%⍁uua˂bQJ|RqAOQQHeJS+ln!u o/ sjS%]e|Tf'%(dvV$D⣩[bSܡW rLK1X33r ͅbX~@qfT H) #1u& $ž_.CLbrA "gG3e6V0İȤ^l鱊8b*x`]j3Ӯzÿf|m&5txC_I2I M_EOHo ٻ1!|`w{_])7y|ǚ2jWLZ8і=&c0EM4aq ^,:x ]I׌3=7ug ^z0玴gN0 śšvUd1U?Kb"s_ɓsNKs \K[CM5SPW! z5!$D,ѕnOIo6 1PSʏ+aI<"խҴHaC-0 ɸndOU[.]_UGJ:Ji`%*H'J'z̅e,(G*SeFi'5xmoHgjZr*F_UIPطނ9麝]Gj0<"=$#ET HGN̑IHn;Ԍg iV1hE.fa]`J+DcKQ~޵:WSk6s>h1fGS_ j:q*Ʈ iIWj3'U]D8.^TpxjYdWePYu6%7٣x83#d Z54!5vI9$Fu&d.*LyZH3dzj#I%:OQQRMPR~<c1/I2Pyj*pB˃b3A 1 ~$WHJ17$pd'/L,VeCAq*8b:)YGSPS%DVG$ D`X'$p7;qoK}<)ԽN x?,(6;{;> g g1 |75 Y35~#Y71(@!(U'3oUT"jBچɩq|k)oʑ9Ri[n~`Z5&"hq,ݎc 5]unOCWTi' ȩ T$by$t]cph+N77:ʊH,tqRU")MUxXWS:-3xʸthnwvCKNQjXn}n1EQAjL_%RV`0TCcXѨV3N#qTi\#tiqY( |1~Y*Up40L P }tf.[&Sj饬H*,:IZ.Y:#L7) 'kj裦INic`{5>C|oy{mq쵯ߗ/ys=t33,^xF1_+=-v?)^z]"AQ?e1F'S6^uQޗ/aYwT#XmV!BxqzƉȈ:2 (ۘ. j< Lw+k)Ʊ:׬$I/)A>QINL뗪юf(sKòZr.5t^j=Xj4I-0teè)iXAK{伉y^o{Um{Z<,Y=@=;sl#-Ob 2x[R\^\U&x'a(yϘ1]eGze3v`9h^[/8^-1%^ 55!"f,i#ی HzO[-ugxQRSVaTM-f]N)j)QFfڮLstk&au3ӂhd5] TGM -2"#xL])dRb(*iQk8r҈*IF.~zw0Sedy8&E q-S3 ERM"]ϙwWL1Y޾&XM.1a#N+r\s^jj'OW$SD<ųR N]lÔ)z7,1*ꜯOVQASK[%;ye I+z|C-eAޒF\6f+qJ0M䕣lI-"+c{ ʻTUT4fècjZJ0{\ŭBoӮw{3Bɸ kse15 t1FaeB )n䞒f'x)+1eK=JJjY*j9#VI}gECX*4PTf,;桫 *5zk+FBz-=Yð|cfLV*:y窪n#6SJJB.bw6Bަc:kjfYi(:Tl)) ֞z DҬtn(|o[x̴9m&](.6!SutN5.MPE uGJG,o \, ;ωO5 7T49dPŁ(7!ӞF3qȹ&"` aE'9| xkiz\23yN f6Y)=?]:SMKcQ?NãH )qZئpJQ,Hr#Jb1gLp,78?+SMGS%!È$MXd]11ɹ9Z/t pr -20IfuT`sg"w?xqc,`1[!ŕ2bUX2VGXu4TP\WH+# !}dg~)z&-NycY{MS| YV$RVa،OLO -Kr#}tg|;t>z_9VbxV\sǘ%ZaC2IRJ JP,5t]>GNxUb4.!Rb3QNPYE9(#ouoܵ!WWRoǰx?cUS U4 |H mrBpoPٗæ¥sq&|G䭬3|UCM$KM*0k"^nF~L,K8,s) ]1aaᦞBKKI  .v/o+UTbyjR:xk*jfiqKjM"C3,D09*ک#·֟CӯUq c+b$-\jӻ!a*ɐ:y_U+Cp|CQS.#CPsTӁ@F$#)}INSm63653u8|xG5;k]򧂧Ev asgVu=K#-EL~vzz q\N:gyZC]Xp|y}y[9곪}Sab8)+S׽EF >RQD<ҾXYFS٧1gLjB;r0 p*(ٙ鲤Uej~md 1<1f OCUS  UG.hB;uuE@:Sa1f\^|Wj*;0DR3Tو Hm1WɺԩreȹwT Lh|fXq#-RKE3DcFXaBwCA<+|Q4/Oc1tw Ob|'7埧~{y5o2oEENO,Vq.fctFjd)8)JdgvEXQcC> sAѼ2 jm.1,/1PE DoҶ4-i0p"Ha>GT_ÒU߈Vi [O3P+kp+U j|>ɌEu_!Y$eMѼܧ VbuQθq *C񗪃"&zi%&X2@²&I9:Xf93ntKIk?#,QOC hwXHU`.}6?ʵB6#C5hqC("B2ICB9*b̀/V!'G}v9*e|B)J Ǭ¨5QRbu@2ʒR|/T5"f<&:Lcy.⯂˄UFТH:3Z2Wt }H_İ\K6j&*X3O,:F+>niNr*ZOUT*F.!sLF4a% T_1*Jb2IRM̡2@S=dӮ|ׇ]d\՜eh*GU0dP7*V1nrrsen8* *:PsZ\a]L" n z_Ӭ$fX|ĩ_Y ѱ6{eq#8rd&ٰfJ(0&JXShZMVn׍AaԾ4w-g pAUDЌ.\>W ZO&X]Zv9U[SN O=v81˄VI~ 8jpi?BM4U7w<0~u+0uf0ŕ1.nRc)SPVS"-,M+JaXU?jO1' =VG# ɘ-t}W!#ZrĖbXIС2'ἥ29)Jp*hQ Й`j(k^?U]l鷨:+vY7tiO`ḾQ+e^ /ylD܄~c8fqu9~LӞi.#K ? iw4SMR^9 wcTt~xYk阗 g/zM:{6X X*iqz CM!i&geRibT=ELBs-n7ÅY//^--=OI-$>h0EB'䞚ˑ2OVp< 4خ\0n+˜qQUS@RCKQD~ꂟOAtn* |x&- \N֒!VMM&yw%H:QMҞ`.>?<A<חJ" ápOީXXg5)1ІLW2V-.x|mSxEb˄V0%bVZh1'3SF}abVgH*uĪljasaȂ8e3) + Δȹfbz:\B꥓ DUO)y`GTܠ2v00>iqL+k*phig歙jysrN7=aVZʝ`ꚟW1'8BGOx+MS$h6O2ȹӮAO_Ŝ#mkWA A i?F$u9` aFy&dKF`̘}!M#Pf1EVrSEM4u8+I*CԞ%9wC2[ʹ,Vفʹ'[:X)bYXTA!KT^ͰfMY,rK$&c0OxJ]T/oW'+m3?1~G=7_v/ѳOY//F49W>+9gx@iE1,&FqU-m't/S瞣:|ˋS Y*G_f$Y$d#"[Kl^z<@4O5 4Tz*j Ye,N )cu nzΙn3Ѿ}=S9j?ASLRw"FTb+=B?%M_EdWYb؍LXDeUUMjRGULR#KY#z̳ lnV $.aMII$RjRt^Dހ=;zAXHȹg^9UO4TҔSy5HsrGs@;9݇zÅ{\=;QWu#k`4$8dvd1p:{w*ԯOvW]M.?pةi936\p2 όᔔUD85[,,QzTjbh`C 7XP.eSg,ax'O |$V jKQ=bQԟJ]N=6e)21yXu\b,.ĔPI,pC{6b>`٧3?)O |Z0J *`RaM,XԎS2Y|#)`u=6Z,D-DI$Z@k+r'K}gK>_r&3+IƄ&S<Ɖ1 {E1G r5́l/]ZXz2f6JsGQR E( iđOHtlEyЍfFtPY r&>\Z,{ X')5\U,mE$ 5E24TmQ4(_OC5b8flj]1*穌UQOiU*2{bΏO!k_*+nHgL4eZc45b Mt+6=UaMV48-5E$p9Zg:hg2G" .fC1C]Y2IJat;H'U|V<얷(PudO+us^qfrF|͵fႶİk TZ.m%FY sa6|فfZ=G <~*$ZU2KMGN:H۝=ku 鷭վ9Qu©tYVMU=LԵ2FineGY징5^ Qd>bTx3<89(q/ 3BSS "PU,f/V7ӿǝks׿*G&M5f<:n[S>'Z^'E1̒5eLS٣pQɒq>欣L2xdOQޏ+E0dY*jpjjZZöWvm>t-R伥zCZl&+* DT:VQDI1+$Tzlr/Tsf5YCc0J`TตE6QWQP<5= Zx /6$Y70\:` ?pL[eǡ8rUVEY&b:JZlEcK!Cy~uEucG8˹xq'z4x& İkѭ:bSL)Ūib?6FPۅӜ #jh1 )p<:cUVjvb6ISR2V :ޓt;s6a\:ZG(# i*$$mpP4^;zъ8it5 v&A12UI;,TS8oх4sN:~_y9dJ݋NuVgc" ,z$`G._:Hk1i*ꖎPtS!I XFru|꿭)RxCG_ICOI%=T5?1A< ^LY&Ee2zʘߧl~Kqzs<1MWQQKQ$U^bMyePnvz6 S枇,u:\0QTmސRWSHm#IKyUnjqWcU_ӏS?7\?S  {%^ gJkpI'6#.G!O+u^fr2u멙t"Yɵ.ixeU2a :[sqezeY8e.U`$ eL>!"@ 5,OQ:юSfl|Ljţu kżx˞}lÃ/&&y*1:jca 5i}oFy)WyC[۾y{mvҿDۣ/$A] rEU54pjy]*&b :ǫ*"zjEGd:x=e3fN:V6FqJMTDE# nCGb?]y}#+C>neh歩$k'JI&j'C3O I{X m/YR6C /5sQ1efYY qH+7L雠8Qz4(<XL/C,11oɼ؍ Sq ]±,RL[i1f1+fl? L|&!,Q8B8x90v:J:w?I Ae="X~=IUsa&fĤ|+ [MBа(-YN7UyNYdYZ*N ax};bPTMBo6 VW%XYl j:aiq\62WI)$ZǓu^TbU1@" nSspT_ Pq/a+U5|Dut"QZ-$ ,FzȘ}/O+L9)*06cYO%"K]IVa'I*D2M$UTcRPNUR5 4OE+e.]JJu1SQRBib8 !DP;Xx1c':zk|zm;0Uǟk*x}-AY ꣣hhD n^rBz+LRVn5ϙŌO,ϲh(#=v6i ; <;U "zZئpθVg)ɗq^! | !%Gv]IN\G=MrT;r#xLE()Xˉ AW#J 0z*W91|+%ztPQSG $׌zmr\;co^9w*,x}%0Q Je[{NѨ7 qf&%$yVLE[FU^He>fHbb$}xHŰ_5 Yrh8s:;)arqjlO0fQ. w|4Ubl4#vy*⁕YXǧ̻ޟN_ (ʹJ k1䂚yj%)&}RЅ_Iz=cZ~M`3# T|bȋ,0UIyȭ=3(GVY`X4t3U æ姭yiѳd*E:WN//'P\ /*SPᭌTYr, Sp_i|Qȍ)z&EJ2mvV3gHҋäv+*J*iZp"j$$eE _='Q뢵F[/R5&\i(&zzfd_=3R͌XdNtԷ@ r#&bϓe\ 8bxpoX)f1dhY U%M^M5Y,0:ᙅ4faZ:JM lRz741,5 DW~,w2_.YS}vZx .+@'cq=M=eWVMF坅K8t^.ƳؖTzY+é%̏aT`^)cHϘLt=+ ~:/`G/`Űꪸjz|_=Ky6y^Xdh#xҢ3xԫX;kC›tCNhUIqJ|M>/Vb zj1*d4SjU8xv8$P>f/N^:Oe7Ϲ~1ts|_ͨ1nay+eS"CU5TTT7R*`PE+[w=V"fߑs`Q`-⸅\ O.T؄i8L`АnsVbˤ:zwF&  pϗ jkږ CmSpx3t#9.4 T5F8yOS4"3YA<}5fϹ3uyjCZz^(LU4>ld60NGaa8z죧aMZN9ջbhTjh3boEM[%)GaflLKW rW,`ȳ3HwR=:gjR}d8L1W1Vd|f,JRsK[I@1 H rn]qt\gyajopLթQK"b0⋌̍Vbei4RBBi *ʤ8X餎DwifR@Ouo8eN|Y-Uzxu3b0Z+j^ GMrWL#h|i,vؙnjs䚬KK&?q5y(&S?]n# mr5|_;ORj졀.U%ullFJXSYdnC8&_ѼY\Oäª4zi*_V:m j DuGp-#HC3>aȔqd #sd՘ =>cx*)+SMQ$PUPb5gIvFR.TaM]'XvJiaa' ,PCGbt񲉣s*XA|W3[7N47R7Pb5yT:XmLʯ,I-7u]WijlTf[8_rE4-OM BJxHj07+XOuO"aT9ctbx!g3x-|mUST RPid4,4"yvI; 3'aΉJ*.D;? oCGVűޙ.=Di13z8iqLZi,Ԛi%а_o'8`YQycqJ*n#8X*D, iYH$.0(OQyó.e|fzWfB>s|4'P4jѴ'j'F'%4(!R+IĻ5`IB71#AX6}4x>dZ:_A򚶧Hy㨟˙6oק^6OE[s>%ӹXGlKAjjLXaZ ^B4"="A="VV;g,&J"%E^YOGcX Z>XѝA.OG]&r 3S=^Δ(ҡ$ J!4GX&_,2IO4'֞t7IꇧYBl 7 L5y錞M+S Y)yOZa9WbƲA臩1~,gϸ|90Ŋ|>\Vh3K IL<)0*B̼B_WYdt,y[lSGCAXҫϝ}PetJKIf j1 F!FˤZBJY6}${/>F3~xEV9pTxZ.*k`U9EQ.r7/s s۞翏=sߝIbW+/N迩XʴRE,XTGVZamJK,J82#,Qrc+3f2eHlXvM<% O tfXG1-$jTq_u ЌKOLayR(aUĪf$SO[#Fx^±º_\ǝ##'N"|O1y\Wis=E> R%#GS aC@7P?2oKsr՘ 5NTMf"*$;ZydxxźE2|Y+"Pc+[`ǧ\7ST8C%|p* _w,f~zSFn3NՏatح&[ǡljSMMNS򧚲=1ܑlv+|EжGa ԌtSam1b=E3!qE+M.pfZ3g Vi7<͏]SU 1[˝ RIȈKL!>l_&̭Q`q7sF^pwâz$Py%g+&>`1ś2xW\nW0()90J|*y1U)jq 89jayjX*rF{ފ?iyt8|c5t5QxXt6YV@I! LQOziEGZ`4sT^N<؟/Rc% ycUMʴ4Ib-=EV]cD$r"OK-5!#w町G徆ȹ_8Bf.5 2iH3(楃J20,4p=`ZndzlSK1O:OG]=U?RIRLUyZ͘np²OTO*3X+[4~S8ROYB' I,CH!SP_et0z=.(?5WH*,3IY&UFԕ05lƕ;\.(o4,teڜ)c4PVa& L3͝/Տ6hSe> %Χ`#RO93'ȃ/GI'O ~M mSP=ḓ:eGU4R-. Y4K#4 4Qc/r[V?MO_XmEltQ*RU\OSġIk˴f60tմQs"0dtp]n#PG9pzso(ѺJ>,Fqa2af7 ٕɎvB#NPX\'n.M6:ZjˊUG2GIQMQ*Eur u($ca)ħj :lJ*輙aC0xWcjߐ:ic֟O?X s~}9n0@S]%RJ!s q{Y);z">ϙ7f!>'^Tf,F (5RTm;B <¯]6;kXYWZ<=sM h:D^=˾WVJ9hN|aϭo0v7knw۷ӟӼBW|-R5~daI4hZG 3J Pt$ yhJ,SW",qpbRW1TVʏA]F^mȘ~gth։)pu~cZZeZ6Ya!KF+W=.tZ< 4,6Q±  ja͔8\usQRyOTya}?U`Y7E:Y`5Xe& @11,&(S t KT:$z\;t+0 TXn/TxpgǪq|6\4xR|4kx1*j@Hf豞Oi뤟.˘C1̛,ƯFl5njgb.]ϘKpu3V+?~U*X M5MEHǍFm]=-$.z䒂HEOOVL3H:Yk6CUT0[a%`VT:>zU;R`O%R3% Q`rMdgG+,-==9`QfRtew,b9j1GZ+eDTʲ4`ǼnEO+:z=1u/$bTYL.t٪񘦂040 h`2(Tp/:t~e4,±[hlBo0ef;M?Z4f}Zϙ3פ.ao3q41)ȫ^ 7<ȉ_k8vϹ0Ő a#_x>]|3 Ɠ7`dR]fs]q'YŰA-brlG/8d4YY .oh#TLG^ngz f=PaYNePbU sQ2 6[q/:,KeܥR6$,GUT*>f6 nd?@¦£-cYg 1x0VRᘭEmY0sI쑺26ceMzQoQu}<5(p<'xMe.cJj_ ī悖Z:Ly.8fp ^s%=7fn~Os^ :l0Rt\ дiOUKK ̉"(8w(7)a1zo0y#]GGSAf\jZ'>3oR2VH~=.^朻QJ\˖΍SbZx0_)ZDGȄ] Ŵ/dׁ笭"fӜ`T8Uu.%YI*yS0K5çSY TQ̩YY>%%yxA#E#O?bUvWL?q>YičRV6̍ ѼDi@*?|YOvڽ3~y_xպ칃f\3Ū1aL:0i)8}9 7p7X7˭|y: ӕvuC7byWİjzih9WGV*ʔ?~)sM: |Z )ټ5^tYVWOP<4X!N՘d8|9ce)H HS-Ntuupn,MS5TPc/zZ驄+XI!II'K[ F,&J )0CSS6]S^Ugep; |kRUf݇lG!*ԗfj&I!kӦHFo">azSSJd< ul-iE?'/y#Oހg>-g%.YΔU}>?0*Z*|-O Ƅ47@_tfW!-5Y}cźًfZn/+ǖ,VJ ze*3b䩀QU62UW? IMEW_U:j :$_.,Bqz)CT)iu-:oUSaJI 1\"(iQ)Ң$$\@QEQ3FZ2Gyϫ;d|wVaOTpj&R owX5Ǐ\=n{t*u3|4RDMm40=;YTHyZak]ƥū8Mp1AauINJJ2@g$15>t;&zutv)p:e7 Idʔ/jhRZ(79W,9?x"ԱV̒K伎ı$8cuF SAYtQ Q7YI G~N.,sIؠrGK?Sbӵ3]c@!bWg>O1|_HN| 9pzJq5B`4 kڬS-9h*E.ePrOLR5q8n_jg/ ~M0l˅SUX.9DΦɟ D&V/?宜He/Vi܍:qDJLA3Z(Pxw 3`VI $j,Hz7,L)M?Mkm-.-+q VLHu5^#JuG4KI F $1c[Osbُ5Ɇz8j78j:MbSx|:\2ASn;eo-D͸XПLX&GI.n3.:ho%gtIc/m)6qu+2g,'>#"9cQze1O UO_Y0*eQQSypI&T&Noi)h5M:qK1Pg4PCG-\rk) XF'*?>)AU-.N φAkb1RUU1ƣˍ)2;uk.ރU2 ]&ƼCVH\JW墊he %<{$Q(##A'QV4eʰ oc9dŪ03"oK<2%3REmNVV5°ܑ7_±||,QVѫ⮯4TK4yCYYPʾ,<F^tRCU*pD G[lKƵ1H,*}9f:\b0hpj$Z&jD:2PFgu>vOyqr_9?*ȪDVPzsz;ϗWqJW(iڨQ*JV'xXlt A.J"殧e*ٟ:mGJ<\xXfL@J\<)dW}7mX0KsN\ͨ-&#<4UVjeo]Fc$r#*aR`8gŲjiq>D0>@GdgUK̅E⹓hJlÃŔJSpD+y2|Ol*b9~/o4kn3ۿ7мSxn`|wҠ$T͈g܁W!)^ ]t) Qɴp"Έ'8sMʽCʵ#S`KPGVW#Y5h0$>Zd"lGzșf>t+5}6dWDpSR;K>+ $f/iv w% => sU*|PK1TM Nj<:+&L4LeUrJo,i]q0l4x`o?12jyZyRO꺟"u+p*|fp|E5ij-KUU#]=@T(>?>TRaJlpzx0ᩋJGᲭl+D%Ҡr`}LH!g1% 3U4NYOS<,E5F_Z0Jjq0M&ǪxT;ě5Szq^X-6K3xra؂X#bƔj %`S&`@xI0nuGdžc_ /PYGYވVKOWY,{D(dYG F37Xe s)\8 CUA2O0v2dybF2!#3]٧,9, q&İaj2_3խ5YӘes5m|og[yw_KwѼCr=&9D Y棯 OM!F͇#=B,H9æV5p*W>T)2L5E:9n&#zA8^s9>:l=3+G3.XD9 "A/IVzk밦^gb5tQb1a894$i%u`̍t#JN4R(ql崣 @*Ny ($qJ<k+eW( ;,QK B4g"È/RޝzVk&}%Ne²$ZH;hcDa)ߤۋ~z/A0})†-EJ56H4*.cD%lX*,@<%=fS̒ M&!bB"85J<2G*؀$L{0b1EMn"jKLIU`!Ia ʼn@TD*%$FZ+lu{@V`WUo`G"\ \KYI=4T+#/u=⦆55XU@U 4 ݇9 u#R8F K(YbM:L_sNZiQ0d4TrV mr2 UkC Hs$+y}CgLqqOyxE6)=F/bɅSyz ipMįUXFVP[gsҼNz8$!cPX7oW*1Fk1/u9*n@/z*7S'!a}zQתX1Qrp2arWQYQlO-zUCb2A)a!2z7&=QCดn1)^|Ӆ$fHlA/6COM&FF*+!h)/!G[y`&m8:+bT,pis#a jJ('Hb5(2~$=?3G>W&wIJ\4rQ*!zI$WqCc.E?!18Ph)qFBWE/Wz[>*+f{3VSap )`ÖBHa9= ܩ 'tǙOC]?lKIGTt"8`MNb1D.E}=`^ 1P_c~XbRCU$3yBfB? \{8YۙExraTHg`KHԿ2,rBGvf,H+r wHqΕfZjLӅ`R_Փa*U4Z !<;7U^hͿWQƝX(*8EEVb|F̩$~[=h`yӼ?spF?1/'.wW?/v2S[W4"ujI><~4gag|= z%Y1%J"~6¿މ>O۳~OWn;{4+c|= l%'I%uOg> stream AdobedC    o!1AQ"aq2 #BR3$bC4% rS&cD5Ts6'E7F򃓣dU()8GHVe*9:IJWXYZftugvwhijxyz?uGTº×0E'1c*t~SEbh!jlţծ,s/΂'5Lrjx L"s:Q]0GQ* Vqw;`b&K*+5͎A8IBKDE0V"rdKiȵb\H*S(cFX٥ MgLf B*F>_hL1Lؼ!*.2B}*GV:Fəv:EYc%A-=TG(fնǧ u-fZکk\FAfE!{ΤDU{+^/Vj6?f(rupWaY ETPȒ yU([.(~lA[`YNqsI-RWQJ6.1{ٝ*=AY37R W&YjU5jɷ62LKg U6SSp%5%,i0HHUUWOν?sV]Q+SbN#}=L1>zHJ6#cÔb9iBWOQ%Gy<ۼ&Ky;tlZmÞ|eCk>d"i)a)Vxjihe$YAtz<[?YQEGNLG欮梎hXd+0DY)gyL8 U^-WUxSl]](ӼԔI_1D)59W͇3U7_&/l}_мk3NS -~Yz: Ȓjzy)*U*6ۨ&+V$J&œ HX51 kI,%2{EsMOpɌeD)T1,Ťmx:0ۜAc'c=o}QUf,3/uVTPL6X KHeXV5tC02A]. (('rrc]^1j q\)2eS\ƪgJ\|hjѤ5R }wD3'ь".eOPԸ>5\aqaU(Ӛ UDآSFz޲g|Vd,㖫=w°ZI52 B|ڈdIdU16;c;Þ*: Z〦sH*h1j(3Q=6)Ea3QOah\VyѠ-$'vg7W7{9KTG A5|Դx>*qWIL%]}F01^5Jӿ78_N32=+a-% \sSO4%LHvGk 7ȷئk|W]3{v+/ѽSp{3~%% $eGO/YQ_KAE5TujZ*6!`iՐ\]?EꊻCpj q:hq DL:Tخ 4De"Sot*Ӣy1HrR YI5VIZ(̱(VSל77ޕK% LCTI!üSyVL2a䠃G&gH=u5TE(fVTj˭JR "TFۼ]j MN_=sBt냩[nt.OǑ< ` F:j G(,qYvIVp:IL՜UeË,!Qq/FK VF'E2o[f w>Gu>aG3ρᘥT/Q#ĘU1J3=+H Ѡ`gJ)1Y/?H3KfmfUQEUU\tkOQMQj)dUO-U"2=L8hĪV}6 5*1R|C/~(iZrJH%06E<;c# 8N뫲. U?šq|ZBk >JcIALvwvU}nҬc :C\"PPLEY-RP%+ T*c'r6t?^C[徟bFjl5fw 8{UTSRdǹ$E:eĽ:&TRg&99UnL]:SI :OT1#u9w CQPT3,sT,*I:}hBE2?#Z3wQ}cӣ9u}JY)"l)Qj~hM1B sߍ8d싄6d8qȰV X`ZE_^9 /|S0050)C'P؏o-v!VYuz}qY8zZ@QPMW >S) -t-Vٓh8\:#2 T`lu7)?XN'.xTX +b TWPD㖞*ƝJ7K>Mʝ'L טs}ED3%-,1,&a6^*cz5?}KO[2>)WU0ʩHz\Z7xSUCm̦D{-Έ:Iwx.XWEI.e$I存NeoGHq\J݂6i&i-:UF S0d dc\hBu'|Ò<ɗsV[M5ITEPԔT,WoXFxS#})f^fiXG2@;Ƕ}>TbURG 5jZui"BȬMcP߰Ⱦz+Y/Ӧo6fj*L$r zDI"J+GM Tz!WsF (rNq+1x62ꧤgE D *źӾǖ)0|wZ1S1;-AJU,G rE[[8ۤCLxMzWRl' F)(bg5xZoR0.;*c`'_k}N s^eZJ4WÇq<6g )!Xes0]!)u 0;/uo7b`ΘUCauTeltڅUqDOI sF_fC8X2URCLR\P4mX"CwG?Lz(| *g4$ð,Gņo>%]\DQ0:, f3aنTF a_ib ӸgD$0@J=9t_5WS`خaZTŚLFsXYQ52\ƊZ6əI˓eàt %F*H2ϷPHN:|䜻 4BIW=UT45fgo;68ƺОd ?o;%PPO릊 *3Jڠ݈">+)@Rgl0N3G$ؑjbip"WZAҬ6"]oN:p|94dL4ؕ9˕UT(FUO ZR](4J2цq>Mkx/Q*j3Rr̘/c$36KxudxU ӱeK40;pY;Σe 8*&?LͅTS4+!wV0cm Czz9+ ZDžbQOJI&fJR(0D0TQ-5u|GAp^&a4bw!R9335UE>#Gb CGBIq _sI$C ?](r ?f Sc$HRasWVS%TP'QBMB T!\:͒:[^ [E!_-OR4Hu%r$kOB^NrT]5h1O4XF3P .I$GNiY!!^bA귣xK"tVgQb=cuUVWđzO"uGxhF+ޑaN) abWl?W e1*03Dkҍ zJVPEHlQ9s}&zu#aax%|oU tBjJ9BY$N]zrNAxZrT={4XM*HPbqᨍ[ GY#;p2Wl++WG+<~kֽ۟WA*>.؉g/X 2SED gh3"󌎡Dppj|~:* ?r<a~ܮ\:u4=)3TRb2Rafɗ^ q%Ю 4Tnpc +cIqJQ Mu<E(+C2MS7>l+CQK=4 jl'hH'z]%t]:CŪk5IK\8TI@U-+q-.cGtIYRS,Mk*m isO%4j5dxP=;'bن*H0ɗǦJz:8g',&U%";XYM?`=v 蟯X7O➳(f$JJ)MM 4jM1G^_QRg <<_aurM^%]- ¶R ǤZK#S(gw˴\*lW+buTu145U 0zyE;E}+iޞ=Jacٗ ~d85e^w>Cj**|2USʳ4UBr~isUs]I2+C!FE,j#Fauu ė<2v+),a84"* M\mM$pKKhY n&GC IOH+Ua%]l }8r^QŘh(⤪ZbCU&*D$Bn5Iuw 8S9Ď< *JkcvfU$LFU 9?zz},n8_VWfUtrJE$Gs)M HzIZc'#+-7(ܬ 'kwA~og?Ϝ˿l9;׽c:y Ǯ<͈SQeؕD0LctP^w)i$rŜHԎTW=SgfLۚ`pe0[2WSfQtGk.eæ\"f gƲ*ed㫵<_:eB,G \C鏫5QưJY>kexTWEP$HޞE"^~9t B+:KA )~7ceZS"̪cBTC=INaM ♧EurTAK`2WeHb8V[ 4p)6źJє٧˹7K_ -]-M$kRY c<f'ޫǩE ~;1$ɞ~UMѫEGekhXD,᝺a1\,q\U{ɭQ U,0TdJ$RBH ýKnY,qGK89 F5Ԣ1jI ّ0ڌbZxn28M\uT_{1?40G1 og\.<+Epzhbw&RУ,$q )YrlòRE[SWN)i)g*I|a (XoR, =]KO M2MB:,%gP9]OpQ:Y,O,pVֶ)KU%I8igC,+*D_vGFgLN]@:w՚E,9X,)`4L<-)(V2;N:?_շP|y>{ݻ^нf7:+t,fZvcUtWʑA") eoK ̹ēä݋ȮD+R8feg@F%6ܨȸc0ks>_Xf>%a.7!fK=,MQKA'*6ߙ:\s%L/8V-+ >.XE>[ de7?w[mEhϠ?]+sGaf3lĦJcu$؎"Udue\-- l\8dUi*bzQ DތnW=;3BL&5d1& &`h Io0+/?CTCUfSt1aSAU&`I$Mjl*!B/Ë9cXJHs\N5MvE*X8AWZc T EgE [Ûe3ϊ1R5R㴰bXuEe]CqI.idQd&I稪♗d#F$j<,ēTN䒬z=Ql -%,v#Ks=BSgZ|vĕcd>“nxgW:k_TS*q /6dz??YN3WM Odc(bI м+"2gLOu8AfeTNMWPс\Fcdܓg/T}Pz#n̘-C1_]ca)I -xgTSȡe#NrDiOU61l3t65?9k(詨'bYHT1Ry]_W铨e#. 8a_UKVpL8J]<8p"ft2e@0Ó1D+0L> . R)皚|H/ ]xs/N^_^@RT|(fH$~[aXK]4űAR9$yeHaWRWFB٬mluSQCC^T|3|Ғ<4;$hrls Mp L>se,rRTVgdC$!ȁd!T p2uK0/O+rN,S[],KO6Lp͹ ˹n?{'ο'<[N_|ߟ̴?ѽRntG"bVaa4x]B4SSU"{>8Qg2sD|3Mn0t:{c# i]dFHEͽBxRX}%by{ TsWTP?,)'XV:JDKVTQz&p:}V)Pc54Hz<2ԫ +MK~,Ø`ƽ9Q֮D4(HՈeehiiv+D,l".h1,-e$ԬfA$`KG#r먾~=P-R=V`+$f%H*(%hIScц$Co-/ݿg}yҼ&^Z8+螱 Orok ~nq'NeuO՞^òї :$_ϕYɖJE)r dG]_#R26#[AI,U&/9L[-XwZ9n,&N'lU&F%l:ciYťaOPto\<J#PvuοMr)>zX:{.NsS|PaMQaDw~WͽU\[a=Q,J*+Zy1f,+GX>Ӛip꣚*l5azY$4OKMD$xr HmOJ\76e\LPISMc_;T:xzduiؐ)=H͝q/M8OrUԘ5V%G&7_Vi"5)K=5E5u4qUCL\ ZF$ҧJ1z>XU(bf⺏6aԘYjA*c<[HLE#oPqqfZ/tBy[ʘhkMd*UdV,#q6e|iz'؞ p-n%.[Q MTQ2K<TǓ=*:d!5r 1,O&2R5pu/`+. CJH5$F)/sӳoR~"2='Np>-I&-+]cx7!D~뫧I3]=3-Յ6\&0:#؏qIH 9dJ5%8iĨp颟fxY^9#uFHe`AOxj+2M :XU)|RJ L*Ex̐nxK\~EQ ӼͯE ywWʀD` }k2ྙ:GZj Ej2_QG4oe(7I;ޓUkW^I_$VL0ièzU:LMEMRb2̫Dbӧy? DZnaؤyJ<Ԛnb5j .( iԼ,A*(],HME_ÇTE*cI 3UD- -,x!h?d E(,q:wE`yL[$i"kWO<ҙf_)9òX2^UZI{?壖\KzʘdZec ^|Lx$d(z˝4[>f:U㴙ʔ65c)KTAMTRaTRCYHL<.֞'-8[/T;18 *ZKPMR; ;Ƭv0۝sNtJΗeLVOT4ҵ=4O4 <7z\j͍dhZy4մm*}NbW7U0?dަ\qlW+V)jzV܄ّцF@##֭tq$Q4$Bd cC+kc{_\s31d9X^!؝.9yUHJ+It`0`}PŽ\xe 5f~Z2J,C(]>v&,p">CЬK܁UKAʣ(IKSTPJ|4΅BU]y\$h186+5mF`xiOԽE# ב~-,78ٳ;`x}p\zW9*W 䏒dÂDF T1pHF|ՎKG%RBdH${ai$eycв7`X3Ҽb|Cz }344fh6, 6 㡎?%މ<7d|zryϸ]e:$lF, :f %02VcnO'nvnԹ^2 fz6,* >G;w#KӀ4 *KdejJ#I#WDDwqEASZ=dcx2QCIWKRE!ӈ﯋5M0Z;XfJY)tdEZ{ C2uquŰ̃}.RV|_41VPSA% J 7R`zĆN}+FKj=fOlSO6^buT$y 0xi:$o$ŕ*2&'FSg㔸zYhX9~ae`0lISroS0pS9d1:xiaJj ^Yˋh9駠/uӦdj*h>j)1 _,2k=DѨHiTt-dM9,VEޢsŊeyc7P-.9_Q;b$O A&**G@8_OӆWQ]U0Nj?ɩlFҲ2BGMU^t=Z1֚lӅgOaض#IQۧW@)V(J, ;O7!]EO-G!;QѲbSPmh3bYD&?͕Y%y pClj6i|Q*̊ ʙOYdz'C#sĺwOK<0R ਄}G/Y]rϨV K|MTƩ0C pҵiU,t,l9!.C\Ö'OI/%NE0Xv Gz8}ㅥs'J%55=PDQ$P+&m_x1>g^m9,fie kI$ `cwIק징qlUJp̈́矚ŝ<+0Sj u\ݔ"FYGg;*<́g3mI?Λ$nxpTtF`ijr>/&r*sIX^a~J徠R=R?NƐ2:OhIY*,n6)}Z!-lG+O,.-Wy{1CQIW_U1wZ4TQ㘥50iW à$S"E%ɬz}@OwV JTaΓ]EZ>-AZ!) `d_΅oLs^2dc9jv)PSP9aR%74)d0ӈ` b6!擤wM K_pZ~j|kgl& h._/Xs>7Ӻj\1&5^؜>'OS$f0i?Ne\J@~,~]+:uiQCW6J++1L:,:xwx$-fUi31fL[JJ&0cX.%AOMTQ ^8>Z1XQ!X; pH8׿Fmɹ-gz4 Xđ),[ot]7Se?WLR90Qųv!$\CYhhp~jE%aWPl g(:hzj?'/QVp|>*ZP; &{G 1 ["]` j)&fëigL ᩂ zji+?/cfC!7E*X0b'4~i&=zlMOKMU[ޒd'bU4%v9/lV3&I0X Z:Nlk ̕hXaJ7>tW͝Ii(9s$PQP Bz:%OM,Uѣym o^PzxFV8Js RWWOGCsIY M ei*J0R͚S6e|ӌHΗ5T-\ˆA;R$JKQ"˸m2f䕨SUo)禨d1 9Q~Nwڥa-Y"D*hxY(J7t5+aV2W d][a 7g`Xx3rfO-uLXS+"5OV%oGej:ƀ͘4+flq |s7@Q=$-6!M1|n(oqYB~!vbٻ3a93U* U|h~yZG%#%ՁoSҎC.bLkcð "ڷiTQyb[u?H!|̲ugdYj(ދ,e%j)`tj^X#qBs'NV٦M:e (Q\i+k"5v ONd0)ZAQW2*;1k_V[1,xMSHؕ,O]Ty2y5؄+S<f(2#a5N7g\n8xt4_II]|bYZ RJtJidrn*ኮׯ*gK 7]}e~Olps$|Tb82IUIOK!y9v7xdwOX87,A?l73kE 4RP4 5b_M:5e<5tنY()1ZzI(8ư`r̠ΛNX}<R@ȱF#UUQ`h<$Ɵ=^qyjsair=EQ'/3;*RXZtV:^gɉk˰W& ±&TUP50Q*DG;<5O[&~f+gy{7vӟװO߉i8O._3n^O ]DTJ5PR$(&$f؊/~#MY rNn|JLj4xZFJgY-[JZHAswR:OVˍc4t&p1H[zD4Zঞ":Ca8f rel%O/ǽ9zI%T[ 7zI K;fhŪ䉰l6 8~^*z:Jʉa9}Xqs6tC(=N'E`5E5b >`]E1fQ 9T`Jr?/G]Kc=7>n,4MYr%,TrTT+iY&6E*HO*L,>'5bpu/ 1͗!R>>ղT044ڀ_zM\+F.6Ն(p/N_Αu +MbSU`i)"<* LeBFoL=Ͻʙ2if p) Jϛw3R$JYi 4z$D}/'U2Z{qSଓ %N1K%bV ù"+dCxɽ.oRYg0c  lTfoG$A S ?N_qLCb0yð.FE5Lꡤh@9E6fq;m:)qxa4G#LbZIcS̱.Ҟ.*1()(\h*̨i!b*Ln7ۭ93h\q C)*CcVGJ/ֿu5ST=LptSh-ZZ[,EJc]gR\r^.SQCcrԴX$hEss::e_`Mܑ*jpd{ 兊4hK +2eo8u9G3I]V φ-I"a_`jJ*2#D?R),=@#ѦIqJ1Կ3QOVG4q=(6ĕbVú%Y G_s7MPezĴlQF8b!;,/o@8R:Yc&f|͉XNP&P{j l)pYO\sTfغ_׼lNxL2NJwlR${G 6BV5_4{{yWsŘ2BZ؎KOMgIəd#6H͝˵>𸨡hi,. (0AUK-ebK]|HNm]o==AtXe^Ҭd0YV5mROF)j%%"DQ̊ Mz7ݯ0N?x Ip|.jsx8ETBJdFڲ _{ $F;jĒrm.5^~ ԲI/K $58Ъ YAL흑Y{y0\ ?RR#yNIVѩG͈I)>sFe} 0AzLocQ.byFëDsp^ԲSOMWK#G W^r'(;U%?Y2g2\x=wJY)_UNZ*?J@Ub:x:̃f|vlG갪\3RbTuTB <s+F,db bO4آqDq%y.a4J0|G#19!$6❖:CԜI3$-!QG-%.ǫ`@L> k{\ݐQ~NC88$5 +)YXV# Ҽlo/㨋Z/ꊘcHD0]zP#Xu/ '0Z.M.-:HTSGb5hFd1L7{*_X EhTUc3aR 4T5m4[a;TdJ޸}/cxFTE6'9!W͇,y1!&"Ī#^ >-,]Si0wJQ$HisުA HA>bYӬ;j.{FZ**iq ) UM& ϰ`u8flɵMTqTaQ!Jbyi=#B&nmGxzeɝK8PbɸutiNS|JtKfFO$#}=7B/Op垣*p(5AgXʾ$a(2_qO7nI5uOSf}S`q6!ބA`]θ HpF&jpijYc%hRV]IeF3NǪs 3 #e 7uN)<nC")hQiJ%1y:P?7I~Y:y ĸtMqU$qKSHcd>kY0^X/Sj G_ð,6?-EudubwGV,("@Hhs)\Ǩ4Xn^ i*jQdy !*mk~5߈~!=5Y+ Q0<-*E PCM2dzR' ʆ6iE}Szx] Z9x`1 y)p|R,3BV=1}Y\Zdy(BQ(jf*+|d55X#mWTwf2& ʹ 5=+ %\M j,op/}G30ưѪIbՒ>%75u+S$-E5,=};Y $Yz?Ꮸ=sıLG5㘥6`?IMGD4V3e%f,w߉/ln˚:I5h jւ(%:63K=7=Sbq g>\3CZȰW LBjwgX)*ڙkFўzTF'W5G3M)DZGK/-ur F_q ^C9s>BlL&c8Xf3KG;OCP 5 ->,&xc}?f,ԇщsfY)W'4TTRIUyeh`[OLsnwk[tL bGyJeFH#P8bE$Cv=UseF_%v#CU[BTpUQX*XPyn'1@:p7_N*Pql O2Ј18ce) cB,Ƿ Y/Fmu*ԤpyIrEEuEʩfo*:$@䠍r43/KgHź.[No0faI)V"qڟf$+!  S_qg-Z]~Vc||Խ?g~E?Wi{w k0;//,)Soi?$%8?+]B[tu{7'::?fWb#C?ǿo;KC1a?!Gpf'y{>?0+Gzgǿ ?: a+jo^P;3;kb~?n O.#}?'>cFrß)$O%Jχޙν_p %>uX7bOgCǿ:?gǁWU!KGqթK1 ß6/o ^7V_+Kw)҇O?7?@o Wa 0??a[ ׮?ގ5$Ko{J_{Mǿ 0Nޏ1_'ҧ{x4zz?*??r;K) endstream endobj 26 0 obj << /Type /XObject /Subtype /Image /Name /Im3 /Width 228 /Height 171 /BitsPerComponent 8 /ColorSpace /DeviceGray /Length 32585 /Filter /DCTDecode >> stream AdobedC    o!1AQ"aq2 #BR3$bC4% rS&cD5Ts6'E7F򃓣dU()8GHVe*9:IJWXYZftugvwhijxyz?g2&'ȱRF$ίǚsS1lV89OfZ*yicUcSΒƪ m9'$Y^|q,CYg ʥFI$I 4RR"ۦ9bnQaؐrauF $m)5]e$5FW(J yF@It}zl+//c5bfjh١(h+d=WFv,Hh [zVUgKq 'zY V!VHb >̒^c .b9%Q,rZ _$1Uc1IMKE%H`g;& qb*PW5Wa pfDF=%6 d" B"_҇IKc=A_ Md,TUˇ :z^͌A1~!8!G`FmS)+$tiC8~_utRt3** 2ᠧij%-Kz6Z6+gP+ƄȐ79E:5m 2U!~g":I L;YDL]Sq]YeG ɕr(% F˸a}c3WHq_M#(0WtgbH8yZ 2) &W˙: -XTQzZ:Rg0!JIs4j)\F2,A,^k'Z.\hskc.EƗ 0~̆A R^YeB$oQ+rvМ3 zٛgO|)_iઑ)h"Q)!D]8i0*Dr5+‘Hꄊ5V}X;0i˗s>oNR0|A!R)4 |B#!з%}LA)TV37/c/~oб .:ܿ$5HjJjy$DѣbܱH9#ʘzx%-<-2DUUoEO)"I'tPuҬg]Ovư|/q՝"ފ IԑmVu4]nMC)˔Yb8+MO[xMY?O09t<& GOP6:-m-V!O:UYXbua(*W|1_k"i*`Ð33S:v.Ӓ}QTəS;e>e`xe05i)k$ zwT GTV] @t N6^*%kc0zLJ0ax~;)]U. :14$y 3P+9bp\2bO,Wج Wv07B161f)xh_ R`V:= 8 ӮSt־IMNU֭=&S]ZQMG=ev^x6բ2Fߤ]9rZy_,fL2DXEFjʹj 9E]$r@pȖ6hx^Uc1\Ոσ<}^5]RWHmU2ʼn+>zlB8*M2ELkLä\_Y+7UjƢ4OSAZ'RTXFfK *\K95rl9cV**M45TU&0"!`[I̹:lӜYK8+$x0}LQET${)!;0;gIsoP,1qK8PaYjJD T(ZցH",kWr#IMTr@[C9wui$t` kiG݉2ƺ)׺ߑrh+V[SD<71FȖZ5rvFj1EpZf[|^Lb:!VصW1NxtS7⸥q(%+5n/1YM"BӺ-[bm,&>fLN'l*|Nlh)\pF1%cp)såjhjC˫uurISPܨ> ^u:ËSG6au-bU=a*㦧o$dy^OP>T=8fU °|_WEWMfZ ih) ,{>&dC@bqaB8!aqh# S!Tt#H٥;N?.uXTRc8(1;h*hE.&w=h ϻyUK_׿p__y)_|3v57ݮ;~pz*G *+q*dz$WVQA @Y 2Gɔ=>X1A4rV=E:]L|ȤBa6S_QbΝO50챉=n4Nq RhqI0) H5vP˸-Pه zZ6Y6'CQ$t&mP˨ JFǟrFLSu+7.#A['_O[Ň64TCQ-E;QH(f ,B+  TUcq,W VeM=4;$ Y"޾TK& zGՌ=23kw*1( $TTX)jI2!7UꯣlfV_L/nUw0wEм,Ѥїfvƥ3f SuƳXs|?i(Z J* BE!Ze*hz1Ւa*L⹻lFJɪlTSMR8!YRi!ί['ռŊWOA$U 1gRΠHb‡ozuo?ðZ}/M$XX䢎4jUB GoPXEN]ĺ)l&T-kLdAOBsGpAf}ιu/HsDk8.6ؚ,Y~~0tbGQڑ$7|bX[ڌ8KHyr*TJxjYi<XS.`I2VRֆ\A3E5klh1XQm,!֌? ._̓U{KOpd&HWm1w^pΪOܽ=?f)GD8}A%J`|<3rc/dNKgCM [| Tn'UE,Q$*<$*me˝M.~T5A',2*Zh)je+O=TRAA3)'SU>ǻJLNe3f,M@(Y!Š,X^q3C$ b嬲,j􃥙7UDZl'u|T1ihEJuIKI$֠XO"e k˘cős(*d(jQXO]KG9HHe+*TOҁ 򄵢KOIH3^k#OҘlT(ç}tzG4t2U0 0=15ĚlYVS^:ZC#5F]V3/Mq+_/'?'+7-o>_F-b4˲`8vAdFiKq6`^Xq =XCO`Ycো "dP*I"ƅBV|8"EX''ISZlT"f*q5Dt%je_u]iٮ$\'qWxWKN"Ƨ(PV8!) >fΓ~e*%~L瓰F[ËbBㅋxP9}򤶜/]zǥ 7+zvi KbTt`pŒ%Yjv/ѧ&+~'إn^VCQ-FOS3a O J$ROu*+z$7Ī.^x1Պ՘TѱuMD%أ4֯ěU2,WSf^ JɉS˅Rc,G4Uʑ2+ɫXt(LIiG-[c"kex*YVpRҁ l+)7H\(ða[S,XTM@.\342ODJJ/.WRs5VIŲwZ;%=,0ck]YO-BST1b K 6]w=o/8w`ؕU-LfJ*/|}˕2Fu+f\_ *T3aO. N^ZzcM.Aÿ k[`e[߳k|>V?6T!\IO.;<֣44QHdT-&Yxu{~ce'lhe4DžfZ% M#1» QO7e̯5X1ozZK5USѪL N*JQY#sQ2%6< ؝'- $49TáIW-Wxg©䖻pX4,{i 39&V,& Y:z݊?ŧbk飧h\jHޯˎF[!\ZΌRM8%>_z*!,5UO_G<*<d j'6t^z2z}Bf,QSqaئS@SWLZG$j"Td2:WRLTcX ~7RbuTx%M3V9q`o5ʖU!\s&tAyM0Ϋ+uP>'& 䞺Hʼ(Ńoڂ=)SSW j*k2f9 d/%+VWPY@tb'IMj3p2oRr6z1Q+WվCW')U6ScWtvظv,Ktv)!MEOUX(֙*VJgTyB_:sp 3oPkH򢦋#\ɴ.@leOMDً2fD_¹>j<'S@$`4 E7elW0LR 24%<5|br=WӤ լ3?[q B<؄g丣qJ\B4 l>iE+V2RR>_۠ggñ [DLaL24ez c*Z> Y3g\XN=KK 6<&#gfd"O.fA!Ƭ7g+g伯՟6}x3l,ϊaTJC=eE8(&2UQQ"L0 Fp`c9ƺEfw͵ySycq]Q>b1Xe\kai(zcIe̲ ȧh-]=&)*]F2peFeHK,15*Sƫ0B@㫹 g՝_ƺ[C1Va)GEn]Ģ`-J<.2U3ef/rST㸦?.%46!gJfzi%J +/n5uOQZ9F- Sc472#$\~" ,?Ptu859%ԩGejx*e ?u0C*s/!KGQctEK%0 jbZQSA@!SŖ`֞t|լ 8 ERzYמZ1",K$`0Efm-jVMUS|FYgWO4q?;[z,ɀ{73;PTQTV-E5J4mt'N \F:))$*Ŧ.-oNu˸Q2e܃SL\_1՚YUR%0*Q^}LafYzǥrvi I((JF$*f  3cr͖^C4Ydz*j:\>RJ΀i}PnoMzb qlFRXx)#\*h1EiSFQs7Qu=8"MU1,2<-7VGabFaWEEQsFlq &_mVCTVH坄,++9:]s|9:7T8.zƩVREVj'fEi >-*gd1+ASnp2!EMXIa.RB' !v̩H"CNQ Q\b@*1:)iڠ3Jhw PΪߤ{T.q)?a>FιupʚYU-m}|qVFj tU5:Njg̻. }5=N9_ĺkfaԕ32SEhRnxwUj._TA()UQPy&ޠ4cy #fL^ҫ l7j1%$4 ]E(f缳z¢??z( z违Ub0E@㞉$WٰGiYP'Pʝrqy Ë`f\"jXj*g*&"a?/ΨHSl:. ֧JS`52IZaiP#y(t2^dk1Rck0|j3a*azi}̂|ߧ.CҖU0Jl9*Z,6*YUj%CRұ <83AdyT N qJVbDcv]-3CMhbh¬8RkW Ī]K :j9,))$t9ř A: +F+CsdϨ59q?*t殧9=J2R8hax!=}ՕLLby|N0~:J1Z)顁j.6;غlƽLT:Vgh#M* `7҄M&TtrٵJS^sTjv3Α%\X24,o#̲1%68Q4r _$ T.faSN\uWTEKB(m.^:se' hϱJdIQB&'xw|?|3߿O?ϓ_/o>K8d^٠`)̱bC[DeXSRMA)Y2-x?Rz[;NdZX"|Ru(9J*0EeTv,EJ|B:o&16 mZJ8i)$ot-'GzB)hyKWc|V%[53@LBFG&C> wB0ξbN-OSǘlÌJT55VKTbT8iC}#e.et^RxY%0s6 WS 7 DgT (.jf1sӁiEVaRR(ؓ= I.usX'jΠ61"œ%N3p'4jLMplk"iqj4[cT-d9\n[(QJLuyRZ<Ï@dz65 UX*)Ş 4Jc~?u>zq3a'KsMb2S`َcC=T YZ(kONT2ys8~uI:ג(3uvThs `S@vOQ (i y_@iS[f*tC57"GFɖV34#=@n9Ն`oʫ(q*谨 ۊIO,{ϺDF6; {Ͽȿy/o*|;oOsU&]1P*bLk/SRLx|ε!GSR2i=/%~K*M?֬)E __8iCS=]$ գFŻ>KfbaQ-nR40чSΰIYB@MNm=ycgTèYG˽I\ӼNʴUc EtTK<Vzu̘ԸO'ʓGfkCBj TYDp׏+=bTŰyJ#EA,-Wzzh$ü|lG`X,I.#e X aYnUx⧝HD%;oOyS'o ES=O)3D5iGOAPCGW ĴQT)@a-쀳V`Vu?F>)p S0&PIhVbWzlאgK/OX9 `->*N䡒*: #X䌂IOȓaدX)Ų$M6/(jzS,q<"Dx怈 lьt{evnxDD*:j(jjrE &Vav/oQޕeYq:.9ypJ*$j$*EX#8x/-3$AK~mEIij>'L'!IM⹯R B|%q6`4҉!wG7X=uRY.L3 ZQY q,2L:8匴Q&ؐ!5iAc;` ӹ:\铱<,S-Auz\# Xު9 of!4YKq} >PG63f:J(`y^|W54QWQCM JKCrgvj,C%;Q`bűJDP5 a#N$h/XI/AF ZK0\> uZYZEwX`/ .c]޳:9:%W348_j.E⪎G Ω $tʝk)p\Abj$0wʑ8xFۄ}\=70]֚9 RrHW]au27S=%]#ɌaT϶UC"&a")DžS>cTTS͸" tM-kH%l9pfYE9FӵGQ:bCʸAGE0鄕eHz*.2|ӬY8ql;ɸ~i,?1ol@HEo:$81"w/֏M}痲H55uyhja+)+S=, H3F$uڢW3տ)+1lG F'}].#È>'Ziکč3;FN)u .Y_f56-%%ҙ$>6(Izf9;e< ud^ ]h1aC_TLaW95R9SCCO' :SKy0Ss͔XN7G+DO"QL0)Y* (Uhƚ[G>`CŢ9* ESKN+i#DM C)sPWgfGQCbxYZ)ĨejI,"*fdb.N&Ads%=M5]y)/=Mm^O"( A^dž>z.(Lr.TOA=D8cC3 A΍\C^(0,:RgJL[6&GO.hI1E4ye6ey (zWԸl[&+{hgுpR Xu8SĐFe]gɝ̝tJf iYj0A_YG69YEDYY0 'vOh ?:)p<*CUN_ފ_tm/t{%,VTIB )j&&ȍ -IXY(6^XngRk0y0Hk!FJ@36ݭgP/Lamc6)*35?DCo3v_/Sߜkv|ם{i?CӮeboI&(jZ8#H?ҵ;| ]6Uu,l[]Rd>zLr-LJ^pA\R#S4Iɵ7 WKX]+4V{_SC7R*U`xX)K.1"ʢLTUoM6&!6@*);E_Zwbn,nTfC8t?gnzƒīA#=JQ&SMFz;ԔCc:M%$u<φc?2)#(, xDPg\+jL |`Z|>ª }:ipŇaVT\.4 cèg3R (GyFLUQFzA0w0ct; -/`TʵT&?}AoWEGcY\25Zj Y%S\Ɓfyn5տNUy[NxϴrzRQ|Pb^| X:6,4P" eizk֙q \g0VM暹\2+jLDzA0F4  rNX‡PrO.!z\G )+ ,lҒ^')r^GnLՎU2o\sf\ĩ (+))c,75LD01!):ipث)Ri$CI;-$26cb_o¼+˾ϟK?gG*acԘef |d&2&|>hd$KbU=DDFls;^zi<76YMSUS YQR`T#Ef (ȞNQUaypՔ j|5d:a{1($Ѽ4TL\C`)3 /u#6zTؖs\)D|4rCxRZw3,J{ʔ7Yv3?]q~朿_Xu؍W8l6 J>Hz"!n g qу5q qi⒦:F}Ɠӷ|}]ĩrq>\ A=L$y -qIzpg_z{9n W8=|"MIM,tKՊgFI v[^iE>W\8R#=eatudu,.)TWR5E$uݲ`8M}.:͌Ay#,RbIG﨓b?јܭ' ʸy9uU#u>NZ'l^av:Fꢕ5(3F9zGu?8!6?QO饭ÂI|XSL)i`/圡^G|ɍt&˾:zĵxfWHfE"r1^:wz!͍A鰄k^zl>5SִuJVX^"|Zzǒ7Lk/˘l k)!3GFƊ:T*TGTR3M/V:쿂e ;y0*+<1z ZAyt4%mfE)S?S1ɺSj*ڜVq3G AE"н4fAKhJYTuMJ?`1KJJ ve?/3$FJS!Ը~[z,6JKȴHll7*Lx1gM2i1|3o9:+GzԌn1Uaޙ(`V4GCg2E<;󊪩/S?lv+~,[3-&748©\lF7m-JR_ԧY`Ԍb#z^1$| iFb|tOHEbyw3btbI$0dLenDQ;ݘ)ۏd=_Ks. F_1dRW.OG%>&ER$P>*P0:߅ՋM_]WφMb4TcoLJ$} B]7+0 K $JJ8jjdK$>CE!:2?FQ(*,Ve /s%,UlE(eQ4oMi"/g?:!+*q,!1U©ڞx(%Zh؈|(T(**'X `Mj+M$S̸SeATRW"ec$sJd>tb&.5F'u4^aHoE]]b@d9!UUE_EKCHQ^)=$N%BJ)`PP0g3rc9?:Z,#if)VND"dge.X ܮ8_E1Լ:})1q l #,e晦4ؒE8kkP3d32cX|خ>P;ޒWWs 줣H+՗+&}ǫ < ;-A/Fl% #C{2 Gǘql̴T-bX6Z0 Ze9U* cTP>^&]1n0II+ha"ZauQ52O컞kzu1+#fI같`UBb)@#Ga5A}@=iӊJizI'UxqH6~YHv袧rmTx?݆a}]f= qaqCG]IO4HLGلdeS1߇burSKFQSGEW*76wnOPi|Ky"O1fgzqIӛz]z͟s j0W˧p0 , [S&8vs+ijslz]0fis MSWEt5u1OY$5S:hccoQ^8~=6=s=c&-AUZSefs:ʄ HAG 3oqlzN`59rJfI vK X$p2Y|pXn%5_B+pDb5?2C,UY͊l_9=TASW豺(40ɬiijy&,GVRTXw lOWİ# jl|0EM8eҡQBrvI%_]'V:"80t`TRB3USSKK'M54BU̖dBcٟ'c~tY؎N48RML0<.:c0Go%t .KKIלs)<9Z0I56/I|8o$5,$FӶI:]%mD|$-#INO4Og72յUdyaƪa5lԘrSi7xYm.ҥd$rQ鿩=(26Wk &JJLwhCE"F?ofU^0dnC_o-^F&5SbTa09U21,CIT5V+$RCET'w4 , Tޣ:18d.fqGBMfZFfh[ZҼ͸QObP3x%p\.,7 p櫧 Bax|؜Jjr`XiVXQ՜őzcsLX:AMQ=l5u|[:q!.$d|ŞUf Y!z᧨OXȼ:m7X/i*㤆jIR *J.N~ :S,[y)6$0S`8V  xH<ꩫ^Y?Hw~8uK=*[cw/亦 ꒎ NvRTG?$,#$,+Da53}()+cEY\# jQ] Rn2UC$ d(D#q][,? l"؎j*\*BRKa ~Ec7{u|0_/ϗo{m29++n[,7R>'j:|t5XuR4FBajf#KLY*!+CRB-^'l1Azyd{+ fq6gp0LRY~zHȣyad $3A M!O$@,~M5's)uYp "j(Zĝ( ,]1$w7CpS ~/$ă+W-1wx"wP]o"K8`fO?^b+CC>c-SIMŸ́k7Wgdhg؛wO49^2b1LFTI,W%F 鮋#urD;NtqXB ^^ViqX8d X?G@/35l8D%Ya8ģeǒ*+=F%|̣%~SʘT.-e]=M5cF]dUt姩dO|(7Kp +'80ˉ(1m f1aQVZI"Yejq+1KPT#$^S G) jh y2P51(ތӮ`NX,SKkIRxU6ʐ͈WMRwҳ{b Leu՞u-˸d &ZJT㞞52 . g[K**?+4(Pb)iajc k-*{w!뾛93!!>#X bTURb1lN@EEp$I9gs.+Q7q,[|VME$.^CGWMW-t 3;aFodz+\RxOIUaq:!gStͶěnt_.I^6YqZ cI"hiA_(wE3%_pK+Շ8},8&&=W=+S-:apS3 ^bdCxZ٣]Z {#" F|ЪÄa8`OZ$PWRS5д°MF&bw<,CLTyʪ lJ}D،t4F ,V})O-ӱxqM0㫊c90d4{Ťy`| Ԍ%4,\ѭ¡jEU\b8XvrT W"JH/$LI X1*~SeEjݱZ"jJE="Nԇ! 斐Ie/UMy?7Ѽt5C.jMs=N1K634m39%#3jYx1 z^at9 TzipZFi ]oGkIOCOjñ+7c,R#Jʊzi̞TLDaeÇ3u W~?28S0bcaCH\bP:K{vpL$b01ՒM!4PJͲD;T: 1躍ð.R RG]KD}nVuap>uF$uGY#QMQ,H+;${O/b,~؄4GOtt{I"h>UB"?B3mD2,*Z|H鰼,RUSJJмlhE[Ϲ:J3Fex:|U3b̿ͦZ5}K6d~5t/6bosPf|դTJƥie`/t$>u=LcF2%=TSHIYWIN,hA>\QY<1>%Ǻwf\J0A3+LV zDxV'*٘2l@=zCLLk;hpvS֐=]l"Dikg6 _H:=\[\Ҷ#4OKS4RP|VUKWoFV|Qe/WOImV)A|Vl2?B "Y6`XJ}+0x& cZLu6Jj?a7'H ǡtLaBh%I4x]3FCyX1VSKZɺTfPI/_}6H}k'8JauKK-ElUtm4RO` %WVsZߜ7Sf3^r/b6"JJ?O0J=]Dțث3XOE~$`rTe쉙p|zZFISAU* 4fQ"q~]]:\Q%$t|w*Ua<~I 5R-[$b}}xNWϹ+-dJ k阱FffhI,Y Q,#ߘnUPSz{{}^f\ݝEaXEKŊUVUQV'`CGLD ;7lAacX:+ s-2QLī0\R M0$B"x!aXO}7gMpa Yڶ6arMC9Tԡ"hL1$w A菨:e|qg.-%u4De<=G LE%TRY]~c67Q!xڡ4OtzJ ,Q7S*p q l7 0 cUxTyJ7-$0<Ƀ22aXU,uudUtsONW(FP Ǎ5cnOQqX(**i**^ $@2F@V0d!e~|K`8>+KTb4XdBiLXZ+] [j} E}t/MezC 5؍4+N1l.O.zf8f#]K8y[䯞&H i r+Re:T>_7x|j-fXi|]o\X>Z$l&ÊK4؅.#C,F@({ 6zLY4bSQ$OE1/"FTGQ-4t,!#wZtn.f`6b15 lO %Tx8$q@(1]3G] PLXMRضn34TIEUF)hiYxF* *!)D+ b4R͹4/#2̰^*M||?"=~0UYO!`}n^!;\"8JQ Lw;HUA$z֞g_BGI6İʄ*ԬT- %dʡjMބaC[;)0L xŨ1oU*ʈjeXڿlyؖ7`/eXފ:"7HD‘3@ǩ>X:ك~uN(eup)f!8}yC*t9-Rx67ZµRSC-M@X'P9%uc-'Ous5.[8OT>L͂df~M]GXHSlr4~~Jc>Ű:WbpI,v6di&L+n%RU b\~']zsB8d(KƦKDmm3EVE?@G<ކ`z:c|~%Lt3S}{JJ>U㔴th+FWH2eC+%(5PQP3Au[6߉ },JGBZsX, q .%#$ZkaLXI 26ϫ_O=<,˙zy3d M/QQR}5]4TJ'kRij+2x#ɋe j ̏0bREKFyu4UKyv2ÊUp &qO(4 &J4Tk65dg)i%"A X_L']:)E}g)zHZ\yj!F}@o y[Rק̣tWú}N_jOX|lqD$kF"f )[X쟅f$3cOTb,V`hMX{Ø3N|XG)V%UҰjD&Vni$#讀lS?F(*Y RŖ(8LA1 =ꂻ*Ve70ŅCSMfDS'yZbROۄ?`xK,' y`VuQA=4xY4&:T3L,Bw{,qLV41]cE&KDъKE5brV_"B$򔀢=e_DWҪ1j\2U&+I&%Lؕ2H%^SW +AhIYX:9+|4-Uvcƪ-J*Z襕j@Ӆh+_prY֟O?myGyٷ^>3f }sD=^TJv1O[($F,h$ 0R vrPYS+b8uͅi /|(lUUH ֠FR0Ψ_G̋0lL !j)hcJxe"Va;ݝD _~?Cp1 ܹ֕G[S-UzUTRS"HcPi *plu#:*\/WIF\IE lCbneN♒X0z¤e1ZSTC%JǍLD^8Y6 ̇ՏQ9&1*Ǩ^e,bYw'Ӝ78ÃgCSqU{%,Ug tإJu+2?-殝g1>E./d sÈQ 9O"4GKD9◢mz垛f+I8Z7vPN󿘅"y`aq,|7?G*1˹[-bTVI]LysFбuddUYVnnI=?AO[ʊh 񔥪4sȲ ,@#kp468m<_ߘ/nwٺlʽG4-K-m}$BTOсF}ᦼii^,ݎCN`lxsLJ8+8O'dAe1գ ]/M]yYc0JgU2M3Dh b 2+9 GQZ=F93E;Vh|QGj@}BV]/FP0ug6TuM1fNs+֢53|Qʐ3y%b!y#`>2>+ӜS&3L#9vHcKF%dMA_WzY6CT\782am%MLf;A+54trJ2nYѼk4xXWbx6*N/$|5^4y8!TpeRTr`XStMESKW U2Қx.7pV귧.kȽnŰOp!baTtefVk 4UzJ^Â)pLS jXLqRMKX$"!FQ`GzY}Qu4>ׂajc:dZJ$\Å[|픽lAfgִR@ZZjh*"l`g>+"zv|+,OEx )E_ D͍+ "fPfQL^pjLkCMR[ #])6v1'8XH Ya|BZJxO)$yBV-vmGs.Wk2B6j$ %He$6eL.,FzihE5HWr*#29e|j!c]fplB\4a2GD'}*w¯BNTygOԿ?&򩼿μk{oۯ?Z|ߖ4yy5>_e}_ ?|nM<+-Xo707x/ʷ_. ?;uB~=1;?[N{o?7ü'|OYē?7o+хmlϿZw|b }s}owܥ XCͯ%l?ۿ6Øw #4+y۳KrrMemv~;-mv[d<ϑo5?7r'+y϶|8#}m!mw/mݻ}Vm|?WnyWŶe)I?˾k#ooϔm~;6{~"b7ï]O Go^;n7f3No_y^ۼ?~E^#?-&f]q?ڎ5P~R̤^-nYbO~COu>_?7mYm9[_{87;>G*/^w~ou~ݿ,dkfy[mo>fSfOʿo?&_C_v_ݿ\K?ˣW<|+ʟ/ۿ'g//?>?n Ko'O+˷nAOyȾC{gOKOm8WwO{/OX_; 7u?=Qݛ-Oo_w1_ۃ_7_Z 8o;ݿ(~ש[?e/? endstream endobj 27 0 obj << /Type /XObject /Subtype /Image /Name /Im4 /Width 228 /Height 170 /BitsPerComponent 8 /ColorSpace /DeviceGray /Length 30468 /Filter /DCTDecode >> stream AdobedC    o!1AQ"aq2 #BR3$bC4% rS&cD5Ts6'E7F򃓣dU()8GHVe*9:IJWXYZftugvwhijxyz?t9ۈWS&IƸqe[D~%]K`4X%7P*`ؔX`\K12I)#j5<:xmM tMK-,!6qQ}MVMT5qRMiRF`haYO43ĨW&u1o.]ENOz)b1zH:4i49 (w~~nbu>bO(%lRƲGN#Kł%CgM]7 '@QK6, QV-kboKDIq > ;AoqGGzЍFZ:9ZgQ,6ɍStl#g`P맯O8Vfr>b9U|T^z.):F  (w$=~^mdꯨ\FJyH:;||PY$xi1B1kQq.ƚX&j*$Q'v #eSIQ)pc4PKHhº#nIF n?O#?ɿ5U<:+|;wo۷_Nаug]lLdk-fZ N:qJ*$41JP94u' * UVR9MMIʿ7-%S3$x,B] JPDz0**,$LXIR vTUYFu17-GzU|wc :Z*8sQ`SbnAGQs՚T°3Ƣ5 O4TH)>Z{vTs!sއelZcI)+O-ZR"bTU@qY`GZSyR:S\c)h $★kH:),/;쥅eڈւ+s.b꿓SG5U;>Hb^-U9#:f,6TMK4tSPJDfm$ '=6+Ԝk" vF*d-f%|o*HyPM Z@سgNq=84-֬2HqZ\*jfhi(("d1j25hA /5XOY!Qa,E" =:9!W'Qd^6_S}V͝tt8R>)p< iYޚJf˙#/ft2"9kP,d^(rEHYi[?^zYS WJ+P,?aH:n6 DL u>|8f|R:<'x8OKEOP@jn9{f^u35]/8YtcIb`ig*<]ofq"\c0f,)f fiL8XU! x5R$uH{YNnZǺTg 0BP"E=%Ve 2e\sQ#L+8$uxI|.ڌЩ#?U 1,9+tj,_g\M-\XG-=_a_UPD4BU=G6|=.²G:cT~\K jsK؎U̞\d1Bs: sIYLb\J9}SQ>!QU;tctP[\^^Qz~-V8w+Ty+FwzFp"Fe1pY ].a8. YQ蚳 ھ%w55NS $M#i" K^qFKˉ0eLLb3T? V%(Up$L v`[5Bl0 yj ,&%v[$LV En s 9ƎyfUƣ0k&]T,(̨C%h-E:WpʬeL*VuS<#B $;}$EZf95XEE^=*熏_+ p kv[h8I:U%F+^ ԭ%YFH,Yu.x\2=bƋ/ LHutWFSaTTղ-F`U7;埕Wiy~G|n6xҶ.D.HN_QVfi+)(*Lh\!UfAr~JUOTq\63WQGAW5Q0--UY򣪫zeYc`@ϞrN { zO0,:ʘ)*".*ںit% EnnP[>Č I1a٫–00%f'<&1 e~XmqgoG-e,M.H6 Rb)8S̓ i3V`^Ux Q-/Rs;RU%M1#SasT'34g%L'WԤ590|"IyCTWKŋ2=2VlqҜ29 :86`&TL]0>gfbl5~ ò)QPxbT&#ELUaJoI)ݥߪBwWTCVe}XI+&.VeD;?usRMPLQT:΅.8c2+96b8cP&7pyREJIDȔ}Nl_HAWd8tQat:lpݔ+lI$GUGink3=:Y*͘ PO<UL )GS˚r=^ҼR+gFhk(-")IDD UЃc,@~U_2Y?.gnf ~Y5`>K:j r.l"1NayhYKS 2<^(H^bjziϋ ql#S0U*"0FR&=J9//tf_J949ꨧebt_):؁J O1UJ1RӐ#)wuP6 pч"|6T每`OlG *,:ga(YY)ݔ()8A"}_K=8t(fEQ@H81|e5[])=$Ͷ(Devdt8I*2o¥\5cJk&YL&aRFY Ҩq g% Ĩ0| . %"*|i~d0iHREwG[*?\>Rw̼O#yӰC#Ӿu.cb9Sw Z=X+6%P>NjŞYq?5xxTxX}cWN$EsK-6sC1\e6RC8(*( 8}^%iOI#u]UYQ}m; '=oq,ZlDCdHj+ |+0r^1O&b*UIY$xWU@ s-EMT."D[,R?':gp'Dp0dqkVWk 5qP m] 7gR-;I#Sk*\s()f~a}FMv12}N4R3I\ۋMD{0. 0PiZzQ4(jhՖwo,IfQQdf|G;c&M4q.!%Ko(&v4p,?]zCCӌ]`?Cűj4xtm'$-PԢG OzI] }vgԮ7xoÅ6C֪I hDnwb4:q4ٽ)0ckt,G$EJǷhk BI͸/\gvoz8držQW,3 r"vbmm^I[/8F3<{il=%D,&6y9"cg,틽v[aU Ƣ)4XK%y,~%L̋Q:0Lf)Uzxf!k$^/AUM.k'Jj hqI*)%iy3$sDz Y3ʞVfQSpz(p%Qx URR*EwT6ryWLM8J˄g \ӌ.v_ar~WvUxXC< uys+ lU7"4U5/p1Nز$lXD˫S%ʹ[ih륤iH S SʈFXْ3[1"y=G>[TctQ(|L2He*)Ĉ39(wF)̘;]d+`J:\=T\:8HR0=nC.d|/.j8RGK$iy2; B߅؍d8No"} }<ǍbS)_b!a$wXRs1d'ET˔IZ5L·ãRzRMCN-oA: kzG=L4m0/Y!ދ4HƑG7+gXfcș:Ma2cw|>:UՑo4!5N'6u֏a93yi*)jkkp#lNi`i Ba5#1MGk- _`1l1:CGY]]QU:I+)RJhs!ݶCqP]lLa7Mp1")Q@+#˵$ui4"IcuW(@:d,^JAMATN D"*f.,S-z|B|>:j9i'+#bU\ڬsNy8$T*SQ[W,Lu5L"W7efO{{n/S%=Qu҂lzjx`_%lb$lO$bo0Ȉo⛧ǩ(%wWֻ3S&; ^ ielY}5>+Q306!M-P 2L-4wZgfeuTnVuxlp#.|+b؅wJ-8R2"4,R!T=TTi3ҮPtV1^#pĩӿ 6i gư槨ʵuQzB&Z77O)eLLX"PK9~c~{ XEQ4oYIctmDEVLQ|Y bʢn@*p(1&S *Rg(D&݆#ynw:sԇJ*3{"<"ZF]6ZMԱ6*F 믫8wL0ܧCA.~.`7jrfCPb!`I׫TX|zlWڣ6VDs.CQO\&a`xbZv Q2=ɝ])>7dCqb{ԚƮ|S'ETdi%$" frEP^)[8u TGYl5VX9Q+b8P+ ~WE=Jtp # NtYS}5˸QBlոg+Z1C u?/j#QS[yb*=ll s&|8X2x=ȴ9STR+(TVuHgSґEh26QRK *VS8_ DTR*K ]:t\k!enj֣i Z-N(%<92`&p"G[O/ZPFhwxT%Y~=Ψ\ qxbai` f%JYG$*e9Ǫ9n*`y+TtAL26yP駫3^sO~ MG=N'CMUWLE*$ l f$GF 0Wg?SLUM%4!QDžt{bV1-LQTcYvkE[ƟqoS3H{. S&Rf4:Z*H%di`K+4;vA rItEf1J!?]b )`t(ϓag?ag G0"h1*Rlg3\h",͊ó/V=V.M_Ch(ҥX(Ztw_-2͵KJ-kyٗzG0ӀeyXiR*NW!19W6dD o>%Qprܸ*VJ5bezQuDA#/ӗΜ?~o.y^_y~gл"|EOpz4!Ϙ7M+ǗŨ*h-}KHP$hL.bΝ^wG"PLS$ʚY`;{RsnWƳ~fq<.*== ]F$^ kI$Sͼ7fΙ4u 4}}>- KIQ<b'/(~bňԌ6遨)-@ZJhƠ0P8` ^Fhhᙖ$Ijze%YcL]"=IS[ @A$-raq|iU&'s]u3eҮQbf[1<׊U~Z F*u #*g:V0i>7boβIis U- Xik,6!C@&4B[BO 3&T|w 2n^0옙3’bo$̔Xe,Fcx0*X GYE.]WLu,'nf|; RIHhUɂKS#- LMTށzFIvLY3gL (^#`8 ~)[[ J$eX>] +@zj,ޗ OUڞi*e<̳f*+XPV]nWKe-k!zD&4Y #8sYՃ fDϓCɁO(2OQdXq/b4ԕU,ԪQG@ %`Q}%7Y_p 3Vr%I,jHZ*ԀTިѨo.FYVZK[*1Ic&ICIJ==dS3dI=,@/=u^3F`.Y_WGUOWGUu-RU8")F ?tC(g*F%am6+4,Hij]C= f^ LBJXaY E4nYPJd_e;}(xUcbxe6_%M6#BAHfUéy֚̆= AFpe2ޚuSXTke|Zy'AkS^lfiHZ-ZAfL XNV͈B9AuY|@XPA\cmU-V`J Jz卌RT&U335 #֞kS!3.PUr7J3FL1n:Ֆ+Q̔wQO3ZjxJj>Nz*$AĄ'fVcw{kP|y|ϙ|~or=ѷεuKfj)$l*:8gjXhaaK)wVls_ sf'`̵ITU]e yi-SWkO'] F:et{.I\B!v`%gڻcU?Džܫfhȸ6bU$y\AM O!DYS`9^1\> s.#_48?- AtUм sC8Z}ѧΡ]BiXv𚚌B OUڸBtQ"@Rh;=TUNp! x璔$J٥|F#]22nNkZz(h~Jjgzj:m%XPt~朣MB{KSb MtGV`1;bwtAK9eOVT;*KU]Q-_PU& GQGP]2GݯFׯgy i-%dbpH40yhDQE\Ep K;P=Qrn1˖Rx}KSI| JtEOhrxTL3}g^Y\S͋z.SU9'H~%LU$RJ1Y}KuOG=(3>V|RZZJV272E%"c9Mz1Uַ|>?Y4O̘x^)r ED XcUW_0)r"ZIdX?lmsLJ$؞#&utl>{VSZ_5 Hdl$Ll'sΘ~ jqfjZ1SBy2DmT-VS͹w0'X7zBW02|,@L#VU$a0BWLT=UAj,[8.Z˙ފJ& eR°C'B0jB ΊUt~GÉ,Х4Ez 2W9 ٣R]>b,Xl2µu8h;hc!4"0`TDS.Oj悲#m=4(?c  sȹ=IN F :ʿ"VtCNR$ A*&}0X> ]%N\ʰk&*+ZԏK;VR &Qa}G 2 y"&!gύB]SYOLTSzdJ i(=MzuKkSaF? ͘.c Zui>蔫%K+Uz]ΎuO} ɘ~5\'5c8CTTk`8AThL$kdu+8)L3yz'1z f_ŒT/IU=\MH,y z:"XO;&妏44QY%U\p¡E'z%[ M2n3 #aIpD844qQ_D!OI@CQ@0u%ڲǩyCꫲoձ{% =L,MWGTZz+4LטsuK,b8 s3.!))& %2JH{>t\k/t5MQK_P,eU撚8 v[fZ::t;-[j]MUOGpX$ lӪ\l^u# sf%&(>e5R1jJ+ˋ,wgX?A.Zy;2*a6!_D1XƉ TAO*)藧ЪŊe+s&k[DZlLӽ]LX5v `$cm=:h^@8лj fc >Kf 0i:JU:mSc^!%gEU4>͙6AGE&ti(|Ѵ H|gsYXKg:< ȹ ǩ1lj,.Lp_4LA[uDED)e,XP?_'ge{O#;1=ӱ>ECzŔ$qj$'y,Jo"y ]˧rקsR1arU*S^jZ#ij*.$΅zSy뢙X-;f6YdǞ , X2峈&?'\Ϗ/dM !W:sbQ*oxwi 4aJ*\d*n8Ue5=lyԵQŒJ8ﲒʻ[_a²KuG՜P.=V8冢ZOH<ĂJ2@#52o=ZlcUd,ęib` qgmG &R˹J8eqLKJI'H:hD%9;׏TxoO1 2kc.#MX6-CF(^d m~%/(Q@[5`2LˀfW2%Ja$->^3D5K6,M7E,C0u/ j(2V/!5U%3Q$T$(4ߣY5\ =e6R լ`a"χUb3S 8eDDRS6^Q3g|!|>keyo[gǟԲ`@zDŽM%XAE--؆#=m-R,nXZ,>%XUMS ]CdOOˊO`egPi7#.fx ǠYlu3*b!řtwb7Gkrxp͔x~"p6l'pz9RӔ"+ĎrY/e~M' \-YLG +ܷMlWɉH!IE xH=NUD~A?S*Ӭ8S>)E=<"TE &IiuhX=Ahո~%-N%[jɾUgrI,TH!гGG7Nr!zq\[1 \[5|RJb()iHDwկ~zE=̉8)MN%%̵u5t΅cD*7Ii4t8UrTQV!>IzR8('O`%%{c}X\̴U9ztb ih̒OM_OS> \SBfh>IU yG s}M uFt䯪kK'3➣s.y&zmC>]ʘ1[?Abfi-sZIы#NP5ONzm9ys'UOQ< "PG iK;31rKSӍenb9b_Nˌc8lL؆1ʵXo=Ԃl9#9x+`ʴ6nw̘Wy0ǭâ5-D ċ#RHX0ξ==ó! 6Z,QQQ&!C.? ,M$de,ۥr;ŲMi+uBR-3Q@KH)"F--,.NE2sUR'P*Ě:EGc"EbX/phZ(0*GQ=,O" FL%DHY\\ٙ0/z\P`簜>HxgddKȻۂE",ϕ^)Ǫb`Jyk$8:zFp~vm2Yްz1ӇE_ %6F Zo5ݦ[@]^rP=Ll. %nLi SVLFjJh8?vyWr 2uUIq<6 a8^?^ij91d`0|Bi< 4rH;}L+YWU]b[ҏm=4V+1SO xK.nP/99/G?I+ML?Y+1׌z*j:o" x89UGX]fƺCWEr;2CJijRJ:ʆP,2<+>eze/UT7sQdءil*+VQ eJq46;ц-o93 90*lObgIhaJhaG {m^C^Ӑ_.#()ʍ.ŢmҩnW2jꯧ~O0 |zL 2dk8^LVYyU!e`mӃGN0 W 0qjiqfh"V/"GeUQDI^FE°S?aY9H))"Je)eysHQI*N+4*JJejڗbDG8ǂuK/N:**Va>%V0+v4s9%o-ddTo/S3V)F6WPb1X=EN A=OOͳ:{W>bS ؂YrANdU.ԗˊu#300Wn,^0 1fMyhO5E7Ȟ\ϼ0X{vÕ^2?ժHLav?#Ḿ$rY T9Xwnv㧪L`VKfU&1WOK$E`RVAQ>`a@pDqT 6#Ԍſbh%eYI-ڮb[Ѫ81CبhdUfKEF)b!XuKO3c h&+^:L4E CsZFY2Y b劑=qW7;dT?RRӝ<"Ir*7pF",cV~|UJojD⯡IKU|TQΓ~8yZDzY`"˒ף3-0%tqBqib4Ɑr996\<pc=bdG&!'PPcyieI dx5VR_zms>j?T`aa+X)]LJG&[6#JUdxvlK{sa-p :; ˤ[QauRϜXb0Hđ-Zcξ(خ4cL8%t8xĘ%E^8PQUT3Ç>WDqʓp1mlW=l&y5j;ž i+qmDT:mFweUlBlq\Z|k .KV!rKMJ%Ec #G$*.s^ uV`tå̸^0j+X5N!S(SIjzq`0hA; :XXn3ZUgQtt,uG oM:4u^pC& a!3T= U3'K?8}v5aX#W* r`BQTON%,Y)̅$K<N1L~1=~w1LL Vh6a%>NV0Ѩ`霱UdxM2&. |Lֈ8̏2SEDH˴&~#GIK8k/bX![WW -=tؔ&DZQ%2ڪEY)=n`]&ƽ8b~XQE3VGM4b6 /cvH\a+!)S*#7Ŷ$3$̍CSKa|Bl[hEuQ =L&# ǍzKеYx+VX `YsM *@:fu.MV<EJX㽒6< Å \SK]g\ۖeU> ؎V4tDu4QMy <k81b1 SL;gং TR&z*ҪWIXd"-Ġˋu/e:g7ӖhzUQјqDǩf+ eܔ(]8ʘ3պ,?=u6 !2,KF*!!'h4Ջ#/qwϜs2 *xa Bzo&iiWڀh t;xoS1l6Qu.2`uq3F@5,n.Usk yp?8;y;O{y>mo};Ѱ s Wn)) %&3⩮e4M; B(DVE.WzAxrfGE0#,1K(1#A|[fŦ{ʾyK4QRUa reU%Y51jꠑ-$񠽏 bz}GLOy S| !giME8I0ŅEJ(j"HL(Sp$nU4M x)*qΫu qFaVoZua@ܖ 5z,ٚ#1VZz:zzqH*V ?Ұ1Ԭ2^] J n২S8c26e>bcxVP0޵c"L2,$WᥦXe@yhʸYQ+i>C7Q.Q1UL'dϷ͇sn50Q!ϔ˜eF_Q_MdI\Aq'x|خ3SNJ(bAyUOVϹ [40:.la-==3µ̴%oѕ`HG θ>TVF+|RVg p# x=AīhwǾGة>b9aFanKb Yn&2K6#K#2,vÚWZ\ʙc8NK ©+@޲1DPk#0>&XkQt~ViZE]I?*8bSV!hF"z2u.FYb)!M9AR1VF_FpވK☾5b-NTUKK/(,HƪAbUpEWM0V*mߺmΫ(1Ih1h)Umdu`C) fzjvr/8#*fjI|_m5=}ePie(*n5FWb8&K]*C2‚ Fj*))*<+$˨^ ';ʙ3=Ulja2MK҆U>c#k+6.T9.u%3&@wRjٌa9<8aԴɋCc4II5Dr8 = OkFf)jMZ'a8j2Vc%^?\&BT1e\~ ٌ7M*u5,$sTF#;yQpP2k=JR~*3"9f.bW.S$nXrOոY˕K40*HPݣw"oZz:+qLAaYUEK'gY[;*=T/3enFǰ<[K ;0ƆaNW-xUƕI&KQe)1LƲMTltD)%OVicK[үf0e1b!4|T8*k!(.v`c`XSf#Mͽ- KI9˸4eDx;m!.[NËuW}eqgnԘYYiE)!妨@C4l r*2>KÝ0/1 )`ZzՕ*`C =kWt8aT ~xBF!SbR1 fg]̄Zz>uQr}Xf.*+p9*ihqڦ)+D/412\:Cmrz̘65(Lt5(ّ*1bԸV 1*d b$qB I YIzztRR{,{ɵ݈.H[nxOwnbzJԣf*[|#X'OQrd|&?,8ypȣZHj$1Ӈd;Zʤ [k5C:d*|&pZ/1攊xJl.A$JJ "GP1 |_>'LM=%pRפk⢎Wɉ̙ep3Tʬ\&c/1z`F,4q8/2;/K]TԢ. лfA G'71&ߟ/y/'??]nK_?䑃s?>-jyZnO5W;0W`jpg [)p_.)_VB/^at$&>J_?&]y\R`F;uW?⯇617POR~?CyoJ_o"?P>Wi;>tg$1WyבVμu?#Ph9OljMT__O?λy{K2_u'K$Jzމ[v/1/ފoo( ?_zs1g)?$z~?q?1xL R?86VG+_/J۠x-I?ޏd[_o_;\hx%U_??_ a /`//dO9,%O&%,?aT+]ga߱_3t?W endstream endobj 29 0 obj << /Length 8481 >> stream BT /F5 1 Tf 9.963 0 0 9.963 149.613 498.16 Tm 0 g /GS2 gs 0 Tc [(Discuss)-9.1(ion)]TJ /F6 1 Tf -8.1659 -1.4454 TD [(A)-499.8(d)0(e)15.1(f)0(i)17.3(n)0(i)18.9(t)0(e)-488(d)0(i)18.9(a)0(g)15.1(n)0(o)15.5(s)0(i)17.7(s)-497(of)-486.8(dr)13.9(ug)21.2(-i)17.3(nd)15.5(uc)20.8(ed)-491.3(pn)15.5(eu)20.8(mo)12.4(ni)18.9(ti)16.5(s)-497(i)0(s)]TJ -1.0015 -1.0755 TD [(di)18.9(f)20.4(f)0(i)11.6(c)0(u)20.8(l)0(t)16.5(,)-296.3(be)15.1(ca)20.4(us)20(e)-302.8(t)13.9(he)-292.2(cl)18.4(in)18.9(ic)18.4(al)-288.8(an)15.1(d)-296.7(h)0(i)18.9(s)0(t)17.7(o)0(l)13.2(o)0(g)21.2(i)0(c)18.4(a)0(l)-288.8(f)0(i)17.3(n)0(d)15.5(i)0(n)18.9(g)0(s)-287.2(a)0(r)13.5(e)]TJ T* [(no)15.5(ns)20(pe)15.1(ci)18.5(fi)17.3(c)-268.6([)0(1)48.1(1].)-265.3(In)-282(addition,)-287.2(the)-278.2(freque)-8.6(nt)-277.1(use)-282.7(of)-276.3(mul)-7.8(tiple)]TJ T* [(drugs)-331(in)-328.3(combi)-9.7(nation)-328.4(and)-332.8(other)-326.9(thera)-8.6(pies,)-331.8(such)-329(as)-327.5(radia)-8.6(-)]TJ T* [(tion)-394.8(or)-390.1(high-)-7.8(dose)-391.6(inspired)-395.3(oxygen,)-398(often)-395.2(confoun)-7.3(ds)-389.7(the)]TJ T* [(chance)-228.1(of)-225.1(identifyi)-12.7(ng)-223.5(the)-221.3(offending)-223.4(agent.)-229.3(The)-223.1(underl)-9(ying)]TJ T* [(disea)-8.2(se)-407.2(may)-409.9(also)-405.4(compl)-9.7(icate)-413.8(the)-403.4(ident)-9(ificati)-11.6(on)-405.6(of)-407.2(drug-)]TJ T* [(induce)-7.8(d)-473.1(lung)-477.7(disease,)-478.3(as)-475.4(may)-478.2(opport)-8.6(unistic)-480.7(infection)-10.7(s.)]TJ T* [(Clinic)-11.1(opathologi)-9.5(cal)-449.3(correla)-12.1(tion)-446(is)-449(requi)-8.2(red)-448.2(for)-455(each)-448.1(in-)]TJ T* [(dividu)-9.3(al)-402.7(c)-6.9(ase)-408.3([76,)-408.3(77].)-408.3(In)-407.2(the)-409.1(final)-414.6(analysis,)-412.8(most)-413.8(drug)]TJ T* [(react)-9(ions)-228.6(remain)-228.7(putat)-9(ive)-227(rather)-232.9(than)-227.8(proved,)-228.9(and)-230.3(the)-227(phy-)]TJ 0 -1.0698 TD [(sician)-369.8(is)-363.6(usual)-7.8(ly)-362.4(confro)-8.2(nted)-364.3(wi)-7.8(th)-362.4(makin)-9.7(g)-359.3(a)-365.4(diagno)-7.4(sis)-365.6(of)]TJ 0 -1.0755 TD [("possibl)-10.5(e")-334.9(or)-333.2("pro)-7.6(bable")-340.8(drug)-334.7(react)-9(ion.)]TJ 1.0015 -1.0527 TD [(Fo)16.3(ur)-316.1(se)19.6(ts)-312.4(of)-316.1(cr)13.5(i)13.9(t)0(e)12.8(r)0(i)17.3(a)-319.8(fo)13.9(r)-321(t)0(h)18.9(e)-325.5(di)18.9(ag)15.1(no)21.2(si)17.7(s)-326.3(o)0(f)-316.1(M)0(T)20.8(X)0(-)15.7(i)0(n)13.2(d)0(u)21.2(c)0(e)14.7(d)]TJ -1.0015 -1.0755 TD [(lu)18.9(ng)-206.4(t)13.9(o)0(x)15.5(i)0(c)18.4(i)0(t)16.5(y)-211.3(ha)15.1(ve)-201.1(be)15.1(en)-201.1(re)19.2(po)15.5(rt)17.3(ed)-201.1([9)13.9(,)-216.6(1)0(4)-7.2(\26116].)-221.3(The)-223.1(most)-231.7(crit-)]TJ T* [(ical)-276.1(criteria)-279.4(for)-272.9(diagnosis)-276.2(appear)-274.8(to)-271.4(be)-269.4(a)-6.9(n)-268.2(appropr)-8.9(iate)-270.4(his-)]TJ 25.1977 2.373 TD [(tory)-263.1(of)-259.2(exposur)-8.5(e,)-263.3(pulmonary)-264.8(infilt)-10(rates)-260.2(o)-6.5(n)-256.8(chest)-264.3(radiogra-)]TJ 0 -1.0698 TD [(phy)-207.2(and)-207.6(exclus)-9(ion)-203.8(of)-208(other)-207.4(p)-6.5(ulmonary)-212.8(diseases,)-212.8(especi)-9.4(ally)]TJ 0 -1.0755 TD [(infec)-8.6(tions)-265.8([13].)-268.4(In)-264.9(ca)-8(ses)-261.2(in)-265.7(whi)-8.6(ch)-263.7(a)-262.9(lung)-267.2(biops)-7.4(y)-262.5(i)0(s)-261.2(perfor-)]TJ 0 -1.0698 TD [(med,)-171.2(the)-164.4(histolog)-8.7(y)-160.1(shoul)-7.4(d)-165.8(b)0(e)-161.3(consi)-7.8(stent)-163.8(wi)-7.8(th)-163.2(what)-169.1(has)-163.2(been)]TJ T* [(descri)-10.6(bed)-292.9(in)-294.1(MTX-)-9(induce)-7.8(d)-291(lung)-295.7(toxic)-9(ity)-291.6([9,)-293.7(14\26116)-9.5(].)-293(The)]TJ T* [(crit)-9.8(eria)-263.9(used)-260.7(in)-260(the)-261.2(presen)-8.2(t)-259.2(study)-263.5(\(table)-267.8(1\))-259.2(depend)-267.2(heavily)]TJ T* [(on)-382.8(the)-380.7(exclus)-9(ion)-380.2(of)-378.7(other)-383.8(causes)-383.7(that)-383.8(might)-381.6(explai)-10.1(n)-376.3(the)]TJ T* [(findi)-10.2(ngs.)-362.4(Serolo)-8.2(gical)-367.9(study)60.9(,)-364.6(pathologi)-8.7(cal)-364(examinati)-12.7(on)-360(of)]TJ T* [(lung)-329.8(biops)-7.4(y)-325.1(speci)-8.2(mens)-326.5(and)-327.1(mic)-8.2(robiologi)-9.9(cal)-329.8(work-up)-331.1(are)]TJ T* [(nec)-8.8(essary)-555.7(to)-550.2(adequat)-8.9(ely)-551.4(exclud)-7.8(e)-547.5(infec)-8.6(tion.)-554.5(In)-549.4(clin)-8.2(ical)]TJ T* [(pract)-8.6(ice,)-165.2(MTX)-165.9(is)-158.7(freque)-8.6(ntly)-167.2(given)-160.2(wi)-7.8(th)-157.6(o)-6.5(ther)-161.1(drugs)-165.9([14,)-163.6(17,)]TJ 0 -1.0755 TD [(19\261)-8(21,)-172.6(23\26125,)-180.6(27,)-178.3(28,)-172.6(30,)-178.3(31,)-172.6(3)-6.5(3)0(,)-171.9(35,)-178.3(36,)-172.6(41,)-178.3(44,)-178.3(45,)-172.6(48,)-178.3(53,)]TJ 0 -1.0698 TD [(54,)-263.7(57)-7.2(,)-256.5(5)0(9)-7.2(,)-256.5(6)-6.5(0)0(,)-262.9(63,)-263.7(66,)-263.7(68,)-263.7(69])-260(an)-7.6(d)-256.8(a)-262.9(lack)-268(of)-264.9(published)-269.3(re-)]TJ T* [(ports)-322(indi)-7.8(cating)-323.1(that)-321.2(drugs)-319.6(other)-321.2(than)-324.5(MTX)-319.6(may)-324.5(cause)-319.2(a)]TJ T* [(pulm)-8.6(onary)-364.3(react)-9(ion)-363.2(does)-363.2(not)-363.2(enti)-8.2(rely)-360.2(e)-6.9(xclude)-366.3(the)-363.6(possi-)]TJ T* [(bility)-162.1(that)-161.9(they)-159.5(are)-158.3(the)-158.7(offending)-155.1(agents.)-157.3(Fo)-6.4(r)-156(all)-155.4(of)-156.8(the)-158.7(above)]TJ T* [(reason)-8.2(s,)-338.1(there)-344.3(rema)-8.6(ins)-341.6(the)-340.8(possi)-8.6(bility)-344.2(that)-344(diseases)-343.3(other)]TJ T* [(than)-165.2(MTX)-165.9(lung)-159.1(toxi)-7.8(city)-161.9(could)-160.2(fulf)-8.6(ill)-163.1(the)-158.7(criteria)-171.3(in)-157.6(tabl)-8.2(e)-160.5(1)0(:)-157.6(a)]TJ T* [(clin)-8.2(ical)-361.4(frustrat)-11.6(ion)-357.5(that)-366.7(must)-362.6(be)-360.4(faced)-359.4(when)-365.9(considerin)-10.3(g)]TJ T* [(drug-i)-10.1(nduced)-341.1(pneumo)-8.1(nitis.)]TJ 1.0015 -1.0528 TD [(Th)17.1(er)13.5(e)-223.1(w)12.4(er)13.5(e)-217.4(n)0(o)-217.8(a)0(p)20.8(p)0(r)19.6(e)0(c)14.7(i)0(a)18.4(b)0(l)18.9(e)-223.1(di)18.9(f)14.7(f)0(e)19.2(r)0(e)19.2(n)0(c)15.1(e)0(s)-213.7(b)0(e)20.8(t)0(w)14.9(e)0(e)14.7(n)-217(th)13.2(e)-217.4(p)0(r)13.9(e)0(s)19.6(-)]TJ -1.0015 -1.0698 TD [(en)15.1(t)-287.7(n)0(i)18.9(n)0(e)-280.8(c)0(a)14.7(s)0(e)19.6(s)-292.2(of)-276.3(MT)15.2(X)-289.2(p)0(n)15.5(e)0(u)20.8(m)0(o)18.1(n)0(i)13.2(t)0(i)16.5(s)-286.5(an)15.1(d)-285.3(t)0(h)18.9(o)0(s)14.3(e)-285.7(re)13.5(po)21.2(rt)17.3(ed)-280.8(in)]TJ T* [(th)13.2(e)-234.5(l)0(i)16.5(t)0(e)18.4(r)0(a)19.2(t)0(u)18.9(r)0(e)13.5(,)-233.7(in)18.8(cl)18.5(ud)15.5(in)18.9(g)-234.1(t)0(h)18.9(e)-240.2(su)20(bs)20(et)-226.2(of)-230.8(th)18.9(e)-234.5(4)0(9)-223.5(l)0(i)16.5(t)0(e)18.4(r)0(a)13.5(t)0(u)18.9(r)0(e)-225.5(c)0(a)14.7(s)0(e)19.6(s)]TJ ET q 228.2595 0 0 225.2975 58.2803 543.3447 cm /Im1 Do Q BT 7.97 0 0 7.97 58.28 531.723 Tm [(Fig.)-327.1(1.)-331.2(\261)-332.2(Photomicro)11.9(graph)-742.7(showing)-738.2(diff)12.8(use)-747.9(alveolar)-739.1(damage)-745.7(with)]TJ 0 -1.0599 TD [(hyaline)-329.5(membrane)12(s)-333.4(i)0(n)-332.5(acute)-330.3(methotrexa)11.7(te)-331.5(pneumonitis)-325.9(\(case)-329.3(8\).)]TJ ET q 228.2595 0 0 169.5685 58.2803 132.548 cm /Im2 Do Q BT 7.97 0 0 7.97 58.28 120.983 Tm [(Fig.)-327.1(2.)-331.2(\261)-332.2(Patchy)-206(fibrinous)-207.9(exudate)-212.2(with)-212.3(mild)-210.1(chronic)-213.4(interstitia)9.5(l)-220.8(infiltrate)]TJ 0 -1.067 TD [(in)-332.5(a)-331.2(subacute)-325.1(case)-331.2(of)-330.3(methotrexate)-326.9(pneumo)13.3(nitis)-332.2(\(case)-329.3(2\).)]TJ ET /GS3 gs q 228.1811 0 0 170.2934 309.6283 608.2999 cm /Im3 Do Q q 228.1811 0 0 170.0342 310.1233 432.5229 cm /Im4 Do Q BT /F13 1 Tf 9.9 0 0 9.9 317.236 764.76 Tm 0 0 0 1 k /GS4 gs (a\))Tj 0.1 -17.9 TD (b\))Tj /F6 1 Tf 7.97 0 0 7.97 309.316 420.605 Tm 0 g /GS2 gs [(Fig.)-334.3(3.)-324.1(\261)-332.2(Low-power)-272.6(microscopic)-271.9(appearance)-271.8(of)-280.5(subacute)-268.2(methotrexate)]TJ 0 -1.0599 TD [(pneumonitis:)-347.5(a\))-357.7(diff)12.8(use)-349.5(moderate)-352.9(chronic)-348.6(interstitial)-353.6(infiltrates)-351.1(without)]TJ T* [(fibrosis)-346.4(\(case)-350.6(6\);)-344.8(and)-348.3(b\))-344.5(patchy)-343.4(parenchymal)-338.4(fibrosis)-346.4(and)-348.3(orga)16.3(nization)]TJ 0 -1.067 TD [(without)-699.1(honeycomb)-690.6(change,)-694.6(associated)-700.5(with)-696(a)-701.1(moderate)-701.4(chronic)]TJ 0 -1.0599 TD [(interstitial)-332.3(infiltrate)-330.7(\(case)-329.3(5\).)]TJ 8.966 0 0 8.966 523.049 797.499 Tm (377)Tj 7.472 0 0 7.472 241.285 797.499 Tm 0.0001 Tc [(METHOTR)-11(EXA)105.4(TE)-339.7(PNEUMONITIS)]TJ ET endstream endobj 30 0 obj << /ProcSet [/PDF /Text /ImageB ] /Font << /F5 8 0 R /F6 9 0 R /F13 31 0 R >> /XObject << /Im1 24 0 R /Im2 25 0 R /Im3 26 0 R /Im4 27 0 R >> /ExtGState << /GS2 11 0 R /GS3 32 0 R /GS4 33 0 R >> >> endobj 34 0 obj << /Type /XObject /Subtype /Image /Name /Im5 /Width 225 /Height 169 /BitsPerComponent 8 /ColorSpace /DeviceGray /Length 27401 /Filter /DCTDecode >> stream AdobedC    o!1AQ"aq2 #BR3$bC4% rS&cD5Ts6'E7F򃓣dU()8GHVe*9:IJWXYZftugvwhijxyz?_PJƪib28 *#RWcU2)Zw!YI[&MUYcrejij[(v 2j1HyWR%xfLĽ4Vc=/abL,#>Ha+O)+M$Z"ąutXռ/U+*xV!_rGIUOW;!4Ҕ%B1rf~QRQR*jWjx/!up;y'^CUn:?>uPB}'~fZ|2V,QZfLRZzUǗt)@zCO⎏ș!!=>)HR*O&JC,6r*q;H`ٻ9ztFcT78+c$L^\F "{G2Bѹn(;7Ed( .RiA[IE,SFj*J ۔G6u=vvm9X=7s^/ʔ+gFb4sK@ʅս;OcM?%**UBY$j!IuFI,d͔Sy8UVY)+ik\. 'hzughy0@L^[>|W:C/.PA:u}v!-ȭ !cp*K\mj0`)!jJ(0bYZxK,UĨɔ1u?#OYrVzlw~,mUO.*P_M-*) : @8̴S2u.i[  QWYWQT-d&V'c|Yv ϡ7,ׅϩJFvtxeUVoe˒P[&ŖrRcxwyDj)#I^cʔTzqW.J\LQWaU50SJghj#da>{s6/d c)ϗҳņTMKbn M3yаgN|p3?LuWVzW ﯫƚ!8DmJ<mqmO+)OYHvXn![*MM 3WKU*<2I3!㷼z/9i̘-ES<$4pHSbT- ڍ8ǽMGa01{0a`*z)$Zi0JѺɲ2q: 2͋a]mc2́a& i++XOlOG:5.3 :m9 'ScqE \ M0噤MOL~uu#he!ڮt y=VD+')01yU<)T)qewS f;EjIY/]7K4\NW8MTeEJHUO+1}: O9GM7 4UTtZe*]~lIlf0([zfy>Q3L< #0_5RUZQHkkr44^{׮9kɹz|3կM n%L 4jgQkql'(܉ |^dvb˘ e ney0fj *asA$մT r5\m#]D03]FQ _6PeWȦlJHVgIaQJGJ֎O6}H0t9QACJҤ4m[-%:]He7-bG1?R2j25qX2>`J|?0e`ILy) X#S6̝F0ܫCR|nZ:djfy2OPh+:(C\Q.~l.VXP2d˂/q\Rh3?]j7dR"3-ת}>Xs_y%nAQ"iʠ xΊg)| p|/08A -ISEkcRd@ ʡ$ =׺߅-x3-嘶[΍A|fq,jzh "N~b2DY`dU]e|OOyG:|{uU|YWTڊ8hfȊմhC<~dݸFטpb}:_J|=SWcPs XTˀWSqs9jTw` >w 0Vj)Z( gߕ=P=h6Q:WK<&SKWPRRjeHd,ØgMgFͥJ"XI{cXut噼QSBNY_ie"/HMy1|Rr4ϝN!$}A=^)=uTaD05),Ff:ȤV5ɹ%'Y `:7Jj4kSI64%L 4Ϲ *lA^Ru?,LS.:ENh%+gL7>w XCFPP]/,U͕_1Ϛ j*V)QR@g4V U :<˗ja1 Xhm$T#e MH1hUh8ϝdwKї:c4OFumZErv5Q16:hx^gӾ֜g40RW-Dw88ժ!JtR5P#)`vDz=n36TƱxikj)E .,⹣xYbW.enu+Cc$:h+* UU=hY"<mq6ߞ3CV0TQ%V-*آ. k[(vW1n ]YC~^B%ZIiɒF09 n!@vQ7`3]=y%fabġ` yDRӂ^ONWk36) J,R|Yb5i_q {27ՏO?PU5GK?8Rbz O0Tc9̵m5+0!O^R+*+r` &/K9x5H(IMԶP{/~AIWBZ`h}E#Ere{_9o#cy/&9CDΫ0LV,M%U:HH$` bUQQ7+9ƸNqq4KWT"9v캩d@:z~#cx]^Gj܋IQ6!#0E M+SRW$JXEPt' $/zj:́X9S=-VbRyH%WjYE?L F4aO> `؊TΕxt3` a椾V wFTX Wg.gdOSujb$杩ָAW̍QҲKK^zgb3F/ l|SWu>we*`XW:0g)`H&!ID3~UUQ[G#aBͶ@Bs\嚿;,s=DŦA'fjij ~:孠e00X\Q$1F0"QzoPkQcIS->KQV HeSq5UP7>=I[/̑F:"j:Q WUN̷ X]7bwK/Ɂ юf0K⌡V#'q$(R?1LqJle7R RbT4VBa䍤MĿXOCW0aRRX∲D4FaG> 9չ Գrhji*2F7/$bxtuF' 6RsS.~&R 5d8},)$r-DơT*7鮷/f|tx%QmŰd@)JEfLbV=/͹:UIGuC,f9 f:SOɉbK?-TS/3R=F| Ծ JuuTFk'C ')c Hѓ?Q|LrK_qudv ],GFB:c{wnl6~)})2Lkl=U^X|5í-ue5Y -D yv!Z9r1pxt8f'*Ҷ 9i騩lѴs˫wJґV.r,iʸ'W4d֥Q4Xm r$FCQ^*}͸m poeΘ6`ح6a8S,JiG#mvamθT[ +5B%1RcONj1% B2+3>I*bI uAR?;Q9X"axJ>  >ֻjEPk^ plOHU3N}d5R0(D7>U zR9㧽8::uCq p!E]| ]L_]Wdzk4JbfVP uUNxgQ!I[ E,\[_Us ./TTGQGeMd4p&&}{z mi˽7p*QUPTC0vM]2VhxW,fz!ӌӌc &3TorbFC[]NE<ԳΣebIP94Wzİ쫞rN=_hW|̈́V%H)* \UZ5pUy8x<}<`s͘fp¥X2<%( ע7&)\%`A9y~F3s(| +]~is'RpBljavbYdy5Oښ1HݨYdkirnAhC% h;: ٵx^KGVfUOXֻ_觪z"uavW:7qβu+P*4lJ*b\Z| C|R+$,𺐗3fr|9x˴؆7[ˇϊ_*UD2y,lJ|όS5n%a]Etf0JfP&EM$,B?ZzI6bͰ7OĦ4 F =}DQv d`KVa2IjFK1*5S}?jΥMs%Ҍ`86GTSTp%RUU8m MEB?IKhuCΐfuX`z#hj䦠z69gDQ<7ܚu.fXtsN\ՋRb_=dMSW132Iv'0lro9kg2F+bE_piVz=Ԯj)j$FWTc.7>^z̢{2d: IJ010 ѻ+Tбv.®F=pcXjxFaƿ,UtrR庺*=Pm6sı5diQ3FZF챳- p=r ,}!cM- èRS2*>SG"gAa4_ɗci(\LZ<٥ $C8U/K=bfnQj(|/TԭGJ0d5xX2Ҭ Ij鷫H[˧7q⥉;,b4U"WqEQ&]P#,4S|;򄎥^ J}VlK5N)S]%55DtȔ]Z,[P"Z ; l 6XG;/j%zfӁpZYDū^LrL!ER?.ҏ?ʝv/2ej ɇ4W*+ =m]jmY&+;\uOIN|#, ))`{Vղ1DJ} _Kbx&[Q%3anmë(jY$ҙ⩲1DYaaxg{ާ|]55]&1)MQ#%WޠsILRp޾t3d֑ S ja%T4+_6{-3l A&DT50{(WDbXUDU4(qg\G{n_<:ko;n̑>s v[ҦPzf&O0gZA)槎hEDagpXl@" Ր0_(?Vs5)OD PKBP.xRpl:`yD'`Jh,"zڤġM,TlR'aFvͬZxR2"Ԝ.\CQS6-Q |Tb a$+2,t?H=u su=Q+eZVE JD_OzEo1Y'E-v Tޤ+pԓp<*/=#D 5h TW`rDa_ +ك"SUe,B`qEVcUf B\ *lJ!$eQ 1TatHIJ7lގ* :zzovX3{$p)=n#7\Sf2Xsf,QWJ̩PZfg3:7^Sd_=MQaxniӬ?5SCc LDI, LJ:N`sc4Šii*栯kWGSMY "S>C%imʬ_0aƳD8[GO[KXDK K %^:7Sy4}ĺPDxf'J)b)g0L!+d=,iWr" >ޒj~XV/rmM}6hjL^cSL* O:UF0ԩ1jR UW:!GCL㸟J}Ch#'qCj˃S|,B .b8n %!Iy8VEQѪFF?ઔEd 0lnWG%+7ˢ20c <&T:||aaLF ?Nk ieHYur,BC$uG>O͔rzz1fkO4sq6s?H8W=:gO?Wa4]#^b|^: +8!JF3-zQ`ƥMauK[=\v'QPM4OuPy%,t;bp7ũåMAP$r- >7!䮞`/d<#Zi⧁$̎JApiGh#UTR,xd[@1XVoE>]Xv3ԜG+M]LV_QM3,JX_8 V.^*?ab6X7򩩖 \Kn!dm$ʀF 7zLt澗4VaEME> 35_:~E+yN*2++#2`8d<93R/K (g1IIie` YQYW5.= :ysop"UbWabZ6H~tjf@5POI ,VEV)06b8O=lgxMYz0WRpӓ1ʗzZ(I"r/r.%z/J X5'M.%MMAI&q+WGk? Oi3tiujHiIJ{aT|bAxd~ GQCK1xV:\[05&<`*(j !Y|!V{ ۣqƧ]5j*lQ;5Yz*BO uMDLk# avotu #%Tl7%x#%8{a?Ը:P,|сPfo/JؖĞ$fyax87FsՔ^:ɎR*'6 :R6!C1zl14iRekd `>! .r jj~y?add p4c|W8^wʙS35OWVWMTG hb+i+ {/^}-dAz̝ba W*Z\c ARҹhjdXKpd`ux!PU\o ĒC5.!%,1JOq݃FXz}Db~2>j"._w0J#.H:NEEN Π zy7 #cΕTY*lNELtn󸳊*+zإC,k %=C_?( ѨE%VEbVESMQC[QTiu"K5vӞ<9ӜEg?W }@7ZhzOVdO Y:ʯ$,Bk\ ^LUWc5WjɢK:A1Z#aS cRȭX5Bx͕(r*2iC!\nyZzeé)qH^YdݶIC=L^zC`U>eT FEed JCך\͋a9cei AÆ$`%IqGx:wYcb+eRctut|&:aZ>Jȑ$Fl{8$(z}=M Puk%a 1\$xmN/Qʼn6(Uؔr)ED n/U>UԏP3}Yʚ WeZ*/FZZIchUeFHG覐zP=FgzlS͘ŀVelifq\Ee*D2$ '$R&rOb5LAS= 9OOAbxMU#lj!E!WVW7;z/?Wzz?&Lq\+èꨫ+(㤊h5bʐ1b4qɯMc2fl/t2_3`3cxcxT%%v-ḍ,9V4|Hb."PEKbW/);fW%8M1bVff)qW%I+UUUHJ%x3' a2I_8yNYឰI&—E26 ϞH2hI0эTWҦjJZIijR <30Qzg=CZZw1V;8x?[P<غ6 \!=KS XD܇ W9>RC2.N=F/Ttx~X->clC\vp tjJ|F)&*qTưz~TXbsKrGY N` z,w0tLdVM <]d@>2x%K[d, 4tT80$3J,$/eoY/: _4Y. _ s`8asP0L/ Z29jH FMQ0Z'JL:F:>xu&=©BDL4J T)@m6~7N,2e:c.e1L|T;R;jH[58bj2C! ۸Ȼsso/?N9/,:r-fJY#;"k(0)Jj)Jc,s?P!U/S |[M˚hB-C U1v^v:ٳ=ZS tتKJVW(wuhVUS7Կ-;ét)RRISi}dXI@cιeďL?x^;&1*ک歉֛sbIVwĴrFݖzf:)h=Bfl]A+pbQM, V90;$P6Lۨk̙[Ԋn[T$F{_tHL=.OsWMpl`ay/+Ua1FjE5Lqy8WRPMbΪﭽ?:|b=FF-@ᩉSkede(20e`Ht+ kS:e:lW ImMWL$HAtg+MY2lSb+58v5a2aDrK3A*Mo,{$7H7|=33 XU$ *)x) $`WǤCyʘ'}QaV|: A-'cԲ2KXR26R`XNՇY:]rEs)O&=K6pvjwe/69`}=X8_˩u%|eT8u'W:nzVb]}*Ǩ0QUc*UbY R"쑣Vys/N/Y:vw xd9,CSQUTRFR>(?9Y9* oO~'TY`xPTV-fV 7ZA BI.UePO>ӄay;0ͫfz| 0Ղ:GU(4-WL:;dl=@IU$4;jIxic], 1 m~Dž.u9]4ihi|B B Ԕ8;H"5 Ž^0IG<wfLטjS1  zɩʙLUtQcXͽ"?g3ж|LS5dA$ JnNte&f=@OeީU&5aaC25M!ARAϱx`A4zQ_MO9ES&r'O6S1f"Zj |F. JWĥ$ GIԞ宷7Ber/RD$S8fkvCu S9)Fd¶&,WS%W6Vcm#`TEa}sEY$Q5ET-#H7w@2ޭs'Yr<~1ezxŞa;ԥdԱJD*SgWu'yW>dr.aق A&|RJ ^SyPGNӍPnI:c:d2>a6VŰ,:: =~'IjTXM[-FD3ߙzYd>^t lO16%W%*S8VUQR$$J+%_?6c4V,I0u1Rᢆ|YeTbMFQuRt,4H|IΙ1~)enboESSR͠QE[E]2&DʮO4l7AzCӪ|K)it9~ ?"SOi0GG}<臢pb}6ᙒ>f@ΧY!$/,UkksOK:&XTq *밌>(릪":Ca"a 4nه&䎵t ưzט&pc0b5]/g4U &gS,ʽNaYǮnt.cX3C-$8Otj9bh uEh\KЖ ?~178T(QPah#Rl62lTN:%E_Xh5tb5Y)bp|+xh+)lrҒfF6AǁWI0ޥgzfe|08U5MELtxF*%*ut U}4XG@RBܝI`#SaT7<*0d6aFpH ?緟Ѵ_yYߡ-#Fk`x}6!VB@q, #Ѵ5Ҟgt· t+pJc*E%lQɈFHd/9/fv^cy!)*e%m4qfq1ƱXL m%JyT,qꡉο6 ךz.by+A&_δxa.%Ig/K2y5ƌn{wP9T.MrvL#19&Z*%W~9#MO$YV냣IXc 7±J_!Zyay〵J,/:0Mqr x[rkA:A eH Ɨ+:QA.)]N*L5d ßO['6`Cbt=aVj:Z|m08c5)wFBb!u!C䜶]Y3VfpLs.Qpͅ CijgMY Dii$D_QV2~sXN0ɳ(a2꧖@pfKBꗩ]R#2~Or[|1'uة蚝(Qh8Xfn`u*bxc#لY\ql1i( s$}ZYpzb=^FX藣W~\z0Ub(+VJZİj n3Ss*gKCsdc4'i`jFD QQyo}ʢ/I:Wa~~RjXXm&[OMiԈ"͖T'hXt߆,͆f<EBcx`|N8UV]gZ*%,ý]VWy7^6O4pOy3 nB-<cWUa2eL;IMfk 0Fgb*iZI2<ϽF3/]%vty$p5l2,Xҳ|3 +l9~}XKnМkyΏ yF*vٱH$?#aCIJm` ~q#7Jzv%JTCQST#%<43 *R#-Q/)a߫Q(I׾aY5\C"c0-)U`rH5IP̱'|q.lR gJMamt42AaA"uVq&%mۗ򿬜j5E)E@bM5fek-Q9tGIUxؒW_'Q0Z/f/ũcH_2)&FUR`GD:WALCtxJC՜G L.ZtJb򣪉ey^#N.YH n^㝋Z:һuBKOPīN!u~WLg8n)QW/)൦zi" mo<ӬuOZ|O-}%6|S'% M#[˶9yNX":džk]oF,2¢L^)rt MѤ1QŽf_")m<3uG@s^L~+Y#5c1UU^ xljSS0mȓaᕒrJo~s48/VrVJZzH+%*K(LY2MǪsUyf\F,3ia*z7Jڈyhf*F_40=Lf2>'TMPc9NWYHLj󆆙h}Y+\}g=J8^ht\&*yb 0o:PUm@MdOkS)tQg+0|[ ^x㪪LPU {H,MK*: '~{ȘV]Hj1jaI>'CY5-5$i%R51RBCOJZmъيNju%Jy(?[S,xJҌZ&7\Q1i0JO$WT%mX TXlvm w(lH(3C_BWr"h\" #w'M~t>l?KOSSS%G,=<l2Q*4s*bIP^?ѧv9;=4RRdlo ť tz92T2 ЁqD^_s%uX٣=B\aT_R5sK~C̙w ͸nYbIRIx' U%XG N=fJv!zMh0G8lғOrIM]* Q<'،=yjdYzZLgԕ~v˸m]o^i!jxfF-n-2wP:} ñY֗˲,u dHjx7G=%R+Km~k/M&b^aTB–i09MxK;ISL&7mULߝsԺ["Q?'"EYr?ac; 3/S8 Yz+V<\Wǝd3 G/`n|/Iǟt#૊/zl[ ΢1*g:/ęgV!5M8չugXk`_WO/AS䓄ාpW\s繊_HG . l1<= endstream endobj 35 0 obj << /Type /XObject /Subtype /Image /Name /Im6 /Width 225 /Height 166 /BitsPerComponent 8 /ColorSpace /DeviceGray /Length 30185 /Filter /DCTDecode >> stream AdobedC    o!1AQ"aq2 #BR3$bC4% rS&cD5Ts6'E7F򃓣dU()8GHVe*9:IJWXYZftugvwhijxyz?Lu>?U2pN(1 t&w"iRoy!H_b[HʛP3I:OGΕt5hiaĿ$4pH3pCL~+f#+b7,1{9 O@ҵeCĢ*UW '~>>VuXwWp3,NTxE/9$SZ2ZOѕ4gOg^u0S㍗'S]OS ;th 0MWTR ̆'# "g^eIXu'0p,-.(LsT(@[ o_s Y2c5.E)멲fR44XOKWEZ GHV_y g.٢3 ئh坱*ǎUkF!#5e&kݵBͨsӝ#Q=nx4gt$cIdp\./x y"^4, p[1Σt2蠥48M-#I뼷bPFPw{ 9]yUTWMSV ,OGQ #6 8 9(S]6jɵ{0|~\'1H*q 鱩ކ,.*"d1.9GONy}6xc]uMD,WͧBOxi7X'/"%Tx~k8,X5<*:>T$H㆖vyQK+߭>:^Rt)/,c8v^Ф ]U !3$5H"UwdLk$NYKW} ͙SD}=c' 6 ]:֧ZR,o 54 O=٤C==SwWiqaGHplEuTػbtRuCi9ʍ#бd#V%)Qv{ư vĖzeuK!ܪCCՐ\gzf>1&' ii**&S\2W˶YԹ(܍:鷬3&I>K:r漻A`mch!I)8Vz ۩^MX󊮞lZzڬ!Eq51y{Y=FzA^s3M<PR+˩XԕR/V)3L <:zXЈq\E%_yT@%S8yL&𸫱o& ڼFÍ QM_6*x)dO=w2#AI[G_N3E=#20dp P2ÖimU42JԵ8FKRD6߀N?Z~;Y3WY0?7%-d=azzJ 銻Fa_ı~oI^Xq:,CRtlKȸ xN%UHv? QVI"SDF#Fus&e'V$7h( eiEi"CKSEM2H%[H9tXwGf;0|_Gߓ[1p^HjZ BR$ZtCLW-Ƴu-1WsTf+ICU/Y#W S,2fq#(VqW[)\]2=!s41utI8JMVO<1۹@s^۠v 0=<SC+%c PUQYUF+^3''1cY $9s˛ iZt} L$c77Pz<լɛ>oLCfWQ=fwo0)eVSWӟJz˸fXDuXUL=&^GQ NH# aUXpY'/tL.?Lq%yU<md(YLnѰ_UYn<_羺f˛i1, Z1'#u1-4^E Tki&x;usX颖Cښxڹ)0I+a4QOI5+hPKyB*LI72P4WO-FRRPVWVƪrT͇r3y2R ~K3ӮVyW y#<ՌFLwtjq0asKF};/ּR cU[~21(r bjam0qD%9yY&Cyd lBϙN2[%0,cQ(\R ^$ۑ kp䜣dhj%j7dH)IM S@O{ȞJHl_qLy˸#f//fLw )j8ZPKd .&C8tg$e6~aSndi9#~ҫc(P>zy=ΝC԰|+x IS$1E-|r=2Jhe 4*{,]UVC<\yƤj ofl6 O4U`B/aAK+VzG1aToQ90mE[_S(̫|RAE ;cXF,pu ԎI~ufaHpspæP)gJR+"!YTW9&\Cx}1J|{J1X)1Yed13I& !w\eqԨ3Az2+Uor8u$W4PUVUAP%G[T#TDr'(E_G!#|U&oeOc8 =Hz駜/.,Ъ;sa՟I,fM#k°,l׬ ~" NLDtF6XU?~ =:O9,gX/paE$8)NqR* M k)8^dcC9̫iSN*p0˘1LVj91+Df !D3̛ԵY0S̙a&GCNVE) QmBWzO<ҧH1Ls_US_+2%CX—Vf%Z|A4r9p2KS箻ޞr&&]DF)lyRC5,RRf9Wp{uҰޞza0qÍPEGŧ1qdy d\lQwLɒ.Wp쵊ZWڬQP#$d "?~:kb͝|y0jjt*KXj池fXܡ1$wy#xʸ+aYf0=K>b$i5\xM|59+U6U8UjsK}Cz9jpwbg-Ը)=SWGE&)W=kDGH@v[_TVrFNw!Y/StN šV* Jc$MRLD~\.ŊNJ!~Q6WZ\6Jua$8f!jzOJz3C}3d6̫>)bԘ̘.A5C VR$6ēI[/?zLFze,J.ݏ W]V=`L}056lêҝ2VRZڊhi%h?$θiȌ+9RV}+pܣCΔXI&;=Ij.Ke$-S,+1 *zwI4ygIㅜ1@}X~zwc6ؕNTxj'e!cjwZ1d2:7bbtnj z7b4cDPAM :J8~n%_1 Nr/Q@j%Z_4aqqzK:N2 2O^e;INfñnOKX|njb8O1ESZvU(Zjʏ_j f=@`:ScYqza6;N!>NTMGSH@9e"Fo"X_XwO:EѬkZ7#QO }41^aEƒ"q8NKB9.uɵ8--nbECC4s)U= pVILϓHVOox6ߢ}:uFl5X5i/s/*|7R̕c-87QUh4\Iatr*WJ7D4Y!*+ Ī L)jVcGFJ"5y#OUG--P8c1jɎ#1m G3fȯ.X꙱SAUD4@ +җd,.wTƕWKNu)Wu#^h¡bM2d)o(Թ#$u!d|⵱C*A[UˇGL(iԜQt i'1LFZB*jUh7%仰 'a8.ʕ1fš!Sby}qI#Ƌ_Lt%Yr .W/ CQObOSTT61ⵔVtf$9)ctM:icI:ˈ-Ӽj9SÅi?])dI: tfEzG2RYʋQRTʼnjS.& Љ3${;IWoٻ3E͍ผTYG[48Dj OI4QdJd"~Hs:zz Q ./Mv5TPbse*|M*bZje0X;efb_Fire-M>!ɇaͫ:ε b>r$'.LjUU؍M\x4W~UCzd^=ɸ ,f.r]^1h*FEHcJƛmX:)QLbBK6>+ޣ JYa⤯t~kQK ?'V__ ;"b.S$T#1_sY=u殙fx[3-.[qpU%]]e<4 4҉:Um<*e~\R*ǂRaXEb kAwjֲGQ-kB|dܒZ(utz%͸]BȘ61# °Zj*/6645" X 6(cud̙êx>6/N6ezV3%6YQ<<04iKxi@hѳ*b@4=pTt 6uv*)%f'Z"l"0P"%U1IYVUDE>=l_P`T`hg*5{A:,aFn[.AxeCO`c'±uW j#U#,^)6y|G{?DY7+Uq`kj08頙i!箤#KbU#/Q1>R΍[)LQ.[\NjhDjSԚi1-HFce\JOս q;3oSp>%K #ENU=>* A+n;UǾ$f[Xvw/W":, YX)"RGeլdB52}ڷ>pai0sA,3-\ҡ!pҳzUSE'*Wu&(Y0 **JvMY Y', !=Gwn dŨq'¤xYfI+4JJbA%ɟTމz Ɔ&Ԝ*3L2TɆZw@lnxKNU̝ՌM\Zj*hJoU5IWaKiH)QD~.ٔ3fEu+*GVVNlJ-QLgS W bG 70Y}V U&!IMKQa6(-VXHcN :u&b9S<$hjMH rrua}/dLSE˞p4zX!J0Cɬ<6O,%uOzGW9b0*GQ]=<ԥ5ӄQBJ {Ц ^f.|ܸun;PIAİŜW:yK*S`*RH7ߥ}ގ5rwZoEjp(aVEhXK4/-V͘nzj8V9 X;RTx u0i&p9DZG0RνtssPÿ|%8H0 R4j"W i4rB1yyˮBJ _901[ z6VdQ0HɘS1YI<5b̯YW>Oau3O$`E4D=ZW u-e.V RUc T  $IDS8/RJi*c QJ.'E$~x.u9:̄q4)q\k|: U' )&/5J FfDU,3<_Lj%YèƪiDu5-Y.|-5)!ݚe,^j!=9f< >u3Jܼrhv3MQ/W&/_eP,.!] :tێtpYʢо[᭬i1+Vo-#=)h'3ǽE!̔\Lmj.#,xr3OSQSuuSPA,aLbIĊf<˫XV-r6Z\Eqj<ˊVZN!Rq*kDpA< !;Juh?-ʟֶ/EkS`2ρVf1R&7ީ")ۯx9"x6cU3QIU*JR$.8 A$5&^z3,⾴&Ups sǏbеn-$buL/Ldy%"&z:,[6Qrtjfxjb:UUVX©.e.Ceg_+*°|Q&-LFz5n=afѤW{{R~gīp<%IK q^**#&idXZWkSʞe(rn ŅFf\\b5φR <ԱU2$YG ⾞z7K\J(V8-Դ,ʰW[Ĺ,Ĩf=Af/QǦنWPbJGBզ#Ke+暝гd镲to5jX67Fɇ' $pC4D <$Jg9 #~As}QvzH3SreZZ81cug$RK L6gzbT a|AjEXhNQ#RX(fkY}>94g>MYG4~l&O+ cJ<9&ᵫzilL?,a IOU %u0 HfW᳟Ǩ*y!FW )ST?js矟׺枘gKAU\Ou]-n iraopp`Cj8?%]m>Y+j BDUnG) kƌӦE |3Qt2bX `cU،E<jssAАO O+y;S,yAQ`NԔQSO[43u&!6b^?zq+6zzI.-O8VbCf*ҷ1USU@EGLO(dFҪc:ˇcz\`U&6wZzY%/C1g(X5eVP7UpzqM>cq(dq\sl 6%Hyk P%TĬD#E,"zp1gbf?gj|j㠦 xq1|.aRY̸̮ȳ%2TTy/,3ujDY7 ̱|ˡ0|gس^0OKpjz>E(ZմTn7جUdŃezq|sI(ST`z !MO(1̭(*͗,_(aLs1=?z +jxgH̱VoHIy:=afsX2n|ZabXTLq̈7y k4.t)1e΋0ɈP%5&?W ̓j\S ZjhUj*Eû#$GGrfm-GԜ8X%_K56h"ѩah|*yxLgOJ94VM`u| Zlb &)cĩ'H-JJ" a]qu' <*e\^eX5U82On+1lEo92X0P_o] K8q,7Ũ+pօʸbGR)d!%fT(Wg<и?N>qO1͌eVjzj($,Ejr)&E#!HxB|.e|k9KK_I欚/UTF7ԵpD@UJs8Y#tVS0&O[Ί\lg.alUb@r͏K$#Q0VXF:4Bcp}bA}pu%#NLb-ϓg j^hfhhϋIE, R,Ǐ>l;VxTT8ŏbyz>XTuV%5];|rCKNQ1IklNrb}\uߊC Ūں h֧b+a2ɼً&ꈲ#DV GYC%?%t.+,AA 6fO*g'h,Մ_LCY{t5mJV& % mҠ C8zf,;ay[Ƣ-cy5*(*|ƍ)(f1leYIX*el!^|g9KpMM]KU]U hLR":XdaoSN\̫figjsZQ]eF,'-`kIJq(ȧAcdf-u,_΀壜* LŚqjr )*1 h̰J/s0l1൹s3>o.PSSQ<Qbv:OvxiJWdk7Yb nZɫLXK+FGbU mb9]wnxtsѵsM1厒g[WAUA[-sPѬ58BU"d.RÂԬ%SQGRZjh##0hhF$p٭rQƲN9Y?ԸK+S RxGxKB .n(YKO\z:lB &w MrcHD!Jh頍b[}>7\nCU-bSxcbqG ADQ6ls&YwLv4ˈ,F±ڬ;jg0QWHTԪ*%Jijdv ju#+ϗsIq^|ς.#.[b?#^KE&dhΏ4q`d!iaEMVɇKSZգA[q-DʓG-&RC`ض)yϰWZOG #YrN|[n,:2 GCZFS«J$ejgl2Hbb&TRQ@MzsbX>OūޯxVKS 4T3SYUSLpSykxÜ+q`X!]Gqw eRKjjVWciJ5vA+70.%6 UTӼ6.=s v&N)螥g%P"T;IҼ7=C'bX}Ff0$Q*T%ELqUJ41;;JIo7qŲGP.M5lNjaCK_5 Kqq|#tk{>`ضu ɱUOOL#50%YMTr^U`dCoD092Tɘs%Y@R òD_W%j)jշ3X:535JY@ϙp{aG[Kuie>J:YH@SĺTG-WḦK{(æjF_̚(id  _S;?Us(1:*HYGSE]TQMSx6d }?ƺ5&f|/B\tTBEc!H{n "X/ѼK36 lJ1O.EQ_]IAT#Þ,!CRWY!U'S/]ZySӤXT%vVeƫ* ꚉի5N!j.Y,jvZ *+ e5udUTCV)iy S<(+?FMWS |f o*aSCB~}&9z0B*EOK UDkFIUj^ GO"f;5N5Ԋ|A@V_U]v7%$DEJ Gu#8O1\݋N)(Aj?Sb<+H#Wb c If5_?8x[wQ 1SQ2+'r,?3 L1 `/K48OseuX~aß1Fj XB?#-=:Hi@MX 4-7J1h#5<Ʀf"ȫ))COf_ưVNhi+|EJh,Y%^f7fbCMuu(L,dF2޹N.oZLZI*ĩ+0TbliZ)eeYw^Qb ݖe\8YlyڎqqB, JlU|>eI(+l5QQyrQ C< IZh.Z]$<*VTy6 )EWL%k XdV$QmQ3fdnpZ\vOI_,m ȓU+M#3-ҞeS,au8!QMD0eJX)fi<æƌ)eMZʸc`R uTj=M在VRTǃ.!Nf5ޡUYR=5\g '33vUL}NSؕU y+a,k.,ʂMpV} 'PR CدO f+1j!sRRɹj/ Nu4W~\^.cu4UTu11-}tVص;D y$[e8Y?cYg?:"l!by775%c >h md47uL`sC&y[ H8zU]g2'nd̙Ywy/3dZ޾)1^k6SIMu٬GVUm>':eGBN1*X+*U͙ (3=$RTⴒNAd2yq*u34czٳ9UR\o 8a0C1!U#IM;HbyN.t17_ ߖUA0UZfo6`TC$ <ހ~>9tDʔ:b7WK4*brUG-6\Ģ 5xhhf؉o9K'\~x6Vp_gq*\LbQS=pJF8Š\Ѳ^S8N]>3n'!E_CXQVc%92+0>z&w^h3OZqZs8h斝i>BT:rK2+XK̭lL_Js'RcXIA Qa԰|_徏yT53ՌNxӷI2Ix4xoL;.z{ijI&al>փ5A)"kQΓ+Vv+Ttx_5u~%gYPioz9#<-廏L_| Q2Ccv8pIqĨBiҰ,[J-M)Y#rm-virK#aj(q hME}R|I fmzQ{NR1lEvC_- Ԫާu 3fx_pzw _ITA[VIGQE_+b5X:S9J "H@g\2F\T^=㣩ërĪDLtHJ!=w/dwLn`ո>^˝5Yn,N A5Sf6icJiJa.H>˲Ϩ^9y &@㝢,eJ<#F1Whp]_l6ebʶyj !Zxnin_OR(:{"fijV*xRTQUhR5βy $.Y?>v1qOQOYM*?}j}f'HGe|"Cz:i'(.ʥIF& O֜;'5n'Qg|c5 :NҾV:w ;XE1Es~O 2WρMO-$.cI$$%7=7&⸟NbG)0RE= E\PC=D=(\?F4YṚ,1J*[e\RJδuRU\&]`.=RM-0G&E3g8yW6`i8%m6!AMtCG {"_`gֵ >_1<" 8T5b c !j9U;*}^OJAO5Rb]s̱U 53O _̌OI q{9ʙ_-USp DղQSO ]1`kHScwL/gɏWatqU OS%K2y-UzҪIr}Lz/~.ֵX0tRL .U ⿩]R|7pގs/W&8 :Q n"BDҤ(MBN=H%g%ePfz_|6a4tVC!&4Oi11U]"RO 0 \c0ѢNѪ4Yʊ!9e|m:,?x%Rf6/]iM?/d2x_(Q=jĩh1l&:*Ӣ ًH5 )KPt eId k0=d9ǘi)ޒ4ThPY#B#d犜3Xwl2|Vi1J<ժյtӭ5c.ro?׵L_Wl_Ь à(XhZ/KI(}\aI]Bަ:W.VF4f,b4qVOBˆTH=ȧldU{(o>f*Q-FbħcyX4L|y/h6b5]ޤ3F+]xU,jZ :L^H)J*8HZ HOKm'RKP\Ԍo %]cLm38ؕb守voww0^=.#<*2FX1/0^)㎞e2B uY! 2j_[]U3+W_8͍aRV0%LQcT2$3N3l:ԌCJk3 bIS<u6h%'2Y)*-/T{}Y:[=v74C)q454]TjԏHE%̺6nތŃ,y1UbXVψz3Ml''$`#"(Tm2+19hM3,Tc0%9 ȩ*jn WKTbXjI,vFdmdm~+ -p5G0\W *7X%I$FYTI+0 <| +G\j|͖dLf?ȥ]e$$Q(mJ@xFbΙ.dl})쥇`+@EK-BRd:QF##O,ɏ̳! O&Cƕ#x4?5-=RVRQfEt0]Gjyg(qk0ϗ6^YBCf=}E ⑁9N"W*Fp}G2qzs᢯ ūj(K Tp'*ƔQKѻ{Ο)uR|s ˅U-&%\0xa2yy$k~8Dǰǫ2frԘ!oI<|Tϸyu.]݉= g {:I=9`.g8e#VYG;SaTԛ54ˈYoJ{4ϊ[JA&-S) zd#jgJTU@%Poа?OLqرxKWM)k,^DcFH,̦*$CH.BÂHUzkz֬\feäj֬TFajy6tm 6HIpoO:8?EU7,Rbx H,eũfpy+hsVrt1UgV0" ʸ-Z^"V Jl!Kam|, jg&X$+i1ڋNpOY?OKm&w3v;bLSGGUTC-Q?~Hl{̱'8J>#1|B)1Z%f'w:-N›0b\pٰ̳+yhqZS$Pd~k#ǤN5fXLnMWO%Jy#|(ǖ+\ht<6lgaf QST{}Ͷu c"uu1RSIW> H>g;Tn6Ta 3殩EW6c6JjIF%QWbT7dY6QenzDh:oԌ%e2FSؽTk)<,}E_Uv˙O.MEF2ܯ]哆T*'byReKnUоfޜeW ͸Ě3.j0y[ʾc5,k$DV lfx u]ýBf }:MMt.eE56 95+SKV%¨:4s-Z/Cnt?DHU^_p|{5b4_)j1l^Qac*WF _|bG=QtU9nY3,OX1,|JCBUP=Je^t3,b`>1n?W_~b5OXُ5ttE9"iV$4 "\u~a? R&ԴQbt|AHgбbQpLpQ]F~gs/' I%Jym QK,E$LH'OvBz%?Rc8|uOYTF֑Qƌ-OGSp:zZ~t9Z㍇D\(0I';.ˑvY5^:u~j *5lN±:\N8i0Xe5ZU)͆/:έPu[3ZJM9s8Rš\5>!cTET Did!~Yݷ-@l(ۼ.=1%~)B`J G)>#ISUaS`tch$9 SrFWY9fɂe914:zvezYMW]A+;+:aőc ;FQ8(zV[2,Z j|SR24aU=BWɉTMAuӄ׎WdLՖb~A_匹*+0ս5KTPWS4c$ eYٷ7~+z`ʯ&4#h8Qi)ަc w+TznF,0Ԍv\߁׌aA"9,h9i#T+\g1_3^1*:b#˘nv 5%5<*,;A;Tg3?K$7!Q'yoϷ᷾.6 n 0_ǪFw Ģd]h Um-W̟QX&p@KK_bf31.G) uY< $\'+bo'Լ_UIEbLE#lԐ˃.jiRE&oi€sYA:Oق:Xj!XjG2_cڧۡq5~S9 J:UFu"c'#(}~z 0jfo;c7N#3b8S0s-0I$Au$"p\qh^(bs/^f**s]VhH)>b EBAjd0XbY2n9Y껨YQf5YGE&`2Ça+]H(yMSO "NsV/]Ԙ>>ega&/6$MPRI** \ݬn}ρ%l-nj)+q !ÒJxEJIDpA\m`A6|n?n/ 8̏I1'\b,n:VjNIX-:Z$P6Į ˏlw^tY.?DUPU2UWW6.'S+TI ajP:E$HѓW/jf endstream endobj 36 0 obj << /Type /XObject /Subtype /Image /Name /Im7 /Width 225 /Height 169 /BitsPerComponent 8 /ColorSpace /DeviceGray /Length 31774 /Filter /DCTDecode >> stream AdobedC    o!1AQ"aq2 #BR3$bC4% rS&cD5Ts6'E7F򃓣dU()8GHVe*9:IJWXYZftugvwhijxyz?Ќ)`q`~^4Kf 驰rZh:p.Jj](n+:>u_%v#˗'i|DC1ORo@Ţujy2ycqJX9nCy{J|Pñz6,X5XtQ,u8{?F}Y厜-NBij&C9 p9i ӬJ0&8$IMQ=2K&C,u0RVy&ejwc,צ$qMd;dhD:COҜ74b=Ex,o$)cUëpy>Y#R=,"UDFnQcGD'ޡbޣ}ETUmtyXS-uLt->2E˝e8dضA45:$tH@UTX*`q ּOCo,Vf XdkK Y$F W=4TI-?P&8{Z%\V4zZ!P5#X٘?/T\V:2}qN)hi-U/%<()b;g|*J:RIM,ySj#kQ4"İ,ƾXWRZF-n~~%=lνQI LCt4toLcy*)$]nwWRipfNQb8SW)̂a`O&p^5u-t=@dp<'0eM>/d,] Guk 5 bLw3b3QSARZJC%S8h`;EzIr¨(목j,XKJ~ aK V=us6"\;-l 3RUMC I,Z9#*VIQ hy#F(g?4cuU0y*BdH*C8G=cts8ǙJ˳1 &+PoIq A*Ufh>$,$ɍ̀ez]1|_3e\/̞EPUUI#G>ڙI64͸e7\zܑeZy"O[[SG%T>-2=UJe kyկS2^r5/RqǏUQVbIrJIħĀ'X|bFl'3fL6m3સ]s,9҆3UZ5Sz9,>aM8X!M2Uy)^B*&1*YF%wOpc~bJzl>)Tk UW+O.WET5ZƂ#y@*R@tQOW3TM"̔#dMn`/܎^|[C`.^OL^ư B]`G|KI)fte3*<`;8WY,F $;i$T iahKF;b&dY0Vvckhqe  *Iq: |Af4[TA噣1 9>L1м\q3O]TVG,X/I5RbPE%$R1LN<0e|FkE\P-}G3+PʾPزH+ ?G:LYSeu\\Q9Q9Vhw6zb67gfzZYč|d`8ڢ$cqueB-e\_'* }$a$@(W{n:L:, ) N^j<TRbtMH|'j ?\]+KEJIGC\|{.ov:0T:bV%G&i'je}QRHg p59y.Ƹy;Yo Z<2pJI5RI\8#!R,<UY,l)k*CɸUGѽ[GIMIUO$*+3.݋a`>5Ԍg5UT>&D:iR)ic S Ѣh(6;義tKij^h|:u0F*8c$ࣕ9-Pǩ ќ_ZjwJy*шV+em)QU3ݡp;r I,r <</Mhq?ΞV6S_O="OrA*()C_PeNtКE:cO53VgFY̩ DC(م9W E;a(2~%Ɍ $iL"WjP Fp ůg\-ӊT-=Jã~e歩ANSF J@̪ ܡ֯YՉ>k(3U¡` e*SyĂ6bBd<{2;9d~a25~&PW($tYeSR-UR1@%W$,9u= ؗHrp~**.ZT9ejdF^;ҕXOؗl zk)@ĩUS]HԜ=6EB\'L%5q,-Vb2MXƒ+=mDSF!&Xg+YiպM`vt,G25 4Q# 8IpZi,\ydasWBcZkuZ7RE4hĈF Fy+Sh'w0aŪ竖|;JĞ-21)Wڮu"ºɛԪ,QI13IQ0>.P<ˁ3 w(=Amd7Eĸ=4u[)L-Iika QS%ET #9 )xok)>ZO *PԬwʙขdp,^#h0j<1.N!9$"1|foST9 3*bVص}<K4PRWgVWb9w;$(雠=- V`A*rO 2c C=9l%tA6FpZx,e,j4~TrbIF'2@dycJiei^"EPok[9>3ab7DdjhcCK;URĞ[DM1V$EGvE$3>NVjzq:j)TX1aĴ[ Ǻ&978uz7WwuzS \nY L5$ju6QʌKվQe:q,Xz{Jz垂)lD$*Z%~c*#uEsS^Áe>lRdsJz# >Ēhq/TA3&[ 31YQSb1b8uCb53-KbԵS;1+ @G8!zoU:& ^U\g58Mj׵,uԼ5J4Y$/l/]UNPeϔaU3ֽ.D&Sbu)FLOBz=9fl+R/=c eg¨(VX u bHVY(,B=u=QM䮠ti+X^)E5* |VTB"C9%(Y`oOKkTʘSV!,6:r*+)#6zfSN.W=1&2ĸ-+խ;GE V"SV1R»%(zYqn\/J |FZ:`Q#L+I#$]t<_VR`F#\f**ZښiV B\BP{20THfg .|ئmzO'HxY$`F9x9=K鯥JΞьN&)V$X|I4G%$L%$ڦ=( #sӰzGKse3D)36=MӃȂ'Y'Xvi'zHW8R1LBJl:EFCE~N!$o?uLZ/bQW-YWUSӘ^ph]u6+^D t\b+dVf2a-)$t5<1uvDމ ўqL )p|TS$ aUt|(b۪ZI]u ]8uóoCzH16J.#/ c &m -KC04tVX1 (Z8`S'"S41lvgV& %OW EQ_W]JRCU1i^9bhF²^E1!/X332Nhv `yʃN/ScTu(Dtv'OGAS,JKYETlI'Na^YjD.qxDXun KU,'kpz:*Z$lYbz,\)sv:aAQ5>1uTY)xڦqB& sE dFq~ae#_Z !ZT(&kۺ C2LeԼZnbV],Ij+:OAÃ4aj! ) X"p֏Ei%eLMHY_0K`%SU^|n7-=C$Jvy(?y?d) v%3.!\>lԱG L)-/7`dz%eiZi$Y% Z'Bdwc#/ +Q_5 ]Lu55s3C^@ vꦐtpіN.# > OezL:64mU$)!6FLt)zOc=RQ8z迫rgF^#4a`v zw Fۿ`o2L}k0_Js?k -\ء1Kҧ JZXL"yaR G)/Rzf[5e%B2%]DSF~lr/P#F϶ܙӟTq\sm) ~NAMS=hWBDYTlы^I1ݕ/b8?[0>f8RHi*ggjI٢x $As/Qr7 s;.Z JثQ`˗̴EIh(d<uW.MGU1,?RbP 5g$;:G38g;]̝4*"`;}1YAYEU͂UEt5X!CQS'H#c6 snq2m6 znKX }M S+VHi6QfDɂᙏ wY/ʰSX$ S )+|Zj ƢCJчIdc49R6(©)hfJŝvJtߧȹlGB< < bL"'A21"2 _u30.|*)kĢHUqEPvbnYwޒMqy#;Rؖ 8-QP;X/P~s:rBdžU6[zF9U,S]mXfP]vl,< u{QCښ_ ӏ: cbɽGՎ^dIk2=F%MEW A 8Bi}<E71aջ|`T)M.#45uT7:'8j>ԓ#- ,Ӆ c o*: UIH-"t,ecwZB'ug q܀X~#l}&͘J|pNLf FTMu5qz\F5JZuYΎHQ,YO#+^pvy &e)(䤫u y 8 lvԼW41bBVTx ؆+F%Uz֬E m $9xQ!.;0`8jy))hd\> E,REWKJŃug91:f Oz(gð:2H%xdo0yt]cylih6 Y9A-5sO=.& ;ӹqfte;}=GU3N@W o0b >`I?$x/+ PnY0DnWIg iޮ¨?n:f+B\F7DbhD2 }2UwԾXVr΍6]W*k#RgS35WHr7[-):Wb#?|C"YPy> ^gec&2!ي:ZQ9"0 1*?p:ƪE^kLx֧誫 Vؗ[ƏNق:}ƺwe|߉zm%lm~ TIbd-VBKOql*!n*LW#6Kj*Y5ZJLhH!qST'k8%V?%~WM7U$u# >jĢ!rw~ps xV+KWQSOSUrұxa R*U"u(p ڬ9zPW<&)`.+QK_z(&($zJ4# XǤpc0*>CNp?)<)Vχ#P xU'YN.~K ՃSb8:W6Rb2x*gB VdEލyeMT˘qGH8g4Xm =UTtdhx4~Mw8Ru0?Nd͙ 08nj:8$kWB4eKe)D=es_?155\kK1Q`O* YhMI<6u$`ce#=/=D]0PaXfOL"i`ߺ(y#1RB&py2ay5T7O"I#ǰʊB,JCDii5MQʀ7OmEj15Qx|FŰe`LNUUde3J:LӘgZp5F+M2>b'qL78x^(Ơ*JH x%#m#S7K=u{Vk qUM n)  $V<p4/H[TkN,0_İZCOP' 4IM(/cHz9O-E>+G[TH5%?2 g)IT;)eXaT-UIӪfziVb؞AG))1>e?#2h5׈ds >1V9V1QـU$RVM!) K(a8~?y׺L\ <+P|ՃC4媊J]Q2J!VQ *.p;F_8.!4ȪV)^(xS)+"8u#yS>Ž;u!S4YsZi`ZRL42SӑfĦU>r\İ;ĩ^a7zM&W~,+1we5^{ɖ$C3,.ly6cW9i*5xve=ME%!)*K̩t{*Lh E>0IRa󡧨,`B)T!nYIU(cX^cΔT`X.`/T8N͈auXZcVƵ[JC' ǥj:1BKS3R\d0O ~UF6AqFSrfP28.cT CYHfZҰ @itw͓3 O]( ,;+<оe!q*Q6gN)3FVi(->(pU=ff|Xxhd z~~~bҮeաÙeS5E;ISQ$3qu =;t8e1nI0W5RjzꦬiޡZQ't0UQUؖm˘d^![CGCTEY0&CC[(ICBE(ӫyNd&d\P㸿 R:Ǒ駖j8&h8j~U^@0c1tsnQ&1T\ҴolD"kndJnŁÐ#!/%4tQ1 iJ.E@@ hi(Va"[ر8]iU\ۈFٖxL7/Q4sb"x}V!,I x]߫E1,.%:8! IVaH0t_-*j $ne]`羫Sfl? 0> JV&|fO )$b*FB˪tۭ^}f~QLwy[p |R$DUS)?+q?L}n}7 NKs~.4KVV2vF%%Xj觑JidGOWˏe8lׄY4`Pc$Y fAQ[92ʩ@6Ƀc?^]=ŰqDKM\f! >i6W3E)z%ۓq_O>]L\-j3*Ҳʍf@;;#8H:G 4UQuTB0پe ucq+fG)aaBAhfy+*tONub c jsuSTHī,˙~q&" kU &0<42o`jk3~i3L.bXN'eq=d6c)U$PT$AME&ynszgs?I:}+M&[*_z4HP!!F&d> Yw=N`}4Ա3Y{"z/]ޣ 9*㧕TF2b2EȘeWV [ VsVIƎ9ii]evbb&ҲbnbbUTYrP͇/5tFf*!R{ZxI0\v'_`YJi1")K"U|+4qR,.$AR5Bu]4rE3YTS}M#;gIJPшm/o@#*+1g\ԚġJJBx5 Rӭe<4AUI;Ȑ-LFO02ѽf -_18*1]bUIKGS4/TD2=a#HU "ntCGTGI=D2`JrlM;F1W |ROZY!DΧc#lp:̽isGPq \2%V'[A&'զOi7m=uE+&TDM290Z/5xm'O-FK+*i%(B|̡gYhܮ#ΤϹc }Usb)Dj^AU5bEz}̍V1sKh|͋RE?Pheū`AIO%LUTkS,O iWΣ\ YG.Kİ9pjo /:EEDe"_^qO=/L&L7 J::@`CQ3*JT%Ɍ~jlݚs95n]x͎b]RSI2]<"*Kź_/d-~%UBYky*1=\A_2[1&GL:XzYS ~Hñ,U?1[]SUQFj2@&`ruˡo J\w8Ta[1S1= S&-\OEú/h_qQZýycoel`.ZIJ`igjy![PPT!"7X ϽLÉ猯iu3da KNB&MQQtT0 Z]p ۜ=F1LWb8E Zj< Wʑ7DfQ](h0Ɏa&9Z]6 ؿjZhxcȥު#1ΠeO2b ʸWECA<˘$>VLJ $2%,՚}Q;dX1.Y*k1Y3MTa!86>[斢zH:4:Eg/a ȕ5-%rXbidüe|73w:ou9ޣɳO]1юVa9(G`A:K1'x]j5a5jeūr骓i Y"v+"RP{ _rsu5 > +Z|T j"Yg <;WfF5ܱD=FgV>p :qjh{vGɬdPK^r掸Y:0*5-e5% KԲTN$Eav]\sXcr>ZY0q^[U uU}%.L(ǣX`tӇiDnd<3qM8j,ռՂÎl>()*8N'SG {XIO@xT-gT:ޙ% e_N+<8PUC!DP‘d &b3'GS>ID0zGidYKO:Xyc"XCƠXz}C:UJW/^**-"yrY0ÉIJRPQNSW4Hw[TVSM 0gJL.C%9`|b;Wd[<#(hgkX s ̭3<`Oق.accdž x2jX*ap1G+jRl]\Y_ }QRc8fNOULj$,C|*Hd%IC_:ys~0UσOy4POWAM|[ʙ$Y9d`=]rFS9{5m/aƫhjlTjYdH%GSsW^sT3n9IKVʘaˆUVUQ,oMձgJ3^j؆;[Ռ݄,5uvY0se1::ㆭ&X)SnЫJn+zX^ JWTԔ&#EYI]OWSTTSdTYYzG|CxMGZir`I:b/YÄ b=K8v% Uؗq/HOLޣ1Ӥt6 bRwiqu$:F4rC`,?c?V3?>ޢ:ɔq)UQW==qa%2&􍼵U)S t:k$yL8OM[4pƦf %k]P %3WBXF`lтc3IW,LX=BS SFɆLJ]b,NI|hs|Ҷ=u&%KYBD`<,aQ%,T J5Tc҂nn~ZqJJ,5KuziϺXM8LXyqʜzUO./,S%VQq>Rb2S;6)GEu҃y(zi:YK=5 (!j*ecUMB;Nܩzc -ΠtJ:U 𵢮iip^v8=]I YeoĄJg^ K=64u+̙,b榞J,F*jϙ4WKXT^t a=It>܇I k )h q(咷+ei*"#e.PcWÈԽYz&a=͟襫S5`˕sUW9"h҉r4U>hFºJ`8]lJ:BY` !)p:Ujzx:5mNಹIce/]JCs؆i2)%Mrxm(abX Cw1>>7=Q8AOPu7]؝Z%K%]u4aU$MI,QJ󣐊&\ϽNuuԕW1L[&CL0Xe5vZV2#2Mdz tנxG}Y͕nSTQcqêqH0ȱZY# sfWV #ߧ~x.zU~cxn8zJp?u*̭.O c5;xf%Id2+I& ?f "\.&zrL<6e`pFz,OET`)<9vG$qlTKce:T䎙Pe\H1栯Î',b|>z6(3y,`4G4|>= g}/ts яC g #bz/5+z`ZG4Ǚ0sEZWtU1NIǺZR4%ۏcroVv#AGpaZke2$Hgt512;22̜o@;z*s̸5qXdqxR",bqԵDbt1S檑1䄍b.P;z鼽?MӺN:a\s4l奂"VgD$៤_Zt*]rGU1|&0jsW +!v5qI`ޡDΔ;M1&2a9qH*ʚ1OYv4cI3Q/VY޿0e\F{\q)ژMTH*%o+,P!TYN'MuFQjf)hFpdHܥ,\=6`3YcjֱhUҼGM32FhiZǁ:3漿ERg쵈XnO-8*Jj#hhi)VIh'Iar42>xVYՏt2^dx(eɍdžQKH X-eT8hS2ӼR!`^wk3}^p>S`.! -ᡧ\*:ʹ2KI ;$m(Y/َ"iq˘*yfJ3USアC]dfV,ӛL+p>[]mmODjjNbhU±Bʠ9.'0|cX1Ơu8M0V4pE94j&)%bNyiK#cX+]?PY;0TGCE1bpzzb5k$rG2TmfNN\Q-S2ռh'F'pU( GUO 1**RȾe=%=*:dHU:RG³謁[z~p9(g&Jzhhj%`zg+NK`*~}8zK ҭ>&y.|85]]wSU.$1v}?zw 18E=fh%U`LBYesʞ C3_ư: R|.-QUGZ*lND2G36WeuRq, 2^Pt;i 58?%j?Bo>=\u/,ӓ'Ӝ5 X 7IOXc¯o(eJ̲CȝtLk3NC&\ZzqIGS O11:jQ"h*a-ݢl`bۤYu fWZpTT: @dhqC#/OE|ʘm5D<8F5"aJq @eQUTۘ=@6\%ó46)kh%RX_˻S$._R"6ر֟S}7tQNcΙ-fZ_j n8䫓IeDUqa5¡|:Ҽk/Oӎ3Q(2h_fOWQUQY,TVJirb_6BO oB~:@L7$xV)4=M/'o7I2dO0#}P/[͸[OO<[\cGVv?Pك0Q0K1JLBsF(FI/fܸwU#__=&cÖ1S&!4uyA dhq+w6~SsVcD٪k`wJZ$E=Lu8KEA̓iOQXT:<Ӌzji^K-<4rMVW $qVTEm$~rBFԘFJx>n)BhksPY$C=63B$i:4F0pUE)EޤaՆcjS]%-`LB=f8G0 P=0>:~sUt 8$h.veetLvQt3k0=8mRH#]&A"ؕI/ӌ|;.`t9PGUMSCY]K5. J3ؐ;bL..5Q2 E.!]M-m>-,8U4kGzHgxS, 7+aPuVj]c؂btx;QPԐ_bV(;II$uxܡ_N߈AnQG'jjCRS;US|0ʬ;}?ej,vNz&\+ӬRIS. ӻ]Y2*,=Jh2nlX5 k4ذYaMȥ|b0\832.T!WI|' _))zJxᖗbT 溪P1쾟*k ธ ,*|9FZF,,WwDzOR))Y#?)q*Ǘ+Q&xB_7IY^ȘQ\1K)Rx:f0N8!O4N)eQD%xchՄ]~"s+uPuy_9oJ0řik]%/_֚ƍ̑-HE4'aM8/'ލj0UQcW̸VE5}K.!SDU4SLt1;Dmyc)"n+ RCծb]LBnX\lءYqh1lezi)R%e@%>P|Ά*׀x[; CL1 \EQyet2Ѥle&SƱ,jCX [UT|WQS:T+2.(g:_GglBB额^V&K҄BV8U#=$]ps1LSİYEQMA"$xutB]xe4$bFm`ޓzÝ3V=@EVw^?}^7zAad[[U9ձUTYk,[Hv>Tudz. ZbMlQj ⒡ *"* fRR=5/fi47&:Z3GهҴl9Ϛk!]RRKCNS̱?d@6=f{m0 6J|e1!$YZIDQ{wǺM/0[ X꣣LQ`dbX4dNC8Z1Yqf+ATbtDˊ4T?O>Jyc.b\G[˘RqBmyk&ؕUƆ5IIx#ZJY0']^a]\_}/TI bFJ9"v1#*R#, gx0<|IYW$4ؾyhhb]"}Q' iYSbiLV1O&hO6ewSh:fpڜ33#B!qL< Kg$p{1眵Ri*wZ|:b$9ZjcY 42 '@M.)c5~b<+ 3a"D]KYY&C P]ȹTP1q./,#b44'v=) Wh;#+f0fUZz3 oB M,HѵZCHeTJv2Q |]|b,?.QRҤrKM3MRI$jf%B2;8u<=ʘ1E7jhb h^JEsU-OjTV2*CU0ũ3qq|_ɸbe\Pؓ1+E %eU.;(4dׯAA8\yoŪ֦\20ŒZ\^\>HQ̕[$ޚ玗g:f̘WM]42TK7iiV&Zeq{KϮ_ r9 ɥ*cU *b)QE@)C!PG*WPW5=[p[4E$81:TTecSfIVt :=B4'PoRZ<̅2V;_;JTbOQ(Ç薜$!e$n,OgphXL4t5VaG6*zj!4e;f]XLl QW_SA%eC?%- MRxdG.e]z=t3^ 3`|K×͍(+fiaRZHc<22^9)d<՟:hǬpGQQM(WVfpѬLj=+Xu=YJϘ+"=/V&#WPGKQ%C":2o)t}5z}.2Iɋs4uMYWs״B*Rʭ,p*Bf=zCϋQj) ñXqfDb<5c)twxQtP_1 ]ܻӰu'̫-v bM% ~/U,{KF%4<R#$E#"7 P]3f|,3-B1#UL< 1&.nl YPUG_W"7<0!Rs&CYiARUy7G`[( śbQ-5TMwN6I'Ƞ tѿ[X3r|K,q,7"VUҶ*~9j0Oüe͈HLq[HF.zRQ2Z̘ZX⒗%$IFȳTK6g[ 12 |SʙZ\Qb=[TOO$)&%lb42t]9zjrlZz *MI=%U2KK"M!_+͍vDPߨn32)P,bd%m}9\,I) *xj(Vc,]Ӈ<ɞMCOK=F!#4Na\(IQ2lA;%zE&dͧ|8X\1Y+1h0VDT7 uǨƯ$z+h_r`X/R0^MSZ"QPYYrRzgF:w".KQWVSQx3$hay`*ؤ%hB[I7LKs ]{8)ȧácJ© $-he꿦P?ʱnA>?ԌԼV1MA0ZzBZ +KY^uL \qfa]Nə\F*hAUVÄ>EξbT#nKvMX#1ي6jÓE:dtfݜF4'MFyWșo%JW,ZΡf f8i P3>2e~Y!u29+1u_jITљ)[@?澘trVy{SUXD4ѲS;%yVFK^uw.F.={0a`[el4[D"2G ?Co5!U!cǤ<Q*c>bl1%Kq-?|OBS/z>}15هv??[M?90?&xS|3_lxyW􆟂(?;Mo$yXxY_cW|/{4tkAU*OeطwoC-4˭o_0'',Z?Yt4^_nxo yg*s'N)5_0{l\WW#fN ͽjy]Ki&sկys endstream endobj 37 0 obj << /Type /XObject /Subtype /Image /Name /Im8 /Width 228 /Height 169 /BitsPerComponent 8 /ColorSpace /DeviceGray /Length 23480 /Filter /DCTDecode >> stream AdobedC    o!1AQ"aq2 #BR3$bC4% rS&cD5Ts6'E7F򃓣dU()8GHVe*9:IJWXYZftugvwhijxyz?>}.nl7֖Xs .V뚶JYb)Y 4Yv'q?L1Se̿Maj19'H"8(ְrGG:= \'=9zlGOEL8<&IpK1Ԟ)ݴokj9&ߝsNqT}I"=ZL\qna5{G gǰ*Yi1! hkQGESI"bE]KLNSzlfLZ8hS5!<2ON#2:2, zK/OQTCζuOevOIS8//hʉIJJJ'~ ޔ=Wf_D\/J(1*z0lW¤<<&jo,QQQ:Θxu2ⱇT$πM#_FC\?3T*0rE9Aä4t8%N'*)PN ;G6/6qԙ>b Hz%yzpW=C~ ԅ>bs>EG&"#3Ԙ򚥢e|Pp']Rs6/-vMC9u,u-6./4MQԤк)!hVQ5=yzDzW]r7KLؖV1|:J|>%Ibd/o?/|GNsо{DkX5\ z+ 4E 4)$.駪5ث#RG7t)azC.`q L;|O:jdi' L[L-GY~u/Q[{]E謸5l9|N3f`SaՑT*JT>Jf_ҫoq g ,w5=(r Ƴ/b4 #Ve+TK T| n#? Qz,+9GW*0IjĆ#]K<$Gk5ew竎 3E6O2R *(p)i)pJZHU@&B®LxD8 i8uETb_͆/USOS{ЀK1 [rޣkdʵTe 0 :"vWFkLy&u9U,c=TyZꉗZV5 H)#AF%cU@ã]p]9K˟ʰo0?q!_.IVj̐*VEKbт@zij.%UzK,S'bykͿZL.5ñZUfZrKh!z,*Rb1GU *sBΓc*BSU|,->YR 9DȬXDRӚ %Y HeC:B>[?%Oߝ/WccgҾtH:sq&O,T@hDL[d,M Zc' &_ɔuG jcp|YI;UD`lP1t?f~  JJʊi ykkP[zIǞ고>2,5y{ UOA]O.TSƳ'IvP7`~Hp" ט}=PlOX!$=,RSˇMjczc"弑,%^5ԼmsF Kcbx4%ǰ)63%,R UnT=}:aه3u|ƪւ(Y- 31 Β9s!./\4NX̬%* Z̎J .$%GQsjt6SMTdz:& Ī'L[ D5% "`A|>e2\UT8ZJ?(pUfJc HX z듥V?z=@XXW`x{ `+ie*52G D%*`Apa8zfJߓjhe֍zq3f],mk<ΊO1PQaԑC=H(aUDEU@`4m_;G^{N<×LՁVIO_qIkjdxR*5#`E< D]en-fUF*Y[#P+c7}Oԏo?_ڷg_1nIӾ{X 9Ś-߈ ZIf_Ih!>=MRSW$4d(]=Ā7S 3NAk髱Jl(dd):G_խ&STOGWSM*ԯ kݍ9K R-G=%~%PTC:R"()zn%0lpSO1ëQ"E]E<'":u:㑽4}\6NJgQST-Lpݰ3 UjIitފzݘ11 +LsY[</T+`G,1x U]U=eOU t1n0up΀z|X~!Z4إn3btVT8tq*ñ; qxJ hS͊$2H4NY'nt'rPe³>\űX)8&go#BHp(VRI)w<ȍw nC;{玃΅~"{ۅaDWԼ̕cəOKT4NjgrAs9q)\w{ў j#o6tIH++G`Tb@VV>URCY3.:Se')ZSⲜS$-<deyONg9b.48fut55ZSύ ))a[!:e\Ug!z*k015evW͘|Jj .HeRKȕECUBS&S_0OUKUX[Ӯ7KFcPI".°ud |2^lյ ]6He|2Y!CS$}=t [MN4 C#$[v@!}^zdWh'bⅾf:`07PXes? &pS)`e%M>!әyT4" 3@1]'}ēD3d*1dL2tUsWSar̖xD DqKOfB9(pLӚj*j迬oSj%*p(REexvu] DPS\/5Dƃi1UxCIS4ILVxy45>O3EO'AKԪWEX)ꤥ$:D\g-s ~!ARIsOA %wXEوi<nZ̽Ij)'PVqH%@l5xHןվ{1[w!]s/F=L̛ å̹NjRXmF#OMU 枤ITZ-# eV;Ma8 ?,[5>$2橢oihW-7G]zcL?͙j<]`ZԸHzG#w/ )%fSXQ$PQ`IAı8* 7B1ng z|*Һ㖚JdtP&ѕ7'$?N][nbt?rH1J)3jDV 2I-T.T=BS9o7`}HQϹ c4ՙK0a3ES-3)ce*o9I^ 2'TgS?dL<٫Yl{'c^U͂-<)WKžyG1iJHIFt擧k5s6]-)Taxx+ zɡGTJtQX =4|Jiz_t)C`Scx"+oXJik%w4fnbfUR ԏUg,I6jXxzIJEX%jaP[foA{՞ ~n'q K00-Z<L:#IEvNʋK+\A%0 >ak#aAEHʛbIGg#{,aSַQqNGjoA_Ty yQ4#E5TeG8gƱ*"8TRC ((&d$<%aîp.G:x9z~ڻ0n/H\~VlNX˪(o$*"Y$U]Y!&fƨs.$I GGSFbn;0VcZ+4f cz^f,SS$u0JYr< -_95U\p̍OIJ; \.R1jO0avJ:)^KSW9q74I]qO\O1Q>.dÍm[͇U`Ѭ ,kW~GoO?~־{X۷Y=Uͽ/;E)(a\J)eUs м~b3F)bDr" լ1fHF/C) flC.b1$8dv.Ȩռ+G_.a.at1vA*Lqq'/8B8՛:S~ fLM|͊-UT^M=LTx)HЕI٠5gh-(+2n`?f<xe|fIZ"p4PSņGC55@]k"8%'IraZ0,_'C%Lx,uHW̗j C%CsoQ0ujLaŪxR 6GTU&S[$̒%׮c3R g1&\LpK]<?,RɷǨ/W(7(t;T}^M2PNhfť)$ HE+7Z>K1@/.Rˮ5[-=3QŘhYYJmc#jaĽK~"O ׂ׏c 1N\*ƒ8)biKKn!\;#t&axoB"1J|+,a41HSŇWEK⦚ql`\:CҞUuk-g.47*z]GY{p:S ls> 1Uvݑޜu+G'S()x cC3.5U)∕"gGWUVm_ZʌόjJ:9$SLYoxр#~st1Ut:ئViTfPct{EW&31q9zRW =Gd@ =4LO[CZh#-MXcMsו7^3Q)zMOOLTvjk0BSQTĕr, *dHʦ:C /oP0훺azƥ)cV|b'XJuH %f KUg1 \ =H@jM p#' $f'5- ?JNzB&J䥥"R#|1Re̽\s/K[31,;0WO[%)d R<b:u?:}IK^N0sϕ ?WK]^+YmLrIqT3T&cϋ|lݲumo׾{pM1[CR17j(8)ԿMPuw-F1 k EO-KcA6 aPWX|DMeCWaņ=|P?o6S(64aM MA(*GL>#Zjh)*U$/ޭ1^ MSs4ŅJjS`}5V-[5+Uŗ±U;s fIyr.KqT°#nMMWE`PDDcu2HNJ|#?e;X]&hʯ[ 3`vL.Z\Fca/c].z*.d֔YEXUc₪SMa(R8@DHڨ^Q^q~«pK3 IY´(ȓR#P19&xm!6K?wI'LFxLN1(췄ńSU4^Lيd"?/ <q,Ҍ5QQOKPIZ0%zv˅u+dj˛3|FxlƦkfdU3{Ȼ㍘-TѬsߨ=;^h',b?f#S]+D3J) 0ˌ(pi bO0 Z7@nd.Ttk**$d$ 3GYF<3$AT̝'uz՜[X`Ny±Tbs+QVjvZӈ"w,;{3%W)rx1SUQWx5oW 2$h'$HddT/^Ξb9ԘEGVpt7L*4풛qNLb'! z{j t(!sʒU]>]BQbb ",Qf2/OẼZ͌+\bQ$;╴-)(!I_N+x| \=S&<إecKQJ=V|%Hi Mp,> Sf W,HF#/mm>d1'e5Q(|D Z*=K]M0 y#vD%g0;j8C в6ȥf"EN]ˉtçXl|Nj?T"OYW^i*GEV܏ݣ[7e?[Pu -\'ʨsV* b.rA.!'oxH:z>`:GL"+in(l:1ʉ!WTqK*1H9fvN:a.c T9NLVWj0꫅6!Y5d4Ѭ3RuS1.5?\0gƒ!-D>_j- ߎAjrFFUcةj骨\QUR4FCUzI#$d% *4 AM`9Fj15~3ԪEY$>HABbH^2iUT>e||-0QYLbT{-EB$ʐFb(,%ѻѾ܃1tp:rH:*Yjti%DB"k$3Yh}Tu؎]-&!8n8VG6IKE]OsJZ#%SY"tYҞ=hux>'m\3\6. i֒YLS3 djaPVGҜnn}i+&Ԕ8^#$FE!)`U=ħ7=G˭N.ECRTwΘ XE~jMM &YjG))Gn=80/]8XX/Lޟ*1jG6-3 Lm0FqXtS#fՙ̿cxv;C!'8"^E"ϘYe}BzFe9r qhs%: ybLu0ƀNc !g«q /bYTYs1fFlOgê#jI ˜ܦzӂ^j wq3OQs%-]lZfzfÅ%;*y"K+)Z2QzRm6g姧. M3OI *MIH,5טX|bO PN:6+G\RITauUpR+U8&pW^zV3cI<5Y|4[寓 +bZ2_HC J̃$jޜc58%*Tttj<t択:9Tm"yӢEU1)r S&%L8ºCUXt]#v źs_^b6wAa5fR%°SYJ1,4p+_&iYt30>ޠ RiUNԙ{.<eZ*ZFPҬNV e!OOC1~Ԛb1l 6e'UUC$4sգȯfp/^ K}@3 r')[ep($8l9$$#e ؐx uҿOzɁݔp#X.UɇlzjȨf0Ҕ*c*_IRCSz\eW?#P5tU=m3llBZl6`H̊c^|\?=nŖc\&EM.EΡ\ + 7ZZdV)ȗ5q 6:T+C#a3DZ 4Xp@cjC5PF9ڢi2v`CIJb]$+Ƙ!]XF9VW0qځ X镖|EG#[F4iRr~qbc58"ǃP``5ՕfN8*E\4-=6 ~inf ψRtZFmrnZfJ fY jТx;%İ)WDz(˵?5YY  ĒX'5bUv5{|YsEN 6%eDLF̍a-%TVU`UWAF; (IGWdhQk&Y.-zLK-bRIh+Iip**1ehXQH% 3x=K8_SץzLCeֺc8lP:VbMv $d`fC_g忖TV_wޫ~ӾMۅS%7K]\3ḰsV!k+a4,/i#dbj'=K`9 .ch3cx&Ii1TKRj2+C.Iig4$P0IO*!$oެO]]ĺkʌ]L38Ef4px =Fi)bCVS9{Px;<˸6>#\*qꞪO0,S I0m'r4ᕵ?+ mf/M-U5.5WƏ ()Q1T_͎n&PRz1k:k+ij"|P`Zh,<Ӽj5u3K0<&jq,ۘi ih1ɰ悔cV13;^ԍ2Ws&-6| ʜDP &J$y3;|؁1AI4y{ ՘,fIqo;H3eU k N x.?5] 1a1aAMWSAOsOM}*1eLR_GTcurDe<:jj"+2@J9#җKR1W(15S4 -2AJ)"Z8,ohyԾ:ΛO΀u>QȽ:ƱL[ 3#B hkqDz`4iOYR9* _նvq/S)I'_{(䭨ƞiDRһQHѩHP(cx[ wd 0Äa#jXa1yҥ7:B(û8[T;U26 l̕ulYAԂ8劾wy&do.U8fQ2x3Nu/6tIxt2-U%< RS+dsDU aܡ=3yJLO/h1A:W/ k˩Y.euQe^TS313YNG1<kŒaBM3+{<"VmXNJ͚q Ԇ Jl;,Å16?OQ+,<+O*GƟG9`uOSE)hѫYNw6< r-wV+EEIGQbMZ+ b2SIVj^Ba˭R$0Ufj:V"V6\fJZ?_4 i 3eSN-r1jqO yCbOEVQK\># ^1bYK 3u--6U*&J>\^WUVJ>XG"eDa*^y̘F7GzȅWgs:"44VJ=$" ΓhuIoJSGX IT-4<,Q% (OHP6m8X<Ƣi2 Qan4GaNO%4 7C}& qYs 4e-V %&)=U51aʐVMUPѤij*)d{Q:ư>40axFi#þV@"jl:R :ŸtcUN6#WI]c=`q1iek,~l5pX^Iމ,R9@OWu}>uj}=`شfp |'&OSI.1UyQ~ei3? X3O1~M9Ʃ+dYV:D;4N*HelKz X@}ScYkq~^#CR&)i劖2{ݹn xC:^G=]#ϐqIS`Y{HڣZfxc7_5IȽBgՉtLWŗ1*<:\nc00"s$|%aF}U]0[ðL: 2x*#QՆ5BZdl>crf!&eʦ3<.X&?1Z+I+ !aCNޞ1|fR3B( 5 ë(*:bA򥤕Q@U]?g?eXgw]#g?;˷}g־7ASԞ/0`Y4[ QǢR,0ovRCpN!wB"IP]M ^sA7ư_(*qsA6&Vy$ C#Da +I=}.U/Os/Y_4԰˩bLy2645g1 g,?P2±Fp#x3e^zYtEJi)̚E_p 3fL׬8GM쩉0RbUc0l 撢Id-[ܯ$M/Եy B6?IO](I⨆}l/ q4`e;f tt*U4!MTrsTN^3}K-QxF%E-34UcP̷ Ceʙv< 1rFeb$\_&1pG25^dz9M$/AE]2F-iª ambRJU-<8`yhL@E%\¡l[ZJ+ER?O.5(6))<+*j<#lH:3θ_T1<0RYy1[Z lR)' )[ˤZ8Asnf0)]q*0:, ̔eǵ;0ZΨ`OKȵ{N׾B2bBj\GSNHMݝ\ۍt/u~u J8juα}Bnq(!U,#Gl#3";uM)r'V(cԙ^1㙗(Hs\ʧ 5WG0>],@^/2ezTV`k!#1e?35e4udy3)YT{3u6٣ !TkIG[_Y*zŰR¥&)&WdM؆?zUS๧ PWOT0GsCSDәىu@謵]f/MUؖ1Odi+#Oe)[ςGi\HFuCTz]%qh1<66e,$V94X,1GTV'aXWA ҧ62R#EIRI'I"%݂0&]XϽCҷL?bpώňQEa58vQ.(;Iic®U-^z( ׬:G5s 7lk-SOKZ7>%4K-EUY7p&^zYrO:ZGfeگzdi&diEyDe_|=оq_2>ݿk|E2ce>5\Wj4}H3\g<CzU7L>]J>AQ #g8k 4 nӄoJNe|W5 'KűU͔-G 8W-T(&B&X^U Mr{ƺ02^T\Vt8(Z>L/ü26ں>`ij6enTTV|-c°xe꣯% Ak+EL(cX^xHs>+NɆȳbtda&"yj%v,*E]MWq'E44ZUy91"EGRt~p|ɚ:?OYSMS_Pkq6j JijM=$4Bسe3T+2vϔ949<C)ESSVbZ NJf[%9I%S] GܕQ 8lRᱺH9i9* ҈G=~K 2BV:5=XDu&5d$j:wvjВ&`h0ip0c̰6Tದʊa),A{[Mu%ȸ ψ:PaY&&TDRVؽm4obt[I\0Jѣ4vt/Scu2Y/=fGфQⵑ"R,4 򴘌D"hAѾz+b>< Q7 +0hB/PµI2@H ,Qt&0TR45"5V`Ȥ+#T#9"TKoa^~qyѾ{|逷8ypLσGK`5=]lQ8G4rWR;SW#-r-nOZKS5.3I=Mz/r'g}`2u%9 uɍf^Q~ءGG/Iג)t[ZV#u#WgN*L(b )"Z*qUФLS1j5zdydĬH=&+z3Kܿ]OPNJ\ᭊhMTqEVyY603cc'ފgwaQgg7{4Ҿ{v7:cq<:ƝĎuskmC<@Ӯ~:e֊_X ԩ5U>DNW$D:%&xa,X5rwy/I18`yʲaT~.S#Re4C߼+Lp[Y!dΚAi0WVB{Yɷa`ŻO=q΋~'{xxyӷoxߝ[8OD'0- ?/'>OO#w|Gc{9ӽt%>'跳ιE=s:߭ Gloi+JB3f, \6G~Ùė%}e=~xnu~v9B=^LWUg+f`=> stream AdobedC    o!1AQ"aq2 #BR3$bC4% rS&cD5Ts6'E7F򃓣dU()8GHVe*9:IJWXYZftugvwhijxyz?ψ4}[G8c㭞]|ë ,2-sT4/"4" s+r8r6O|KښH )6:m,M&!)OfL^#+TMQv Q"Q|bJ:Z:L>-SYr챪;;8O=DdZd#yWlC$j1_ZָY@* ?~V:c`y,TUM ]FIC$>\8t%41GLYO2*DX ֜ɐ&ƺUɗxp<¸$A/ʂnXfh]Qn 3?HLCMAښ7&r1TRQPSUTVMT(ڶg"FcY`/dow9.Z+)p'Γ5\"7:IJ5HXͤ;TF'.cqg+&弹NXXG58Fb t5\ȿ(3+oFFz1Q1enuF5\aq̽aZl>亼N K(qzHAKҙj'`fv=Oܡ1A1u/-:Z,.*ljO\qN1I'@и Z4 O&IUҩ*fd*AH+cxPH'7EGaߘAַ?м yki;&]UΡzĽz_%^/Nq,:YFE=u!1SKJL 34O ޷IaXR.b8yLŖ҆0j\Ӛ* YVJ ~X +V#bx t꫰pzj&h*dZZ(K20RUb.')Is3U☲S3qڌN8ّ#4beNPR,XƄu"e2DXDH~O-S K[SðjI*%9*xCyΠzԧIq\VNcTUY?#MDEM 5H*+VZgZXa1jtxb=8?IU:V*Jz̙8M""0a4Q4WчG2A0jw'\j\jȤ\A\`H0?2.Cآ~[=]~)]lGk QSTTZI4O WZӌۘ_OzwӯOY(ɛKUS ]%w\1L9TQ0CIRPAUa0>nfW|]K!0\yf*h(zZF('],J{5#0|GuXqѲ$CH݋yKO5=|·c ǁ|TTOE}fej.)#gZhdx8ב gS,stߦ:,WjUUӆXe,JH$ YO:g|~8* 4X'4x]T42"HάZ Dςl͙[/t5ɹ[49c^2È%n+SVԘ=u=-44aH"IVg>c*y*`\Id^])9i[x  x稃T&5/D4~_*W3=yʷFB0\ŎbbZ\6լZI4d$i'u[ScN8oGQTԡY(# 4]YfrtZK gR釤CsȘb¥08c8 (v_twDɅcZˆE:OSO LsBA a6?Yvw\ҺNu,uYs.V8=-u]5 UODMO-"s,xglUÇWT|<PHy#Q1h.-pE@4x EVյKGp$pJ@mk;KrT.V,Xˌ͉MjY a9ZXXa8IOTw_+Igjj?*qk))X1 & ZXiª* U:$aExTzK,'m!QaQ{ k^'zjd6k& <&@id Y5cN0U+,__YH%X阣GF}^Gn)1,y h08*VTn$iSoVD)DW"~ ُP6_P*I1챕2'Y˒4VW[S, :(Sn˒X+1z|3.`&MQSSQ9 ̫QѧW.u8b͸fVǰ70ޑf\lTBVĕSD2k2I=?;լ)l ʙ_̸M^|k Jpfj!媌dޟ.mՙ  f ]md$x%SS$M"TEeP/Xg1pndɘ*1N `ġJ,3uMH@CNţJD$pXɸ)2|0x*\2c5 0٩15/3ԎA,EV8ovp-V}5Or2&~ǤızKLMbUsGb4Кt5j$tK }$R^Oϸ;2e+y U[ lQi@HQF5uI7R:t!Qd\-䌲TV UP`Ѿ+ @@>uN| Ǎ漌8#8pı1seJ*7"e{n!,+uRښ\LMQĸ6Y#GJFbbSʌYM̲_Mx~%zl7i5~QEPRa Y_,-dIW2,w;eԏc6bMzl;8 qLE 5S'lF*JFˎ|I#E +ʌNa޶}%łO9λ Mzj$iU*RJ&=h(/K0SIJ8}U&.#<ܱʢH 3ylJNtJ1\˄/S+g++kibzi$$~bdj^/޷}vc>z#MYӅbԏM-b-55+uley=D '.gHn 4FfG.b9Sk)>^ZTq$lJ@KzcW=]GrF9=eER0k8K3=<1G;!k1OBEn6o²J튾%4Fy<&BCQ 7s& <ٝ9QVjcI09b7A"D*{Y ޔuөNV3<5Ckȍ!$8}>(d|W,idzN@^I.olIϖi`ktIWQQUѼ^Z⡦o.Uة#Q'zș#1sj`8}MI6+Y("kHdv2쌲+lh 0fR*.!aч|W5UaEƑpSS)(l{lz P0&T8A MQS%,R,,Fz8 1G,Gz=N% °<9_h)4Y,,+Gp'eXaOon2H :Qat5b^ ˪(ḁ!I#+)#WNgֹ:0䪪Ūi0lEKS& +IFU>\|˲]f͊ C jZieVˑ %jQUO쯘MSM M%dtخ)U% USHӼs7":9~e?UoSfNJ|_8w%+5~4T8\O:A0UTr'PiqGɐa~%G.Ajy~H1|IYE>%O,yD6roޘnOU95͓q82&.Ɋ9IF ;U zOpg NIU8;b'UT?aOU}_:$ʹKS>9U]W( We\R x*0(pŨHetU>TdJLa\ı: 8-ZVbPM]PFvM,rBI=@g$l4df?S]rʘoHqAsnẸJd4SOC,DxRF,et7*? ]Un/AJ1<ńcUq S0KSTkx/Jts͙ Ve\sV#B M_9Ѽu&gˍK>b^NqLlOC-U!S&[YSaQ6%SRO!$o,/[` GM4iziQ=3GUvY5cIAz6d5M3m/v7e?7<}#3˼/<"7:;oᘶS~_0 v@MM=! "ZHcy%D O7S:,.Q>}/lى󖊲hi[d:x%"K$nv3,޽uxN9,ח:yL[ RжS*IN$YkVƋ dG ^2Q1ɑ:Q._ܫËѶ`.&h)g#z$ ̺zX~fә|f<[RPCC,86Ѻ*^RO}0⹧<ՁWtĪ\;rCaҾ))2*aLDNXKY5k1N˚GY)瞓Qlj 1aCCEDc3ZR` Lv;)ɕzSĨ*(RQM_H \F8̑Dp8hN-ŗ5L$2 Eaqbqbm#%%&)WƓ%TTT4h~t,^Qz6JG`4E iٚ1 e!fTqrfأ3 >5[U)#)aBau[6%M൵ŠS^X%)!c1aJkQUW|W (hz1xB4!4P$8}o]8Prf`ӭ66`T9qZ ֞S4;A1Uv xs:yq=DVfax=V7\#`&^?f9&gHO2E,R}.H2PpsOJ<˙rDU?ɫ0i0ZF=2GH#2.&N1_!)Q~[6y{S~y-{UղWԶg&\:-z>fB9#IQMLvEQE|OYbp(]H$~Yuz̀u>W*ۘ\;0SA-IKP(风8%+8Rkz1޲&ag)!2SQf iezIGHIPa8^l]C̴TOcfjj[(+j储ѱIc,V;G:O:u ɆV 1| \GV؊,B%O3<{7H=09.eޟ`5O =$Rat6E+#Zu ZTsWGP5GIxDXe 1shİ'9JGưI%u>,3e**+0K_/ddE r6w`4aU-du ZdrK H*v$fuX@HjYdUCu T1bhuDmG!m^y\~)8T4qİ*0UGQNh]c8dAnJC2%']1QldžX^VO!SRfs6NzE`Q\:*"b8~{>-jǏ-ULXxZ%jzTJ*vu>Ռ*@d 9d[*0#-m=M6=LMM%sL3hZ`t% K콂F/L3 G q &a((+lJ%1bGH$FyRYCGN7zv2}t,ś35byc*25.dat B4"Y4;$tyv}]&/վ`X]݇W< гeѝJ"Sfު?2a8UM]W,u3aXUS4;ElY=Tdxft*Y;\8g% VZ"dRyߪ?3F(£ٳX.ץ5DU y-CkX=Nd5LN,? Θcḅ=R!XI2g7E:k'qḳt7Sb5bXL 8%OK%42yVEʹSp@rCCYOPtľƺث(e7y%~c|#m;{;~Z7V1oU1|W0La5& yo.xbv:cjFy9 {`YS"pW4υVTUaȑg vI K,[ѧ'=.I|BIűTnX4JjhHcAW:e~J+0ܱ@g hQnCKPƥQ,z^̸E>g/Rb df<2z+ W<QqΕ ֆMmD GgYsvIJU*2jˉMW ؎VZ?#Ò2K4 ƊVY }wޙe|H*D\:/x#IKITUM5kQLႂaF#e; >|)3&Fǫ(eQF!:JT4M "wL2-,Q8bp*h? $LBqXdpʔ,IVYo&|J)i3fc1Xe8(*X)Vo~aƊjE>0 *I3.{ŠI[c1>bcL+M$;̽=szTVJjXCg4j>f<<4SSe(j5*K-Xi)9LFW>~q_e\bUt,?K]M0X*Hu1x{C3k?U9ãŲ!M?AĢ9bHX37M NpªVɊ |U@YbČl":\C)D)JFN ںCa,jj3Mh#[KXwE0VL3/GU 5O !Ӥu2cPV.%<{\I#1☿QEe,(hJ)!5 QI=f{U49(u/1RQ,K*=U'bԆL=5Tub'4dHrO๖mylH3UQ`,9f,Ha0Yc]ŪUUT?*^gԦ]3Y͸OVUrnPKSW%)%Xz:-b8/J+PfEq>Yɑji$UyS}&iaFxe[ ?` .i":<> ?IAC$_C,dT! 9^tS1JNes}Rg՘U:VCY[NSS=4'̲LRXt4x^g8k0V$UT,Uީ,2#He`T؂87|^eeƺm ܧU4t4O5btNRS̥AdI̅|jjڼ㘰jŤ6Zc1]:PyROM_W84BxՇ?FU2*EwϵװP(θ?:^MfNg/>- =TS,8B*'J|44wI%D>2':tŌUL I)jY7hQLQ4DSyli(IP7k }_1(G&+ +qjiUZ yd“PF1(X) d|쏅 xUT,,DPľ3m4EUUuSW#UbMZz,NYbh[@7 Oc֟Sz9.a48G ==JV-GP93|p|4x:T l8;M%]4:j4;l+^5"#UV^uX:]ަ 1u~GWM8d4"E&̕%mHȭ"0\Je΢a OX%ñ03D0PaUt5}6'M1OH6#{4ҏOW!trUJ,vcZb[SP%ID/[Vpc×YCYAJ+yxãyC<|oϮKdk njc dhуyoSVu x%N>VJp衡y+)*" N:iޞo(@O$K$LY^~}͸_?a^]p*\=1\n:Y**e kd a~.f/xy=1|??4<͞owso{?ᙗCI#J|K)㥫a` Exd(` γO ̍l37Wq):@ոp5=3“Fk\ν}^I)KyN)[Y^+U ڎKT_"z K[ $Rbz|Vj:OqLQs_N1lÚ+1 ,-D z S%cgV,Ӌa!ɚ޿*Z aJgJL6fHk1Bcg&};Uto>t0  35M%F)T | S %elqlVLFPծ!KlrGM1L+1R|2e\B:<  \: ڪ+"o1]䀥Kvh2d*\xAy,IWڢRjBJ_aQ5OnUIUtոI]jyb'zs)*OQ7Ty6x1ji%O*i7Đucm*'lD*ޠUMMTU1TL )b/Y$AT1YY侞e}q)㸔%..`LT5=Pvoz#lc*{+Ub yq((q#[J"xjZb>Zȉ4PV 3S5ujԹ Eސ$ ,QhWQC; è"Ú/:C#AO5YI s@d(P<=LʽW̘6@±1R AEQ&! BT3REM((s$ ,\QcXT QIa$cf-U sMVArOs:0ZZh:x\TMO>!0MLGW1LA@ ~OIu*ܽLo!t[E: !?edACMedɄTIIUH$,t% gU}"cwɸp2!f^+՚jINX/f'4,(zҷ.~RϸK3b'Q[(*1:R5liAD<^E[1* G%c8{&)V1/K -\qUK7vX)N$m^'_j1uv/:|o~?Ѱ~zcdl_h}!Xf IbT9|Kp*4M0ע}8,u9jycf $)O iV Ru"}j`+\˃Sgz  41jībRAWMY q]8&إ_se-EDs#OESFr&+-IKY +=U0ܳj0Wn\h\/fl/XeN)ĞপH$3=rtPuW='4ě}L5C(ʯ`rBd|?9rr xEm"AaB(F*:m33H^>dĠ}͉`(a^!6M3ICPдNƍ֙լɪ8RϚpΌSQ`PɕEpjY掐{D Q-HxcI7aϸ\+ܘDU5dOW|1Ҥu=-QZY|b.[kwu&٧9"Vaf ՌTҫUID 5Gj#6=hU$a9>:SbjUɳT=4h$sڢ@%jj%RCkVE #dt醢zZ^ycicgB_zuONfǪ*JzWlN"KbF9o $i* 6v7Yj<=u&g6DQRǂ K- 5 5%ъ[EÞ)FhȰ8SJ+hhvz74m5SmUK]7" u}FQm! {F 0 C\WtX NAgUcȹp* g,Oɪ󢥧Z3q)A۱Gڸ^s5G""8Dى!߽~&hl#4,)x++5&*S IvBɠ n7M걌Ac4=,GR jXTܐ5MeU0{3ֺ'c9*: "L4 :zXNEk+ x~g͐JH~9!MGSC &SRba0GuY2wJUMjiQ8sQBa"$,+x#6k ~J.WYpf/дxn/VuHHHEhgO1>#c8CTK(2Ϩf6&#HU+pT}QL#,`XE% Q]]Gږ4O@Z+Ƣ@R=Zd|ɗc0z+d#q d)gy])VsREvh?3O';>԰|;;ҟGWbaURUINGeFh" I~-BCL;XN=nn vk$yi+J:妧DH<6;7L&p&b\>8HL[| e*UxeH ցޣgG<30%~W͹;aISBoIJ!TgQ4t A#>uxM=Լ3/A6oW`h8h]%je mJZ-@C؏S4fܷIW4 81*5 `JEKB1_t=U9Sr՜ۄ1|DLZ3X]tHG;8fi9㨸T:S9C}$jy8AIi2|܈ruG_,GbhVD_>iMQW[PBX t1[W)ΐ&d+R,GsL"w͖ >UM,2\`T >`N)bacJ b*m>!${Bb`]rq Vm`Ta QOUY$aUXF a㸝Us5v5>%yRyU)Hd~oygu?g|_r,txU)"X!wf P$\Jzg05&7SHI%*2c;wkn-u'Ξ'UYsx[$u.T8e)eǀ$t5`Lԛh꤇TeI?LZ5_WN+.k8RzyGA;W#_2U*L2W -<—;Ip,)!K_@khnh",largӎG/zf JJE4Fa2; JbBnseCC ̘vi?D姢.RѤ2!yu<2Dlp+y*`~<_Ǘs.HƠīäk0d4W r2d40$W&zxqџz/6+!ov>X}U:%_鳧?Ps& ¨ʯ؞&5I]PIej _J%NCh+JCl~[JS5Xd+M5PHif򑏘Ėk˽ߩ.厣|fJ,,8&IABP,qb>RJqOə:ꓭ牱[sQJ$ĪE Ɠ Qa1S/Ƚ Ӹ]l6|r<.Rv_0Z!T #3 )ypU:ysgY*mipGīzis!e3Gx=fǟrYqT54RSн|ubW`D<_.dvS /ؾq88 + =Xūh_xfĩReyV'#eګXu.⹎jl*CW1db#^aT,zJ(GCUFX)dhkyvd3Lh1>z:X`EN""@92bt40u),J2My pH+f6y*xXmP` 4{E]*Vbʺ=HÖP}ULb cm`Cg bځ Vzjkhz#KF&=\IJۚ9.d7xOOX%e85f+" G*FDU+HbTъ'ShpZ)h<z25D._14TS`P0SmGD#Q٪x*tf XCX.1L[˘Usf)ψRZȿ=5bIiUcv2Qzmּ i*颤'zbϭꊶ)")f|o˿4s>!R?։1O¢^IZ)Yxu,c* ),]tur2b9Fl]㩪gYʔH\Hߋ0F#0a1ZbÄnE 5+=e %'IH0JӉUR+_Eӽ6MjXUK>Jz4}@Ya9V0*6 #0%^uqgTc ZhS2AQ00p*=A(.E J<K3ȑ!Q4w'i \ʹ^2RH!R0jrHRƟ6*VIvo|3-3:AOGRxTbMVuXж)QjYY]&+$pEKY=5̚ TRUJАX(mRlɇcsŌft䤕lZYxnTH[5URNDiZ79ġd !{v(xWz.,A`2aI]ǻ"\lXnVKcŤzgߎjȥ<ָ)HVO7Mexe<TTKY%5V'IR* ?^iZ9w,~l,K?KL?'a9 G-%TW5T=&W=4FT zy1yln_Pb'b]wج2-UZMS,T3I̥)!հbY17814tN) M)Rj3 * ɋ 1ެ)|b+Př0T Ek)v46t:Gܝשρ`QŅ0 '34)T L$<4rGGb*geT]Ξq  3=Q]D W%%$/Via,7Hg*X+u7y6zxɄ`12FJ\5*㤦l2VZi_ $ҟO]!Ʊ[='g6&W¤űb2EIW QOYRD%S=ɽ!ߒοo'~svnuyױ?UCкʼϚr.K83P͊IRI~o Ė4J-"+A,q#XHGzDŽѶ)Çe" |^^1IRQ%C|RMx"ypL'X-`)Ჴ8=Mf*$33@VS,'DX0DrWMF7]3e z؆W 玞H@h4so4]gav3JյN[Y6igX1)?KƩ+[)ӑfڌ;>b("ZR"ìMۈݵl['a30cjlZz,;8Bc@iv_ k*qW궧2zi ?T>MCȂ9Pѹ'@=/u+-F2 Zx㎖|NJxw<$B*3 dF*cO$7C3HLWf">I̫\CCA.dM>3\tx0RUAT)H6؛ފy'&>'ԁGUR>3S> RƸ$xufUsPIIF Oc= Lƨ$[;>] aAḑ,vX*%M@v: UsV*d94Y>*ڊ1KUTpp1 01ACe`u~ Fr\]h3]ñ1ggjjZzRWVۑepu}6}2][{.(0}CQ MeNŇ1Ԛj`4K8P*zvf eǂVClB\,"i 8]hb$xſ F#s(pcQVr _*M1~XD飒E0<֊eý!t :S -MR v,?ˊJx 805MyCOWd]<ʙk+`Sr/E|F-M<..?B]+˗pn  4}걚:ÁvS==<%o.ʨSlqFw=SA޻e'i:e5Nuzj )VI-W,IUd9Y3Wa3A5TV^DX%Lf VpNs8_s_ gA[|o7޽ѳV-&Hr3)YVh:SS-R$aYU`8}E갬G2jl؃нKTh:C*H ҤO$kua=jK8Lq|ϊ8Q&i 0gً1|Gpq璙r)hi ZijjJ7OAz1\>nkhiqRDzq¼0y#jD]Y:uêTsX56,p":STJ kj)jhj]X=#yG}\zf" xFNy02 *$"i>vIQJ($dibfV/nTq~=5h;MMWL45TRP.a0Px`Ԙ`g0Rq -]\Day r%Dtڂ?q*z)R**SUx'׌3%lh)ZxT&##HKYl?h[qUɯST,/*,$4+\61#jtO?A(c"X5\J+ĘQ}K[tlϖ_ l&&%Yʢ)>t`N䀛~2⹻+ EZ 'f G[4.@uɀ!cQk5U2YD ֕[. ) -ӮQ*j1JXPcfjy-j$ƨ`Yeޏ*]S0̸0hk_F5PYIWfWhYx-. <)TSJi^j$2GXJR4'EStxF9z1夨lg8Wԥe4#K xHLn`r^MdO[H4!h&% K5#K+T5[ j4ݥe1Sx&m0}*VbX;VG1Bq*|6Ik*43SbQƊcNfUIdyeJpٱf~b٧ CM]GVYiRq^b͵QNҶcty& E˝JYYư&#GCM%T|4TR@̝̀5/R˘n#6TiZu1jz i<%U#Y*t. XnE!WbLJZ qLF]X*EyTE-#EhdU7)gW"ű>yTPOTh*کmA)(A $Oft _O_j%Q]XEfE-8VTfŤTːuu+Ira\'x ttjHEw0fbN8L854r$ *JThܖx5Ofܟ`GXWu<ӀJƞ{;% Iӿ!)ExE"%=DؤO4rIS hV 9&cLG͉K"JX_m&yeB31Bثx;N$]CF0U'UP{ N)LTQ|̎;u@3Z52cઢϕ{_=KfI(I+<$.u@(RCdq瓍&g蠨ZMKL? ئ3OKM#[ρGO6TM1>2Fl]S0A5my~_* tQaHXRGӼ61b%1iPRaUO;UFUTbԁ)1MdI#DNZ+Ө]d|jZʙK.j9L\fa5M`TӬۤ(ǵ"-g\-t 5ϊ㹃|I-a-69[ňWMG([^"0+H٭GD=HF q˘q˹j484]X??K( uYVlROJbkRզ1.^*M0bP5_A#%G$m(E>GOI%\Ht#'I;HBdqʼ;$Fu)cو%$PGQ>Er Wfŝ0 ̘=>K$3%=h4BaR0 deKa/aT0ڜ0WFp" K#IAe0`/qf;`Fle޺""Oh Aycq؂YW7Qj10NՊyuZ\Xt< Rfq cA+mc mY7MtDҊ2ެ)HTlnIp͘`têO"|1()֊(R9{YA!=wWS.)((ΌՕhx%=$TdFg,#PX1^T1 z7*Ta U&;:lW3$a=²gsU[I[TaYD)|Fz8N2T fu^)Pꪯ 7Lq,G*!\$Sޠ5IF>]\,FIЃ-z=k'&+axSM2*`wj 9cIȐɡA//NUSk-bF\C>1Iw _H%mSPZ*V]$;coo? endstream endobj 40 0 obj << /Length 8199 >> stream BT /F6 1 Tf 9.963 0 0 9.963 58.28 771.647 Tm 0 g /GS2 gs 0 Tc [(in)-254.3(wh)17.3(ic)18.4(h)-262.5(h)0(i)18.9(s)0(t)17.7(o)0(l)13.2(o)0(g)21.2(i)0(c)18.4(a)0(l)-254.7(s)0(t)17.7(u)0(d)15.5(y)-262.5(wa)16.9(s)-263.7(p)0(e)20.8(r)0(f)18(o)0(r)13.9(m)0(e)17.7(d)-262.5([8)19.6(,)-273.5(10,)-275.1(14,)-275.1(17\261)]TJ 0 -1.0755 TD [(49].)-140.8(Patie)-8.6(nts)-136.7(general)-10.5(ly)-140.5(presen)-8.2(t)-134(with)-142.6(acute-)-9.8(to-subacut)-10.3(e)-137.7(sym-)]TJ T* [(ptoma)-9.7(tology:)-257.2(short)-9(ness)-256.2(of)-259.2(breat)-8.6(h)-251.2(o)0(r)-259.2(dyspnoe)-6.9(a,)-257.6(cough)-260.3(and)]TJ T* [(fever)43.4(.)-461.3(C)0(r)-7.8(ackles)-470.3(were)-470.3(audible)-471.8(in)-464.8(more)-474.8(than)-466.8(half)-468.4(of)-469.8(the)]TJ T* [(patien)-10.1(ts.)-284.3(Althoug)-8.3(h,)-285.7(there)-293.1(wer)-8.2(e)-285.7(none)-288(in)-288.4(the)-289.6(presen)-8.2(t)-282(seri)-8.6(es,)]TJ 0 -1.0698 TD [(some)-241.1(reported)-240.1(cases)-240.7(show)-8.2(ed)-235.2(a)-234.5(chroni)-9(c)-234.5(clinical)-244.5(course)-241.5(or)-236.4(a)]TJ 0 -1.0755 TD [(delaye)-8.2(d-typ)-7.8(e)-325.5(react)-9(ion)-329(after)-328.9(disco)-7.8(ntinu)-8.6(ation)-327.7(of)-333.2(MTX)-331([25,)]TJ 25.1977 6.4474 TD [(36,)-240.9(57].)-243.3(T)63.4(y)0(p)-7.2(ical)-241.9(chest)-241.5(radio)-8.2(graphi)-9(c)-234.5(findi)-10.2(ngs)-236.8(incl)-8.2(ude)-241.7(inter-)]TJ 0 -1.0698 TD [(sti)-8.2(tial)-266.7(and)-270.2(mixed)-271.5(interstiti)-13.7(al)-266.1(and)-264.5(alveol)-10.1(ar)-265.3(infilt)-10(rates)-271.6(with)-267.8(a)]TJ 0 -1.0755 TD [(predi)-8.2(lection)-206.8(for)-199(the)-198.6(lower)-205.6(lung)-198.9(fields.)-206.4(Additional)-209.3(radiogra-)]TJ T* [(phic)-301.8(findi)-10.2(ngs)-299.4(that)-304.1(have)-299.8(been)-305.5(reported)-302.7(in)-299.8(the)-301(lit)-9.4(erature)-302.3(re-)]TJ 0 -1.0698 TD [(view)-9.8(ed)-497(incl)-8.2(ude)-497.8(hila)-8.2(r)-497.4(o)0(r)-503.9(mediastinal)-512.8(lymphadenop)-9(athy)56.8(,)]TJ 0 -1.0755 TD [(pleur)-8.2(al)-271.8(effusion,)-269.7(alveolar)-281.1(pattern)-274.3(only)-272.9(an)-7.6(d,)-268.6(rarely)57.3(,)-273.5(normal)]TJ 0 -1.0698 TD [(findi)-10.2(ngs.)]TJ 1.0015 -1.0527 TD [(Th)17.1(e)-428(e)0(x)15.1(t)0(r)17.3(a)0(p)20.8(u)0(l)13.2(m)0(o)18.1(n)0(a)20.8(r)0(y)-418.5(c)0(o)15.1(m)0(p)18.1(l)0(i)16.5(c)0(a)14.7(t)13.9(io)13.2(ns)-418.1(re)19.2(po)15.5(rt)17.3(ed)-417.3(fo)19.6(r)-429.2(M)0(T)20.9(X)]TJ -1.0015 -1.0755 TD [(in)13.2(cl)18.4(ud)21.2(e)-280(g)0(a)20.8(s)0(t)17.7(r)0(o)13.9(i)0(n)18.9(t)0(e)18.4(s)0(t)17.7(i)0(n)18.9(a)0(l)-271.8(i)0(n)18.8(t)0(o)18.8(l)0(e)18.4(r)0(a)13.5(n)0(c)20.8(e)0(,)-269(s)0(t)17.7(o)0(m)18.1(a)0(t)18.5(i)0(t)16.5(i)0(s)17.7(,)-273.5(he)15.1(pa)15.1(t)13.9(o)0(t)13.2(o)0(x)21.2(i)0(-)]TJ 0 -1.0698 TD [(ci)12.8(ty)81.4(,)-262.1(h)0(a)20.8(e)0(m)12(a)0(t)18.5(o)0(l)18.9(o)0(g)15.5(i)0(c)18.4(a)0(l)-254.7(a)0(d)20.8(v)0(e)15.1(r)0(s)18.4(e)-262.9(ef)24.9(fe)19.2(ct)18.4(s)-263.7(a)0(n)15.1(d)-262.5(mi)15.7(sc)19.6(el)18.5(la)12.8(ne)20.8(ou)15.5(s)-263.7(a)0(d)20.8(-)]TJ 0 -1.0755 TD [(ve)15.1(rs)18.4(e)-382.4(e)0(f)30.6(f)0(e)13.5(c)0(t)18.4(s)-383.2(su)20(ch)-371.8(as)-373(al)18.5(op)21.2(ec)14.7(ia)18.5(,)-381.6(u)0(r)19.6(t)0(i)16.5(c)0(a)14.7(r)0(i)17.3(a)-376.7(an)15.1(d)-382(s)0(m)16.9(a)0(l)18.4(l)-378.7(ve)15.1(ss)18.8(el)]TJ 0 -1.0698 TD [(va)15.1(sc)19.6(ul)13.2(i)13.9(t)0(i)16.5(s)-303.6([1)13.9(2,)-302.7(78].)-311.6(Adve)-7.4(rse)-318.5(central)-320.2(nervous)-315.8(syst)-7.8(em)-312.4(reac-)]TJ 0 -1.0755 TD [(tion)-7.8(s)-314.9(incl)-8.2(uding)-319.2(headache,)-327.2(dizziness)-328.2(and)-315.7(mem)-9(ory)-316.9(impair-)]TJ 0 -1.0698 TD [(ment)-395.9(wer)-8.2(e)-388.1(also)-394(reported)-399.4([79].)-393.6(Overall)-10.7(,)-387.3(approxi)-9.7(mately)-394.6(a)]TJ 0 -1.0755 TD [(qua)-8.4(rter)-213.9(of)-219.4(the)-215.6(patients)-220.1(with)-222.3(MTX)-217.2(pneum)-7.4(onitis)-217.8([10,)-214.8(14)-7.2(,)-210.9(15,)]TJ T* [(22,)-292.1(29,)-292.1(30,)-292.1(37,)-292.1(39,)-292.1(40,)-292.1(42,)-292.1(43,)-292.1(45,)-292.1(48,)-292.1(50,)-292.1(52,)-292.1(55\26157,)-294.4(60,)]TJ 0 -1.0698 TD [(61,)-553.9(63,)-553.9(67,)-548.2(68])-555.9(\(and)-551.3(on)-7.2(e)-547.5(o)0(f)-555.1(the)-551.4(nine)-552.1(presen)-8.2(t)-549.4(cases\))]TJ 0 -1.0755 TD [(demon)-7.4(stra)-8.6(ted)-238.4(extra)-8.6(pulmonary)-247.7(effects)-235.2(o)-6.5(f)-235.7(the)-244.1(drug.)-244(Thus,)-242.1(it)]TJ 0 -1.0698 TD [(is)-227(helpf)-8.2(ul)-225.8(to)-220.2(look)-227.4(for)-227.4(extra)-8.6(pulmonary)-230.6(symp)-7.4(toms)-226(and)-230.3(signs)]TJ 0 -1.0755 TD [(when)-343.1(entertain)-11.1(ing)-334.7(a)-331.2(diagno)-7.4(sis)-337.1(of)-338.9(MTX)-336.7(pneum)-7.4(onitis.)]TJ 1.0015 -1.0471 TD [(RA)-146.8(wa)16.9(s)-235.3(t)0(h)18.8(e)-234.5(mo)18.1(st)-227(fr)18(eq)15.1(ue)15.1(nt)-225.8(un)21.2(de)15.1(rl)17.3(yi)18.8(ng)-223.5(di)18.9(se)14(as)19.6(e)-234.5(i)0(n)-225.8(p)0(a)15.1(t)0(i)16.5(e)0(n)20.8(t)0(s)]TJ -1.0015 -1.0755 TD [(wi)14.9(th)-407.9(MT)15.2(X)-414.4(p)0(n)15.5(e)0(u)20.8(m)0(o)12.4(n)0(i)18.9(t)0(i)16.5(s)-417.4(in)-407.9(t)13.9(h)0(e)-411.7(p)0(r)19.6(e)0(s)13.9(e)0(n)20.8(t)-418.6(se)19.6(ri)17.3(es)-407.2(an)15.1(d)-416.2(i)0(n)-407.9(t)0(h)18.9(e)]TJ T* [(li)16.5(te)18.4(ra)13.5(tu)18.9(re)-242.5(\(t)17.3(ab)20.8(le)18.5(s)-246.7(2)-251.2(and)-258.8(7\).)-259.6(This)-261.1(may)-261.9(simply)-264.1(refle)-10.2(ct)-254.7(the)-261.2(po-)]TJ 0 -1.0698 TD [(pulat)-9(ion)-232.3(of)-230.7(pa)-7.6(tients)-235.3(recei)-9(ving)-233.1(MTX,)-234.6(but)-232.3(it)-233.9(rais)-8.6(es)-230.8(the)-232.7(ques-)]TJ 0 -1.0755 TD [(tion)-366.3(that)-366.7(RA)-363(itself,)-368.1(or)-361.6(other)-366.7(drugs)-365.1(used)-363.2(in)-362.4(its)-361.1(treat)-11(ment,)]TJ ET /GS3 gs q 225.3108 0 0 168.5742 58.9862 520.4604 cm /Im5 Do Q q 225.3108 0 0 165.4952 58.9862 349.2805 cm /Im6 Do Q q 225.3108 0 0 169.0874 59.3746 174.8331 cm /Im7 Do Q BT /F13 1 Tf 9.8 0 0 9.8 68.477 673.536 Tm 0 0 0 1 k /GS4 gs (a\))Tj -0.05 -17.95 TD (b\))Tj 0.05 -17.45 TD (c\))Tj /F6 1 Tf 7.97 0 0 7.97 58.28 163.162 Tm 0 g /GS2 gs [(Fig.)-327.1(4.)-331.2(\261)-332.2(Photomicro)11.9(graph)-458.1(showing)-446.6(subacute)-453.2(methotrexate)-454.9(pneumo)13.3(n-)]TJ 0 -1.067 TD [(itis:)-384.4(a\))-386.2(mild)-380.8(chronic)-384.2(interstitial)-382(infiltrate)-380.5(around)-384.9(an)-378.9(alveolar)-383.4(duct)-384.2(with)]TJ 0 -1.0599 TD [(prominent)-205.8(perivascu)11.1(lar)-208.6(inflammatio)7.7(n)-211.3(and)-206.1(no)-209.2(significant)-199.2(fibrosis)-211.2(\(case)-201.2(2\);)]TJ T* [(b\))-373(focus)-374(of)-380.1(airspace)-374.1(or)18.2(ganization)-374.3(\(centre\))-374.3(with)-375.9(surrounding)-364.9(interstitial)]TJ 0 -1.067 TD [(infiltrate)-209.8(\(case)-208.3(7\);)-209.7(and)-213.2(c\))-208.4(cellular)-215.1(interstitia)9.5(l)-213.7(infiltrate)-209.8(with)-212.3(increased)-208.4(alve-)]TJ 0 -1.0599 TD [(olar)-377.3(macrophage)-366.6(numbers)-377.1(and)-376.8(mild-to-m)10.8(oderate)-376(alveolar)-376.3(septal)-375.4(thick-)]TJ T* [(ening)-325.2(without)-329.3(honeycomb)-320.8(change)-325.8(\(case)-329.3(3\).)]TJ ET /GS3 gs q 228.1811 0 0 168.9974 309.3152 330.9495 cm /Im8 Do Q q 228.1811 0 0 165.6279 310.149 158.9072 cm /Im9 Do Q BT /F13 1 Tf 9.9 0 0 9.9 315.411 484.758 Tm 0 0 0 1 k /GS4 gs (a\))Tj 0.2 -17.75 TD (b\))Tj /F6 1 Tf 7.97 0 0 7.97 308.976 146.494 Tm 0 g /GS2 gs [(Fig.)-327.1(5.)-331.2(\261)-332.2(Photomicro)11.9(graph)-365.7(showing)-361.2(granuloma)11(tous)-372.2(reaction)-362.1(in)-368.1(metho-)]TJ 0 -1.0599 TD [(trexate)-221.9(pneumonitis)-212.1(\(case)-222.6(1\).)-222.5(a\))-229.7(The)-215.9(granulomas)-215.7(in)-225.8(methotrexate)-220.2(are)-219.5(typ-)]TJ T* [(ically)-405.1(small)-414.4(and)-405.3(ill-defined.)-403.4(b\))-408.5(A)-413(single)-404.9(case)-409.4(in)-410.8(this)-403(series)-410(showed)-402.6(a)]TJ 0 -1.067 TD [(necrotizin)9.6(g)-453.2(granuloma)11(,)-454.2(indistingui)10(shable)-451.3(from)-447.5(the)-450.3(necrotizin)9.6(g)-453.2(granu-)]TJ 0 -1.0599 TD [(lomas)-326.7(of)-330.3(infections.)]TJ 8.966 0 0 8.966 58.28 797.499 Tm (378)Tj 7.472 0 0 7.472 262.431 797.499 Tm 0.0001 Tc [(S.)-328.4(IMO)-9.6(K)0(A)70.4(W)102.5(A)-329(E)0(T)-263.8(AL.)]TJ ET endstream endobj 41 0 obj << /ProcSet [/PDF /Text /ImageB ] /Font << /F6 9 0 R /F13 31 0 R >> /XObject << /Im5 34 0 R /Im6 35 0 R /Im7 36 0 R /Im8 37 0 R /Im9 38 0 R >> /ExtGState << /GS2 11 0 R /GS3 32 0 R /GS4 33 0 R >> >> endobj 43 0 obj << /Length 19179 >> stream BT /F6 1 Tf 9.963 0 0 9.963 58.28 623.735 Tm 0 g /GS2 gs 0 Tc [(may)-324.5(play)-330.2(a)-319.8(role)-331.8(in)-322.6(this)-327.7(advers)-8.2(e)-319.8(react)-9(ion.)-323.7(Many)-329.8(RA)-323.2(pati)-8.2(-)]TJ 0 -1.0755 TD [(ents)-223.3(with)-222.3(this)-219.6(disea)-8.2(se)-219.4(had)-218.9(a)-217.4(history)-223.4(of)-219.4(treatmen)-11.1(t)-219.4(with)-222.3(other)]TJ 0 -1.0698 TD [(disea)-8.2(se-modif)-10.7(ying)-375.3(anti)-8.2(rheumati)-10.7(c)-376.7(drugs)-376.5(\(DM)-9.8(ARDs\))-383.4([14,)]TJ T* [(15,)-292.1(20,)-292.1(21,)-292.1(23,)-292.1(26,)-292.1(27,)-292.1(29,)-292.1(31,)-292.1(34,)-292.1(37,)-292.1(38,)-292.1(57\26160,)-294.4(63,)-292.1(66,)]TJ T* [(68,)-314.9(69)-7.2(].)-315.7(Some)-318.8(of)-316.1(these)-321.2(also)-320(show)-8.2(ed)-314.9(advers)-8.2(e)-314.2(react)-9(ions)-319.6(to)]TJ T* [(their)-346.3(DMARD)-10.9(s)-337.7([14,)-340(15,)-343.3(20,)-337.7(2)-6.5(3)0(,)-336.9(26,)-343.3(31,)-337.7(57,)-343.3(60,)-337.6(66,)-343.3(68],)]TJ T* [(which)-346.3(might)-347.5(sugges)-7.4(t)-338.9(that)-344(RA)-345.9(patients)-345.3(are)-346.1(prone)-341.6(to)-345.3(drug)]TJ 0 -1.0755 TD [(react)-9(ions)-541.5(in)-538.8(general.)-545.8(Unfortu)-9.1(nately)58.1(,)-541(the)-540(prevalence)-548.5(of)]TJ 0 -1.0698 TD [(MTX)-234.2(pneum)-7.4(onitis)-234.8(in)-225.8(RA)-232.1(relat)-11(ive)-227(to)-231.5(other)-235.8(disea)-8.2(ses)-227(treat)-11(ed)]TJ T* [(with)-415.8(MTX)-416.3(is)-414.8(unclea)-8.2(r)-412.1(and)-412.4(the)-414.8(significa)-11.9(nce)-412.8(of)-412.8("RA-sus)-9.5(-)]TJ T* [(ceptib)-10.1(ility")-335.7(rema)-8.6(ins)-335.9(to)-334(be)-337.7(clarifie)-12(d.)]TJ 1.0015 -1.0471 TD [(Al)14.9(th)18.9(ou)15.5(gh)-183.6(th)18.9(er)13.5(e)-194.7(w)12.4(er)13.5(e)-194.7(n)0(o)-183.6(c)0(a)14.7(s)0(e)19.6(s)-195.4(of)-185.2(ne)15.1(op)21.2(la)18.4(st)17.7(ic)-186.4(di)13.2(se)19.6(as)19.6(e)-194.7(i)0(n)-186(t)0(h)13.2(e)]TJ -1.0015 -1.0755 TD [(pr)19.6(es)13.9(en)20.8(t)-293.4(s)0(e)19.6(r)0(i)17.3(e)0(s)19.6(,)-290.6(ov)21.2(er)-282.4(a)-291.4(t)0(h)18.9(i)0(r)17.3(d)-285.3(of)-282(pa)15.1(ti)22.2(en)15.1(ts)-278.2(re)13.5(po)21.2(rt)17.3(ed)-280.8(wi)14.9(th)-277.1(MT)15.2(X)]TJ 0 -1.0698 TD [(pn)15.5(eu)20.8(mo)18.1(ni)13.2(ti)22.2(s)-292.2(h)0(a)20.8(v)0(e)-280.8(h)0(a)20.8(d)-291(un)21.2(de)15.1(rl)17.3(yi)18.9(ng)-280.4(ne)20.8(op)15.5(la)18.4(sm)16.9(s.)-275.5(Th)17.1(e)-291.4(d)0(o)21.2(s)0(e)-282(o)0(f)]TJ T* [(MT)15.2(X)-266.5(i)0(n)-265.7(t)0(h)18.9(e)-268.6(se)19.6(tt)16.5(in)18.9(g)-273.9(o)0(f)-259.2(n)0(e)20.8(o)0(p)15.5(l)0(a)18.4(s)0(m)16.9(s)-269.4(te)12.8(nd)21.2(ed)-263.7(t)13.9(o)-273.9(be)-258(hi)18.9(gh)15.5(er)-259.6(th)18.8(an)]TJ T* [(th)18.9(at)-357.1(fo)13.9(r)-366.6(n)0(o)21.2(n)0(-)19.6(n)0(e)15.1(o)0(p)15.5(l)13.9(as)13.9(ti)16.5(c)-365.4(d)0(i)18.9(s)0(e)19.6(a)0(s)13.9(e)0(s)-355.9(\()0(t)17.3(a)0(b)15.1(l)13.9(e)-371.1(2\).)-367.7(Some)-375.7(of)-378.7(these)]TJ T* [(patien)-10.1(ts)-261.2(had)-264.5(also)-268.8(been)-265.6(treated)-269(with)-267.8(other)-270(cytotoxic)-270.9(agents)]TJ T* [(in)-351(addit)-9(ion)-351.8(to)-351(MTX)-353.7([19,)-351.4(24,)-354.7(25,)-349(30,)-354.7(35,)-349(40,)-354.7(45,)-349(48,)-354.7(53,)]TJ 0 -1.0755 TD [(54],)-465.2(and)-463.6(it)-461.5(has)-464.8(been)-464.8(reported)-467.7(that)-463.5(the)-466(use)-459.1(of)-464.1(mul)-7.8(tiple)]TJ 0 -1.0698 TD [(chemo)-7.8(thera)-8.6(peutic)-391.4(agents)-395.9(in)-390.9(can)-8.8(cer)-391.7(patients)-396.5(may)-392.8(predi)-8.2(s-)]TJ T* [(pose)-334.7(to)-339.7(pulmonary)-344.4(drug)-334.7(toxi)-7.8(city)-338.3([80].)]TJ 1.0015 -1.0471 TD [(Th)17.1(e)-376.8(p)0(r)19.6(o)0(g)21.2(n)0(o)15.5(s)0(i)17.7(s)-371.8(of)-367.3(pa)15.1(ti)16.5(en)20.8(ts)-363.6(wi)14.9(th)-368.1(MT)20.8(X)-374.6(p)0(n)15.5(e)0(u)15.1(m)0(o)18.1(n)0(i)18.9(t)0(i)16.5(s)-371.8(ha)15.1(s)]TJ -1.0015 -1.0698 TD [(be)15.1(en)-195.4(co)15.1(ns)20(id)18.9(er)13.5(ed)-195.4(re)13.5(la)18.4(ti)16.5(ve)20.8(ly)-203.1(fa)19.2(vo)15.5(ur)19.6(ab)20.8(le)-203.5([7)19.6(,)-216.6(1)27.7(1],)-219.7(but)-220.9(not)-215.2(enti)-8.2(r-)]TJ 0 -1.0755 TD [(ely)-369.3(benign)-7.4(.)-364.6(According)-374.1(to)-368.1(the)-369.3(literat)-11.6(ure,)-368.9(13%)-368.8(of)-367.3(patients)]TJ 0 -1.0698 TD [(died)-199.3(becau)-10.7(se)-196.6(of)-196.6(respi)-9.4(ratory)-204(disea)-8.2(se)-196.6(\(table)-205.2(6\).)-197(In)-202.3(the)-198.6(presen)-8.2(t)]TJ T* [(series,)-177.1(two)-167.9(\(22.2%)-8.2(\))-167.4(died)-170.9(because)-173.2(of)-173.8(respirato)-11.1(ry)-168.2(disease)-176.3(and)]TJ T* [(one)-139.3(develo)-7.8(ped)-139.3(c)-6.9(hronic)-139.8(respi)-9.4(ratory)-147.1(failure.)-145.4(All)-141.9(three)-145.2(of)-139.7(these)]TJ T* [(patien)-10.1(ts)-437.6(showed)-442.6(an)-440.1(acu)-8.8(te)-436.8(and)-440.9(organizing)-441.6(DAD)-440.9(patt)-8.2(ern)]TJ T* [(pathol)-9.7(ogically)54.2(,)-182.5(probabl)-9.7(y)-182.9(unders)-7.8(coring)-185.4(the)-187.2(signi)-9.8(ficant)-188.1(mor-)]TJ 0 -1.0755 TD [(bidity)-341.8(associated)-340.7(wi)-7.8(th)-334(the)-335.1(DAD)-338.4(patt)-8.2(ern)-334.3(in)-334(g)-6.5(eneral)-339.8([81].)]TJ 1.0015 -1.0471 TD [(Mo)13.6(re)-333.6(th)18.9(an)-332(ha)15.1(lf)-335.6(of)-333.2(th)18.8(e)-342.6(p)0(a)15.1(t)0(i)16.5(e)0(n)20.8(t)0(s)-335.2(w)0(i)14.9(t)0(h)-334(M)0(T)15.2(X)-340.4(pn)15.5(eu)20.8(mo)12.4(ni)18.9(ti)16.5(s)]TJ -1.0015 -1.0698 TD [(ca)14.7(rr)18(ie)18.4(d)-188.6(a)-183.3(di)18.9(ag)15.1(no)15.5(si)17.7(s)-184.1(o)0(f)-179.5(R)11.6(A)-192.5(\()0(t)17.3(a)0(b)20.8(l)0(e)-180.7(2\),)-185.6(a)-200.3(condition)-202.2(whi)-8.6(ch)-195.4(com-)]TJ T* [(monly)-333.7(invol)-8.6(ves)-328.2(the)-329.4(lung)-335.5([82].)-331(The)-331.2(pathologi)-8.7(cal)-329.8(findi)-10.2(ngs)]TJ 0 -1.0755 TD [(observ)-7.8(ed)-201.1(by)-200.7(the)-204.2(author)-9(s)-201.1(i)0(n)-203.1(MTX)-205.8(pneum)-7.4(onitis,)-206.8(such)-203.8(as)-202.3(cel-)]TJ 0 -1.0698 TD [(lular)-397.5(inte)-8.2(rstitial)-402.5(infiltrates)-14.1(,)-393(DAD)-8.4(,)-393(tissue)-399.1(eosinophil)-10.7(s)-394.6(and)]TJ T* [(granul)-9(oma)-267.6(form)-9.4(ation,)-271.1(are)-266.5(all)-269.2(report)-10.5(ed)-269.4(in)-265.7(RA)-271.9(lung)-267.2(disea)-8.2(se)]TJ T* [([82].)-348.1(Thus,)-344.5(histolog)-8.7(y)-342.2(alone)-342.7(cannot)-349.2(differentiate)-344.5(betw)-9.8(een)]TJ T* [(these)-355.3(two)-350(condit)-9.7(ions.)-354.1(Clinical)-356.9(history)-354.3(a)-6.9(n)0(d)-348.7(follow)-9.2(-up)-351(are)]TJ T* [(critical)-12.7(.)]TJ 1.0015 -1.0528 TD [(Ac)16.9(ut)18.9(e)-598.7(a)0(n)15.1(d)-598.3(or)31(ga)15.1(ni)18.9(zi)18.5(ng)-587.7(DA)13.4(D)-596.5(a)0(n)15.1(d)-598.3(ce)20.4(ll)16.5(ul)18.9(ar)-589.7(in)13.2(t)13.9(e)0(r)13.5(s)0(t)17.7(i)0(t)16.5(i)0(a)18.4(l)]TJ -1.0015 -1.0698 TD [(in)18.9(fi)17.3(lt)16.5(ra)19.2(te)12.8(s)-229.6(w)12.4(it)16.5(h)-228.4(o)0(r)-225.1(w)12.4(it)16.5(ho)15.5(ut)-220.2(gr)19.6(an)15.1(ul)18.9(om)18.1(as)-219.4(we)11.2(re)-219.8(th)18.9(e)-228.8(m)0(a)17.7(i)0(n)-220.2(h)0(i)13.2(s)0(t)17.7(o)0(-)]TJ T* [(lo)18.9(gi)18.9(ca)14.7(l)-384.4(f)0(i)17.3(n)0(d)15.5(i)0(n)18.8(g)0(s)-372.6(i)0(n)-379.5(t)0(h)18.9(e)-382.4(pr)13.9(es)19.6(en)15.1(t)-384.4(p)0(a)20.8(t)0(i)16.5(e)0(n)15.1(t)0(s)-375(w)0(i)14.9(t)0(h)-373.8(M)0(T)15.2(X)-386(pn)21.2(eu)15.1(-)]TJ T* [(mo)18.1(ni)18.9(ti)16.5(s.)-258.4(Th)17.1(es)13.9(e)-262.9(p)0(a)15.1(t)0(t)16.5(e)0(r)19.2(n)0(s)-258.8(a)0(r)13.5(e)-268.6(no)21.2(ns)20(pe)15.1(ci)18.4(fi)17.3(c)-268.6(a)0(n)15.1(d)-268.2(ca)20.4(n)-268.2(b)0(e)-258(s)0(e)13.9(e)0(n)-258(i)0(n)]TJ T* [(ma)17.7(ny)-240.5(co)15.1(nd)21.2(it)16.5(io)18.9(ns)14.4(,)-245.1(i)0(n)18.9(c)0(l)18.4(u)0(d)15.5(i)0(n)18.9(g)-251.2(in)18.9(fe)19.2(ct)18.5(io)13.2(ns)-236([8)13.9(3,)-245.8(84].)-260.3(One)-262.7(of)-259.2(the)]TJ 0 -1.0755 TD [(presen)-8.2(t)-282(cases)-286.2(show)-8.2(ed)-280.8(necrot)-9.4(izing)-287.8(granulomas)-289.9(in)-282.7(ad)-7.6(dition)]TJ 0 -1.0698 TD [(to)-180.3(non-nec)-7.7(rotizing)-191.7(granulomas)-11(.)-176.8(Cultur)-10(es)-179.5(wer)-8.2(e)-177.6(negati)-10.1(ve)-178.3(for)]TJ T* [(organisms)-187.5(in)-186(this)-191.1(case.)-193.6(Some)-193.6(patients)-191.6(recei)-9(ving)-193.2(MTX)-188.7(ther-)]TJ T* [(apy)-395.3(may)-398.5(be)-394.6(immunoc)-8.7(ompr)-7.8(omised)-398.7(d)-6.5(u)0(e)-394.6(t)0(o)-390.9(bon)-8(e)-393.8(marrow)]TJ T* [(suppre)-7.8(ssion)-304.5(by)-303.1(the)-301(drug)-300.6([78])-307.8(and)-298.6(may)-307.4(be)-297.8(prone)-307.4(to)-299.8(infec)-8.6(-)]TJ 25.1977 66.1583 TD [(tion)-7.8(s.)-446.2(Rec)-7.8(ently)59.3(,)-449.9(i)0(t)-450.1(has)-453.4(been)-453.4(reported)-456.3(that)-452.1(opport)-8.5(unistic)]TJ 0 -1.0471 TD [(infec)-8.6(tion)-411.8(is)-414.8(a)-410.9(potential)-421.2(complicat)-12.7(ion)-408.7(of)-412.8(low-dos)-8.7(e)-410.9(MTX)]TJ 0 -1.0528 TD [(thera)-8.6(py)-212.1(even)-214.4(in)-208.8(the)-215.6(presen)-8.2(ce)-212.9(of)-208(a)-211.7(norm)-7.8(al)-209.2(perip)-8.2(heral)-213.5(leuko-)]TJ 0 -1.0471 TD [(cyte)-211.1(count)-205.8([85].)-211.5(For)-202.3(these)-207.4(reason)-8.2(s,)-207.2(the)-204.2(careful)-211.3(exclus)-9(ion)-203.8(of)]TJ 0 -1.0528 TD [(infec)-8.6(tion)-150.1(is)-141.7(an)-144.2(imp)-7.8(ortant)-147.9(clinical)-153.4(and)-145(pathol)-9.7(ogical)-146.7(criterio)-11.6(n.)]TJ 0 -1.0471 TD [(BAL)-242.7(may)-244.8(be)-235.2(a)-240.2(very)-238.4(useful)-243.5(tool)-241.1(for)-244.5(detecting)-248.5(an)-235.2(infec)-8.6(tious)]TJ 0 -1.0528 TD [(proces)-8.2(s)-223.9(i)0(n)-225.8(some)-229.7(patients.)-231.9(When)-226.6(lung)-227.4(biops)-7.4(y)-222.7(i)0(s)-227(performed,)]TJ 0 -1.0471 TD [(the)-295.3(tissue)-296.7(samp)-7.8(les)-290.8(shoul)-7.4(d)-285.3(b)0(e)-292.2(evalua)-8.2(ted)-295.3(for)-290(infec)-8.6(tion)-292.3(with)]TJ 0 -1.0527 TD [(app)-8.4(ropriate)-339.2(speci)-8.2(al)-334.4(stains)-342.2(and)-332.7(cult)-8.2(ures.)]TJ 1.0015 -1.0527 TD -0.0168 Tc [(T)-16.8(h)0.3(e)-251.3(p)-16.8(a)4(t)-16.8(ho)-16.8(ge)-16.8(ne)-16.8(ti)-16.8(c)-237.4(m)-16.8(ec)-16.8(ha)-16.8(n)4(i)-16.8(sm)-16.8(s)-244.6(o)-16.8(f)-236.2(m)-16.8(et)-16.8(ho)-16.8(tr)-16.8(ex)-16.8(at)-16.8(e)-237.4(p)-16.8(n)4.4(e)-16.8(um)-16.8(o-)]TJ -1.0015 -1.0471 TD 0 Tc [(ni)13.2(ti)22.2(s)-229.6(r)0(e)19.2(m)0(a)17.7(i)0(n)-214.5(u)0(n)15.5(k)0(n)21.2(o)0(w)11.6(n)-222.7([7)19.6(,)-233.7(1)27.7(1].)-236.8(Some)-239.1(cases)-235(of)-236.4(met)-8.2(hotrexate)]TJ 0 -1.0528 TD [(toxi)-7.8(city)-338.3(may)-341.6(be)-337.7(due)-338.4(to)-339.7(folate)-347.5(deficiency)52.7(,)-336.1(wher)-9(eas)-340(others)]TJ 0 -1.0471 TD [(are)-442.9(probably)-443(linked)-436.5(to)-436.4(imm)-11(unoallergic)-433.7(or)-435.6(idio)-7.8(syncra)-8.2(tic)]TJ 0 -1.0527 TD [(react)-9(ions)-228.6([1].)-233.5(Findings)-233.2(sugges)-7.4(ting)-229.7(a)-223.1(hype)-9.2(rsensitivit)-13.3(y)-222.7(reac-)]TJ 0 -1.0471 TD [(tion)-195.6(in)-186(the)-192.9(lung)-193.2(include:)-196.1(interstiti)-13.7(al)-186.4(pn)-7.2(eumonitis)-195.2(with)-193.8(small)]TJ 0 -1.0527 TD [(non)-8(-necrotizing)-236.9(granulomas)-233(on)-223.5(biops)-7.4(y)-222.7([10],)-222.9(incre)-8.6(ased)-227(tis-)]TJ 0 -1.0471 TD [(sue)-345.3(eosin)-7.8(ophils)-346.3([10,)-345.7(14,)-343.3(18)-7.2(,)-341.8(23,)-343.3(26],)-345.7(lymphocyt)-9.5(es)-344.6(and)-344.1(a)]TJ 0 -1.0528 TD [(revers)-9.8(ed)-240.9(CD4/)-8.4(CD8)-244.2(ratio)-243.9(on)-240.5(BAL)-242.7([72,)-243.3(73])-242.9(and)-241.7(the)-238.4(clin)-8.2(ical)]TJ 0 -1.0471 TD [(findi)-10.2(ngs)-276.6(of)-270.6(fever)26.3(,)-279.2(perip)-8.2(heral)-281.7(eosinop)-9.3(hilia)-278.8(and)-281.5(respon)-7.8(se)-276.3(to)]TJ 0 -1.0527 TD [(corti)-10.6(costeroids)-193.6([10\2611)28.7(1].)-185.6(Rep)-7.4(orts)-184.6(o)-6.5(f)-178.8(spont)-7.4(aneous)-188.7(remi)-10.6(ssion)]TJ 0 -1.0471 TD [(durin)-7.8(g)-302.4(methotre)-10.7(xate)-307.8(treatmen)-11.1(t)-299.1([8,)-305.1(22,)-303.5(53],)-305.9(and)-304.3(of)-304.7(rechal-)]TJ 0 -1.0528 TD [(lenge)-234.6(wi)-7.8(th)-231.5(the)-232.7(drug)-232.3(without)-238.3(recurr)-10.2(ence)-231.9(of)-230.7(pneum)-7.4(onitis)-234.8([8,)]TJ 0 -1.0471 TD [(10,)-280.7(15)-7.2(,)-273.5(1)-6.5(8,)-280(22,)-280.7(42,)-280.7(54,)-280.7(60,)-280.7(69],)-283.1(argue)-273.7(for)-278.6(an)-280.8(idio)-7.8(syncra)-8.2(tic)]TJ 0 -1.0527 TD [(react)-9(ion.)-306.7(A)-306.3(toxic)-304.9(drug)-306.2(react)-9(ion)-306.3(is)-301(sugges)-7.4(ted)-306.7(by)-303.1(the)-306.7(accu-)]TJ 0 -1.0471 TD [(mul)-7.8(ation)-344.7(of)-338.9(met)-8.2(hotrexate)-350.2(in)-339.7(lung)-341.2(tissue)-347.9([86],)-342.4(the)-340.8(biops)-7.4(y)]TJ 0 -1.0528 TD [(findi)-10.2(ngs)-236.8(of)-236.4(alveolar)-241.3(or)-236.4(b)-6.5(ronchial)-240.9(epit)-8.2(helial)-240.2(cell)-236.2(atypi)-9(a)-234.5([26,)]TJ 0 -1.0471 TD [(45])-305.5(an)-7.6(d)-302.4(lung)-307(injury)-306.8(pattern)-314.1([18,)-305.9(20,)-303.5(45,)-303.5(47,)-303.5(49],)-305.9(and)-304.3(res-)]TJ 0 -1.0527 TD [(olut)-7.8(ion)-215.2(of)-213.7(lung)-216(disea)-8.2(se)-213.7(after)-215.1(stopp)-7.4(ing)-215.2(or)-213.7(loweri)-9.6(ng)-212.1(the)-215.6(dose)]TJ 0 -1.0471 TD [(of)-276.3(the)-278.2(drug)-272.1([8,)-276.6(14,)-275.1(40,)-275.1(55,)-275.1(57,)-269.4(60)-7.2(].)-270.2(The)-274.3(fact)-281(that)-275.7(the)-272.5(pa)-7.6(th-)]TJ 0 -1.0528 TD [(ologi)-8.6(cal)-295.7(changes)-303.7(generally)-304.7(do)-291.7(not)-294.9(appear)-303.3(to)-294.1(be)-297.8(related)-297.4(to)]TJ 0 -1.0471 TD [(dose)-192.4(or)-190.9(duration)-195(of)-185.2(met)-8.2(hotre)-8.2(xate)-188.3(thera)-8.6(py)-183.6([7,)-191.3(1)27.7(1)0(,)-183.2(13])-191.7(argues)]TJ 0 -1.0528 TD [(aga)-8.8(inst)-270.8(this)-276.5(hypothesis)-9.5(.)-267.8(Furthe)-8.2(r)-269.8(inves)-7.8(tigatio)-9.6(ns)-270.2(are)-272.1(needed)]TJ 0 -1.0471 TD [(to)-203.1(elucidate)-209.1(the)-198.6(mecha)-8.2(nisms)-205.2(of)-202.3(methotre)-10.7(xate)-199.7(pneum)-7.4(onitis.)]TJ /F16 1 Tf 7.97 0 0 7.97 380.523 414.482 Tm [(Acknowled)11.4(gements.)]TJ /F6 1 Tf 8.55 0 TD [(The)-436.4(authors)-429(thank)-431.9(the)-436.1(fol-)]TJ -9.5458 -1.1239 TD [(lowing)-457(physicians)-453.6(for)-463.5(providin)11.9(g)-467.4(clinical)-459.2(informa-)]TJ T* [(tion)-473(or)-479.7(pathological)-472.1(materials)-477.7(pertaining)-475.1(to)-481.9(cases)]TJ T* [(discussed)-255.3(in)-254.3(this)-260.8(series:)-260.9(S.)-264.9(Y)99.2(ousem,)-259.2(B.A.)-257(Little,)-260.8(P)111(.)0(T)71.6(.)]TJ T* [(Steinmetz)9.6(,)-532.4(D.C.)-534.4(Olsen,)-527(R.)-535(DeFelice,)-530.8(J.C.)-533.1(W)76.3(atts,)]TJ T* [(M.M.)-447.1(Pevzner)41.1(,)-454.2(C.L.)-442.1(W)33.6(isseman)-450.7(and)-447.9(R.S.)-444.3(Zeiders.)]TJ /F5 1 Tf 8.966 0 0 8.966 402.349 339.647 Tm [(Refer)11.6(ences)]TJ /F6 1 Tf -10.3759 -1.998 TD [(1.)-1766.5(van)-213.2(Ede)-210.4(AE,)-217.3(Laan)-216(RFJM,)-208.4(Blom)-215.6(HJ,)-215(De)-217(Abreu)-210.1(RA,)-218.6(van)-213.2(de)]TJ 2.5165 -1.1128 TD [(Putte)-626.6(LBA.)-619.9(Methotrexate)-627.7(in)-627.4(rheumatoid)-628(arthritis:)-629.4(an)]TJ 0 -1.1065 TD [(update)-416.2(with)-417(focus)-423(on)-416.3(mechanisms)-420(involved)-417.8(in)-418.7(toxicity)58(.)]TJ /F3 1 Tf 0 -1.1128 TD [(Semin)-331.7(Arthritis)-340.8(Rheum)]TJ /F6 1 Tf 9.5286 0 TD [(1998;)-334.9(27:)-329.6(277\261292.)]TJ -12.0451 -1.1128 TD [(2.)-1766.5(W)70.8(einstein)-338.9(GD.)-337.3(Methotrexate.)]TJ /F3 1 Tf 14.6692 0 TD [(Ann)-337.1(Intern)-336.4(Med)]TJ /F6 1 Tf 6.7908 0 TD [(1977;)-334.9(86:)]TJ -18.9434 -1.1128 TD (199\261204.)Tj -2.5165 -1.1065 TD [(3.)-1766.5(Kaplan)-527(MM,)-528.1(Knox)-526.1(T)72.9(A)0(.)-524.2(T)34.9(reatment)-534(of)-524.8(primary)-527.2(biliary)]TJ 2.5165 -1.1128 TD [(cirrhosis)-548(with)-543.5(low-dose)-541(weekly)-545.9(methotrexate.)]TJ /F3 1 Tf 19.7654 0 TD [(Gastr)26.1(o-)]TJ -19.7654 -1.1128 TD [(enter)31(ology)]TJ /F6 1 Tf 4.5399 0 TD [(1991;)-334.9(101:)-329.1(1332\2611338.)]TJ -7.0564 -1.1065 TD [(4.)-1766.5(Kozarek)-366.7(RA,)-364(Patterson)-367.2(DJ,)-366.8(Gelfand)-369.4(MD,)-366.3(Botoman)-365.6(V)123.6(A)0(,)]TJ 2.5165 -1.1128 TD [(Ball)-418.2(TJ,)-411.2(W)32.8(ilske)-420.5(KR.)-414.6(Methotrexate)-419.1(induces)-410.5(clinical)-422.1(and)]TJ T* [(histologic)-252(remission)-251.8(in)-248(patients)-250.4(with)-252.6(refractory)-253.4(inflamma-)]TJ T* [(tory)-273.2(bowel)-268.5(disease.)]TJ /F3 1 Tf 7.9353 0 TD [(Ann)-267.5(Intern)-273.2(Med)]TJ /F6 1 Tf 6.5885 0 TD [(1989;)-265.4(1)32.1(10:)-272.7(353\261356.)]TJ -17.0402 -1.1065 TD [(5.)-1766.5(W)70.8(einblatt)-220(ME,)-221(Coblyn)-225.3(JS,)-223(Fox)-218.4(DA,)]TJ /F3 1 Tf 16.7684 0 TD [(et)-222.4(al)]TJ /F6 1 Tf 1.7009 0 TD [(.)-217.9(Efficac)9.1(y)-220.8(o)0(f)-221.3(low-)]TJ -15.9527 -1.1128 TD [(dose)-315.1(methotrexate)-319.1(in)-317.5(rheumatoid)-318.2(arthritis.)]TJ /F3 1 Tf 17.1351 0 TD [(N)-314(Engl)-320(J)-315.4(Med)]TJ /F6 1 Tf -17.1351 -1.1128 TD [(1985;)-334.9(312:)-329.1(818\261822.)]TJ -2.5165 -1.1128 TD [(6.)-1766.5(Kremer)-370.3(JM,)-364.2(Alarcon)-363(GS,)-370.5(W)77.1(einblatt)-371.7(ME,)]TJ /F3 1 Tf 19.5062 0 TD [(et)-361.6(al)]TJ /F6 1 Tf 1.84 0 TD [(.)-363.3(Clinical,)]TJ -18.8296 -1.1065 TD [(laboratory)62.1(,)-369.6(radiographic,)-369.5(and)-365(histopathologic)-371.7(features)-373.8(of)]TJ 0 -1.1128 TD [(methotrexate-associated)-251.1(lung)-247(injury)-243(in)-241.7(patients)-250.4(with)-246.3(rheu-)]TJ T* [(matoid)-433.3(arthritis.)-434.4(A)-432.8(multicenter)-442.4(study)-431(with)-429.7(literature)-442(re-)]TJ 0 -1.1065 TD [(view)59.8(.)]TJ /F3 1 Tf 2.447 0 TD [(Arthritis)-334.5(Rheum)]TJ /F6 1 Tf 6.7655 0 TD [(1997;)-334.9(40:)-336(1829\2611837.)]TJ -11.729 -1.1128 TD [(7.)-1766.5(Barrera)-294.2(P)103.1(,)-287.4(Laan)-291.9(RFJM,)-290.6(van)-295.4(Riel)-291.8(PLCM,)-292.9(Dekhuijzen)-293.1(PN,)]TJ ET 1 i 58.28 758.834 239.981 -0.51 re f 58.28 649.247 239.981 -0.51 re f BT /F2 1 Tf 8.966 0 0 8.966 58.28 772.667 Tm [(Table)-331.9(8.)-336.7(\261)-333.2(Summary)-232.7(of)-229.2(pathological)-227(findings)-235.8(in)-229(nine)-231.5(cases)]TJ 0 -1.0559 TD [(of)-330.4(methotrexate)-337.3(pneumonitis)]TJ /F5 1 Tf 0 -1.7072 TD [(Acute)-335(cases)]TJ /F6 1 Tf 0 -1.0559 TD [(Diffuse)-327.5(alveolar)-336.1(damage)-333.3(with)-334.8(type)-335.2(II)-336(alveolar)-336.1(cell)-331.1(atypia)]TJ /F5 1 Tf T* [(Subacute)-332.2(cases)]TJ /F6 1 Tf T* [(Mild)-332.2(alveolar)-336.1(damage)-339.6(manifesting)-333.9(as)-335.1(interstitial)]TJ 0.6639 -1.0559 TD [(inflammatory)-341.4(infiltrate)-337.1(with)-334.8(lymphocytes)-336.9(and)]TJ T* [(type)-335.2(II)-336(cell)-337.4(hyperplasia)]TJ -0.6639 -1.0559 TD [(Small)-337.6(foci)-329.9(of)-335.1(organization,)-326.7(perivascular)-342.3(inflammation,)]TJ 0.6639 -1.0559 TD [(eosinophils)-338.8(and)-333.4(granuloma)-335.3(formation)-338.9(may)-328.9(be)-333.9(present.)]TJ -0.3288 -1.0559 TD [(\(most)-332.7(granulomas)-336(are)-334.1(non-necrotizing,)-338.8(but)-336(rarely)]TJ 0.3288 -1.0559 TD [(small)-340.2(necrotizing)-336.9(granulomas)-336(may)-328.9(be)-333.9(present.\))]TJ -0.6639 -1.0559 TD [(Acute)-337.8(and)-333.4(or)12.7(ganizing)-335.4(diff)10.4(use)-334.6(alveolar)-336.1(damage)-333.3(may)-335.2(be)-333.9(present)]TJ ET 1 g 285.449 765.354 15.024 -14.627 re f* 285.449 656.56 15.024 -15.931 re f* BT 8.966 0 0 8.966 523.049 797.499 Tm 0 g (379)Tj 7.472 0 0 7.472 241.285 797.499 Tm 0.0001 Tc [(METHOTR)-11(EXA)105.4(TE)-339.7(PNEUMONITIS)]TJ ET endstream endobj 44 0 obj << /ProcSet [/PDF /Text ] /Font << /F2 5 0 R /F3 6 0 R /F5 8 0 R /F6 9 0 R /F16 45 0 R >> /ExtGState << /GS2 11 0 R >> >> endobj 47 0 obj << /Length 18020 >> stream BT /F6 1 Tf 8.966 0 0 8.966 80.844 772.157 Tm 0 g /GS2 gs 0 Tc [(Boerbooms)-604.6(AMT)76.3(,)-603.6(van)-605.3(de)-599.4(Putte)-607.6(LBA.)-600.9(Methotrexate-)]TJ 0 -1.1191 TD [(related)-342.9(pulmonary)-341.8(complications)-346.7(in)-342.8(rheumatoid)-349.8(arthritis.)]TJ /F3 1 Tf 0 -1.1128 TD [(Ann)-330.8(Rheum)-332.8(Dis)]TJ /F6 1 Tf 6.7339 0 TD [(1994;)-334.9(53:)-329.6(434\261439.)]TJ -9.2504 -1.1128 TD [(8.)-1766.5(Clarysse)-227.2(AM,)-227.2(Cathey)-231.2(WJ,)-230(Cartwright)-233(GE,)-230(W)32.8(introbe)-229.6(MM.)]TJ 2.5165 -1.1128 TD [(Pulmonary)-226.6(disease)-228.1(complicating)-225.9(intermittent)-231.9(therapy)-227(with)]TJ 0 -1.1192 TD (methotrexate.)Tj /F3 1 Tf 5.7349 0 TD (JAMA)Tj /F6 1 Tf 2.8011 0 TD [(1969;)-334.9(209:)-335.5(1861\2611864.)]TJ -11.0524 -1.1128 TD [(9.)-1766.5(Alarcon)-261.9(GS,)-263(Kremer)-269.1(JM,)-263(Macaluso)-265.1(M,)]TJ /F3 1 Tf 18.3175 0 TD [(et)-266.7(al)]TJ /F6 1 Tf 1.7388 0 TD [(.)-268.5(Risk)-259.2(factors)]TJ -17.5398 -1.1128 TD [(for)-177.4(methotrexate-induced)-178.8(lung)-177.4(injury)-179.7(in)-172.1(patients)-180.9(with)-176.8(rheu-)]TJ 0 -1.1192 TD [(matoid)-212(arthritis.)-213.1(A)-211.5(multicenter)25.5(,)-211.6(case-control)-215.8(study)62.2(.)-205.2(Metho-)]TJ 0 -1.1128 TD [(trexate-Lung)-395.4(Study)-403.1(Group.)]TJ /F3 1 Tf 11.4065 0 TD [(Ann)-394(Intern)-399.6(Med)]TJ /F6 1 Tf 6.9742 0 TD [(1997;)-398.2(127:)]TJ -18.3807 -1.1192 TD (356\261364.)Tj -2.5165 -1.1065 TD [(10.)-1266.5(Sostman)-518.7(HD,)-527(Matthay)-526.2(RA,)-522(Putman)-524.4(CE,)-522.2(Smith)-521.2(GJW)80(.)]TJ 2.5165 -1.1192 TD [(Methotrexate)-286.3(pneumonitis.)]TJ /F3 1 Tf 10.9955 0 TD (Medicine)Tj /F6 1 Tf 3.9581 0 TD [(1976;)-290.7(55:)-285.4(371\261388.)]TJ -17.4702 -1.1128 TD [(1)32.1(1)0(.)-1298.6(Cooper)-236.3(JAD,)-243.1(White)-241.5(DA,)-242.4(Matthay)-241.7(RA.)-237.5(Drug-induced)-247.6(pul-)]TJ 2.5165 -1.1128 TD [(monary)-322(disease.)-325.9(Part)-328.5(1.)-324.9(Cytotoxic)-323.2(drugs.)]TJ /F3 1 Tf 16.7873 0 TD [(Am)-321.9(Rev)-324(Respir)]TJ -16.7873 -1.1192 TD (Dis)Tj /F6 1 Tf 1.7072 0 TD [(1986;)-328.6(133:)-335.5(321\261340.)]TJ -4.2237 -1.1065 TD [(12.)-1266.5(Goodman)-355.5(T)72.9(A)0(,)-359.8(Polisson)-355.7(RP)98.9(.)-357(Methotrexate:)-364(adverse)-358.3(reac-)]TJ 2.5165 -1.1192 TD [(tions)-471.3(and)-478.8(major)-476.7(toxicities.)]TJ /F3 1 Tf 11.4255 0 TD [(Rheum)-478.2(Dis)-479.6(Clin)-475.3(North)-473.6(Am)]TJ /F6 1 Tf -11.4255 -1.1128 TD [(1994;)-328.6(20:)-336(513\261528.)]TJ -2.5165 -1.1128 TD [(13.)-1266.5(Cannon)-469.3(GW)80.6(.)-470.8(Methotrexate)-476(pulmonary)-468.3(toxicity)58(.)]TJ /F3 1 Tf 22.5728 0 TD (Rheum)Tj -20.0563 -1.1192 TD [(Dis)-334.1(Clin)-329.9(North)-334.5(Am)]TJ /F6 1 Tf 8.0554 0 TD [(1997;)-334.9(23:)-336(917\261937.)]TJ -10.5719 -1.1065 TD [(14.)-1266.5(Carson)-212.2(CW)79.2(,)-211.6(Cannon)-216.4(GW)80.6(,)-217.9(Egger)-216.7(MJ,)-212.4(W)70.8(ard)-214.2(JR,)-216.4(Clegg)-219.3(DO.)]TJ 2.5165 -1.1191 TD [(Pulmonary)-460.6(disease)-462.1(during)-461.9(the)-462.2(treatment)-466.3(of)-455.2(rheumatoid)]TJ 0 -1.1128 TD [(arthritis)-387.2(with)-385.4(low)-383.5(dose)-384.6(pulse)-386.5(methotrexate.)]TJ /F3 1 Tf 17.9255 0 TD [(Semin)-382.3(Arth-)]TJ -17.9255 -1.1192 TD [(ritis)-335.8(Rheum)]TJ /F6 1 Tf 5.0077 0 TD [(1987;)-328.6(16:)-336(186\261195.)]TJ -7.5243 -1.1128 TD [(15.)-1266.5(Searles)-296.1(G,)-302.9(McKendry)-297.6(RJR.)-302.8(Methotrexate)-305.3(pneumonitis)-301.5(in)]TJ 2.5165 -1.1128 TD [(rheumatoid)-590.1(arthritis:)-597.7(potential)-598.8(risk)-596.9(factors.)-592.4(Four)-591.9(case)]TJ 0 -1.1192 TD [(reports)-298.9(and)-301.8(a)-296.5(review)-300.3(of)-303.5(the)-297.8(literature.)]TJ /F3 1 Tf 15.2129 0 TD [(J)-296.5(Rheumatol)]TJ /F6 1 Tf 5.3365 0 TD (1987;)Tj -20.5495 -1.1128 TD [(14:)-329.6(1)32.1(164\2611)27.8(171.)]TJ -2.5165 -1.1128 TD [(16.)-1266.5(Golden)-647.3(MR,)-652.2(Katz)-654.5(RS,)-650.1(Balk)-656.1(RA,)-648.5(Golden)-653.7(HE.)-653.6(The)]TJ 2.5165 -1.1128 TD [(relationship)-365.5(of)-360.4(pre-existing)-370.4(lung)-367.1(disease)-360.9(to)-368.1(the)-361(develop-)]TJ 0 -1.1192 TD [(ment)-324.5(of)-322.4(methotrexate)-331.7(pneumonitis)-326.8(in)-323.8(patients)-332.6(with)-322.2(rheu-)]TJ T* [(matoid)-332.2(arthritis.)]TJ /F3 1 Tf 6.7149 0 TD [(J)-334.4(Rheumatol)]TJ /F6 1 Tf 5.4061 0 TD [(1995;)-328.6(22:)-336(1043\2611047.)]TJ -14.6375 -1.1065 TD [(17.)-1266.5(Goldman)-307.3(GC,)-313.4(Moschella)-311.2(SL.)-307.5(Severe)-312(pneumonitis)-314.2(occur-)]TJ 2.5165 -1.1192 TD [(ring)-425(during)-423.9(methotrexate)-432.9(therapy)57.6(.)-420.2(Report)-428.4(of)-429.9(two)-427.8(cases.)]TJ /F3 1 Tf 0 -1.1128 TD [(Ar)34.3(ch)-333.9(Derm)]TJ /F6 1 Tf 4.8181 0 TD [(1971;)-334.9(103:)-329.1(194\261197.)]TJ -7.3346 -1.1128 TD [(18.)-1266.5(Everts)-257.7(CS,)-258.1(W)70.8(estcott)-257.2(JL,)-259.5(Bragg)-255.8(DG.)-261.4(Methotrexate)-261(therapy)]TJ 2.5165 -1.1192 TD [(and)-327(pulmonary)-335.5(disease.)]TJ /F3 1 Tf 9.8384 0 TD (Radiology)Tj /F6 1 Tf 4.4134 0 TD [(1973;)-334.9(107:)-335.5(539\261543.)]TJ -16.7684 -1.1065 TD [(19.)-1266.5(Lisbona)-382.6(A,)-378.7(Schwarts)-387.6(J,)-376.6(Lachance)-384(C,)-386.5(Frank)-382.5(H,)-378.7(Palayew)]TJ 2.5165 -1.1192 TD [(MJ.)-674(Methotrexateinduced)-676.7(pulmonary)-677(disease.)]TJ /F3 1 Tf 20.0373 0 TD [(J)-675.8(Can)]TJ -20.0373 -1.1128 TD [(Assoc)-331.9(Radiol)]TJ /F6 1 Tf 5.6211 0 TD [(1973;)-334.9(24:)-329.7(215\261220.)]TJ -8.1376 -1.1128 TD [(20.)-1266.5(Cannon)-254.3(GW)80.6(,)-255.8(W)70.8(ard)-252.1(JR,)-260.7(Clegg)-257.2(DO,)-255.1(Samuelson)-264.6(CO.)-256.5(Acute)]TJ 2.5165 -1.1192 TD [(lung)-246.9(disease)-247.1(associated)-254.1(with)-252.6(low-dose)-250.1(pulse)-247.4(methotrexate)]TJ 0 -1.1128 TD [(therapy)-517.8(in)-513.5(patients)-516(with)-518.2(rheumatoid)-520.5(arthritis.)]TJ /F3 1 Tf 19.4746 0 TD (Arthritis)Tj -19.4746 -1.1192 TD (Rheum)Tj /F6 1 Tf 3.0919 0 TD [(1983;)-328.6(26:)-336(1269\2611274.)]TJ -5.6084 -1.1065 TD [(21.)-1266.5(Engelbrecht)-382.3(JA,)-379.4(Calhoon)-382.7(SL,)-377(Scherrer)-388.7(JJ.)-377.3(Methotrexate)]TJ 2.5165 -1.1191 TD [(pneumonitis)-775.8(after)-772.7(low-dose)-774.9(therapy)-777.1(for)-771.8(rheumatoid)]TJ 0 -1.1128 TD (arthritis.)Tj /F3 1 Tf 3.6293 0 TD [(Arthritis)-340.8(Rheum)]TJ /F6 1 Tf 6.7718 0 TD [(1983;)-334.9(26:)-329.6(1275\2611278.)]TJ -12.9177 -1.1128 TD [(22.)-1266.5(Robbins)-289.2(KM,)-290.4(Gribetz)-295.9(I,)-294.2(Strauss)-297.7(L,)-290.4(Leonidas)-293.4(JC,)-292.3(Sanders)]TJ 2.5165 -1.1192 TD [(M.)-616.4(Pneumonitis)-616.3(in)-614.7(acute)-618.8(lymphatic)-623.6(leukemia)-615.2(during)]TJ 0 -1.1128 TD [(methotrexate)-338.1(therapy)63.9(.)]TJ /F3 1 Tf 8.9722 0 TD [(J)-334.4(Pediatrics)]TJ /F6 1 Tf 5.1658 0 TD [(1973;)-334.9(82:)-336(84\26188.)]TJ -16.6545 -1.1128 TD [(23.)-1266.5(St)-682.8(Clair)-690.5(EW)80.4(,)-685.8(Rice)-693.8(JR,)-684.3(Snyderman)-691.9(R.)-683.7(Pneumonitis)]TJ 2.5165 -1.1128 TD [(complicating)-611.6(low-dose)-610.5(methotrexate)-610(therapy)-612.7(in)-608.4(rheu-)]TJ 0 -1.1192 TD [(matoid)-268.9(arthritis.)]TJ /F3 1 Tf 6.5948 0 TD [(Ar)34.3(ch)-277(Intern)-273.2(Med)]TJ /F6 1 Tf 6.8857 0 TD [(1985;)-271.7(145:)-278.6(2035\2612038.)]TJ -15.997 -1.1128 TD [(24.)-1266.5(Case)-585.1(records)-587.1(of)-588(the)-582.3(Massachusetts)-590.7(General)-590.4(Hospital.)]TJ 2.5165 -1.1128 TD [(W)77.1(eekly)-429.4(clinicopathological)-435.8(exercises.)-433.1(Case)-433.4(37-1990.)-430.3(A)]TJ 0 -1.1192 TD [(28-year-ol)12.9(d)-252.4(man)-246.7(with)-246.3(increasing)-254.1(dyspnea,)-246.7(dry)-246(cough,)-246.7(and)]TJ 0 -1.1128 TD [(fever)-378.3(after)-374.4(chemotherapy)-383.9(for)-373.5(lymphoma.)]TJ /F3 1 Tf 16.9517 0 TD [(N)-377.3(Engl)-376.9(J)-372.3(Med)]TJ /F6 1 Tf -16.9517 -1.1192 TD [(1990;)-328.6(323:)-335.5(737\261747.)]TJ -2.5165 -1.1065 TD [(25.)-1266.5(Case)-585.1(records)-587.1(of)-588(the)-582.3(Massachusetts)-590.7(General)-590.4(Hospital.)]TJ 2.5165 -1.1191 TD [(W)77.1(eekly)-334.5(clinicopathological)-341(exercises.)-338.2(Case)-338.5(6-1985.)-329.6(Pro-)]TJ 0 -1.1128 TD [(gressive)-753.6(pneumonitis)-756.8(after)-760.1(chemotherapy)-756.9(for)-752.8(breast)]TJ 0 -1.1192 TD (carcinoma.)Tj /F3 1 Tf 4.6916 0 TD [(N)-333(Engl)-338.9(J)-328.1(Med)]TJ /F6 1 Tf 6.07 0 TD [(1985;)-334.9(312:)-335.5(359\261369.)]TJ -13.2781 -1.1128 TD [(26.)-1266.5(Elsasser)-328.3(S,)-323.5(Dalquen)-330.5(P)109.4(,)-325.4(Soler)-327.9(M,)-325.6(Perruchoud)-330.1(AP)106.6(.)-325.4(Metho-)]TJ 2.5165 -1.1128 TD [(trexate-induced)-227.9(pneumonitis:)-233.9(appearance)-228.4(four)-227.5(weeks)-229.1(after)]TJ 0 -1.1192 TD [(discontinuation)-416(of)-410.9(treatment.)]TJ /F3 1 Tf 12.14 0 TD [(Am)-410.4(Rev)-412.5(Respir)-416(Dis)]TJ /F6 1 Tf 8.4095 0 TD (1989;)Tj -20.5495 -1.1128 TD [(140:)-329.1(1089\2611092.)]TJ 25.4813 73.5671 TD [(27.)-1266.5(van)-289.1(der)-296.4(V)104.7(een)-295.2(MJ,)-288.3(Dekker)-297.9(JJ,)-288.8(Dinant)-295.6(HJ,)-290.9(van)-295.4(Soesberge)10.9(n)]TJ 2.5165 -1.1191 TD [(RM,)-266.5(Bijlsma)-270.4(JWJ.)-268.6(Fatal)-265.9(pulmonary)-266(fibrosis)-270.6(complicating)]TJ 0 -1.1128 TD [(low)-282.4(dose)-289.8(methotrexate)-287.5(therapy)-283.9(for)-291.3(rheumatoid)-286.6(arthritis.)]TJ /F3 1 Tf 22.3831 0 TD 0 Tw (J)Tj -22.3831 -1.1192 TD (Rheumatol)Tj /F6 1 Tf 4.6347 0 TD [(1995;)-334.9(22:)-329.7(1766\2611768.)]TJ -7.1512 -1.1065 TD [(28.)-1266.5(Mulherin)-318.3(D,)-315.5(Cummiskey)-323.4(JM,)-319.9(Doyle)-319.1(GD,)-318.3(FirtzGerald)-320.8(O.)]TJ 2.5165 -1.1192 TD [(Methotrexate)-564.5(pneumonitis)-567.1(in)-564.1(rheumatoid)-564.8(arthritis)-570.6(\261)-562.2(a)]TJ 0 -1.1128 TD [(dramatic)-243.1(response)-239.1(to)-235.3(treatment.)]TJ /F3 1 Tf 12.6016 0 TD [(Br)-237.6(J)-239.6(Rheumatol)]TJ /F6 1 Tf 6.4431 0 TD [(1992;)-233.8(31:)]TJ -19.0446 -1.1192 TD (356\261357.)Tj -2.5165 -1.1128 TD [(29.)-1266.5(Kerstens)-333.3(PJSM,)-335(van)-333.4(Loenhout)-330.3(JW)101.7(A,)-334.5(van)-327.1(de)-333.9(Putte)-335.7(LBA.)]TJ 2.5165 -1.1128 TD [(Methotrexate,)-523.1(pneumonitis,)-519.4(and)-516.7(infection.)]TJ /F3 1 Tf 17.9381 0 TD [(Ann)-520.5(Rheum)]TJ -17.9381 -1.1192 TD (Dis)Tj /F6 1 Tf 1.7072 0 TD [(1992;)-334.9(51:)-329.6(1)32.1(179\2611)27.8(180.)]TJ -4.2237 -1.1065 TD [(30.)-1266.5(Rohatgi)-543.1(PK,)-547.5(Halvarson)-546.6(L.)-543.3(Unilateral)-551.8(methotrexate-in-)]TJ 2.5165 -1.1192 TD [(duced)-256.2(pneumonitis.)]TJ /F3 1 Tf 8.0427 0 TD [(J)-258.5(Nat)-258.5(Med)-258(Assoc)]TJ /F6 1 Tf 6.9742 0 TD [(1980;)-259.1(72:)-253.8(896\261899.)]TJ -17.5334 -1.1128 TD [(31.)-1266.5(Gispen)-168(JG,)-170.8(Alarcon)-173.3(GS,)-168.2(Johnson)-169.5(JJ,)-168.7(Acton)-173.6(R)52.7(T)72.9(,)-167.3(Barger)-161.2(BO,)]TJ 2.5165 -1.1128 TD [(Koopman)-469.3(WJ.)-470.2(T)60.2(oxicity)-471.3(to)-475.6(methotrexate)-470.9(in)-475.6(rheumatoid)]TJ 0 -1.1192 TD (arthritis.)Tj /F3 1 Tf 3.6357 0 TD [(J)-334.4(Rheumatol)]TJ /F6 1 Tf 5.3998 0 TD [(1987;)-334.9(14:)-336(74\26179.)]TJ -11.552 -1.1065 TD [(32.)-1266.5(Ridley)-486.7(MG,)-480.1(W)70.8(olfe)-488(CS,)-485.7(Mathews)-484.1(JA.)-486.9(Life)-485.1(threatening)]TJ 2.5165 -1.1192 TD [(acute)-454.4(pneumonitis)-453.3(during)-455.5(low)-446.8(dose)-454.2(methotrexate)-458.2(treat-)]TJ 0 -1.1128 TD [(ment)-273.9(for)-266(rheumatoid)-273.9(arthritis:)-275.3(a)-271.2(case)-270.4(report)-272.9(and)-270.1(review)-275(of)]TJ 0 -1.1191 TD [(the)-335.8(literature.)]TJ /F3 1 Tf 5.6653 0 TD [(Ann)-330.8(Rheum)-332.8(Dis)]TJ /F6 1 Tf 6.7339 0 TD [(1988;)-334.9(47:)-336(784\261788.)]TJ -14.9157 -1.1128 TD [(33.)-1266.5(Newman)-365.4(ED,)-369.1(Harrington)-371.4(TM.)-366.5(Fatal)-367.1(methotrexate)-376(pneu-)]TJ 2.5165 -1.1128 TD [(monitis)-234.3(in)-235.3(rheumatoid)-236(arthritis.)]TJ /F3 1 Tf 12.4814 0 TD [(Arthritis)-233.3(Rheum)]TJ /F6 1 Tf 6.5632 0 TD [(1988;)-233.8(31:)]TJ -19.0446 -1.1192 TD (1585\2611586.)Tj -2.5165 -1.1065 TD [(34.)-1266.5(Green)-368(L,)-372.6(Schattner)-372.1(A,)-372.4(Berkenstadt)-372.1(H.)-366.1(Severe)-375.2(reversible)]TJ 2.5165 -1.1192 TD [(interstitial)-619.3(pneumonitis)-617.7(induced)-611.7(by)-612.3(low)-617.5(dose)-612.3(metho-)]TJ 0 -1.1128 TD [(trexate:)-420.7(report)-418.3(of)-423.6(a)-416.6(case)-415.8(and)-421.9(review)-420.5(of)-417.3(the)-418(literature.)]TJ /F3 1 Tf 22.3831 0 TD (J)Tj -22.3831 -1.1191 TD (Rheumatol)Tj /F6 1 Tf 4.6347 0 TD [(1988;)-334.9(15:)-329.7(1)32.1(10\2611)27.3(12.)]TJ -7.1512 -1.1128 TD [(35.)-1266.5(Hand)-690.2(SH,)-693(Smith)-698.2(JK,)-695.6(Chaudhary)-689.8(BA.)-692.8(Methotrexate)]TJ 2.5165 -1.1128 TD [(pneumonitis:)-518.4(a)-511.4(case)-517(report)-519.5(and)-516.7(summary)-514.3(of)-512.1(the)-519.1(liter-)]TJ 0 -1.1192 TD (ature.)Tj /F3 1 Tf 2.5481 0 TD [(J)-334.4(Med)-333.8(Assoc)-338.2(Ga)]TJ /F6 1 Tf 7.0627 0 TD [(1989;)-334.9(78:)-329.7(625\261628.)]TJ -12.1273 -1.1065 TD [(36.)-1266.5(Schwartz)-531.6(GF)75(.)-527.7(Methotrexate)-532.9(induced)-529.5(pneumonitis)-529.2(in)-532.5(a)]TJ 2.5165 -1.1192 TD [(young)-357.9(woman)-356.5(with)-353.8(psoriasis)-358.6(and)-358.7(rheumatoid)-356.1(arthritis.)]TJ /F3 1 Tf 22.3831 0 TD (J)Tj -22.3831 -1.1192 TD (Rheumatol)Tj /F6 1 Tf 4.6347 0 TD [(1990;)-334.9(17:)-329.7(980.)]TJ -7.1512 -1.1065 TD [(37.)-1266.5(Pourel)-397(J,)-389.3(Guillemin)-401.9(F)71.5(,)-388.6(Fener)-394.9(P)103.1(,)-394.9(W)70.8(ebanck)-394.6(L,)-391.6(Bene)-394.2(MC,)]TJ 2.5165 -1.1192 TD [(Delorme)-364.9(N.)-366.1(Delayed)-361.8(methotrexate)-369.7(pneumonitis)-364.8(in)-368.1(rheu-)]TJ 0 -1.1128 TD [(matoid)-332.2(arthritis.)]TJ /F3 1 Tf 6.7149 0 TD [(J)-334.4(Rheumatol)]TJ /F6 1 Tf 5.4061 0 TD [(1991;)-334.9(18:)-329.7(303\261304.)]TJ -14.6375 -1.1128 TD [(38.)-1266.5(Leduc)-715(D,)-720.2(de)-713.3(V)47.8(uyst)-716(P)103.1(,)-711.1(Lheureux)-720.7(P)103.1(,)-711.1(Gevenois)-723.1(P)84.1(A)0(,)]TJ 2.5165 -1.1192 TD [(Jacobovitz)-581.9(D,)-574.8(Y)92(ernault)-577.1(IC.)-583(Pneumonitis)-578.3(complicating)]TJ 0 -1.1128 TD [(low-dose)-420.8(methotrexate)-426.6(therapy)-423(for)-424(rheumatoid)-425.7(arthritis.)]TJ 0 -1.1192 TD [(Discrepancies)-338.8(between)-336.5(lung)-341.8(biopsy)-335.6(and)-333.4(bronchoalveolar)]TJ 0 -1.1128 TD [(lavage)-333.8(findings.)]TJ /F3 1 Tf 6.7465 0 TD (Chest)Tj /F6 1 Tf 2.5924 0 TD [(1993;)-334.9(104:)-335.5(1620\2611623.)]TJ -11.8555 -1.1128 TD [(39.)-1266.5(T)60.2(sai)-551.9(JJ,)-560.7(Shin)-555.4(JF)70.8(,)-553(Chen)-558.9(CH,)-553.7(W)70.8(ang)-554.7(SR.)-561.6(Methotrexate)]TJ 2.5165 -1.1128 TD [(pneumoitis)-213.5(in)-203.7(bronchial)-215.7(asthma.)]TJ /F3 1 Tf 12.7976 0 TD [(Int)-210.5(Ar)27.9(ch)-207.4(Aller)31.3(gy)-213.8(Immunol)]TJ /F6 1 Tf -12.7976 -1.1192 TD [(1993;)-334.9(100:)-329.1(287\261290.)]TJ -2.5165 -1.1128 TD [(40.)-1266.5(Sharma)-497.4(A,)-498.9(Provenzale)-501.8(D,)-498.9(McKusick)-496.2(A,)-498.9(Kaplan)-495.4(MM.)]TJ 2.5165 -1.1128 TD [(Interstitial)-301.7(pneumonitis)-295.2(after)-292.2(low-dose)-294.4(methotrexate)-300.1(ther)11.6(-)]TJ 0 -1.1192 TD [(apy)-346(in)-342.8(primary)-343.8(biliary)-352.1(cirrhosis.)]TJ /F3 1 Tf 13.2718 0 TD [(Gastr)32.4(oenter)31.5(ology)]TJ /F6 1 Tf 7.2777 0 TD (1994;)Tj -20.5495 -1.1128 TD [(107:)-335.5(266\261270.)]TJ -2.5165 -1.1128 TD [(41.)-1266.5(Clearkin)-252.5(R,)-247.4(Corris)-253.8(P)84.1(A)0(,)-246(Thomas)-249.9(SHL.)-253.3(Methotrexate)-254.7(pneu-)]TJ 2.5165 -1.1128 TD [(monitis)-392.4(in)-393.4(a)-391.3(patient)-395.1(with)-391.7(rheumatoid)-394.1(arthritis.)]TJ /F3 1 Tf 19.1774 0 TD (Postgrad)Tj -19.1774 -1.1192 TD [(Med)-333.8(J)]TJ /F6 1 Tf 2.8643 0 TD [(1997;)-334.9(73:)-329.7(603\261604.)]TJ -5.3808 -1.1128 TD [(42.)-1266.5(Arnett)-321.9(FC,)-321.3(Whelton)-316.4(JC,)-323.9(Zizic)-321.4(TM,)-315.9(Stevens)-320.6(MB.)-323.4(Metho-)]TJ 2.5165 -1.1128 TD [(trexate)-222.8(therapy)-220.6(in)-216.4(polymyositis.)]TJ /F3 1 Tf 12.6648 0 TD [(Ann)-216.9(Rheum)-219(Dis)]TJ /F6 1 Tf 6.3925 0 TD [(1973;)-221.1(32:)]TJ -19.0573 -1.1192 TD (536\261546.)Tj -2.5165 -1.1065 TD [(43.)-1266.5(R)]TJ 7.173 0 0 7.173 337.833 232.498 Tm (aw)Tj 8.966 0 0 8.966 346.167 232.498 Tm [(bone)-497.2(RG,)-503.1(Shaw)-505.5(MT)72.7(,)-502.4(Jackson)-504.2(JG,)-499.6(Bagshawe)-503.9(KD.)]TJ -1.5934 -1.1192 TD [(Complication)-534.3(of)-531.1(methotrexate-maintained)-537.8(remission)-530(in)]TJ 0 -1.1128 TD [(lymphoblastic)-334.3(leukemia.)]TJ /F3 1 Tf 10.1546 0 TD (BMJ)Tj /F6 1 Tf 2.194 0 TD [(1971;)-334.9(4:)-336.5(467\261468.)]TJ -14.8652 -1.1128 TD [(44.)-1266.5(Lascari)-617.1(AD,)-621.8(Strano)-618.3(AJ,)-619.7(Johnson)-618.5(WW)84.7(,)-616.2(Collins)-622.8(JGP)105.9(.)]TJ 2.5165 -1.1192 TD [(Methotrexate-induced)-455.8(sudden)-446.8(fatal)-451.7(pulmonary)-449.3(reaction.)]TJ /F3 1 Tf 0 -1.1128 TD (Cancer)Tj /F6 1 Tf 3.2563 0 TD [(1977;)-334.9(40:)-336(1393\2611397.)]TJ -5.7728 -1.1128 TD [(45.)-1266.5(Bedrossian)-314.7(CWM,)-315.9(Miller)-315.3(WC,)-315.7(Luna)-311.1(MA.)-315.7(Methotrexate-)]TJ 2.5165 -1.1128 TD [(induced)-238.6(diff)10.4(use)-239.7(interstitial)-246.2(pulmonary)-240.7(fibrosis.)]TJ /F3 1 Tf 18.5514 0 TD [(South)-240.1(Med)]TJ -18.5514 -1.1192 TD (J)Tj /F6 1 Tf 0.7714 0 TD [(1979;)-334.9(72:)-329.7(313\261318.)]TJ -3.2879 -1.1128 TD [(46.)-1266.5(Gutin)-403.9(PH,)-408.4(Green)-405.9(MR,)-405.6(Bleyer)-409.2(W)102.4(A)0(,)-404(Bauer)-407.3(VL,)-407(W)32.8(iernik)]TJ 2.5165 -1.1128 TD [(PH,)-383.1(W)70.8(alker)-379.7(MD.)-385.2(Methotrexate)-387.5(pneumonitis)-383.8(induced)-384(by)]TJ 0 -1.1192 TD [(intrathecal)-237.9(methotrexate)-236.9(therapy)63.9(.)]TJ /F3 1 Tf 13.158 0 TD (Cancer)Tj /F6 1 Tf 3.1615 0 TD [(1976;)-227.5(38:)-234.8(1529\261)]TJ -16.3194 -1.1128 TD (1534.)Tj -30.5144 76.3934 TD (380)Tj 7.472 0 0 7.472 262.431 797.499 Tm 0.0001 Tc [(S.)-328.4(IMO)-9.6(K)0(A)70.4(W)102.5(A)-329(E)0(T)-263.8(AL.)]TJ ET endstream endobj 48 0 obj << /ProcSet [/PDF /Text ] /Font << /F3 6 0 R /F6 9 0 R >> /ExtGState << /GS2 11 0 R >> >> endobj 50 0 obj << /Length 17396 >> stream BT /F6 1 Tf 8.966 0 0 8.966 58.28 772.157 Tm 0 g /GS2 gs 0 Tc [(47.)-1266.5(Bernstein)-354.4(ML,)-353.8(Sobel)-352.3(DB,)-351.3(W)26.5(immer)-352.1(RS.)-352.9(Noncardiogenic)]TJ 2.5165 -1.1128 TD [(pulmonary)-531.5(edema)-529.8(following)-531.6(injection)-529.3(of)-531.1(methotrexate)]TJ T* [(into)-331.5(the)-335.8(cerebrospinal)-335.5(fluid.)]TJ /F3 1 Tf 11.514 0 TD (Cancer)Tj /F6 1 Tf 3.2626 0 TD [(1982;)-328.6(50:)-336(866\261868.)]TJ -17.2932 -1.1065 TD [(48.)-1266.5(Laosombat)-307.4(V)123.6(,)-312.7(Mitarnun)-311.9(W)83.4(,)-306.4(Mo-suwan)-311.6(L,)-309.4(W)70.8(acharasin)-315.2(R.)]TJ 2.5165 -1.1128 TD [(Methotrexate-induced)-379.9(severe)-384.1(pneumonitis.)]TJ /F3 1 Tf 17.5461 0 TD [(J)-385(Med)-378.1(Assoc)]TJ -17.5461 -1.1128 TD (Thai)Tj /F6 1 Tf 2.1498 0 TD [(1982;)-334.9(65:)-336(61)32.6(1\261617.)]TJ -4.6663 -1.1065 TD [(49.)-1266.5(Hilliquin)-282.5(P)103.1(,)-287.4(Renoux)-279.6(M,)-287.6(Perrot)-284.1(S,)-285.5(Puechal)-281.2(X,)-283.9(Menkes)-289.2(CJ.)]TJ 2.5165 -1.1128 TD [(Occurrence)-441.6(of)-442.6(pulmonary)-436.7(complications)-447.9(during)-442.9(metho-)]TJ T* [(trexate)-267(therapy)-271.2(in)-266.9(rheumatoid)-267.6(arthritis.)]TJ /F3 1 Tf 15.5607 0 TD [(Br)-262.9(J)-271.2(Rheum)]TJ /F6 1 Tf 4.9888 0 TD (1996;)Tj -20.5495 -1.1128 TD [(35:)-329.6(441\261445.)]TJ -2.5165 -1.1065 TD [(50.)-1266.5(V)104.7(erdich)-600.5(J,)-604.3(Christensen)-607.4(AL.)-603(Pulmonary)-606(disease)-601.2(com-)]TJ 2.5165 -1.1128 TD [(plicating)-421.8(intermittent)-434.2(methotrexate)-426.6(therapy)-423(of)-423.6(psoriasis.)]TJ /F3 1 Tf T* [(Acta)-332.4(Derm)-334.3(V)104.5(ener)32.9(eol)-335.7(Suppl)-334.9(\(Stockh\))]TJ /F6 1 Tf 14.7324 0 TD [(1979;)-334.9(59:)-329.7(471\261473.)]TJ -17.2489 -1.1128 TD [(51.)-1266.5(Robertson)-320.6(JH.)-328.8(Pneumonia)-320.3(and)-327.1(methotrexate.)]TJ /F3 1 Tf 20.8783 0 TD (BMJ)Tj /F6 1 Tf 2.1877 0 TD (1970;)Tj -20.5495 -1.1065 TD [(2:)-330.2(156.)]TJ -2.5165 -1.1128 TD [(52.)-1266.5(Filip)-401.5(DJ,)-411(Logue)-405.4(GL,)-400.7(Harle)-408.3(TS,)-408.6(Farrar)-409(WH.)-402.8(Pulmonary)]TJ 2.5165 -1.1128 TD [(and)-529.4(hepatic)-538(complications)-542.7(of)-537.4(methotrexate)-534.1(therapy)-543.1(of)]TJ T* (psoriasis.)Tj /F3 1 Tf 4.0403 0 TD (JAMA)Tj /F6 1 Tf 2.801 0 TD [(1971;)-328.6(216:)-335.5(881\261882.)]TJ -9.3579 -1.1065 TD [(53.)-1266.5(Pasquinucci)-561(G,)-568.4(Ferrara)-566.3(P)103.1(,)-565.7(Castellari)-567(R.)-569.9(Daunorubicin)]TJ 2.5165 -1.1128 TD [(treatment)-327.2(of)-322.4(methotrexate)-331.7(pneumonia.)]TJ /F3 1 Tf 15.6555 0 TD (JAMA)Tj /F6 1 Tf 2.7947 0 TD [(1971;)-328.6(216:)]TJ -18.4503 -1.1128 TD (2017.)Tj -2.5165 -1.1065 TD [(54.)-1266.5(Whitcomb)-343(ME,)-341.2(Schwarz)-346.3(MI,)-338.7(T)60.2(ormey)-341.5(DC.)-345(Methotrexate)]TJ 2.5165 -1.1128 TD [(pneumonitis:)-524.7(case)-517(report)-525.8(and)-523.1(review)-521.6(of)-524.8(the)-519.1(literature.)]TJ /F3 1 Tf T* (Thorax)Tj /F6 1 Tf 3.2057 0 TD [(1972;)-334.9(27:)-329.7(636\261639.)]TJ -5.7222 -1.1128 TD [(55.)-1266.5(Phillips)-270.8(T)72.9(,)-268.5(Jones)-271.5(DH,)-267.7(Baker)-274.6(H.)-271.3(Pulmonary)-270.9(complications)]TJ 2.5165 -1.1065 TD [(following)-209.2(methotrexate)-217.9(therapy)57.6(.)]TJ /F3 1 Tf 12.7976 0 TD [(Acad)-209.9(Dermatol)]TJ /F6 1 Tf 6.266 0 TD [(1987;)-214.8(16:)]TJ -19.0636 -1.1128 TD (373\261375.)Tj -2.5165 -1.1128 TD [(56.)-1266.5(From)-416.7(E.)-423.2(Methotrexate)-425.4(pneumonitis)-421.7(in)-425(a)-416.6(psoriatic.)]TJ /F3 1 Tf 23.4833 0 TD [(Br)-421(J)]TJ -20.9668 -1.1128 TD (Dermatol)Tj /F6 1 Tf 4.1289 0 TD [(1975;)-334.9(93:)-336(107\2611)34.2(10.)]TJ -6.6454 -1.1065 TD [(57.)-1266.5(Louie)-243.4(S,)-247.6(Lillington)-250.6(GA.)-248.7(Low)-245.5(dose)-251.9(methotrexate)-249.5(pneumo-)]TJ 2.5165 -1.1128 TD [(nitis)-334.6(in)-330.2(rheumatoid)-337.2(arthritis.)]TJ /F3 1 Tf 11.6089 0 TD (Thorax)Tj /F6 1 Tf 3.2057 0 TD [(1986;)-334.9(41:)-336(703\261704.)]TJ -17.3311 -1.1128 TD [(58.)-1266.5(de)-479.3(Bandt)-491.2(M,)-483.6(Rat)-485.9(AC,)-484.1(Palazzo)-489.7(E,)-486.4(Kahn)-481.6(MF)71.3(.)-483.5(Delayed)]TJ 2.5165 -1.1065 TD [(methotrexate)-331.7(pneumonitis.)]TJ /F3 1 Tf 10.9703 0 TD [(J)-328.1(Rheumatol)]TJ /F6 1 Tf 5.3934 0 TD [(1991;)-334.9(18:)-329.7(1943.)]TJ -18.8802 -1.1128 TD [(59.)-1266.5(Harg)10.6(reaves)-365.1(MR,)-367.7(Mowat)-370.3(AG,)-368.9(Benson)-363(MK.)-366.3(Acute)-369.4(pneu-)]TJ 2.5165 -1.1128 TD [(monitis)-310.1(associated)-311(with)-309.5(low)-307.7(dose)-308.8(methotrexate)-312.8(treatment)]TJ T* [(for)-234.4(rheumatoid)-236(arthritis:)-243.7(report)-235(of)-227.6(five)-235(cases)-239.4(and)-232.2(review)-243.4(of)]TJ 0 -1.1065 TD [(published)-329.9(reports.)]TJ /F3 1 Tf 7.5179 0 TD (Thorax)Tj /F6 1 Tf 3.2057 0 TD [(1992;)-334.9(47:)-329.6(628\261633.)]TJ -13.2402 -1.1128 TD [(60.)-1266.5(Cook)-748.8(NJ,)-746.2(Carroll)-753.7(GJ.)-752.5(Successful)-757.3(reintroduction)-750(of)]TJ 2.5165 -1.1128 TD [(methotrexate-after)-719.2(pneumonitis)-712.5(in)-709.5(two)-712.3(patients)-712(with)]TJ T* [(rheumatoid)-280.3(arthritis.)]TJ /F3 1 Tf 8.3715 0 TD [(Ann)-286.5(Rheum)-282.2(Dis)]TJ /F6 1 Tf 6.5885 0 TD [(1992;)-284.4(51:)-285.4(272\261274.)]TJ -17.4765 -1.1065 TD [(61.)-1266.5(T)34.9(renkwalder)-292.7(P)109.4(,)-287.4(Eisenlohr)-290.1(H,)-283.9(Prechtel)-290.4(K,)-283.9(L)53.9(ydtin)-286.8(H.)-290.2(Three)]TJ 2.5165 -1.1128 TD [(cases)-435.4(of)-436.2(malignant)-440.3(neoplasm,)-433.8(pneumonitis,)-443.6(and)-434.5(pancy-)]TJ T* [(topenia)-557.2(during)-563(treatment)-561.1(with)-562.5(low-dose)-559.9(methotrexate.)]TJ /F3 1 Tf 0 -1.1065 TD [(Clin)-329.9(Investigator)]TJ /F6 1 Tf 7.1512 0 TD [(1992;)-334.9(70:)-329.6(951\261955.)]TJ -9.6677 -1.1128 TD [(62.)-1266.5(Schoenfeld)-413.5(A,)-410.4(Reuben)-412.2(M,)-414.1(V)104.7(ardy)-409.7(M,)-414.1(Ovadia)-413.2(J.)-408.3(Metho-)]TJ 2.5165 -1.1128 TD [(trexate)-412.5(pneumonitis)-409(in)-412.4(nonsurgical)-405.5(treatment)-409.4(of)-410.9(ectopic)]TJ T* [(pregnancy)61.2(.)]TJ /F3 1 Tf 4.6537 0 TD [(Obstet)-334.8(Gynecol)]TJ /F6 1 Tf 6.5505 0 TD [(1992;)-328.6(80:)-336(520\261521.)]TJ -13.7207 -1.1065 TD [(63.)-1266.5(Bolla)-240.7(G,)-239.6(Disdier)-246.7(P)103.1(,)-236.9(Harle)-243.9(JR,)-241.7(V)104.7(errot)-248.1(HD,)-242.4(W)77.1(eiller)-244.9(PJ.)-241.9(Con-)]TJ 2.5165 -1.1128 TD [(current)-423.9(acute)-429.1(megaloblastic)-428.7(anemia)-430.5(and)-428.2(pneumonitis:)-423.6(a)]TJ T* [(severe)-162.8(side-effect)-160.4(of)-170.7(low-dose)-167.9(methotrexate)-167.4(therapy)-170(during)]TJ T* [(rheumatoid)-286.6(arthritis.)]TJ /F3 1 Tf 8.3779 0 TD [(Clin)-285.7(Rheumatol)]TJ /F6 1 Tf 6.5822 0 TD [(1993;)-284.4(12:)-285.4(535\261537.)]TJ -17.4765 -1.1065 TD [(64.)-1266.5(Hassan)-489(W)83.4(,)-489.8(Carpenter)-496.9(M,)-489.9(Kelly)-498.5(C.)-487.7(Acute)-495.9(pneumonitis)]TJ 2.5165 -1.1128 TD [(associated)-614.5(with)-613(low)-611.2(dose)-612.3(methotrexate)-616.3(treatment)-611.7(for)]TJ T* [(rheumatoid)-330.8(arthritis.)]TJ /F3 1 Tf 8.4727 0 TD (Thorax)Tj /F6 1 Tf 3.2057 0 TD [(1993;)-334.9(48:)-336(191\261192.)]TJ -14.1949 -1.1128 TD [(65.)-1266.5(Cottin)-299.7(V)130(,)-300.1(T)60.2(ebib)-297.3(J,)-294.5(Massonnet)-303.9(B,)-298(Souquet)-294.3(PJ,)-298.8(Bernard)-299.8(JP)102.4(.)]TJ 2.5165 -1.1065 TD [(Pulmonary)-321.5(function)-323.9(in)-323.9(patients)-326.3(receiving)-329.3(long-term)-326.2(low-)]TJ 0 -1.1128 TD [(dose)-327.7(methotrexate.)]TJ /F3 1 Tf 7.891 0 TD (Chest)Tj /F6 1 Tf 2.5924 0 TD [(1996;)-334.9(109:)-335.5(933\261938.)]TJ -12.9999 -1.1128 TD [(66.)-1266.5(Alarcon)-495.8(GS,)-490.6(Koopman)-494.6(WJ.)-495.5(Nonperipheral)-502.2(accelerated)]TJ 2.5165 -1.1065 TD [(nodules)-556.2(in)-564.1(a)-562(methotrexate-treated)-567.6(rheumatoid)-564.8(arthritis)]TJ 0 -1.1128 TD (patient.)Tj /F3 1 Tf 3.2689 0 TD [(Arthritis)-334.5(Rheum)]TJ /F6 1 Tf 6.7655 0 TD [(1993;)-334.9(36:)-336(132\261133.)]TJ -12.551 -1.1128 TD [(67.)-1266.5(Cook)-420(NJ,)-417.4(Lake)-424.6(FR.)-416.2(Hypercalcaemia)-425.8(with)-423.3(methotrexate)]TJ 2.5165 -1.1128 TD [(pneumonitis,)-272.8(possible)-281.1(association)-275.1(with)-277.9(pulmonary)-278.6(granu-)]TJ 0 -1.1065 TD (lomata.)Tj /F3 1 Tf 3.2689 0 TD [(Aust)-333.8(N)-333(Z)-333.2(J)-334.4(Med)]TJ /F6 1 Tf 6.8414 0 TD [(1996;)-328.6(26:)-336(715.)]TJ -12.6269 -1.1128 TD [(68.)-1266.5(Ohosone)-721.5(Y)123.6(,)-730.1(Okano)-727.7(Y)123.6(,)-723.7(Kameda)-728.6(H,)]TJ /F3 1 Tf 19.0256 0 TD [(et)-728.3(al)]TJ /F6 1 Tf 2.2067 0 TD [(.)-723.7(Clinical)]TJ -18.7158 -1.1128 TD [(characteristics)-428.5(of)-423.6(patients)-427.4(with)-423.3(rheumatoid)-432(arthritis)-425.2(and)]TJ 27.9978 71.1138 TD [(methotrexate)-477.2(induced)-472.6(pneumonitis.)]TJ /F3 1 Tf 14.8715 0 TD [(J)-467.2(Rheumatol)]TJ /F6 1 Tf 5.678 0 TD (1997;)Tj -20.5495 -1.1381 TD [(24:)-336(2299\2612303.)]TJ -2.5165 -1.1065 TD [(69.)-1266.5(Salaffi)-330(F)71.5(,)-344.4(Manganelli)-343.5(P)109.4(,)-344.4(Carotti)-344.1(M,)-338.2(Subiaco)-338.4(S,)-342.4(Lamanna)]TJ 2.5165 -1.1381 TD [(G,)-707.5(Cervini)-714.8(C.)-715.3(Methotrexate-induced)-715.1(pneumonitis)-712.5(in)]TJ T* [(patients)-383.2(with)-379.1(rheumatoid)-381.4(arthritis)-387.2(and)-377.6(psoriatic)-383.6(arthritis:)]TJ 0 -1.1318 TD [(report)-487.9(of)-480.5(five)-488(cases)-492.4(and)-485.1(review)-490(of)-486.8(the)-487.5(literature.)]TJ /F3 1 Tf 21.1122 0 TD (Clin)Tj -21.1122 -1.1381 TD (Rheumatol)Tj /F6 1 Tf 4.6347 0 TD [(1997;)-334.9(16:)-329.7(296\261304.)]TJ -7.1512 -1.1128 TD [(70.)-1266.5(Horrigan)-616.6(TJ,)-619.9(Fanning)-616.8(J,)-616.9(Marcotte)-621.3(MP)102.9(.)-616.2(Methotrexate)]TJ 2.5165 -1.1318 TD [(pneumonitis)-478.6(after)-481.9(systemic)-478.7(treatment)-485.3(for)-480.9(ectopic)-481.1(preg-)]TJ 0 -1.1381 TD [(nancy)59.9(.)]TJ /F3 1 Tf 2.8959 0 TD [(Am)-334.6(J)-328.1(Obstet)-341.1(Gynecol)]TJ /F6 1 Tf 8.9722 0 TD [(1997;)-334.9(176:)-335.5(714\261715.)]TJ -14.3846 -1.1128 TD [(71.)-1266.5(Cron)-224.9(RQ,)-224.9(Sherry)-224.9(DD,)-229.8(W)77.1(allace)-228.4(CA.)-224.9(Methotrexate-induced)]TJ 2.5165 -1.1318 TD [(hypersensitivity)-582(pneumonitis)-579.8(in)-576.8(a)-574.7(child)-577.4(with)-581.4(juvenile)]TJ 0 -1.1381 TD [(rheumatoid)-337.2(arthritis.)]TJ /F3 1 Tf 8.479 0 TD [(J)-328.1(Pediatr)]TJ /F6 1 Tf 4.072 0 TD [(1998;)-328.6(132:)-335.5(901\261902.)]TJ -15.0675 -1.1128 TD [(72.)-1266.5(White)-266.8(DA,)-267.7(Rankin)-269.4(JA,)-265.6(Stover)-270.5(DE,)-267.9(Gellene)-269.4(RA,)-262.8(Gupta)-268.5(S.)]TJ 2.5165 -1.1318 TD [(Methotrexate)-324.2(pneumonitis.)-329.7(Bronchoalveolar)-325.3(lavage)-327.4(find-)]TJ 0 -1.1381 TD [(ings)-222.9(suggest)-222.3(an)-220.1(immunologic)-220(disorder)49.4(.)]TJ /F3 1 Tf 15.4026 0 TD [(Am)-220.8(Rev)-216.5(Respir)-226.3(Dis)]TJ /F6 1 Tf -15.4026 -1.1381 TD [(1989;)-334.9(139:)-329.1(18\26121.)]TJ -2.5165 -1.1065 TD [(73.)-1266.5(Schnabel)-350.3(A,)-347.1(Richter)-354.2(C,)-342.2(Bauerfeind)-357.3(S,)-342.4(Gross)-351.9(WL.)-346.1(Bron-)]TJ 2.5165 -1.1381 TD [(choalveolar)-422.8(lavage)-416(cell)-425.9(profile)-420.2(in)-418.7(methotrexate)-426.6(induced)]TJ T* (pneumonitis.)Tj /F3 1 Tf 5.4883 0 TD (Thorax)Tj /F6 1 Tf 3.2057 0 TD [(1997;)-334.9(52:)-336(377\261379.)]TJ -11.2105 -1.1065 TD [(74.)-1266.5(Akoun)-348.5(GM,)-347.3(Mayaud)-344.9(CM,)-348.7(T)66.6(ouboul)-347.1(JL,)-348(Denis)-351.9(M.)-344.5(Meth-)]TJ 2.5165 -1.1381 TD [(otrexate-induced)-366.5(pneumonitis:)-366.6(diagnostic)-369.5(value)-359.8(of)-366.7(bron-)]TJ T* [(choalveolar)-277.4(lavage)-276.9(cell)-280.5(data.)]TJ /F3 1 Tf 11.6089 0 TD [(Ar)34.3(ch)-277(Intern)-279.5(Med)]TJ /F6 1 Tf 6.8983 0 TD [(1986;)-271.7(146:)]TJ -18.5072 -1.1318 TD (804\261805.)Tj -2.5165 -1.1128 TD [(75.)-1266.5(Akoun)-215.7(GM,)-214.5(Mayaud)-218.5(CM,)-215.9(T)60.2(ouboul)-214.3(JL,)-221.5(Denis)-212.7(M,)-218.1(Milleron)]TJ 2.5165 -1.1381 TD [(BJ,)-286(Perrot)-284.1(JY)123(.)-281.1(Use)-287.3(of)-284.5(bronchoalveolar)-289(lavage)-283.2(in)-285.9(the)-285.2(eval-)]TJ 0 -1.1318 TD [(uation)-437.8(of)-442.6(methotrexate)-445.6(lung)-436.6(disease.)]TJ /F3 1 Tf 15.5227 0 TD (Thorax)Tj /F6 1 Tf 3.3195 0 TD [(1987;)-436.1(42:)]TJ -18.8423 -1.1381 TD (652\261655.)Tj -2.5165 -1.1128 TD [(76.)-1266.5(Irey)-246.3(NS.)-244(T)34.9(issue)-248.6(reactions)-241.9(to)-248(drugs.)]TJ /F3 1 Tf 16.4206 0 TD [(Am)-239.7(J)-245.9(Pathol)]TJ /F6 1 Tf 5.1342 0 TD [(1976;)-240.1(82:)]TJ -19.0383 -1.1318 TD (617\261647.)Tj -2.5165 -1.1128 TD [(77.)-1266.5(Colby)-440.8(TV)127(,)-439.2(Carrington)-442.4(CB.)-434.9(Interstitial)-447.1(lung)-436.6(disease.)]TJ /F3 1 Tf 24.242 0 TD (In)Tj /F6 1 Tf 0.822 0 TD 0 Tw (:)Tj -22.5475 -1.1381 TD [(Thurlbeck)-299(WM,)-292.7(Churg)-281.3(AM,)-296.7(eds.)-293.2(Pathology)-295.7(of)-297.1(the)-297.8(Lung.)]TJ 0 -1.1318 TD [(2nd)-352.6(Edn.)-358.9(New)-358.9(Y)98.4(ork,)-356.4(Thieme)-358.3(Medical)-361.6(Publishers,)-358.4(1995;)]TJ 0 -1.1381 TD [(pp.)-330.7(589\261737.)]TJ -2.5165 -1.1128 TD [(78.)-1266.5(Bannwarth)-252.9(B,)-247.4(Labat)-249.5(L,)-252.5(Moride)-247.3(Y)123.6(,)-249.5(Schaeverbeke)-251.3(T)72.9(.)-249.5(Meth-)]TJ 2.5165 -1.1318 TD [(otrexate)-317.1(in)-311.2(rheumatoid)-318.2(arthritis.)-314.2(An)-318.4(update.)]TJ /F3 1 Tf 17.7484 0 TD (Drugs)Tj /F6 1 Tf 2.801 0 TD (1994;)Tj -20.5495 -1.1381 TD [(47:)-336(25\26150.)]TJ -2.5165 -1.1128 TD [(79.)-1266.5(W)70.8(ernick)-404.5(R,)-399.1(Smith)-407.4(DL.)-400.7(Central)-404.8(nervous)-403(system)-401.7(toxicity)]TJ 2.5165 -1.1318 TD [(associated)-279.4(with)-277.9(weekly)-274.1(low-dose)-281.7(methotrexate)-274.8(treatment.)]TJ /F3 1 Tf 0 -1.1381 TD [(Arthritis)-334.5(Rheum)]TJ /F6 1 Tf 6.7655 0 TD [(1989;)-334.9(32:)-336(770\261775.)]TJ -9.282 -1.1128 TD [(80.)-1266.5(Ginsberg)-591.6(SJ,)-602.3(Comis)-602(RL.)-604.4(The)-602.4(pulmonary)-601.1(toxicity)-605.9(of)]TJ 2.5165 -1.1318 TD [(antineoplastic)-340.2(agents.)]TJ /F3 1 Tf 8.9343 0 TD [(Semin)-338(Oncol)]TJ /F6 1 Tf 5.5199 0 TD [(1982;)-334.9(9:)-330.2(34\26151.)]TJ -16.9707 -1.1128 TD [(81.)-1266.5(Katzenstein)-542.6(ALA.)-542.6(Acute)-540.1(lung)-544.1(injury)-540.1(patterns:)-541.7(diffuse)]TJ 2.5165 -1.1381 TD [(alveolar)-405.6(damage)-396.5(and)-402.9(bronchiolitis)-405.6(obliterans)-402.1(organizing)]TJ 0 -1.1318 TD (pneumonia.)Tj /F3 1 Tf 4.7928 0 TD (In)Tj /F6 1 Tf 0.822 0 TD [(:)-128.3(Katzenstein)-137.9(ALA,)-125.3(Katzenstein)-137.9(and)-124.7(Askin)]TJ /F8 1 Tf 16.351 0 TD (')Tj /F6 1 Tf 0.2213 0 TD (s.)Tj -22.1871 -1.1381 TD [(Surgical)-303.3(Pathology)-321(of)-316.1(Non-neoplastic)-314.6(Lung)-317.6(Disease.)-316.5(3rd)]TJ T* [(Edn.)-302(Philadelphia,)-301.4(Saunders)-299.7(Company)60.4(,)-300.1(1997;)-303.3(pp.)-299.1(14\26147.)]TJ -2.5165 -1.1065 TD [(82.)-1266.5(Y)92(ousem)-348.1(SA,)-351.5(Colby)-346(TV)120.7(,)-350.7(Carrington)-347.5(CB.)-352.7(Lung)-349.2(biopsy)-348.3(in)]TJ 2.5165 -1.1381 TD [(rheumatoid)-280.3(arthritis.)]TJ /F3 1 Tf 8.3652 0 TD [(Am)-271.3(Rev)-279.7(Respir)-276.9(Dis)]TJ /F6 1 Tf 7.8594 0 TD [(1985;)-278(131:)-278.6(770\261)]TJ -16.2246 -1.1381 TD (777.)Tj -2.5165 -1.1065 TD [(83.)-1266.5(Katzenstein)-618.4(ALA.)-612.1(Infection)-615(I.)]TJ /F3 1 Tf 16.0602 0 TD (In)Tj /F6 1 Tf 0.822 0 TD [(:)-615.2(Katzenstein)-618.4(ALA,)]TJ -14.3657 -1.1381 TD [(Katzenstein)-555.2(and)-554.7(Askin)]TJ /F8 1 Tf 9.5792 0 TD (')Tj /F6 1 Tf 0.2213 0 TD [(s.)-553.7(Surgi)13.3(cal)-556.8(Pathology)-554.9(of)-550.1(Non-)]TJ -9.8005 -1.1381 TD [(neoplastic)-230.2(Lung)-229.1(Disease.)-234.3(3rd)-233.4(Edn.)-226.2(Philadelphia,)-231.8(Saunders)]TJ 0 -1.1318 TD [(Company)60.4(,)-331.7(1997;)-334.9(pp.)-330.7(247\261285.)]TJ -2.5165 -1.1128 TD [(84.)-1266.5(Katzenstein)-561.5(ALA.)-561.5(Infection)-564.4(II.)]TJ /F3 1 Tf 16.1677 0 TD (In)Tj /F6 1 Tf 0.822 0 TD [(:)-558.3(Katzenstein)-567.9(ALA,)]TJ -14.4731 -1.1381 TD [(Katzenstein)-555.2(and)-554.7(Askin)]TJ /F8 1 Tf 9.5792 0 TD (')Tj /F6 1 Tf 0.2213 0 TD [(s.)-553.7(Surgi)13.3(cal)-556.8(Pathology)-554.9(of)-550.1(Non-)]TJ -9.8005 -1.1318 TD [(neoplastic)-230.2(Lung)-229.1(Disease.)-234.3(3rd)-233.4(Edn.)-226.2(Philadelphia,)-231.8(Saunders)]TJ 0 -1.1381 TD [(Company)60.4(,)-331.7(1997;)-334.9(pp.)-330.7(286\261310.)]TJ -2.5165 -1.1128 TD [(85.)-1266.5(Lemense)-463.9(GP)106.6(,)-464.5(Sahn)-464.2(SA.)-459(Opportunistic)-469.7(infection)-464.7(during)]TJ 2.5165 -1.1318 TD [(treatment)-339.8(with)-341.1(low)-333(dose)-340.4(methotrexate.)]TJ /F3 1 Tf 15.8768 0 TD [(Am)-334.6(J)-334.4(Respir)-340.1(Crit)]TJ -15.8768 -1.1381 TD [(Car)33.6(e)-334.4(Med)]TJ /F6 1 Tf 4.3818 0 TD [(1994;)-334.9(150:)-335.5(258\261260.)]TJ -6.8983 -1.1128 TD [(86.)-1266.5(Anderson)-241.4(LL,)-236.5(Collins)-243.4(GJ,)-240.3(Ojima)-247.4(Y)123.6(,)-236.9(Sullivan)-241.7(RD.)-243.8(A)-236.8(study)]TJ 2.5165 -1.1318 TD [(of)-385.7(the)-386.3(distribution)-387.3(of)-392(methotrexate)-388.7(in)-387.1(human)-384.8(tissue)-389.6(and)]TJ 0 -1.1381 TD (tumors.)Tj /F3 1 Tf 3.3322 0 TD [(Cancer)-331.2(Res)]TJ /F6 1 Tf 5.0204 0 TD [(1970;)-335(30:)-329.7(1344\2611348.)]TJ 12.9683 73.9401 TD (381)Tj 7.472 0 0 7.472 241.285 797.499 Tm 0.0001 Tc [(METHOTR)-11(EXA)105.4(TE)-339.7(PNEUMONITIS)]TJ ET endstream endobj 51 0 obj << /ProcSet [/PDF /Text ] /Font << /F3 6 0 R /F6 9 0 R /F8 16 0 R >> /ExtGState << /GS2 11 0 R >> >> endobj 52 0 obj << /Type /Halftone /HalftoneType 1 /HalftoneName (Default) /Frequency 75 /Angle 45 /SpotFunction /Round >> endobj 53 0 obj << /Type /Halftone /HalftoneType 1 /HalftoneName (Default) /Frequency 75 /Angle 45 /SpotFunction /Round >> endobj 11 0 obj << /Type /ExtGState /SA false /OP false /BG /Identity /UCR /Identity /HT 52 0 R >> endobj 32 0 obj << /Type /ExtGState /SA true /OP false /BG /Identity /UCR /Identity /HT 53 0 R >> endobj 33 0 obj << /Type /ExtGState /SA true /OP true /BG /Identity /UCR /Identity /HT 53 0 R >> endobj 54 0 obj << /Type /FontDescriptor /Ascent 0 /CapHeight 0 /Descent 0 /Flags 4 /FontBBox [-169 -227 1003 776] /FontName /PIJAPB+AdvP6EC5 /ItalicAngle 0 /StemV 0 /CharSet (/C101/C111/C102/C112/C103/C104/C114/C105/C115/C116/C77/C97/C117/C58/C108/C118/C99/C109/C119/C100/C110/C120) /FontFile3 55 0 R >> endobj 55 0 obj << /Filter /FlateDecode /Length 1306 /Subtype /Type1C >> stream HdSkLW܅J0P.]bEG|0`"XElTĶ+"(mQVmL-c؞&chnsfιA8#JO>i|RΆtdKM*'N[0u GWz!ۈ»>cG&͚b4-F#!IC$C L*0YfKifKt `2H 8B4.˦ )GI%CjH=A.Ԓd')#vRAv*ԑ{-|Y\'1brXETd~ÅsrePUWk%Z P *W_kZx<\9%jnJS1eCv ^!(!_?BD$E֊/L_tN 7[RPug?t;*Zm^U MusOvE9GGjQT]ϕ uSZAih̨s? q[P| ꅁ#?9mK0>Yr-%E9z?8Ca ;pw~y=fN|$CÿO ժ UR"9Yxp~k?+~> endobj 57 0 obj << /Filter /FlateDecode /Length 3287 /Subtype /Type1C >> stream HtT{TT߁ ؋k"O"\P!E#(iVQDRiZ** (>">h[|ӤT$J s̝|37CTj7!'- q,q,7%kڱ_|VV[뫚H1g^xsBdF'&LK{9_V5JחoZY]s Nj?+d(ɒ.p. !"!L$[M I6eYeY eE6[dEZdQln-VYZeٟA&ll6l&.[.f(!(X "^I+NMWgr Qp#[vRGc 9O֓cԓrT]d/9LZԐO~r md# 'd79JFJI))'JRK>#M$ M {ALNSMdMVU9ߪJT/TOx澁|V]rHPgWepܟ>m[)\Ԫ) m1cG y ^^)^j2vk*q.Qp,&q_4 t v=k{L~Tz !Aӧq`}.z\lA:hvR![cӣj0y nX&Aef0c   AX|9"Dm=.}5N)w`mfF^B<4@])zG:unQ"fRøi4/gbU%1g |D<^~CѨ?g0라BY9wkLΡmk}@S39n #,@eEJܲ 3} h(vSZ)J-=1:'7Y(-0o.=kM"o0q nT_<Яg}_ F)trg;|JZ'v]aoܔYbETk8|kyVrDSZ PR7o]Bz7&i091 lT_+i\ktc_P,x7,@aGu1Ҥ2şHgEUFq w n3\W,ء]Ț"J@ kHci##WxZGB`VZ0ԹvNndMu͜3~_BY*vI ,\2f2t`}kϝ<d'@C{!'hRq ,ʼ<0Prh ULOp=AhoKb#ЗL܇3a 6 V> e0N\<́16{{dɜu6C 9 +, UO[N55J uro[[l['Wd`4fm qgN8ci㹎KuǷIew}` ]{tGSm7C ~0ͩnz. M;0W D1B)┗h"ЇOƜ*9WHx/qf\ IB u܄f[}X}(< 1c` ˇ^%+A0܎##QI6,^ P&BpuV6K )"Ѹsn=[1c"\5;7oKW/NNz?jX=Γv[V X1[zߗLz 6BRf (H]/` ]L&n30Vq &f# HЇ \)nQX<(11SΓ~)>rLgW+aٟk͐Zrn8fA;+e[W4{ x+]JtIy!}8(0D  AQu6AP□#h:KjJQj{u1;iI@N$tXZ,HJȓm}fMdeP&>gLE>tB~>׽rgSk:n"Y|D=[a`EGklrqԿ[}  `)6scQbklK%u"pU+_ŗdXiAmZ endstream endobj 58 0 obj << /Type /FontDescriptor /Ascent 0 /CapHeight 0 /Descent 0 /Flags 4 /FontBBox [-172 -215 986 700] /FontName /PIJAPF+AdvTTf90d833a.I /ItalicAngle 0 /StemV 0 /CharSet (/C101/C111/C121/C72/C82/C102/C112/C53/C73/C83/C103/C44/C74/C84/C104/C114/C45/C55/C65/C75/C105/C115/C46/C56/C66/C76/C86/C116/C67/C77/C177/C97/C107/C117/C48/C58/C68/C78/C98/C108/C118/C49/C59/C69/C79/C99/\ C109/C119/C50/C40/C80/C90/C100/C110/C120/C51/C41/C71) /FontFile3 59 0 R >> endobj 59 0 obj << /Filter /FlateDecode /Length 8513 /Subtype /Type1C >> stream HdTipg@#w.$$˖,)!a G-d[%V +YdIeI>c$i Ӧd mighNJ3]ڦgvg}go+U1ZTRRzy}?/{M[tߛ*ؙuµ+/6nFm;vy'GI}S[[K{zmN'RS|w8x y3 ^1.(%!Jp>q90qR.0RRbB\(y ̣OE@pOŸ@qp~.*E ǀǠp>_K;W;dyE,!x-?⽼XP=?|p| &,>0F@@D(%`.`)0.;p8zP*` R .k/s,3k#!y/|_ce?T hYݫ^x{5Uk뎬_ 6fkh 76 X#+KԖ[~c%_v`ۃo֎š+|&L>y7^'4ʞ׶gΡCe~g|΅2nJ8 .nzmzZcO9Qd z5^^GUܫR5J_>LB7>҃R$"$1kbF{fumj5`DhJ頜+?88{܈q5N:-S^F^g)fήA̓!ZT8sjޯ)+&кxJ5"vW G&%{~vJIUt6Xm~̧rJa~'>OhሤjT&ҩt4o=F_oB#~`ʢ,Z|ơbۂ}V7B-&0:txɄ^X&^R@TZI$d+/!&%;c؃V(48,٢(egsl9%V BinC78O翜OCTK- 4\_HꈎA]0&'"sذ+;=uymU{ ^FC>z<-?c:dWliIYBjFצ[S{ VB,f0XH:u>ՆF35OdD)4ҏb2݉8{IxHAYih&mX[4\N !}]mpE^I@%}!F a7k/ݧN)AHC霄 t**FQ_Rv9qI`bP4 L@{z~qlmVNSdNsa9k2+>nJ~'lHǡ^jR_K}88&h;Sꑦatw9U_c<,wP(jN?Y*ZZ>痌7 cԷ¦&sw!Idh8BE+i#p `pJ !R1T[=,%UQK0eOr K _jжF6SN3YPJO$CKf?(Iy-ɽ619d]˸i;7.2gUJ Fhe/07.W؟{VH'S蓋s\* {]H00 Cް#f Ǟ62gB{-6&g5aҬ3PK]'ϭ s9k^s.^jW . 13v?qroN;.?dФ1&HQY'>&-Jt6DA&Ev[y&3^vǦr22>̏ d(`11Ѯ'`IF֣ŝd(4z#a,GO&Χ3V06cH4IvƦqqMۦj_FgI4UڦHVUui5UIlc1qqr1lcl'ΒɒyYf[:E}}a:cҞ'T>sw{}*:RˮeU˛LV2)(LF%XN* (RW$0lTB;,342FΒ(4ĵQMˤSmjӣ&?`l ޳ڔO_{'@a68Ǡ K[΁n{`71O=ݕn*6U^P<rܡIf O|-$(-$q:} jiL1n/s5i7K +AD.,f\`u21X}]i(y]t8=(|q3r3`FG\mwW¶'fTz{06`r6kri+i'v%YdIv˖dYmYIq&ޥ7(G٭pd=vq:7|+]Gs]M2Bw55#kbo-c 166ic;GN&ljhp'qW^Cj9a9xOYpܝgWԘL|"KW.ܵA=JŇ gMWW5VP}ZJ3_nʚ)ZXqq=Ai8fuݨ떊{x9^$' dDCzIPee+#ǣ6ϔpRbA4 r~;3 ;7ു;jƄQ3ʆR,jn"WblYP %fX҉{k =~;'R,Id5 ~bZ5.%X֋]<9m}ݨ֪%!k_8ǃ1r=cQGV#^"c@ ^ 3~ZRP )\ m|5;>&qQ,Z3i XRn~o/NH%8KF}ֲ[6#p, Y\ȯ%T?>a4*ig\xٍ[@$r Oy?bӍ6Ro5Ɖ~gTNWdk^s6ֱ26t۽GQ0+-_xZ |Ά5aml7i0 ǕBSXpjeFn墱4R_v]`B(E_ь:cwCgom5kmi[Vp*.s*d3XVx6Ͳ<, ;-2iQATT\ӥZm0F12ffL94N~0^l(+K=jcgHx Vk P^> 2ٔ@aY6djRdDN8p&WfɅW=E4zlLk]5_D݂?bJNci(hluȊٲ:sG4 ++ T͛*^P'gMޘwAn>;x=? 'x=i?u~&?Q͇v&Uۨ:} L_!W۳)3ILMڢ<͋ik)b&PH_5#xؤ7PuMk؝S={";;FT5-]{³179L~EqѬuͻMѪ\6'h& ,&YN@1-AIl /j(#DӈKpP#C3):M,HEWW8&EOŨx2``&xpZ.gsY1|!ɒ(˨8 taYr R3"lBu6fbȠo&>&63L}s#h䪥E,Qr]TAPx)nA|B\bC^;{|E;W݋恧[y{fֿ\e4 2%dt `QQjVRV0fsqy %Ÿv~=v"X@*oH~1z|VZzkT)@:PcVdFȗ`g3ȏ]'] -K+²?*2 #/x?1W@x}ĘEYPY4(.0'|.^Y]Z*PIWRp$BDsCo|ׂZC!)Osja,@'CH)_H洬 0~B!}0jjfkz݂/.+/k,qjT.9˭-lŚ*;ȭ*Jt9&Sqt|k>'wڟ3nn7M~?|T7_;/7HNo[ۅlo4vnaw8ޱ=9t 95tqRҷjAፏ7w2P+G'|n7~H,D67 %^g'Ab4̲] @$!H#s olݯ[T-p}i 6GBJlŦIx2Ipr|rd`}=Bw컋軱^mvNVc83F!$'atʬwYNpoU.dQw/뾨⵾ofsT)tETaI L(XEt5KGZL>EtF&Č9u.?ίz$A㒚D*f2Y fWgȕ&'cHyʈC !hŨD:S"xĨ[!ׅ=BS`sU]([mDZB:קv%kF>d)3M[*+X6TYvcĹX4MI6|skav*pr&kNY;hI3Mh}SWԐ OݛVD57؍+AF#.'/_&, Ӭ(sGR0`nk-'dr9JGt*#0ӳh^`e9)&iʃyKad^ })J*syY]+]C7v>韤ΰQÄ?ʍt>Ibi> ݉n!tw^2"̡3 ??hoh7]h/"X]N;H4\7 r$ nE$D#nJ :EDCo fE]"Y5A@y祖_n1KsOwAY yBQc%CZ~} 锖Z;{w[фd;!-d|'9p483Sdt!229Q8$FL>_vV Pva3 2 Ʋl~zEjpblӻLƮFG1 # lv`GPx]y!c ,I!eAt΀^\@{yro5ᘻfʥRte-( NqbɭS;vL5:{;ځm6Ʀ‚-m״n> endobj 61 0 obj << /Filter /FlateDecode /Length 1484 /Subtype /Type1C >> stream H,T9%G}w՝G8"$HL4 !Y ͽFN %%$p@"~/*U}s{tz꣟g?߿w[ygowݧ'/_}#wwϾ)9=7=>HO{oɽ雎i놅!߈ȌQR-0"&pdnafi әQvc fo,钂EL|*':ҩ۱5x}ճ/7H:`oܘ艑0%K2s0 ڕ\uGL39nGP23|*x(M1#Puu˛Ӳ %/r(Ҙ iE}@PETy:qQbLHFЙ,//ffVa=4G Qz":6e^=-Z5XٜڌNoQ7U `^ `XόDOĹ!kbkj"!tŻj&0 U蹂!G m>{ oɫZy]lj>K;zXyiqfk@]<Յ64]E"ńt4jQ'(Sۙ98U&B-!UJb~n_Jڀ&4I_{qgWA5:Y[,' lQ$} T/^hf&| ] ȟʃ #WwgwVor&kF>'6Q6g17GؒqLI+XGU$5I+!6-&Y8^vb%OOP4I?$1;6m:n]U@}q$ ~KQ:[uꨉML`RKagU*ZM-W}iE6 ݍyDqQ Ba21K O ۠u[vkݜ#$uEWx]t.nyQj)}IEjAMxiέ\P4 #G_0+;^N!QiS6gSJս Q( 7::SsJaK%Ws\d1G5<չ80mdiI u]c=(B F&bNP`*Th\QUp7wh]Bb)rKW[{[/2}븵jOpCա!C3٪t".%UKv!*Q 3;?6,۲|a.ңZBW!"w'G"|]75"7 I^UV!* tC endstream endobj 62 0 obj << /Type /FontDescriptor /Ascent 0 /CapHeight 0 /Descent 0 /Flags 4 /FontBBox [-27 -215 1009 696] /FontName /PIJAPJ+AdvTT2cba4af3.B /ItalicAngle 0 /StemV 0 /CharSet (/C101/C111/C121/C72/C82/C102/C112/C73/C83/C103/C113/C44/C84/C104/C114/C45/C65/C105/C115/C46/C66/C76/C116/C67/C77/C97/C107/C117/C58/C68/C88/C98/C108/C118/C99/C109/C119/C40/C80/C100/C110/C120/C41) /FontFile3 63 0 R >> endobj 63 0 obj << /Filter /FlateDecode /Length 5646 /Subtype /Type1C >> stream HTkp[)nfiI10 ր1ccjzd,ɲ䷰]l Cf@L3$43%Igљ>3 $YtHg̽w;=Q"`;ݯ{mC 7Jٹ(S^o|n~9޲̆+E/WAƗ6lQ=?;PU}]V#ddL&PF‰Y!Q(,6EEDi +"[(.&J*!JJ%WbK)Q\J[K32aUX m%6MD쑺k_yXCq6Q]`/':ZT[$~}`A apt~S,q0 \ z@/H1p>A0&4p6 "\Xyb(*9 *a r΂{OK/ɲ?-^ŊM+KW3*\vujnMkS,-]ǽoej{KE֏ގSa\_?|aM,Kv:ƇS 8(9+Y.̿!`wo|.e߫>~;cvJԠ%N (8jHLL 2zpZqN '_ ̄EņFF&Ro6p }-^I{B/<{.[Ռ,K*$܅IP8K)L /􇢞gT\=! \c1>!&eK~2&WrV&ZDRg,MlAܧ(~~3V|eqNJrmZ0Bⴵ] nX 86ɤ;{~eYk Ü.3^`V/0%36M`;.h8+nSzz\4&6d%\ha1|`'8zbpqH] skӞ~94M‘ddrUu6UW޿/(ȕ-џYIʝUe8>x}M(R^Gt5lGY RKKf>ϝ`Ŕ4fUErm*8 65S$H0Ը߷4f#z_5bR '-3lA۹&Mm3mj8ԬH j:U$uMc~ASsiGXDSFT::=G&~C>WG#.%iSzǏOfž^O}==4kF0^umdem"!!"uFh-HeEղK@i6ݦuI?w4 UjW5 y"&ץjBEpϐgB(J*aBT&}?elŐ *rse;ES0͟LeV:t8Z(UtNMC}S˝,k ˢ(ʱ:5z|#rm؝@~?xeIclMV[ꡉHV3&2$VV(\l(f۲E g)_$U* x>*geȴՒڄk 2MXdNaUUSIl:iȒN"r|`>}yw"Qrq%S#tߧV 8g .S*(MQ[C1hbi%CBMDfXl &aܴ+ݎ#4[ԭƶwxplE~~;1{ ۽&njŴ3 QR撙?,27"H<$԰¢3XWm| 6j?Mp=Bq!2gy-H/MWE&@M^\ 8s6OZzٿ-%=ji:y][si.WJ'hnf뤮5(JeZԶ:]t͛+CF/wlkPV^~ ɤ&G0椩#:?P.MC+wK2lJzT(t:ː؜ӹVFFNzv$<ŔT*r(D泼AjȶD9S $&Yih@3̚E@ \y `!%! IKlp \$ HPtP-uHû&hZX+:AIO`)Z4T!r69uۦl :&-41cUyD=,,'$8)j q5Ao?x/RC?qJy$}EeR.1ojWP .kZI j||ӒR%k^Ky9 4S91%>uѩGC&ƿW<3**@ҕ"Mց0fPqUTl9v -SE, @rJx|"ؾ\eyvҁn٪Eh#T)f#ӼiU:v JJ.kDlIL/S%:伄R}Z<vŶMaM,y!ْ&!@ 㦁l4ֵk6mėq|5O۹8'i-]) 6n Ld q2|W{jPrzwx? Baf8<1XJVLy<ipsK /:C|+CЕϢ~1:|~0>FkmN#ύVV.#.zx-|Ѯڪѳ+zpc"܎2O\6b˽X[5c\#Wf/N=9aRLe(l &% BR\A)QaVz\ߎ4Bwh9BB5Λof3S$'3 16\ 8q[FYX9 ,BC[5.?1sos /,ǣz8=P# ?!? Ο$,_EBC9Fj IKKey"Δ[Q\IoהQ@L:H&z&tD,&1*F'߂{_nE^@ Y* eGg q,7HvG9E/O]i3f,4n6F_Jnf?益ʆEh0zIr^PѬt-EuH_ZZՀJ XirBnggxpvHޓ~8@8vjzdrI/`sZՕ.77.@qV\"ReJF[@5m={C"&2b IWJjPf}z;T.͒0V[Z{r)j7p;H*PiKEniD-v{w2BaZ4Wә ,ul uhkDWhZ!|mq{¿3U-t#ޟuN0@r eeMqQa(̫ TFj]lj)\ ֜_BOzQ:yhAH`s#ރCޏ nv&S7r ,t,IGkJ9_ؙ/:i"3*sU`[~?60|1ӳr ~K s YM /,Bպrc}!39T%J9[r0P,dxoP`b$, 9[((T8 wG@QH,$e)4 > endobj 65 0 obj << /Filter /FlateDecode /Length 9959 /Subtype /Type1C >> stream HTSkp7֒P9݄)-YR; 0;15LL `eKȲծ,َaYe8W;Ii:II;e&LGr^3{g!{ @;nۼ|#++jEiR%DLͼs3YUz"P `1(Kr:Xւ(lTwnA8jI:`lN<@1 z@C` ! I0 n|?[  d@σXN%rJYB)J(U .AeCOyn_B)K)U).4( / JJJA"(JJʔJI F%(eTY*hŨ*UQJUT*JAbR)*SS VS5b(TPJP\!9 SbJUL)M1 #J)R)R*T,ތZ( Eyx>0ð W:އm0#Qx N8exށ!c0 qxނ3pav^8Wa ޅ5tB/ NGp~]Ep^O= /<pV#}jxV szE5XYzkf=娭׆ttp)Pt\_N4'Fk:%muh5Ș?a?dj$6+k1vA҂=%B8AtBfهRC/ @=`ѳс~ rq ~oENQ.m^,lh٠Yf1i.L3=DG(!nkJ}t{M`O6w&hvh(m* V[b2~1ܞV7q\45{OWHӾY_{*.|"5Y Cژ7!5F>!D>a&D6ߒاyi6i{; #鯥%G'>>6#ph xwxj.QԻړ6)h}a.LWi۶ o*N~*6 [97>EU;sԬm2a&#,;Vb$uS!]J*tuЌԡ/f0}Wx{IUNٝX cpʌiw\rcH\ 3&IV!wLyznfl6fisYޓe7$n#֙۶yF!ukU$$Fb {M-H t c'IJ,۲l4eQEIDN-~.֕Y/I\/u d - "lT@/'-hwx-Dzpas|.ٵN(RnQu~9s#dQ*2ZP͋בǼQjt7d'$M[o@R4tʥcmC]J~]DMz/gR!*L_w֙}릥qAĠ QZ:La(A$NǠ@\ twX,kƆ3 5tu%^x1岙_|%\]B'7ֱ37߭H\|-[CMŰŨpԟ?]w⡻XuYG*x _\Ool!-FX]30w页=xfjR-'ʉHÿmot.AO&еQ]=I`6=JC)7, e`{jU<l`rӧ=J0N eT<&:8 ^\\SNsΆANGU}cXs(V g*x7ʫWj^թ30JXQESP 6 ,{c^σZn[V居oARf'[?k[w?yĴ+g P7v,;~MܖG{]FWGva]gP?bCD))/q6lր9KyN\n[Bk',e.\uF fHv[F=2mn'0S "r8EA0 #fٴ`Mx`~??!֚Rxq&f"c -svk*ux .w&5-T^brCr֛;l otPCy>5avA&h0˼C "qTzELv7v9φ`BO}$zݪ5׾LG;v[_C(JKPKEMIQL@^vvRHI$k HTa+& 7C><\6>ClP5L2!_QBt%E՗04@)$d3]l[l2fxGꕫ< ۿ*6}Q-۶yb hL&1`@KtE&]eiufmtN$*-KDREEJźM4fA654^6eP5l$'<99S}ZlfW<Uw<->% _Vs/C[}89퇫ft[ (^pOJ`qz@H(*@?bn5O͠RsR|p+{yfzizmnTJL 'S@x1i?Iyា=iw0 xӜ/A,,rXP۬Z ͩFD2´D0M!ASމ>O铻:A6v##=.qP%t&XC#L4ÌRKHu .pq,* ꗈ<$譓NUpN[pmmW/joB'WNN&q( b$ϋX*fO*0J¥rvX֡׌& ˍuRPPӌBHN`MFiZmڠV/ؐbvK= 6UAmy={ ybo|a;-~W ~z 瀳un~dogML7 o8m֡ܙ.ЧC_iC} vr>w mP)!8cI 0,CӘm/k`r(ֆIk%Nn;9`tƚ`O#~Jצ!R&sxL:%,ٸ><<ݨ{pwx44o6)ʹ|cjn޵߽&5?>{|lZ/:s֥0t@RO/"S ^ ^vzG~鵗' Cx@met|3#e_cmci%[,Ų"g0T_[E˻Tg{u8zkHĚ^m(F,*I\7 /ƍnk6q6 @r9c}փ``8($ x>2ivTI\d]׭5| r~_ OdHpd*/Q 6Yh}<=C6 ,|QK/' 6P49?*mZz"a)) 衠6z^@85vS-lmK~XD%vsDA`DD,'gz(Ϛ4 4Fh.0"χR1#KUat.&b +O@P2 1#`iHjͪQsU%flj.7$ 9Y:tE;0f]SH<2 cB q8< $?s%͙}CUa{.IȊ a^H%UFU 4=/F`Sjj)duTm!mTb)&IQs0o߼*Sq>;$DRTyU"0$1%ć0C#t2XH@d5I"cbLelh* Qg7l=vB`IHX&bpBBhK38+6񷄩0E#LZgp Lxgҩ.?uUM%1&JכD9{0}~X4Q$DŤTF( ` ϓxJYYAJ{Ҟբ,$dEL0L< tW0@nE(n/2/KGj]ڶ? DjDF9N؉nW7Vw>dh͏-&%%/۶yF_ $1V`:`VtC6 6+d4mNKvdY(xI%JEQ7JQKl-il{X60 :Pm{?9>?>^}A=)3aX(5|*1PTJP44*Pl^#^mTWKh%.q)MGdd\l,²N*Ns-SPD,D*EG7xw%cFVņ+0!RڡmRQł Ro !*޾4QCb. r@a.w & K>{с8[2ہ_I) LIE/ʎ,ghR`T#c\aȍun%VVyE7p+O1lbJk9*na6_RvT|9E,VUipw9٬fsB +Κ9\7E p,',d`p7֢S5-Ig6*O4`R Dr%f{؆Pfew' n?wfWzKjaؽo!W{W"`T-k;Q\svnx7?ww٬4b;?Ek!qfKjNQ0MtXJc#|}}?˔NA@:c}$tӵAhP;[^|q\uwv=r -L]z'),L&+w'>eqd5;[FT4An5UUT}`Thit|M\Kz:tӱ4?Ch輼P5FJ0Z!4+q&p//1f0VvFjx i̪3@ I)Gi8$<|&gaS3_f0x,9{֙_$sb"DSS(JύbkV‡6G?moXWMion` h^6< 5]m!ra*&B *QQ VQ-e\'$2M&;;NmK ">$(d$mI9wNLyi%l(T D#h{q_|}`ug)"u:o7ystL! TC%$$\US35 CN(W, Jt!p$dz5YTc+e^j0JGѿ($4#v<6\gEreث܁$Q=O'V-_ tԅHL2Ça7ihsXpTuiC7˯XUqf 53z2M^qtWlRӁH i\3X2Wڽv`,$jvt},=%\4~ %KX\֚hSSaNyP#BŨG& YOޱmAҵ 40[PKe|ү֯twUx`sI@Y/%;" `L0+< "WzK. [x{ )Vg*EC.h3dR/Z a\!Xm:0{gQ*'syBQDLȼdLi SG[u:RTi 5gi$72y#}FPSaUK6%!u]"OG,F3.uV޻x CLq u,|Ŗ$;GdV =g ỌQF:& T TUAֶݑF[ <  8Q:OԒSJ1Zr{6|pxlEVNPPgEĮtn{hea0g@8VhYu4mz;"`y iz*lcM@r]һX]UV %tlt p&iPDk,TB1o6 =ylϾV]+)bO%W50Ƈgc<5fK&3L[1UKj cs<6: 1W%IbtqT'C[xO /Qui-˽\t9yqڨ5}ݴ΄{`ZM;hm.c)#}7-=gw5ڸDzpG%N(eUQK <}"n@nHBڶc\#!87=0$i\ٱZiQ7Ou&`ŧ |LdBG.X}|0 jJ'ls^'{wnZuͤ_كv? endstream endobj 66 0 obj << /Type /FontDescriptor /Ascent 0 /CapHeight 0 /Descent 0 /Flags 4 /FontBBox [-179 -292 1090 1010] /FontName /PIJAPN+AdvP697C /ItalicAngle 0 /StemV 0 /CharSet (/C62/C61) /FontFile3 67 0 R >> endobj 67 0 obj << /Filter /FlateDecode /Length 142 /Subtype /Type1C >> stream Hbd`ad`ddr vL) 04wIe!#_~H3## ;!\cc;HYʲǞkHYcoy$<?߫X} &H (5 endstream endobj 68 0 obj << /Type /FontDescriptor /Ascent 0 /CapHeight 0 /Descent 0 /Flags 4 /FontBBox [13 -323 958 824] /FontName /PIJEOH+AdvPi1 /ItalicAngle 0 /StemV 0 /CharSet (/C39) /FontFile3 69 0 R >> endobj 69 0 obj << /Length 156 /Subtype /Type1C >> stream PIJEOH+AdvPi1 R. C39AdvPi1'Jn0T] endstream endobj 70 0 obj << /Type /FontDescriptor /Ascent 0 /CapHeight 0 /Descent 0 /Flags 4 /FontBBox [-253 -211 1078 766] /FontName /PIJEOJ+AdvTimes-i /ItalicAngle 0 /StemV 0 /CharSet (/C46) /FontFile3 71 0 R >> endobj 71 0 obj << /Filter /FlateDecode /Length 182 /Subtype /Type1C >> stream Hbd`ad`dd rvL) M-Ja!#{_~Nb)p`wO!&FF>g3$ z )nljfmbiko2uR)٦M7ľ'L:sJɭZz[z[{X[ؚٚ;Z:ZZ ;EC endstream endobj 72 0 obj << /Type /FontDescriptor /Ascent 0 /CapHeight 0 /Descent 0 /Flags 4 /FontBBox [-170 -215 1009 704] /FontName /PIKIHD+AdvTT212dd343.BI /ItalicAngle 0 /StemV 0 /CharSet (/C101/C111/C103/C65/C115/C46/C116/C107/C108/C99/C109/C119/C100/C110) /FontFile3 73 0 R >> endobj 73 0 obj << /Filter /FlateDecode /Length 2471 /Subtype /Type1C >> stream HtoƭraM$r -ntŰ&ð,Eus]ڲ,KDJEQ$E[o(ZmYIYnkf l-'K*S>r ðy~{غwtl6;'Oư}>?W?ǧ=ϙ׾+]{l6g8|Ԛq;xıcd|W-]]14<261r{}.[6kmMI-alrsYWw][>f< oz~˽hpPU0Η*T-)y1J VbȀPPAZ/c Ma9nOꌩQBrў'O~=>#N 3Ş!4BKrRXPGvs`gMslO- ZϚzQԋ{) Ȕp+&*܆ kך@Vז UI2"pii&i !FU TCC눞-U,;3Ru : L%^ћEaWI֙tV4 ͥz8Trؠ]" VB$&`.x;[DHiG< ̰^.]BUciV7o1|P l#ϖ_~t`'cN& H$n]WkjZsNXwLh|<z\dAs;ڣO6j5 EJ""28 7ꅣވ? d(QkV#2%:СЌp=e<$BS80 !DTc9L c8`h={>j;FN").űV$Cg|ڧ+A,BR|xpk: PV2u̔ j5]U$H bRjUnN9?FQͰҢ)/"M\u04$Fd H$ ('S<[ё "yʮ6*XdtR5p4^:_JC`c9X²‚,!Ag\2p9KIv:",\Ok9Ϳ[B1 M#D*YNQ\~=)bKe;pDY&Ģq")4fؕP-e CP ~@]ۿ5G f1d .86`C6QjCh^l6hl[[`V`P |^cufӫIK8A !H E[zs<?Kov:λd~aŲm ds'&*[10 '`a*T$i2$iMl_Wrb?)v8Bj;! #xfdi3TtiɼݲF`X=Obٲ]%IA(+/~?DzV)vqh۵m{D.2p̫ 3> gq0uj }``ov~ MI~?֞o^6TBWnQm%,%dwZ6]2.F!1G~D}s}_.2e389hXRSUb:AV̺qt^g:V3 ST#Txu32Ցƙx2ߟ HUް%79q5fkZa endstream endobj 74 0 obj << /Type /FontDescriptor /Ascent 718 /CapHeight 718 /Descent -207 /Flags 32 /FontBBox [-136 -225 820 931] /FontName /Helvetica-Narrow /ItalicAngle 0 /StemV 88 /XHeight 523 >> endobj 4 0 obj << /Type /Font /Subtype /Type1 /Name /F1 /FirstChar 32 /LastChar 251 /Widths [281 333 479 552 552 885 718 281 333 333 385 583 281 333 281 281 552 552 552 552 552 552 552 552 552 552 333 333 583 583 583 614 979 718 718 718 718 666 614 781 718 281 552 718 614 833 718 781 666 781 718 666 614 718 666 947 666 666 614 333 281 333 583 552 281 552 614 552 614 552 333 614 614 281 281 552 281 885 614 614 614 614 385 552 333 614 552 781 552 552 500 385 281 385 583 0 0 0 0 0 718 614 666 614 833 833 0 583 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 333 552 552 166 552 552 552 552 239 500 552 333 333 614 614 0 552 552 552 281 0 552 354 281 500 500 552 1000 1000 0 614 0 333 333 333 333 333 333 333 333 0 333 333 0 333 333 333 1000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1000 0 375 0 0 0 0 614 781 1000 364 0 0 0 0 0 885 0 0 0 281 0 0 281 614 947 614 ] /Encoding 75 0 R /BaseFont /PIJAPB+AdvP6EC5 /FontDescriptor 54 0 R >> endobj 5 0 obj << /Type /Font /Subtype /Type1 /Name /F2 /FirstChar 32 /LastChar 251 /Widths [281 281 354 552 552 885 666 218 333 333 385 583 281 333 281 281 552 552 552 552 552 552 552 552 552 552 281 281 583 583 583 552 1010 666 666 718 718 666 614 781 718 281 500 666 552 833 718 781 666 781 718 666 614 718 666 947 666 666 614 281 281 281 468 552 218 552 552 500 552 552 281 552 552 218 218 500 218 833 552 552 552 552 333 500 281 552 500 718 500 500 500 333 260 333 583 0 0 0 0 0 718 552 666 552 833 833 0 583 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 333 552 552 166 552 552 552 552 187 333 552 333 333 500 500 0 552 552 552 281 0 541 354 218 333 333 552 1000 1000 0 614 0 333 333 333 333 333 333 333 333 0 333 333 0 333 333 333 1000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1000 0 375 0 0 0 0 552 781 1000 364 0 0 0 0 0 885 0 0 0 281 0 0 218 614 947 614 ] /Encoding 75 0 R /BaseFont /PIJAPD+AdvP6EC0 /FontDescriptor 56 0 R >> endobj 6 0 obj << /Type /Font /Subtype /Type1 /Name /F3 /FirstChar 32 /LastChar 251 /Widths [250 322 416 500 500 822 770 322 322 322 500 666 250 322 250 270 500 500 500 500 500 500 500 500 500 500 322 322 666 666 666 500 916 604 604 666 718 604 604 718 718 322 437 666 552 822 666 718 604 718 604 500 552 718 604 822 604 552 552 385 270 385 416 500 322 500 500 437 500 437 270 500 500 270 270 437 270 718 500 500 500 500 385 385 270 500 437 666 437 437 385 395 270 395 531 0 0 0 0 0 718 500 604 500 750 750 0 541 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 385 500 500 0 500 500 500 500 208 552 500 322 322 0 0 0 500 500 500 250 0 520 343 322 552 552 500 885 1000 0 500 0 322 322 322 322 0 0 0 322 0 0 322 0 0 0 0 885 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 885 0 270 0 0 0 0 0 718 937 302 0 0 0 0 0 666 0 0 0 0 0 0 0 500 666 500 ] /Encoding 76 0 R /BaseFont /PIJAPF+AdvTTf90d833a.I /FontDescriptor 58 0 R >> endobj 7 0 obj << /Type /Font /Subtype /Type1 /Name /F4 /FirstChar 33 /LastChar 126 /Widths [1000 1000 1000 1000 1104 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 0 1000 1000 1000 1000 1000 1000 1000 1000 0 1218 0 770 1000 1000 1000 1000 822 822 666 822 666 718 822 718 666 666 718 666 1000 822 822 822 822 822 822 718 718 822 1000 666 822 718 1000 333 1000 1000 0 0 1000 822 718 822 666 1000 718 1104 822 885 1104 1000 1104 1156 666 822 666 822 937 1000 822 1000 1156 822 822 937 1000 1000 1156 1000 ] /Encoding 77 0 R /BaseFont /PIJAPH+AdvPi3 /FontDescriptor 60 0 R >> endobj 8 0 obj << /Type /Font /Subtype /Type1 /Name /F5 /FirstChar 32 /LastChar 251 /Widths [250 322 552 500 500 1000 822 322 322 322 500 562 250 322 250 270 500 500 500 500 500 500 500 500 500 500 322 322 562 562 562 500 927 718 666 718 718 666 604 770 770 385 500 770 666 937 718 770 604 770 718 552 666 718 718 1000 718 718 666 322 270 322 572 500 322 500 552 437 552 437 322 500 552 270 322 552 270 822 552 500 552 552 437 385 322 552 500 718 500 500 437 385 218 385 510 0 0 0 0 0 718 500 604 552 750 750 0 541 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 322 500 500 0 500 500 500 500 270 500 500 322 322 0 0 0 500 500 500 250 0 531 343 322 500 500 500 1000 1000 0 500 0 322 322 322 322 0 0 0 322 0 0 322 0 0 0 0 1000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1000 0 291 0 0 0 0 0 770 1000 322 0 0 0 0 0 718 0 0 0 0 0 0 0 500 718 552 ] /Encoding 76 0 R /BaseFont /PIJAPJ+AdvTT2cba4af3.B /FontDescriptor 62 0 R >> endobj 9 0 obj << /Type /Font /Subtype /Type1 /Name /F6 /FirstChar 32 /LastChar 251 /Widths [250 322 406 500 500 822 770 322 322 322 500 562 250 322 250 270 500 500 500 500 500 500 500 500 500 500 270 270 562 562 562 437 916 718 666 666 718 604 552 718 718 322 385 718 604 885 718 718 552 718 666 552 604 718 718 937 718 718 604 322 270 322 468 500 322 437 500 437 500 437 322 500 500 270 270 500 270 770 500 500 500 500 322 385 270 500 500 718 500 500 437 479 197 479 531 0 0 0 0 0 718 500 552 500 750 750 0 541 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 322 500 500 0 500 500 500 500 177 437 500 322 322 0 0 0 500 500 500 250 0 447 343 0 437 0 500 1000 1000 0 437 0 322 322 322 322 0 0 0 322 0 0 322 0 0 0 0 1000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 885 0 270 0 0 0 0 0 718 885 302 0 0 0 0 0 666 0 0 0 0 0 0 0 500 718 500 ] /Encoding 78 0 R /BaseFont /PIJAPL+AdvTT5843c571 /FontDescriptor 64 0 R >> endobj 10 0 obj << /Type /Font /Subtype /Type1 /Name /F7 /FirstChar 32 /LastChar 254 /Widths [250 333 708 500 552 833 781 437 333 333 500 552 250 552 250 281 500 500 500 500 500 500 500 500 500 500 281 281 552 552 552 447 552 718 666 718 614 614 760 604 718 333 635 718 687 885 718 718 770 739 552 593 614 687 437 770 645 791 614 333 864 333 656 500 500 635 552 552 489 437 520 406 604 333 604 552 552 572 520 552 552 520 552 604 437 572 708 687 489 687 489 479 197 479 552 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 625 250 552 166 708 500 750 750 750 750 1041 989 604 989 604 395 552 406 552 552 708 489 458 552 552 552 552 1000 604 1000 656 822 687 791 989 770 770 822 770 770 708 708 708 708 708 708 708 770 708 791 791 885 822 552 250 708 604 604 1041 989 604 989 604 489 333 791 791 781 708 385 385 385 385 385 385 489 489 489 489 0 333 270 687 687 687 385 385 385 385 385 385 489 489 489 ] /Encoding 79 0 R /BaseFont /PIJAPN+AdvP697C /FontDescriptor 66 0 R >> endobj 16 0 obj << /Type /Font /Subtype /Type1 /Name /F8 /FirstChar 33 /LastChar 126 /Widths [1000 437 1000 385 1000 1000 218 1000 1000 1000 1000 1000 0 500 1000 1000 1000 0 0 1000 1000 1000 1000 385 1000 1000 1000 666 1000 666 1000 385 0 437 822 666 437 718 666 666 0 0 552 718 0 0 718 822 0 552 666 0 718 1000 552 666 822 666 437 822 437 1000 1000 0 552 552 666 500 437 666 500 885 333 666 552 552 552 500 666 552 500 552 666 437 500 0 552 500 500 437 500 0 385 822 ] /Encoding 80 0 R /BaseFont /PIJEOH+AdvPi1 /FontDescriptor 68 0 R >> endobj 17 0 obj << /Type /Font /Subtype /Type1 /Name /F9 /FirstChar 33 /LastChar 251 /Widths [270 458 583 500 1000 718 270 500 500 500 1000 270 333 270 333 500 500 500 500 500 500 500 500 500 500 333 333 1000 1000 1000 385 1000 718 666 718 770 666 604 718 822 385 500 718 666 989 770 770 666 770 718 604 666 770 718 989 718 718 718 500 333 500 500 500 270 500 500 437 500 437 333 500 500 270 270 531 270 770 500 500 500 500 385 385 333 500 437 666 552 500 437 437 270 437 500 0 604 822 822 562 0 0 0 0 1000 1000 968 1000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 270 437 500 114 718 500 604 822 0 500 500 333 333 552 552 0 500 604 604 270 0 0 0 0 500 500 500 1000 0 0 385 0 166 166 166 166 0 166 0 166 0 166 166 0 0 0 166 1000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 989 0 333 0 0 0 0 0 770 1000 333 0 0 0 0 0 604 0 0 0 270 0 0 0 500 604 500 ] /Encoding 81 0 R /BaseFont /PIJEOJ+AdvTimes-i /FontDescriptor 70 0 R >> endobj 45 0 obj << /Type /Font /Subtype /Type1 /Name /F16 /FirstChar 32 /LastChar 251 /Widths [250 385 552 500 500 822 770 322 322 322 500 562 250 322 250 270 500 500 500 500 500 500 500 500 500 500 322 322 562 562 562 500 822 666 666 666 718 666 666 718 770 385 500 666 604 885 718 718 604 718 666 552 604 718 666 885 666 604 604 322 270 322 562 500 322 500 500 437 500 437 322 500 552 270 270 500 270 770 552 500 500 500 385 385 270 552 437 666 500 437 385 343 218 343 562 0 0 0 0 0 718 500 604 500 750 750 0 541 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 385 500 500 0 500 500 500 500 270 500 500 322 322 0 0 0 500 500 500 250 0 500 343 322 500 500 500 1000 1000 0 500 0 322 322 322 322 0 0 0 322 0 0 322 0 0 0 0 1000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 937 0 260 0 0 0 0 0 718 937 291 0 0 0 0 0 718 0 0 0 0 0 0 0 500 718 500 ] /Encoding 76 0 R /BaseFont /PIKIHD+AdvTT212dd343.BI /FontDescriptor 72 0 R >> endobj 31 0 obj << /Type /Font /Subtype /Type1 /Name /F13 /FirstChar 32 /LastChar 255 /Widths [228 228 291 456 456 729 547 157 273 273 319 479 228 273 228 228 456 456 456 456 456 456 456 456 456 456 228 228 479 479 479 456 832 547 547 592 592 547 501 638 592 228 410 547 456 683 592 638 547 638 592 547 501 592 547 774 547 547 501 228 228 228 385 456 273 456 456 410 456 456 228 456 456 182 182 410 182 683 456 456 456 456 273 410 228 456 410 592 410 410 410 274 213 274 479 0 547 547 592 547 592 638 592 456 456 456 456 456 456 410 456 456 456 456 228 228 228 228 456 456 456 456 456 456 456 456 456 456 456 328 456 456 456 287 440 501 604 604 820 273 273 0 820 638 0 479 0 0 456 456 0 0 0 0 0 303 299 0 729 501 501 273 479 0 456 0 0 456 456 820 0 547 547 638 820 774 456 820 273 273 182 182 479 0 410 547 137 456 273 273 410 410 456 228 182 273 820 547 547 547 547 547 228 228 228 228 638 638 0 638 592 592 592 228 273 273 273 273 273 273 273 273 273 273 ] /Encoding 82 0 R /BaseFont /Helvetica-Narrow /FontDescriptor 74 0 R >> endobj 75 0 obj << /Type /Encoding /Differences [] >> endobj 76 0 obj << /Type /Encoding /Differences [] >> endobj 77 0 obj << /Type /Encoding /Differences [] >> endobj 78 0 obj << /Type /Encoding /Differences [] >> endobj 79 0 obj << /Type /Encoding /Differences [] >> endobj 80 0 obj << /Type /Encoding /Differences [] >> endobj 81 0 obj << /Type /Encoding /Differences [ 128/C128 ] >> endobj 82 0 obj << /Type /Encoding /Differences [ 0/NUL/SOH/STX/ETX/EOT/ENQ/ACK/BEL /BS/HT/LF/VT/FF/CR/SO/SI /DLE/DC1/DC2/DC3/DC4/NAK/SYN/ETB /CAN/EM/SUB/ESC/FS/GS/RS/US 39/quotesingle 96/grave 127/DEL/Adieresis/Aring/Ccedilla/Eacute/Ntilde /Odieresis/Udieresis/aacute/agrave/acircumflex/adieresis/atilde/aring /ccedilla/eacute/egrave/ecircumflex/edieresis/iacute/igrave/icircumflex /idieresis/ntilde/oacute/ograve/ocircumflex/odieresis/otilde/uacute /ugrave/ucircumflex/udieresis/dagger/degree 164/section/bullet/paragraph /germandbls/registered/copyright/trademark/acute/dieresis/notequal/AE /Oslash/infinity/plusminus/lessequal/greaterequal/yen/mu/partialdiff /summation/product/pi/integral/ordfeminine/ordmasculine/Omega/ae /oslash/questiondown/exclamdown/logicalnot/radical/florin/approxequal/Delta /guillemotleft/guillemotright/ellipsis/nbspace/Agrave/Atilde/Otilde/OE /oe/endash/emdash/quotedblleft/quotedblright/quoteleft/quoteright/divide /lozenge/ydieresis/Ydieresis/fraction/currency/guilsinglleft/guilsinglright/fi /fl/daggerdbl/periodcentered/quotesinglbase/quotedblbase/perthousand/Acircumflex/Ecircumflex /Aacute/Edieresis/Egrave/Iacute/Icircumflex/Idieresis/Igrave/Oacute /Ocircumflex/apple/Ograve/Uacute/Ucircumflex/Ugrave 246/circumflex/tilde /macron/breve/dotaccent/ring/cedilla/hungarumlaut/ogonek/caron ] >> endobj 1 0 obj << /Type /Page /Parent 12 0 R /Resources 3 0 R /Contents 2 0 R >> endobj 13 0 obj << /Type /Page /Parent 12 0 R /Resources 15 0 R /Contents 14 0 R >> endobj 18 0 obj << /Type /Page /Parent 12 0 R /Resources 20 0 R /Contents 19 0 R >> endobj 21 0 obj << /Type /Page /Parent 12 0 R /Resources 23 0 R /Contents 22 0 R >> endobj 28 0 obj << /Type /Page /Parent 12 0 R /Resources 30 0 R /Contents 29 0 R >> endobj 39 0 obj << /Type /Page /Parent 12 0 R /Resources 41 0 R /Contents 40 0 R >> endobj 42 0 obj << /Type /Page /Parent 12 0 R /Resources 44 0 R /Contents 43 0 R >> endobj 46 0 obj << /Type /Page /Parent 12 0 R /Resources 48 0 R /Contents 47 0 R >> endobj 49 0 obj << /Type /Page /Parent 12 0 R /Resources 51 0 R /Contents 50 0 R >> endobj 12 0 obj << /Type /Pages /Kids [1 0 R 13 0 R 18 0 R 21 0 R 28 0 R 39 0 R 42 0 R 46 0 R 49 0 R] /Count 9 /MediaBox [0 0 595 842] >> endobj 83 0 obj << /Type /Catalog /Pages 12 0 R >> endobj 84 0 obj << /CreationDate (D:191000124091827) /Producer (\376\377\000A\000c\000r\000o\000b\000a\000t\000 \000D\000i\000s\000t\000i\000l\000l\000e\000r\000 \0003\000.\0000\0002) /Creator (3B2 Total Publishing 6.03d/W) /Title (99-395 373..381) >> endobj xref 0 85 0000000000 65535 f 0000467660 00000 n 0000000017 00000 n 0000016637 00000 n 0000455982 00000 n 0000456943 00000 n 0000457905 00000 n 0000458843 00000 n 0000459442 00000 n 0000460386 00000 n 0000461320 00000 n 0000417929 00000 n 0000468485 00000 n 0000467749 00000 n 0000016810 00000 n 0000036876 00000 n 0000462351 00000 n 0000462912 00000 n 0000467841 00000 n 0000037052 00000 n 0000054383 00000 n 0000467933 00000 n 0000054536 00000 n 0000072203 00000 n 0000072344 00000 n 0000110279 00000 n 0000138481 00000 n 0000171262 00000 n 0000468025 00000 n 0000201926 00000 n 0000210466 00000 n 0000464802 00000 n 0000418038 00000 n 0000418146 00000 n 0000210700 00000 n 0000238297 00000 n 0000268678 00000 n 0000300648 00000 n 0000324324 00000 n 0000468117 00000 n 0000353993 00000 n 0000362251 00000 n 0000468209 00000 n 0000362487 00000 n 0000381726 00000 n 0000463859 00000 n 0000468301 00000 n 0000381879 00000 n 0000399959 00000 n 0000468393 00000 n 0000400077 00000 n 0000417533 00000 n 0000417663 00000 n 0000417796 00000 n 0000418253 00000 n 0000418573 00000 n 0000419978 00000 n 0000420460 00000 n 0000423846 00000 n 0000424322 00000 n 0000432934 00000 n 0000433153 00000 n 0000434736 00000 n 0000435149 00000 n 0000440894 00000 n 0000441452 00000 n 0000451510 00000 n 0000451733 00000 n 0000451973 00000 n 0000452186 00000 n 0000452418 00000 n 0000452638 00000 n 0000452918 00000 n 0000453207 00000 n 0000455777 00000 n 0000465873 00000 n 0000465933 00000 n 0000465993 00000 n 0000466053 00000 n 0000466113 00000 n 0000466173 00000 n 0000466233 00000 n 0000466304 00000 n 0000468631 00000 n 0000468688 00000 n trailer << /Size 85 /Root 83 0 R /Info 84 0 R /ID [] >> startxref 468948 %%EOF 1 0 obj << /Type /Page /Parent 12 0 R /Resources 3 0 R /Contents 2 0 R /Thumb 88 0 R >> endobj 13 0 obj << /Type /Page /Parent 12 0 R /Resources 15 0 R /Contents 14 0 R /Thumb 90 0 R >> endobj 18 0 obj << /Type /Page /Parent 12 0 R /Resources 20 0 R /Contents 19 0 R /Thumb 92 0 R >> endobj 21 0 obj << /Type /Page /Parent 12 0 R /Resources 23 0 R /Contents 22 0 R /Thumb 94 0 R >> endobj 28 0 obj << /Type /Page /Parent 12 0 R /Resources 30 0 R /Contents 29 0 R /Thumb 96 0 R >> endobj 39 0 obj << /Type /Page /Parent 12 0 R /Resources 41 0 R /Contents 40 0 R /Thumb 98 0 R >> endobj 42 0 obj << /Type /Page /Parent 12 0 R /Resources 44 0 R /Contents 43 0 R /Thumb 100 0 R >> endobj 46 0 obj << /Type /Page /Parent 12 0 R /Resources 48 0 R /Contents 47 0 R /Thumb 102 0 R >> endobj 49 0 obj << /Type /Page /Parent 12 0 R /Resources 51 0 R /Contents 50 0 R /Thumb 104 0 R >> endobj 84 0 obj << /CreationDate (D:191000124091827) /Producer (\376\377\000A\000c\000r\000o\000b\000a\000t\000 \000D\000i\000s\000t\000\ i\000l\000l\000e\000r\000 \0003\000.\0000\0002) /Creator (3B2 Total Publishing 6.03d/W) /Title (99-395 373..381) /ModDate (D:20000124092359) >> endobj 85 0 obj [ /Indexed /DeviceRGB 255 86 0 R ] endobj 86 0 obj << /Filter [ /ASCII85Decode /LZWDecode ] /Length 87 0 R >> stream J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T (7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4 PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD' dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\ 9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue> gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R endstream endobj 87 0 obj 488 endobj 88 0 obj << /Filter [ /ASCII85Decode /LZWDecode ] /Width 74 /Height 105 /ColorSpace 85 0 R /BitsPerComponent 8 /Length 89 0 R >> stream J2Q7]3$]7K#D>EP:q1$o*=mro@So+\<\5,=TOSSDU'^=DV5TS$TkNY.Vab.>*4o[/oe'SNgHTS\9O1XhI4KnSmr4c$#f).ce494uh:`KW?TWi_O !^]_B.\&+&K3\\tDZYIs1^UMpT>W.j0+:4pdU_#uYMu)h.Nek*)9.f?D&]H-ZoJH/ /t>o`a:\o8+ioftN?cOX9U-osW!E~> endstream endobj 89 0 obj 499 endobj 90 0 obj << /Filter [ /ASCII85Decode /LZWDecode ] /Width 74 /Height 105 /ColorSpace 85 0 R /BitsPerComponent 8 /Length 91 0 R >> stream J2Q7]3$]7K#D>EP:q1$o*=mro@So+\<\5,H7Uo;k$3i4*O@Wl%3@'nb-\Y*&;Rp>D #;)<:A'inNIUtI#6g#,nI-tu&TLEMBa;#2'%\lnbZDn:=P;7_gjg*Zef)en`EIpuk'!2QY3C.^bTcd3`I?WD^YUSE46?1ZB"-bO [L>n8mt8Ab0\BK>6Pj%JjKMc\V5lV"alXd-Cu0dt=3TGT3\0WB.uMdA2:.m@cI94S kqW#4L3lY)WphZ(.Le1:WekW#g[1=\%;=Je[[YK_Vl?-JoK)inO(5<,l#q:c4k6oW]s^^pn%po-k!HMP=X$[UepC@Y4+-kJDB !C/)ti7GWbg?,P*/\@=T5]=N20/Qed_!u^[#t@c)8J4Fi6n'., ":O#s`=YdIW@Y,3#9HGI<&j$\0q+^C6.*'9.E[gTXXhR-bdB%GP3fk8bS(DfJ:I~> endstream endobj 91 0 obj 534 endobj 92 0 obj << /Filter [ /ASCII85Decode /LZWDecode ] /Width 74 /Height 105 /ColorSpace 85 0 R /BitsPerComponent 8 /Length 93 0 R >> stream J2Q7]3$]7K#D>EP:q1$o*=mro@So+\<\5,H7Uo<*Z3EH6O@US#kiA%(-^6uo1:^r' !s=l`A^[QBejD-Z8Z'tI,R=E8TMT<$3ZnK&%%^1jPaT`&R8'JUjthmZZBnRVeLM7. 4>sZOY?0lZfM.7Cf<\O02OStSfjoe@/[ZOG]$j`e6$jU;05%86mVb"t*ZpH@ igKQ9rT`jXV endstream endobj 93 0 obj 561 endobj 94 0 obj << /Filter [ /ASCII85Decode /LZWDecode ] /Width 74 /Height 105 /ColorSpace 85 0 R /BitsPerComponent 8 /Length 95 0 R >> stream J2Q7]3$]7K#D>EP:q1$o*=mro@So+\<\5,H7Uo;k$3i4*O@Wl%3@'nb-\Y*&;Rp>H >pt7(-;uq#enm@9:1mL-FEt&1T?F"X.MRaD7\IQY;&TT>PoujKl4b.Y(99p+;C2rI e5j1cYX@W_3\8ATArt7'TF2/LM,KVTWHR$meerP<S;t^@Q;Qp,$gmA[HFr-S F\29Z3K;'i@e`Wmq\r(mjKXr>*2aC;]&dmt/+.%-T?Y5-=q,)Pq4b0&mhS$FI_S\. CS_sXrlVQ9a'L^OS\FELT"OK#gWb^^91$a;[T+WcnW_OD8mh\WD__ L;HcfJI4`hA#TDmE6LHH5gM6Zd6hd3+V2IF4AcI);-Y=]`R-M/^HYScD&]:u9?.K/ &_'Gk7gtnMrP#NN/H<\Om#N1.&dl;qac1s^+A*&9I4%"8.S1/m& endstream endobj 95 0 obj 610 endobj 96 0 obj << /Filter [ /ASCII85Decode /LZWDecode ] /Width 74 /Height 105 /ColorSpace 85 0 R /BitsPerComponent 8 /Length 97 0 R >> stream J2Q7]3$]7K#D>EP:q1$o*=mro@So+\<\5,H7Uo<*Z3EH6O@US#kiA%(-\46WNP`#I ^tb5+&2"U&Gc]\;9H/u`$F.2!D_!+Fk6lhBh4E$EPKBSF^>NmoS.3#o*g8pF[Yi>/ F+(MqQ8^>b[geT(i1Q`WNTU][4Pt$9>I9%i=h`^2eL%bP72hKNP#bem`ne_:Ih_XKfS!]=2MB(Ai?Y%W"'-D97uZiHMEIO=dLc%cqN> \*^CKPgHOfULR;k=`gH[o7.Pjqn85UOTjjkpHqscP9R=J^6%JS#lVZ ZgZ4^<;MfF(RZ*nPRb^sGFS*4pB D]>S$Yf7Ue$CotgY00).Rc`Ul%\QN'MO6\e6].A5/"8qpWGt6ES3IQ7cOhHh>3m!= M,Y7_W2hBPZDO[d5&[UL$KSuZ8SVqL\P?o1r[t)&ZD*fQ!nuGBM,CGMTM`5$%4fUg b.+AZ'*ejU1ICG`)mSDFkdM2"HJ5:AA*Y]hDYggi8b,4+V`r?4JASCk!ZIKAN`=$b ].:N\\N*./g$4Lgn=ddEZ1/]:nL6AdR9 /]XuN
    ;!t9cUW]ZCQ;p%/K:b:.L9USH8FEF"SWU$TB`C5U.;H:n8FdkHePAin7'P\85fk%^gM[ )kNF"M0=:ND]8h8'q>KR4X)\U?>En@.qAdXgGJOZ[^d!ej*k?omO5B?m,;((ono0F f<),(D/dh*/l)g2er5ou8$;].<,+b%^P!nT'WR>^jY]PkP3f4-Z&jO9/HW3[DJ0q; $:h-+.13l[SarG.c)TE18MJE$"fC@DS3Td2nH,@S:t1=oQ7bYj]Ge\0 h[DO[/r9Rs&E6&!j91#Ykm_IDA0=C!Tk>bu.-C3/l!*cIF]q6$/D@Loj8?'uA WqB>Fe[heSaXphiF_7pUC;e;2/P;a;VPDZ+TiUJr;6BLt[T?Y7=K@ulY1;C==).6) @[UeYVLe3')7d'D1UBO.qGD[6K5eF@+q@##u+T4(LWnM /2UEcm7+H?CK\pMPY3FH9[uXI(K&XYQWBrX29>h&fIL%FeK1]5.sP<>+_*;k/YW9_ :.DjecfeZaq[hI`K(fJh`ks?4F;R=7NdW";iYQ[3r\i#^q%fo") b[HION+l;uic@i'I3,"j*&^Af;a/i"09[efe"2OWcL%@,0$KhPX$10l29($*S+U+[ 7Z#Mr01KX2*M`7]Oj[E/8nhQ_V=_ci+ endstream endobj 97 0 obj 2380 endobj 98 0 obj << /Filter [ /ASCII85Decode /LZWDecode ] /Width 74 /Height 105 /ColorSpace 85 0 R /BitsPerComponent 8 /Length 99 0 R >> stream J2Q7]3$]7K#D>EP:q1$o*=mro@So+\<\5,H7Uo;k$3i4*O@Wl%3@'nb-\Y*&;Rp>D #;)<:A'innelOMo:1;V>jPkG?PYbhqq6^!T/Y1;O1hp!iP>.B/WYHEeT>?f$!F^mDmp\R)e4T)J[.0& fXbX'*JLelDJfVhk4*/'gatKJc5NNfNl.>FXG)eNi4e.=QN^h%^P^%\iQ`5#[DLR5 lE%UueWd2CcX!2eh6(sOAB5Lpp^MY@)5#8lm#BH%U@d;\jgu!,j(j"XctHjr7a=Z3 [I+H+,3qO=Uekh_ds$e4Gq/VB_#Tu+,I D]?QuY\_&?,lmQ&_ln&h1(A#euj`lIPka YWKA^^^_6pE%gN"h7]":@dEfTM%oJmnKpa3cMDUb\&1PP)I.: +d#X7D9fB-\@+mS_7:=5-"47u0edpbfp_7XI_c<-2t5/j,TY5W;DD]Nbi]d)F7N&gQ$051\R9e 54W8D&MH3-ECE@$E3PoX]L=W&`2:?3U`)Fp`Y/N1F IbfXcomEFJ_N>K82:3;%ECnXFh!9,Cp_g6BRr7mi]N[BJJ@T5kqZ09Wm5_]RXQV;B CpaX^q7?'$D3:9#9q?2L*!3K8f!:5d0\TR\,D+Qm3GqCSki<0Ug.+i4R('MKUD9Z% 1*(j&h!W*A_/Z[gcXt7MVqXeqc0eI5E6F&=8%3h4Z, mS#H55:0?]/p-BL:ZG\6/sVbH6*seJUaJ9:m(T,l$?=Gi9kQqu*[_0l&5?t2KM1i, \)X@TQrscU8T<<,!rur[U"(cn9sc^3&9\U6\S['R#=/&,`"etlGd+m5*I1n"%T;7c n_%AD&e_D&\bCqLV77;imZYk`,E,KW=h&Y-CtYcA"_Lm>]h&cuL6d14CftUmTm0Y7o >-['t\h6KP^,S&$RLd4E9o,IV]VhXt=&XHVW)1#E2GF,dOP-4`20u3QhItO]l6,48 OtHqe?Ih0(5t0m>+K4@_j+@Fd8;PD/kD5ZP^tp"4I9"`?mX($HW@`]*CmqcIPF$!( 2=s;Md,VE^Mu)+-e2\Ne)(a?3M1edl+V1P0"N_$^#^!un\daF`FO04o/Eq9\%JBL! )7edlMB\!/jiIuEdZYW.pqS[P#*'kcCcPDsqAk7$!pZfW+gBp+1.@4ibAA!!BgFYP !X?.S6$!u&?H\%$._M^; ^H4@`?'iQ'@$fSE;oRa41.@g:;JS"$X#T2]_lG6L_>,dA*=n:`*/+\t%P@!1TTGu9 `0s:X;pl`mb8V5_iT#DsN:d2ilqCe$g'V-/L96Q\(3X53&2Hp=jWr=j@d<4-)`($9 :)$+J;#O7bm;[(iQ28^EiO92[4dB!Cu;:D^Ra?`<+YWr]TsXD9,uk.0%-,!(ihV;i]EJ[?7$ *&Z"k+?QL(GcfV^6s-lq/Hi):*Rm?H9UStlGqMTGaD.R([V*[bi2IlcVde"N+Ftof 'Mu+Y;q>578U13:1IMS":[J#5'is"c'>oDq+fI/LFUt+mr=3&3(qZYLC`rsM@u7)G 9Ec)UW]fcd\&sfi>QgYf6H$:A7g\-Z08=H&*Q.Z-&`R%kMK)rS`V@Ik,m4>~> endstream endobj 99 0 obj 2607 endobj 100 0 obj << /Filter [ /ASCII85Decode /LZWDecode ] /Width 74 /Height 105 /ColorSpace 85 0 R /BitsPerComponent 8 /Length 101 0 R >> stream J2Q7]3$]7K#D>EP:q1$o*=mro@So+\<\5,H7Uo<*Z3EH6O@US#kiA%(-^6tD1:^r( 56I6GA^K\+^*>M*9qd(DjS"!dTMT$[REX)H.ASibP:/:@CIY)=.FcFU:.5Ji9^3?R 9m3R?Q:'di3s;^q@"["0<`p_p(M/;).eW[=@c]Y[6#QFTNU6g8^I+qZ4='dpH,!_S QaqhU%sl8gYrMXc7jj5,j)LJ\en6^Xc9SWoW`DUHQdY$g3fQ=m+/@-F1\T(RdmL+\ A>sa#[dqhHe8$h0/%/Yf`RSr&4FB@+&[9Z(/Ni?C6ZKEdlh[#ThThbH^@$:@?Nrj- hV[lc]<4q*cg:1KWSUs"DS+K]FK)`6VjFL^4-%3nXJ-6SqMIG>@5E?3+ W5.o(!pi/`)W;(5CZH2d\g_sG$UcY,57PM+HWnicM\INP5:OMg%m4_d',njYR`tCh O_QN]UQ>0nd#K@B]XXhR-bdB%GP3fk8bS(E(1!GFt!W~> endstream endobj 101 0 obj 538 endobj 102 0 obj << /Filter [ /ASCII85Decode /LZWDecode ] /Width 74 /Height 105 /ColorSpace 85 0 R /BitsPerComponent 8 /Length 103 0 R >> stream J2Q7]3$]7K#D>EP:q1$o*=mro@So+\<\5,H7Uo;k$3i4*O@Wl%3@'nb-\f]R;Rp=q "YH*8A'kUIej0J/9qjD_]YY[LR7$0ORDatm.&9`hFEr9eR6m07A(:9B3a4hL:SS#-DqI%B7J 3(ijY,t>s[n+eqT#1o0W@;>D8?)nW$MW(Bk9C;#"Pgi$6d(IA6)2GQ]o@_m#O%"*. C3NYtG)p"3f'P(O/WS;"P)o$U40;80/[sYLW4K]m/#A6Ylo9CoK4nRNp=3j:_D&u>$6FKWT_Z_n=' YV\-D_(Y_"PX`deE8j*%>]g(aOj%)<_U;DQ+heGnIjd``]2^,Lb+^m<85c0T,/mDQ N?cSB'U[+=C[B#!c4c/u3R3him5rW-bk4-FPNk\hJ,~> endstream endobj 103 0 obj 580 endobj 104 0 obj << /Filter [ /ASCII85Decode /LZWDecode ] /Width 74 /Height 105 /ColorSpace 85 0 R /BitsPerComponent 8 /Length 105 0 R >> stream J2Q7]3$]7K#D>EP:q1$o*=mro@So+\<\5,H7Uo<*Z3EH6O@US#kiA%(-^6tD1:^r( 56[BIA5YsOb&&e`94]e+]Y7YRT$Lip)AMV!$)1+&1moVl@8)tbcn0Om:8(O>e`ZOl SQ7UOOOVEUJZ7:C=H,1%]1S",/f>YJs&WC> Ap(Pq9mZ&Nh=!/jD'o^B^YNVsS;n#$s.@HhG^=4-;l,t;k]XUfIYamjX\NA"4I aQ<3^rOu#Z`K00EWLRmE[i*ZBe8UY1[%kS%^(6C"gq>BSd.joLF(k5*$e+D44-257 [6_pG<<^/K40n63mp%@I_^\U$%_ui'3;Q"egeRQ2YsN!E5`l/$!3a]?:?]W8g`m_$ /*_T^T^h(<$pfokB&go@oM$FL9lqHuV(_b)"MGD3,lAp&C4d\I:X"YG_U=(S0$@q_ Y1QC/N7.1,&eoH]ac^JZ3R3him5rW-bk4-FPO/64ckHom6-tiJ%"b,p~> endstream endobj 105 0 obj 593 endobj xref 0 2 0000000000 65535 f 0000470817 00000 n 13 1 0000470919 00000 n 18 1 0000471024 00000 n 21 1 0000471129 00000 n 28 1 0000471234 00000 n 39 1 0000471339 00000 n 42 1 0000471444 00000 n 46 1 0000471550 00000 n 49 1 0000471656 00000 n 84 22 0000471762 00000 n 0000472046 00000 n 0000472099 00000 n 0000472682 00000 n 0000472703 00000 n 0000473359 00000 n 0000473380 00000 n 0000474071 00000 n 0000474092 00000 n 0000474810 00000 n 0000474831 00000 n 0000475598 00000 n 0000475619 00000 n 0000478156 00000 n 0000478178 00000 n 0000480942 00000 n 0000480964 00000 n 0000481661 00000 n 0000481683 00000 n 0000482422 00000 n 0000482444 00000 n 0000483196 00000 n trailer << /Size 106 /Info 84 0 R /Root 83 0 R /Prev 468948 /ID[<551516f65bc042c7f7c37e3660cb2474>] >> startxref 483218 %%EOF